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PREFACE 
The material in chapters I-IX is intended to be an in-
troduction to the experiments of the author and the reader 
who is familiar with the glucocorticoid effects treated in 
these chapters may elect to omit them. However, each of 
these chapters is intended to be a complete summary of an 
aspect of glucocorticoid action related to the experimental 
problem. Since most of these aspects of glucocorticoid ac-
tion are still under investigation, no final evaluation can 
be made. Rather, these chapters may suggest interrelations 
between glucocorticoids, growth hormone and insulin, one of 
which has been chosen for experimental study. 
It may be helpful to the reader to put these chapters 
into context. Chapter I explores the relationship between 
hereditary diabetes and cortisol metabolism. Having found 
support for such a relationship, Chapter II examines the 
relationship of other hormones to the diabetogenic effect 
of cortisol. Chapter III describes those insulin inhibitors 
iv 
p 
which have been reported but not yet characterized. These 
chapters clarify the concept of insulin inhibition. 
Chapter IV discusses the relationship between gluco-
corticoids and mineralcorticoids with respect to the use 
of the latter in maintenance therapy in the study of glu-
cocorticoid effects in adrenalectomized rats. Chapter V 
relates current concepts of the action of glucocorticoids 
in_ glycolytic inhibition. Chapter VI describes the role 
of growth hormone and glucocorticoids in lipolysis and 
shows that lipolysis is not necessary for the anti-insulin 
effect of cortisol. In Chapter VII the mechanism of the 
glucocorticoid effect is discussed in light of known con-
trol mechanisms. 
Chapter VIII describes lipoprotein structure rela-
tive to the problem of the lipoprotein insulin inhibitor. 
The transport function of the lipoprotein is emphasized. 
Chapter IX compares the effect of glucocorticoids and 
other steroids on serum lipoproteins. 'Similarities be-
tween the effects of glucocorticoids and estrogens are 
noted, especially with respect to their interaction with 
growth hormone. 
Lipoprotein lipase is discussed because it also af-
fects serum lipids. In addition, the effects of steroid 
hormones on its activity are reviewed. The mechanism 
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which decreases the activity of this enzyme in diabetes· 
is discussed in conjunction with the mechanism of action of 
insulin. Finally, an analysis of the efficacy of steroids 
in the treatment of mammary cancer leads to the concept that 
glycolytic inhibition is an important factor in the effects 
of glucocorticoid analogs. 
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GLUCOCORTICOIDS AND GLYCOLYTIC INHIBITION OF LIPOPROTEINS 
(Abstract) by Theodore S. Musiala, Loyola University of 
Chicago. 
The effect of the synthetic glucocorticoid 6a-fluoro-
11s, 17a, 21-trihydroxy-l, 4-pregnadiene-3, 20-dione (f1upred-
nisolone, m p 206-208°C) on the production of physiologic 
inhibition of glucose oxidation in male alloxan-diabetic 
adrenalectomized Sprague-Dawley rats was studied. Flupred-
nisolone was chosen for study to minimize mineralcorticoid 
effects on glucose oxidation. Electrolyte balance was main-
tained in the adrenalectomized rats by the oral administra-
tion of sodium chloride and the sodium salt of. 8-glycyrrhe-
tinic acid. The rats were maintained on a diet containing 
approximately 55% casein, 21% fructose, 4.4% succinate, 5% 
safflower oil, plus vitamins, minerals and fiber. 
Only those anti-insulin factors transported by a-lipo-
proteins at least 6 hours after final injection of 10 mg/kg 
of steroid were evaluated. In order to define the relative 
specificity of the effect, the fluprednisolone metabolite 6a-
fluoro-11S,17~,208,21-tetrahydroxy-l,4-pregnadiene-3-one (mp 
188-192°C) was synthetized and administered to control donor 
rats. Anesthetized steroid-treated donor rats were exsan-
guinated via the abdominal aorta and the 8-lipoprotein frac-
tion was isolated by dextran sulfate and transferred to 
vii 
isotonic tris(hydroxymethyl)aminomethane-HCl buffer, pH 7.40 
at 37°c, through use of a gel exclusion column containing di-
ethylaminoethyl anion exchange groups. In alternate experi-
ments one week apart, each recipient rat received intraperi-
toneally the S-lipoprotein fraction from f luprednisolone-
treated donors and weight-matched 6a-fluoro-11S,17a,20S,21-
tetrahydroxy-l,4-pregnadiene-3-one treated donors. The re-
cipient rats anesthetized with 2,2-dichloro-1,1-difluoro-
e.thyl methyl ether also received a priming dose of glucose-
6~14c followed by a continuous infusion of excess insulin 
and labeled glucose so that glucose transport was not rate-
limi ting for glucose oxidation. The specific activity of 
expired carbon dioxide was measured at 45-minute intervals 
during a 225-minute period by liquid scintillation spectrometry. 
The rate of glucose oxidation was apparently less follow-
ing the administration of S-lipoproteins from f luprednisolone-
treated rats than following the administration of S-lipopro-
teins from rats treated with 6a-fluoro-11S,17a,20S,21-tetra-
hydroxy-l,4-pregnadiene-3-one. Provided that the latter 
steroid treatment did not enhance glucose oxidation, the 
apparent effect is indicative of high specificity for C-21 
steroids. It is possible that structurally related compounds 
with hyperglycemic effects act by binding to the same growth 
hormone-dependent receptor protein hypothesized to bind glu-
cocorticoids and mediate their anti-insulin effects. 
viii 
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CHAPTER I . 
INTRODUCTION TO DIABETES MELLITUS 
~tiology of Beta Cell Exhaustion 
The academic problem presented by diabetes mellitus is 
not the relative insulin deficiency but how it develops. 
The two most important expressions of this disease from this 
standpoint are "juvenile" diabetes and "maturity-onset" or 
adult diabetes. These two types of diabetes differ primarily 
in their rates of development. That juvenile diabetes is an 
accelerated form of adult diabetes is not unreasonable in 
view of the rapid rate of fetal growth. 
What is the genetic basis of inherited insulin antag-
onism? In particular, what single gene might be responsible 
for it? What is the relationship of known diabetogenic fac-
tors to the genetic factor? The purpose of this dissertation 
is to explore the role of cortisol in insulin resistance and 
the possibility that a genetic defect in cortisol metabolism 
may lead to the overproduction of a circulating insulin 
antagonist. 
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Knowledge of the genetic defect in diabetes mellitus 
will not only aid in understanding the progression of the 
disease, but also will aid in its more accurate detection 
·in the population before it is expressed clinically. 
The Relationship to Obesity, Cancer, and Vascular Disease 
Yalow and Berson (118) found that the response of in-
sulin to glucose was delayed in obesity. This delay is 
apparently related to the high fasting insulin levels which 
are also found in obese subjects. The continuous output of 
insulin in the fasting state prevents the maximal storage 
of insulin granules in the B cells and abolishes the initial 
burst of insulin release in response to glucose. 
Arendt and Pattee (19) performed combined insulin-glu-
cose tolerance tests on obese subjects. They administered 
0.1 unit of insulin per kilogram of body weight intraven-
ously followed in 30 minutes by 0.8 grams of glucose per 
kilogram of body weight orally. In 32 obese subjects the 
response to this procedure was a fall in blood glucose to 
2 
50 percent of its fasting level at 90 minutes and then a 
maximum rise to 164 percent of fasting levels at 120 minutes. 
Glucose remained high at 180 minutes. In contrast, the 
normal response consisted of an initial fall in blood glu-
cose to 38 percent of the fasting level followed by a maxi-
mum rise to 114 percent of the fasting level at 90 minutes. 
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'· rurthermore, the blood glucose level in control subjects fell 
J:)elow the fasting level before 180 minutes had elapsed. · The 
obese group was clearly resistant to the administered insulin. 
In addition, their insulin response· to glucose was clearly 
subnormal. 
That this subnormal response is not due to lower serum 
insulin levels is illustrated in the work of Karam· et' al 
(562). These workers measured blood insulin levels at 30, 60, 
90, and 120 minutes after oral and intravenous glucose admin-
istration. They found that obese diabetic patients had 
higher insulin levels at each interval compared to normal 
subjects. In addition, basal insulin levels were 30-146 
microunits per ml in the obese group compared to 30-84 micro-
units per ml in the control group. These results show that 
the decreased glucose tolerance in ob~sity is not due to a 
decreased level of insulin in the blood. It is clear evidence 
for increased insulin antagonism in obesity. More than 51 
percent of male diabetics and 59 percent of female diabetics 
are 20 percent heavier than ideal weight. In many cases a 
remission of diabetes follows weight loss. 
Another interesting finding in this interrelationship 
has been reported by Yalow et ·al (1181). They found that 
prolonged fasting Aecreases the glucose tolerance of normal 
subjects but that it did not affect the glucose tolerance of 
• 
4 
obese or diabetic obese subjects. These results indicate that 
obesity impairs the response to insulin by the same mechanism 
operative during fasting. 
The Heredity and Detection of the Diabetic Genotype 
Although the inheritance of abnormal ~lucose tolerance 
does not follow a simple recessive or dominant pattern, if 
diabetes melli tus is due to .. a single gene, its inheritance 
must follow one of these patterns. As noted earlier, insulin 
resistance will not produce abnormal glucose tolerance unless 
insulin output is deficient. Therefore, in the general pop-
ulation, the inheritance of the diabetic phenotype may be 
multi-factorial, including genes for insulin production and 
insulin destruction as well as for insulin resistance. Be-
cause of these modifying genes, the incidence of diabetes 
among the children of O, 1, and 2 diabetic parents is 0.2, 
1.6, and 12-14 percent respectively. 
In more homogeneous populations containing more uniform 
modifying genes diabetes is inherited in dominant fashion. 
Pavel and Pierptea (817) studied a homogeneous population of 
14,000 diabetics ~n Bucharest over a 26-year period. They 
observed a 27.7 percent incidence of diabetic descendants 
in 385 families in which both parents were diabetic. When 
this figure was corrected for the increasing life span of 
the descendants, the corrected incidence was 31.7 percent. 
This percentage is less than the 50 percent incidence of 
heterozygotes expected for dominant inheritance. However, 
the difference could be due to an increased mortality among 
diabetic compared to non-diabetic fetuses. Vallance-Owen 
(1086) also found that the synalbumiri insulin antagonist 
was inherited as an autosomal dominant but that overt dia-
betes developed in only 16 out of 58 individuals with in-
herited insulin antagonism. This percentage (27.7 percent) 
is similar to that noted above. 
Glucocorticoid-Glucose and Fucose Tolerance Tests 
The detection of the diabetic genotype is much more 
difficult than the detection of the diabetic phenotype. Al-
though elevated fasting glucose is often indicative of dia-
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betes mellitus, the results of the standard glucose tolerance 
test are less definitive. Fajans et al (303) have shown that 
standard glucose tolerance is randomly distributed in the pop-
ulation. Therefore, only a probability factor can be assigned 
from the results of this test. 
In contrast to the random distribution of standard glu-
cose tolerance, the cortisone-glucose tolerance test of Fajans 
and Conn (300) is somewhat more definitive in that 30 percent 
of the positive responders to this test later suffer marked 
deterioration in standard glucose tolerance due to the pre-
sence of the diabetic genotype. Since diabetes mellitus is 
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responsible for only one out of three positive cortisone-glu-
cose tolerance tests, other factors besides the gene may 
impair glucose tolerance following cortisone. Three factors 
which may influence the cortisone-glucose tolerance test 
are: 1) the rate of cortisone metabolism; 2) hepatic glucose 
output in response to cortisone, and 3) peripheral glucose 
utilization in response to cortisone. Apparently, the gene 
for diabetes mellitus influences only the last factor. 
Fajans and Conn (301) reported the details of the corti-
sone-glucose tolerance test. In the test approximately 8.0 
mg/kg of cortisone acetate is administered to the subject 
8.5 hours and 2.0 hours before the administration of 1.75 gm 
of glucose per kg of ideal weight. The long treatment period 
is noteworthy in reference to the mechanism of cortisone in 
this effect. When glucose is measured by the Somogyi-Nelson 
method, the 2-hour value should be less than 1.40 gm/l com-
pared to 1.20 gm/l in the standard glucose tolerance test. 
Fajans and Conn pointed out the utility of the cortisone-
glucose tolerance test in deciding borderline results from 
the standard glucose tolerance test. They found that 90 
percent of "probable" positive responders to the latter test 
to be positive responders to the cortisone-glucose tolerance 
test. They also observed that 28 percent of the relatives 
Of diabetics gave positive cortisone-glucose tolerance tests, 
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but that only 4 percent of non-diabetics did so. This latter 
percentage is that expected from random error alone. 
Prior to the cortisone-glucose tolerance test Thorn et al 
(1064) found that when a daily dose of 50 mg of prednisolone 
is withdrawn from normal and diabetic subjects, the latter 
continue to excrete glucose after 3 days while the non-dia-
betic subjects do not. This result suggests that glucocor-
ticoid effects are prolonged in diabetics. 
Duncan (259) has described an intravenous cortisone-
. glucose tolerance test in which 200 mgs of cortisone is ad-
ministered 2 hours before glucose. He described the merits 
of plotting the glucose tolerance curve on semi-log paper. 
When the logarithm of the increase in blood glucose above 
the fasting level is plotted versus time,. a straight line 
is obtained. A glucose disappearance rate can be calcu-
lated from the slope of this line. Approximately 83 percent 
· of patients with mild diabetes but no non-diabetics have 
s~bnormal glucose disappearance rates. These results suggest 
that the severity of diabetes may be measured by the half-
life of blood glucose. Thus, one may refer to 30-minute 
diabetics, 60-minute diabetics, etc. Furthermore, .since 
half-lives are inversely proportional to glucose disappear-
ance rates, relatively few equally spaced half-lives encom-
pass a wide .variation in the severity of diabetes. These 
reports also indicate that glucocorticoids are involved in 
the mechanism of genetic diabetes. Berger et al (68) con-
cluded that the mechanism of the cortisone-glucose tolerance 
test involved peripheral insulin antagonism. The fact that 
juvenile diabetes is often evident at birth may be an indi-
cation of the effect of insulin inhibitor concentr~tion on 
the rate of S cell exhaustion. 
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The standard glucose tolerance test has two deficiencies: 
elevations in glucose stimulate insulin release and, secondly, 
most of the glucose is converted to glycogen so that the 
rate of glucose disappearance is not equal to the rate of 
glycolysis. 
Pituitary basophilism results in an overproduction of 
ACTH in Cushing's Syndrome. Conn (103) has observed that 
· . 70 percent of these patients exhibit an insulin-resistant 
diabetes mellitus. Pfeiffer (831) found that both Cushing's 
Syndrome and acromegaly were preceded by long periods of ·im-
paired glucose tolerance associated with elevations in plasma 
insulin and an inverted circadian rhythm of ACTH secretion. 
On the other hand, insulin resistance due to insulin anti-
bodies is not associated with the excretion of cortisol 
metabolites. The insulin requirement is not proportional 
to cortisol production even though cortisol output may be 
4-23 fold elevated when the diabetes is uncontrolled. Rose 
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(g03) has also demonstrated increased adrenocortical activity 
in alloxan-diabetic rats. The treatment of insulin resist-
ance with excess insulin may actually increase the resistance. 
Somogyi (1003) noted that insulin hypoglycemia increases glu-
cagon and glucocorticoid secretions which have hyperglycemic 
and anti-insulin effects. 
What is needed is an extracellular indicator of the 
int~acellular concentration of glucose-6-phosphate. This 
·hexose phosphate is the precursor of several other hexoses 
~hich are incorporated into serum glycoproteins. The most 
convenient of glycoprot~in hexoses to measure is fucose, 
6-deoxy-L-galactose. The level of free serum fucose is 
negligible and it can be quantitated specifically in the 
presence of other reducing sugars by means of the Dische 
methylpentose reaction using cysteine and sulfuric acid. 
This colorimetric reaction at 400 nm is no more difficult 
than glucose measurement by ferricyanide reduction. 
Fucose is incorporated into glycoproteins by a multi-
step reaction sequence consisting of the conversion of 
_9lucose-6-phosphate to fructose-6-phosphate, then to 
mannose-1-phosphate, then to guanosine diphosphate~D-mannose. 
This .nucleotide sugar is converted to guanosine diphosphate-
L-fucose and subsequently attached to the completed protein 
chains of serum glycoproteins. Shaw et al (975) performed 
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the standard oral glucose tolerance test on a group of patients 
and classified all those whose one and two hour glucose con-
centrations were above 1.60 gm/l and 1.20 gm/1 respectively 
as frank or overt diabetics. The cortisone-glucose toler-
ance tests was performed on the remaining patients and all 
positive responders were classified as subclinical or genetic 
diabetics. The remainder served as normal controls. When 
serum fucose levels during the standard glucose tolerance test 
were evaluated, the overt diabetics had two-hour fucose levels 
in excess of 0.75 gm/l, the subclinical diabetics had fucose 
levels in excess of 0.50 gm/l, and the controls all had 
fucose levels lower than 0.30 gm/1. Little overlap was ob-
served between these groups, indicating that glycolytic in-
hibition is a good indication of gen~tic diabetes. 
Navarete and Torres (776) reported the superiority of 
the synthetic glucocorticoid dexamethasone (9a-fluoro-11B, 
16a, 17a, 21-tetrahydroxy-l, 4-pregnadiene-3, 20-dione) in 
glucocorticoid-glucose tolerance tests. They found 80 per-
cent positive responses in prediabetics compared to 30 per-
cent positive responses in the cortisone-glucose tolerance 
test. This is an important finding because it suggests 
that differences in the rates of the metabolism of synthetic 
and endogenous glucocorticoids may exist. In particular, a 
more rapid metabolism of cortisone in certain individuals 
may prevent the expression of the diabetic gene. Lundback 
(G83) has also noted that individual variations in the re-
sponse to cortisone or prednisolone were partly responsible 
for the false negative responses in the cortisone-glucose 
tolerance test. 
These results suggest that the measurement of serum 
glycoprotein fucose during the dexamethasone-glucose toler-
ance test may provide almost complete detection of subclin-
ical diabetes and, as such, may be of great utility in 
genetic studies of diabetes, including genetic counselling. 
More importantly~ these reports indicate glucocorti-
coids are involved in the expression of genetic diabetes. 
Berger et al (68) concluded that the mechanism of the cor-
tisone-glucose tolerance test involved peripheral insulin 
antagonism. Furthermore, if juvenile diabetes is simply 
a double dose of insulin antagonism, the fact that juvenile 
diabetes is of ten evident at birth may be an indication of 
the effect of insulin-inhibitor concentration on the rate 
of 8 cell exhaustion. These same considerations also sug-
gest that fetal glucocorticoid metabolism may be an impor-
tant factor in the development of juvenile diabetes. The 
extent to which juvenile diabetes may be influenced by 
11 
maternal glucocorticoid metabolism remains to ·be determined. 
Insulin resistance in tissues other than adipose tissue 
may lead to obesity as long as the islet cells can respond 
with increased insulin output because andipose tissue is 
especially sensitive to insulin. Both the. B lipoprotein 
insulin inhibitor and the synalbumin insulin antagonist are 
more active on muscle than on adipose tissue. In c~ntrast, 
Antoniades (16) has demonstrated that bound insulin is more 
active on adipose tissue than on muscle. However, all of 
the insulin effects reported here have been demonstrated 
with unbound insulin in vitro. Therefore, the activity of 
bound insulin in the presence of excess of unbound insulin 
appears to be insignificant. Furthermore, an effect of 
glucocorticoids or other hormones on bound insulin has not 
been demonstrated. 
Does diabetes mellitus like sickle cell anemia have 
., survival value under certain conditions? When Eskimos 
t ·f 
subsist on a diet of lipid and protein with minimal carbo-
hydrate,· their incidence of overt diabetes is low. How-
ever, when they switch to a standard American diet, their 
incidence of diabetes is increased. Apparently, insulin 
resistance is relatively unimportant when dietary carbo-
hydrate is low. As noted previously, an insulin antag-
onist which is active on muscle but not on adipose tissue 
promotes fat synthesis as long as islet cell insulin re-
serve can meet the demand. Accordingly, the gene for 
12 
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with gonadal dysgenesis. Although a small amount of cortisol 
is found in normal urine, patients with gonadal dysgenesis 
up to 5 percent of administered cortisol unchanged. 
Forbes and Engel (323) have also noted a high incidence of 
gonadal dysgenesis in diabetics and their close relatives. 
Interestingly, Dilman et al (233) also attributed an ob-
served lower incidence of endometrial carcinoma in diabetic 
women to hypothalamopituitary hypoactivity. This negative 
correlation between diabetes mellitus and malignancy has 
also been observed by others. Hudan (487) observed that 
the occurence of malignant tumors in diabetic males was 
87 percent of that in the total population; the corres-
. ponding figure for diabetic females was 37 percent. Al-
though diabetes is equally prevalent among men and women, 
the ratio of male to female diabetic deaths observed by 
Malins et al (702), 0.60 in recent years, indicates that 
diabetes mellitus more adversely affects women despite 
the protection which it affords against cancer. 
Although the above studies have ruled out a causative 
role of ring A reduced metabolites in diabetes mellitus, 
this does not imply that such steroids are devoid of anti-
glycolytic effects. The anesthetic activity of 21-hydroxy-
5~-pregnane-3, 20-dione 21 succinate (Viadril) has been 
noted previously. Furthermore, Dundee (261) has recently 
-compared 3a-hydroxy-Sa-pregnane-ll, 20-dione and 3a, 21-di-
hydroxy-Sa-pregnane-ll, 20-dione 20 acetate (CT 1341) with 
other intravenous anesthetics. Compounds of this type seem 
to produce anesthesia by reducing the rate of glycolysis in 
brain (398-399). The overall impression of these studies 
.is that glucocorticoids may have an especially effective 
anti-glycolytic effect in brain and in malignant tissues 
with high glycolytic rates. 
Some preliminary experiments were conducted with the 
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aim of studying cortisol metabolism in diabetes. Basically, 
one may expect to find higher levels of cortisol in the 
plasma of diabetics •. However, since the level of cortisol 
may fluctuate, meaningful results can only be obtained if 
the rate of metabolism of labeled cortisol is corrected 
for the rate of cortisol production. If there is deficient 
SB reduction of cortisol in diabetes, this will be reflected 
.;; · in an increased ratio of Sa to SB reduced urinary cortisol 
l~~'. . . . . . 
metabolites. 
The determination of cortisol metabolites in urine by 
published procedures is lengthy because of the long period 
of glucuronidase treatment which is necessary to hydrolyze 
glucuronide conjugates. Furthermore, the large number of 
closely related metabolites present often necessitates 
multiple successive chromatographic steps in which the 
'•'.t: 
separated metabolites must be located by non-destructive 
techniques. The problem of detecting ring A reduced cor-
tisol metabolites during column chromatography can be 
solved by chromatographing ultraviolet-absorbing aromatic 
steroid esters. The choice of the particular ester for 
this use is based on several considerations. First, the 
esterifying reagent should form distinct steroid deriva-
tives. Practically, this requirement translates into a 
reagent that will esterify only unhindered primary and 
secondary hydroxyl groups. Secondly, the derivative 
~ormed should be more soluble in carbon disulfide than 
their parent compounds to facilitate infra-red analysis 
in solution. Thirdly, the esterifying reagent should be 
capable of being conveniently labeled with an isotope 
that can be distinguished from both carbon-14 and tritium. 
In addition, a procedure using such a reagent should be 
designed to minimize the number of metabolites which must 
be separated and quantitated without reducing the meta-
bolic information present in the metabolites. Although 
these studies are primarily concerned with 11-oxygenated 
steroid metabolites, the procedure described below is 
applicable to 11-deoxy steroids as well. 
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Generally, the first step in urinary steroid analysis 
begins with the collection of a 24-hour specimen. Secondly, 
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an aliquot of pooled urine from non-diabetics who have pre-
viously received an identical dose of glucocorticoid labeled 
with an indicator is added to both non-diabetic and diabetic 
urines. For example, if the metabolism of carbon-14 labeled 
cortisol is being studied in diabetics then pooled urine 
from diabetics given a comparable dose of tritiated cortisol 
will be added to each carbon-14 containing urine. If iden-
tical aliquots of indicator metabolites are added to the 
24-hour specimens from control non-diabetics and diabetics 
such an addition then permits recovery corrections to be 
.. applied to each steroid metabolite measured. This proce-
dure has the advantage that each indicator conjugate is 
i:: 
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similar to the conjugate which is to be measured so that 
it is a true indication of procedural losses. 
The next step is to separate the urinary steroids 
and their conjugates from the bulk of the urine. This has 
been achieved by the absorption of both the free and con-
jugated steroids on diethylaminoethyl Sephadex anion ex-
change dextran gels. The absorbed steroids are washed 
with buffer to remove residual urine and then eluted from 
the gel with an aqueous base. Methanolic ammonia has been 
used, but other volatile organic amines such as triethyla-
mine might also be used to elute the conjugated and non-
conjugated steroids. The eluate from such a separation is 
18 
evaporated to dryness under reduced pressure and the residue 
is dissolved in water. A solution of sodium borohydride is 
. then added which reduces steroid ketones over a period of 
several hours. Although many different ketone groups may 
react with this reagent, its primary function is to reduce 
.the c-20 ketone to the corresponding C-20 hydroxyl group 
60 that glucocorticoid metabolites with the dihydroxyace-
tone side chain will be measured along with their corres-
_ponding metabolites with glycerol side chains after the 
latter are converted to 17-ketosteroids by sodium meta-
periodate treatment. Metaperiodate oxidation of vicinal 
glycols provides an alternate method for liberating steroids 
from their glucuronide conjugates. Essentially, the proce-
dure oxidizes the glycerol side chain to a 17-ketosteroid 
and other glucuronides to formate esters which are readily 
hydrolyzed by weak bases. As in the enzymatic glucuroni-
dase hydrolysis procedure, the metaperiodate procedure 
. may give low yields when applied directly to diabetic urines 
,.~;: containing high levels of glucose. However, this is not a 
problem if the conjugates are first isolated by column ab-
sorption as they are here. The chemical equations illus-
trating these reactions are shown in the Figure I. 
Following oxidation and destruction of excess periodate 
the mixture is treated with sodium bicarbonate to saponify 
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FIGURE I 
PERIODATE OXIDATION OF STEROID GLUCURONIDES 
'98URE % 
PERIODATE OXIDATIO• CW STEROID 8LUCURONIDES 
~ 5 :to3 +HCOCOOH + !HCOOH 
j) ~H a 104 + e I03+HCOCOOH. 4HCOOH 
.. HCHO 
anY formate esters produced. Treatment with sodium boro-
hydride is then repeated to convert alkehyde groups arising 
from corticosterone and deoxycorticosterone to primary 
hydroxyl groups. Although newly formed 17-ketosteroids may 
also be reduced, such hydroxyl groups are later re-oxidized 
along with llB-hydroxyl groups by chromium trioxide in py-
ridine. During these reactions all 17a-hydroxy steroids 
which differ only in their side chains are converted to the 
same compound. This conversion affords a real advantage 
in the diagnosis of virilizing adrenal hyperplasia in, which 
both 5$-pregnane-3a,17a-208-triol, characteristic of C-21 
hydroxylase deficiency (salt-losing type) and 3a,17a-dihy: _ 
droxy-58-pregnane-20-one, characteristic of 118-hydroxylase 
deficiency (hypertensive type) are converted to 58-andros-
tane-3a,178-diol. This latter steroid is also formed in 
a negative metapyrone [2-methyl-l,2-bis(3-pyridyl)-l-pro-
penone] test thereby indicating normal feedback control of 
adrenocorticotrophin production by the pituitary. 
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Following acidification and concentration under reduced 
pressure, the sulfate conjugates are solvolyzed by the pro-
cedure of Burstein and Lieberman (139). In this procedure, 
the sulfate conjugates are protonated by p-toluenesul-
fonic acid and transferred to the tetrahydrofuran phase. 
The low dielectric constant of this solvent discourages 
· .. ~. .. . ·~ .. 
" ~I!~ ..... ··• ~ ~ . . . . . 
the ionization of the conjugate and promotes the following 
reaction: 
H 0 OH OH 
" 
I I 
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\ S=O ---> S=O ---> S=O + ROH 0: + 
I I \ / I 
' 
I ~ 
H HO OR HO 0 OR HO 0 H 
The fact that oxygen from water is not incorporated into the 
steroid product supports the above mechanism. 
Following solvolysis, sodium hydroxide is added and the 
non-phenolic steroids are salted out in the tetrahydrofuran 
phase. This phase is then evaporated to dryness under nitro-
gen. The steroid mixture is then dissolved in pyridine and 
esterified with o-chlorobenzoyl chloride. The temperature 
·and reaction time are controlled so that llS-hydroxy and 
17S-hydroxy groups present in the metabolites are not es-
terified. They will therefore be available for subsequent 
oxidation with chromium trioxide in pyridine. The conver-
sion of llS-hydroxyl and 178-hydroxyl groups to their cor-
responding ketones reduces the total·number of individual 
steroids in the complex mixture of urinary steroids, thus 
simplifying the subsequent chromatographic separation. 
Ketone groups in these positions also produce more defin-
itive steroid spectra in the fingerprint region and aid 
in the separation of steroids from other steroids which 
cannot be converted to 11- and/or 17-ketosteroids, i.e. 
22 
ll-deoxy and 17a-alkyl steroids. 
Ellingboe et al (281) have described the use of Sephadex 
LH-20 in the separation of steroid ketones. Their work indi-
cates the feasibility of partition chromatography using ul-
traviolet-transparent solvent systems such as dichlorome-
thane-cyclooctane combined with ultraviolet detection and 
collection of steroid o-chlorobenzoates directly in liquid 
scintillation counting vials. Each fraction can then be 
heated to remove the dichloromethane which would otherwise 
quench the liquid scintillation process. Following this 
· step a concentrated toluene solution of scintillation f luor 
could be added to the higher boiling cyclooctane solution 
of the steroid ester. 
Although many gas-liquid chromatography procedures 
have been developed for steroids, these are not as useful 
as liquid partition chromatography when the recovery of 
the separated steroids is required. The principles in-
volved in these liquid partition procedures have been 
described by Bush (144) and by Cartensen (161) and useful 
chromatographic separations have been reported by Katzen-
ellenbogan et al (569) and by Wilson et al (1158). The 
following compounds derived from the metabolites of 
labeled corticosteone and cortisol are listed below in 
order of their elution from a straight-phase column: 
Major Derived Steroid Esters 
-
3 lla-dihydroxy-18-oxo(ll 18)-lactol-513-androstane-1713,18-a, µ . 
carbolectone 3-o-chlorobenzoate 
56-pregnane-3a,2013-diol di-o-chlorobenzoate 
21-nor-513-pregnane-3a,20-diol di-o-chlorobenzoate 
3a-hydroxy-5a-androstane-ll,17-dione o-chlorobenzoate 
Ja-hydroxy-513-androstene-11,17-dione o-chlorobenzoate 
3a-hydroxy-5a-androstane-17-one o-chlorobenzoate 
Ja-hydroxy-513-androstane-17-one o-chlorobenzoate 
In the method described so far for the separation of corti-
costerone and cortisol metabolites the detection and col-
lection of steroid peaks is less of a problem than their 
identification and quantification. The exact identity of 
the eluted steroids must be made by comparison with authen-
tic compounds on the basis of chromatographic behavior and 
infrared spectra. Quantification is also dependent on 
identification since the number of o-chlorobenzoate groups 
,... per steroid molecule varies. Furthermore, synthesis must 
also be used to confirm the identity of the metabolites 
of synthetic glucocorticoids. The synthetic glucocorti-
coids most difficult to prepare are those reduced in ring 
A of the steroid nucleus. These derivatives, however, 
may be prepared using serum enzymes. Rongone et ·a1 (809) 
~:· have shown that ring A reduction of steroids takes place 
~~. 
l 
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the presence of serum, isocitrate, and NADPH. 
Although the actual chromatographic separation of steroid 
o-chlorobenzoate esters has not been achieved, Ellingboe ·et al 
~ 2 91) have studied the factors which influence the separation 
of ketonic from non-ketonic C-19 steroids during molecular 
sieve chromatography. They found that ketonic steroids were 
eluted more rapidly due to the interaction of polar solvent 
molecules with the ketone which increases the solvated mol-
ecular weight and excludes it from gel pores. Although 
they used chloroform in their studies, a similar effect may 
be expected with dichloromethane which is more polar than 
chloroform. Cyclooctane may be used as the second component 
of the solvent system to adjust the partition coefficients 
of steroids between the polar Sephadex LH-20 stationary 
phase and the non-polar mobile phase in the straight phase 
separation. 
Many procedures employing double isotope dilution for 
the analysis of urinary steroids have been devised. In 
these procedures accuracy is achieved through the use of 
indicator isotopic steroids which permit correction for 
incomplete recovery of steroid metabolites. Sensitivity, 
on the other hand, is achieved by stoichiometrically forming 
a steroid derivative with a reagent of accurately known 
specific activity. However, procedures using only carbon-14 
25 
and tritium isotopes cannot be used to measure the excretion 
of carbon-14 or tritium-labeled steroids. Either recovery 
or mass measurement must be sacrificed. 
36 b . . when Cl-o-chloro enzoate esters are used to estimate 
mass, tritiated steroids can be used to estimate recovery 
.of carbon-14 labeled steroids and vice-versa, i.e. a triple 
isotope dilution procedure can be employed. Chlorine-36 can 
be readily distinguished from both tritium and carbon-14 by 
liquid scintillation spectrometry. The energies of the 8 
emissions are 0.710, 0.018 and 0.156 Mev. respectively. 
In addition, a simple route exists for the preparation of 
chlorine-36-labeled o-chlorobenzoic acid via the diazonium 
salt of anthranilic acid. The labeled acid can be con-
verted to its acid chloride in refluxing thionyl chloride. 
Alternately, the tritiated or carbon-14-labeled acid chlor-
ide may be formed more directly from labeled o-nitrotoluene 
in a vapor phase reaction with thionyl chloride at 200-220°C 
~ as described by Meyer (738). 
~ 
t 
~.·.·· .. l 
The use of the o-chlorobenzoy1- 36c1 group to estimate 
steroid mass is limited in sensitivity by the maximum pos-
sible specific activity of chlorine-36, which, on the basis 
Of its half-life of 3 x 105 years, is 0.3 percent of the 
maximum specific activity of the u- 14 C-labeled acyl group 
and to only 0.0006 percent of the maximum specific activity 
~·· 
~. ·. . 
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of the same o-chlorobenzoyl or acetyl group containing three 
tritium atoms. However, even the tritiated o-chlorobenzoyl 
group has only 7.5 percent of the maximum specific activity 
of a sulfur-35-containing acyl group such as the o-methyl-
35 
sulfonylbenzoyl- S group which contains only one sulfur-35 
atom. 
A three-step synthesis of o-methylsulfonylbenzoic acid 
from acetophenone and chlorosulfonic acid has been described 
by Weston and Suter (1135} and it appears to be well-suited 
for the preparation of the labeled compound. Although the 
sulfone is resistant to base and to chromium trioxide oxi-
dation, it appears that o-methylsulfonylbenzoyl chloride 
may spontaneously cyclize in pyridine to 3(2)-thianapthen-
one-1, 1-dioxide and therefore may not be useful as an es-
terifying reagent. An alternate sulfur-containing aromatic 
acid chloride is 4-chlorothiophene-3-carboxylic acid chlor-
ide. Whether this latter reagent is best prepared from 
fumaric or maleic acid is an interesting chemical question. 
A suggested synthesis from the less stable maleic acid is 
shown below. 
It is not possible to distinguish the B emissions of 
carbon-14 (0.156 Mev.} from those of sulfur-32 (0.167 Mev.} 
efficiently. However, these isotopes may be distinguished 
by the 10.4 percent decay in sulfur-32 activity which occurs 
FIGURE II 
SUGGESTED SYNTHESIS OF 4-CHLOROTHIOPHENE-
3-CARBOXYLIC ACID CHLORIDE 
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when measurements of the total activity of both isotopes are 
made at exactly two-week intervals. This delay in the analy-
tical procedure is relatively unimportant for the types of 
clinical determinations for which the triple isotope dilu-
tion procedure would be used. Furthermore, the delay is not 
necessary for the measurement of unlabeled steroid metabo-
lites using 35s-4-chlorothiophene-3-carboxylic acid chloride 
and tritiated indicator steroids since radioactive tritium 
and sulfur can be readily distinguished. Thus, sulfur-
labeled esters could be used routinely in both double and 
triple isotope dilution procedures. 
Brooks et·al (121) have investigated the absorption 
,, chromatography of steroid benzoates on alumina. They 
formed the benzoyl derivatives by treatment of the alco-
hols with the acid· chloride in pyridine for 18 hours at 
room temperature. Under these conditions 17S hydroxyl 
groups as well as the less hindered C-20 and C-3 hydroxyl 
groups were esterified. Esterification of the 17S hydroxyl 
group has also been observed with pentafluorobenzoyl chlor-
ide after 48 hours under similar conditions. Brooks et ·a1 · 
achieved separation of the benzoates by eluting them from 
the alumina with increasing proportions of benzene in pe-
troleum ether. They observed that the separation of C-5 
epimers of steroid benzoates was better in every case than 
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that obtained with the acetate esters. 
In particular, the benzoyl esters appear to magnify the 
stereochemical difference between epimeric C-20 hydroxyl 
groups. Those differences are relatively s~all in the 
steroid alcohols and acetate esters. This effect of the 
c-20 benzoyl group occurs despite the free rotation about 
the bonds involved. Therefore, there is reason to expect 
that separations will.be further improved by chromatographing 
ortho substituted benzoyl esters. In addition, the electron 
withdrawing chlorine substituent, increases the selectivity 
of the acid chloride for unhindered hydroxyl groups such 
as those in the C-3;. C-17, and C-21 positions. 
The separation of steroid derivatives by partition 
chromatography depends on their physiochemical differences 
relative to their similarities. Steroids epimeric at C-5 
differ primarily in conformation and therefore may show 
their greatest differences in partition coefficient in 
rigid allicyclic solvents which interact simultaneously 
with portions of the A and B rings of these steroids. 
Examples of ultraviolet-transparent solvents that have been 
used for this purpose are cyclopentane, cyclohexane, and 
methylcyclohexane. Commercial decalin is a mixture of cis 
and trans isomers which may have opposing interactions with 
steroid solutes. Although cis decalin may be useful, it 
be separated from trans decalin which forms a hydro-must 
peroxide that may adversely affect steroid solutes and the 
liquid scintillation process. 
Hayes et al (438) have reported the pulse heights of 
several aromatic and allicyclic solvents relative to tolu-
ene. They found that methylcyclohexane and dioxane pro-
duced 25 and 20 percent of the toluene pulse height respec-
· - tively. However, their most significant finding was that 
dicylohexyl had 48 percent of the toluene pulse height. 
Although contamination of the dicyclohexyl (m.p. 2.5-3.0, 
b.p. 236.5-237.5) with phenylcyclohexane (m.p. 7.0-8.0, 
b.p. 235-236) formed during the catalytic hydrogena.tion 
of biphenyl could explain the results, the high pulse 
height obtained may be due to the greater rigidity of 
dicyclohexyl compared to methylcyclohexane. 
The counting efficiencies of aromatic and non-aroma-
tic liquid scintillation solvents increases as their vis-
cosity increases. Cyclohexane is 3 times as viscous as 
n-hexane. Cyclooctane and decalin are 7 and 8 times as 
viscous as n-hexane respectively. The aromatic ether 
phenetole is over twice as viscous as toluene. A compari-
~' son of aromatic alcohols reveals that phenethyl alcohol 
is 50 percent more viscous than benzyl alcohol which, in 
i turn, is over 16 times more viscous than n-hexane. Thus, ,,_ 
"l~ .•. · .... -~ . 
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viscosity may explain why 2-phenoxyethanol is 86 percent as 
efficient as toluene as a scintillation solvent while benzyl 
alcohol is only 60 percent as efficient as toluene. 
Non-bonded interactions contribute to the rigidity and 
viscosity of cyclooctane. Brown and Borkowski (123) found 
that l-chloro-1-methyl-cyclooctane had a solvolysis rate 
in 80 percent ethanol at 25°C. that was greater than any 
other ring containing up to 15 methylene units. A cyclo-
pentane analog, the next most active compound, was less 
than half as reactive. 
More polar solvents of this type such as L-3,3-diflu-
oro-p-menthane and 1,1-difluorocyclooctane may be prepared 
by the reaction of L-menthone and cyclooctanone with sulfur 
tetrafluoride (434) or carbonyl fluoride (308). Cyclooctan-
one may be prepared from cyclooctene by hydroboration fol-
lowed by chromic acid oxidation (126). 
Efforts designed to optimize the steroid partition 
chromatographic process by the use of selective solvent 
systems and stationary phases are justified (144, 161, 365). 
Many chromatographic procedures used in clinical determina-
tions require many steps to separate steroid derivatives 
from labeled urinary impurities. No systematic study of 
the liquid partition chromatography of steroids has been 
made in spite of the availability of automated equipment 
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adaptable to such a study. The criterion of adequate separa-
tion in the above processes is the presence of a constant 
isotope ratio across each elution peak. 
steroid partition chromatography may also provide a 
model in which to study the thermodynamic interactions of 
solvents and solutes, especially departures from non-ideal 
behavior. Those solvents, especially cyclic hydrocarbons, 
which can interact with steroid solutes in only a limited 
number of conformations, appear to afford a better chance 
of separation, but the theoretical and experimental basis 
of such an assumption has not been determined (144, 365). 
However, the partition chromatographic process described 
above may be optimized with the aid of infrared analytical 
techniques. For example, solutions of the Sa and 58 epimers 
of steroid benzoates dissolved in cyclooctane solutions 
'' containing various mole fractions of dichloromethane may 
r-. 
be added to a given amount of the stationary phase support, 
Sephadex LH-20. After an equilibration period, the sta-
tionary phase can be separated by centrifugation and the 
composition change in the mobile phase determined by infra-
red spectrometry. Such a procedure could permit a deter-
mination of the optimal mole fraction of dichloromethane 
required for the separation. Furthermore, there appears 
'to be no theoretical reason which would rule out the 
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· separation of a large number of compounds in a single chro-
step, provided that derivatives and solvent 
systems are chosen so that all the compounds to be separated 
·have significantly different partition coefficients. 
---
CHAPTER II 
DIABETOGENIC FACTORS 
Human Placental Lactogen 
Normal pregnancy is accompanied by a two-fold increase 
in fasting insulin levels and a lower fasting blood glu-
cose. Insulin response to intravenous glucose may be three 
times that postpartum (1206). Kalkhoff et al (283) also 
found decreased glucose tolerance during pregnancy, espec-
ially in diabetic women. Although the absolute values of 
plasma non-esterified fatty acids were significantly 
higher throughout the glucose tolerance test in diabetic 
subjects, the percent decrease from initial fasting levels 
was the same pre- and post-partum in normal and diabetic 
women despite more marked deterioration of glucose toler-
ance in the latter groups. Subclinical diabetes may be 
detected by the standard glucose tolerance test during 
pregnancy. The detection of latent diabetes is especially 
important because the fetus may develop hyperplastic is-
lets as well as other abnormalities if the diabetes of 
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the mother is not properly managed. Conn and Fajans have 
estimated that the mother of a twelve-pound baby will develop 
overt diabetes in the next 25 years of her life. 
Fitzgerald et al (320) noted that the incidence of dia-
betes increases with parity. Compared to nulliparous 
women, the incidence of diabetes in women with three child-
ren is twice as great, and in women with six children, six 
times as great. 
Human placental lactogen and estriol appear to be re-
sponsible for the diabetogenic effect of pregnancy. Josim-
ovich (550) attributed this effect of human piacental lac-
togen to a potentiation of the effect of growth hormone. 
Samaan et al (929) also came to this conclusion. The 
exact nature of this potentiation is obscure. One interpre-
tation is that the placental hormone can occupy some of the 
non-specific binding sites which are normally available to 
growth hormone, thereby rendering the secreted grow_th hor-
mone more effective at specific sites. 
Beck and Daughday (59) estimated that 290 mg per day 
of the placental hormone was produced near term. They also 
noted that the hormone impaired glucose tolerance even 
though it increased insulin response to glucose. 
Growth Hormone 
The overall effect of growth hormone is to stimulate 
'. 
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the formation of lean body mass at the expense of adipose 
tissue. Growth hormone promotes the secretion of insulin 
and glucagon, both of which promote the transfer of carbo-
hydrate from the liver to the extrahepatic tissues. For 
example, the decreased levels of free fatty acids (FFA) 
following hypophysectomy have been implicated in the failure 
of the heart to accumulate glycogen as it normally does in 
fasting. 
Young (1192) first indicated that the diabetogenic 
principle of the pituitary might be identical with growth 
hormone. Although growth hormone is not diabetogenic in 
normal rats, it is diabetogenic in animals with less pan-
creatic reserve. Dohan and Lukens (247) observed that in-
sulin resistance was associated with diabetogenic doses of 
growth hormone but not with the permanent diabetes that 
followed the cessation of hormone administration. Similarly, 
Coggeshall and Root (185) noted that the diabetes occurring 
in 17 percent of patients with acromegaly was not marked 
by insulin resistance. However, they reported that 36 per-
cent of all patients, more females than males, had some 
degree of glucosuria and that diabetes generally became 
overt 9.2 years after the diagnosis. Froesch ~t al (342) 
have also been able to obtain hyperglycemia without anabolic 
effects with bovine growth hormone in hypopituitary dwarfs. 
l 
37 
It appears that the anti-insulin effect of growth hormone in 
man is independent of the anabolic effect so that separate 
regions of the protein may be responsible for each function. 
Reid (872) demonstrated that the diabetogenic activity of 
bovine growth hormone paralleled its growth activity during 
a series of structural modifications when the assays where 
conducted in rats. These results suggest that the anti-
insulin effect of human growth hormone is in an invariant 
sequence in the hormone while the anabolic effect is in 
a more variable sequence. 
De Bodo and Sinkoff (218) also found that growth hor-
mone increased gluconeogenesis and insulin release from 
the pancreas. When an increased dose of 3.0 mg/kg/day of 
growth hormone is administered to normal dogs, they become 
diabetic in 5-7 days. De Bodo and Altzuler (221) observed 
that growth hormone was also diabetogenic in hypophysec-
tomized dogs maintained with deoxycorticosterone. Low 
doses of growth hormone alleviated the insulin hypersensi-
tivity of these animals. Glucocorticoids also partially 
reduced this hypersensitivity. The combination of gluco~ 
corticoids and growth hormone abolished the hypersensi-
tivity. These workers also observed that the adrenalec-
tomized dog was not as sensitive to insulin as the hypo-
physectomized dog, but that both glucocorticoids and 
L 
growth hormone were necessary to restore normal insulin 
sensitivity. 
Luft et al (679) confirmed the ketogenic effect of 
growth hormone in hypophysectomized diabetic patients. And 
both Hunter and Greenwood (498) as well as Roth et al (912) 
reported that hypoglycemia is a potent stimulus to the pro-
duction of somatotrophic releasing factor.and growth hor-
mone secretion. Patients with pituitary stalk section fail 
to respond to hypoglycemia with increased growth hormone 
secretion. The production of the releasing factor is in-
versely related to the level of blood glucose. Also, the 
inhibitory effect of glucose on the production of somato-
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trophic releasing factor can be blocked by 2-deoxyglucose, 
as can glucose-stimulated insulin release from the pancreas. 
Alloxan-Diabetes 
Alloxan (pyrimidinetetrone) produces experimental dia-
betes by destroying the insulin-secreting cells of the pan-
creas. This effect was discovered by Dunn et al (263) and 
several reviews of the use of this drug have appeared (31, 
679). Repeated doses of 100 mg/kg are also capable of 
destroying human islet tissue as demonstrated by Cann· ·et al 
(192) in their description of the treatment of islet tumors. 
Blood glucose undergoes a triphasic change after alloxan 
is administered (479). First, there is a hyperglycemia 
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due to glycogenolysis in the liver. Secondly, a hypoglycemic 
phase occurs which is not due to the liberation of insulin 
from the pancrease. While uncertain, the cause of this hypo-
. glycemia may be due to a block in gluconeogenesis in the 
liver. It is this hypoglycemic phase which damages the B 
cells. Thirdly, permanent hyperglycemia ensues due to the 
destruction of the insulin~producing B cells. 
The effects of alloxan in hypophysectomized and adren-
alectomized animals has been studied by Kirshbaum et al 
(593). They stressed the necessity of feeding these animals 
after the administration of alloxan to avoid deaths from hy-
poglycemia and of allowing at least 48 hours for the dia-
betic state to fully develop. 
Interactio·n of Growth Hormone and Cortisol 
Moody et al (756) showed that insulin increased the 
formation of glycogen in the absence of glucose, indicating 
that some of the glycogen was derived from glycolytic in-
termediates. Bornstein and Trewhella (95) noted that al-
loxan-diabetic rats had low levels of muscle glycogen 
which could be restored to normal by hypophysectomy or 
adrenalectomy. Thus, adrenal hormones increase glycogen 
formation in the non-diabetic animal but decrease it in 
the diabetic animal. Furthermore, they observed that in-
sulin in vitro could not reverse the 50 percent drop in 
. " 
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glycogen levels in the muscles of diabetic rats, but that 
adrenalectomy could. On the other hand, Park and Daughaday 
(808) observed that the glycogen content of the hypophysec-
tomized rat was unaffected by either growth hormone or adren-
al cortical extract. However, hypophysectomized and adren-
alectomized rats had higher glycogen levels that normal. 
These results suggest that growth hormone is necessary 
for the glucocorticoid effect on glycogen synthesis. 
Russell (919) reported that pituitary extracts alone_ 
were sufficient to maintain muscle glycogen in fasting 
hypophysectomized animals but that adrenal cortical hor-
mones were also required to maintain muscle glycogen in 
fed animals. These results may indicate that growth hor-
mone increased basal glucose transport in the fasted animals 
but that growth hormone and glucocorticoids are both re-
quired to reduce glycolysis, increase glucose-6-phosphate 
concentration, arid thereby increase glycogen formation. 
Long and Lukens (672) reported similar findings in 
hypophysectomized-adrenalectomized-alloxan-diabetic cats. 
They demonstrated that the beneficial effects of hypo-
physectomy on survival were partly due to the loss of 
ACTH. The removal of the source of adrenal epinephrine 
by adrenodemedullation did not protect the animals from 
ketosis. Although hypophysectomy and adrenalectomy did 
L 
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immediately improve carbohydrate oxidation, the animals 
who survived longest had the best glucose tolerance. Des-
pite the absence of growth hormone, ACTH and glucocorticoids, 
the doubly-operated animals eventually utilized all their 
depot fat so that inanition rather than acidosis was the 
ultimate cause of death. These experiments emphasize the 
lipogenic effect of insulin. 
Villee and Hastings (1103) also found that hypophysec-
tomized rats had higher rates of glycogenesis compared to 
adrenalectomized rats. Growth hormone treatment, however, 
decreased glycogenolysis more than glycogenesis. 
Luft (679) investigated the effect of growth hormone 
on the levels of pyruvate, lactate, and citrate during the 
intravenous glucose tolerance test in diabetes. He found 
that growth hormone elevated all three metabolites when it 
accentuated the diabetic-type glucose tolerance curve. 
Although growth hormone had no effect on fasting blood 
glucose, it did raise the concentration of free fatty acids 
and fasting insulin 3-fold. However, the drop in free fatty 
acids in response to glucose was not affected by growth hor-
mone. These results suggest that the anti-insulin effect of 
growth hormone is not mediated by free fatty acids. 
Renold et al (877) have shown that hormones affect the 
metabolism of glucose by the liver. Liver slices from 
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r.2 ~ hypophysectomized rats have a rate of glucose uptake which 
is 80 percent of normal. On the other hand, liver slices 
from alloxan-diabetic rats assimillated glucose at 50 per-
cent of the normal rate. Hypophysectomy of the alloxan-dia-
betic rats restored their hepatic glucose uptake to the 
level of that obtained with livers from hypophysectomized 
animals. From these experiments it can be concluded that 
insulin increases and pituitary factors decrease glucose 
.uptake by the liver. Krahl (614) demonstrated that insulin 
'in vitro could overcome the pituitary inhibition of hepatic 
glucose uptake. When 0.1 unit of insulin per milliter was 
added, the maximal rates of glucose uptake by liver slices 
from normal and hypophysectomized animals were the same .. 
Hypophysectomy increases hepatic glucose uptake in spite 
of the fact that it also increases glucose-6-phosphase 
activity. Furthermore, Steiner and Williams (1028) found 
that the levels of glucose-6-phosphate in the livers of 
alloxan-diabetic rats was one-third normal. These reports 
merit further investigation. However, these hepatic ef-
fects are in agreement with the extrahepatic results of 
Russell (916) who found that the rate of glucose utiliza-
tion in the hypophysectomized-eviscerated rat was 2 to 3-
fold greater than that in eviscerated controls. 
In addition to the effects of the adrenal and pituitary 
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hormones studied separately, many investigations have been 
carried out in which the combined effects of both types of 
hormones have been determined under identical conditions. 
Russell (915) found that anterior pituitary extract in-. 
creased the amount of muscle glycogen in adrenalectomized 
rats without influencing the amount of liver glycogen. 
Also, the extract did not depress glucose oxidation in the 
adrenalectomized rat although it did cause this effect in 
intact rats. In contrast, adrenal extract did not increase 
muscle glycogen but it did slightly decrease glucose oxi-
dation in adrenalectomized rats. These results show that 
the adrenal gland is necessary for the anti-insulin effect 
of growth hormone. The increased production of lactate 
and pyruvate following the administration of pituitary 
extracts to adrenalectomized rats is not sufficient to 
influence their glucose oxidation. In an attempt to assess 
the role of the liver in these effects, Russell (917) de-
termined the effects of the extracts in hypophysectomized-
eviscerated rats. She eviscerated fed rats which had been 
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hypophysectomized for two weeks or adrenalectomized for 4-14 
days prior to the experiment. When administered, anterior 
pituitary extract was given 24 hours before evisceration 
and cortical extract 1/2 hour before this procedure. She 
found that anterior pituitary extract alone as well as 
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adrenal extract alone were capable of reducing the amount of 
glucose which had to be infused to maintain the blood glucose 
of the hypophysectomized-eviscerated rat. No synergism was 
noted when both extracts were administered. The anterior 
pituitary extract, however, was more potent than the adrenal 
extract in maintaining muscle glycogen. The fact that the 
anterior pituitary extract did not exert its effect until 
one hour after its administration does not allow one to 
rule out the possibility that the effect was mediated by 
the adrenals and was due to ACTH in the crude pituitary 
extract. The absence of synergism may mean that the liver 
is required for the synergistic effect of pituitary and 
adrenal hormones (growth hormone and cortisol). 
Deoxycorticosterone did not affect the glucose re-
quirement of the hypophysectomized-eviscerated rat but 
I 
it did reduce the glucose requ,irement of the adrenalec-
tomized-eviscerated rat. It appears from these studies 
that deoxycorticosterone exerts an inhibitory influence 
on glucose utilization only when pituitary factors are 
present. Ventura and Selye (1092) also found that grow~h 
hormone was required for the inhibitory effect of deoxy-
corticosterone on the anti-inflammatory action of gluco-
corticoids. These results suggest that growth hormone 
may affect the metabolism of these steroids. In Russell's 
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e~periments this effect could have required the presence of 
the liver since both hormones were administered prior to 
evisceration. However, she attributed the lower glucose 
requirement of the deoxycorticosterone-treated animals to 
. their "better condition." McGarack et al (689) also found 
that the abnormal glucose tolerance curve seen in Addison's 
disease could be restored to normal by deoxycorticosterone 
acetate. 
Russell (915, 919) further demonstrated that gluco-
corticoids were necessary for the glycogenic effect of 
growth hormone. She postulated that glucocorticoids in-
hibited the conversion of carbohydrate to fat thereby 
making it more available for glycogenesis. Heart muscle 
was found to be especially sensitive to the glycostatic 
effects of growth hormone~ Heart glycogen is elevated 
in diabetes while the glycogen content of other tissues 
remains essentially normal. This elevation in cardiac 
glycogen is probably caused by the stress-induced increase 
in glucocorticoid levels. Furthermore, the well-known 
preference of the heart for the respiration of fatty 
acids, which is probably related to its rapid rate of 
acylcoenzyme A formation, may also be the basis for its 
increased glucocorticoid sensitivity. 
Park (810) investigated the influence of the pituitary 
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on glucose metabolism in the isolated rat diaphragm from al-
ioxan-diabetic rats. This muscle is thin enough so that 
diffusion is not rate-limiting for glucose metabolism. Park 
studied the effects of crude pituitary extracts and purified 
growth hormone in vivo and in vitro. The administration of 
2 µg of crystalline growth hormone to alloxan-diabetic-
hypophysectomized rats caused an initial drop in their blood 
glucose which was followed by a prolonged period of hypergly-
cemia. In vitro, purified growth hormone caused an increase 
in the glucose uptake of the isolated rat diaphragm muscle. 
The secondary in vivo elevation of blood glucose was also 
produced by injections of crude pituitary extracts. In 
fact, the crude extracts had a more rapid and direct effect 
compared to purified growth hormone. In addition, adrenal 
•· cortical extract was found to potentiate the effect of the 
.. 
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pituitary hormone. Since these in vitro experiments were 
carried out in protein-free media, the results cannot be 
attributed to changes in insulin binding by serum proteins. 
Spiro (1012) found that growth hormone is necessary 
for normal glucose transport in the liver. Hypophysectomy 
of alloxan-diabetic rats did not effect the rate of hepatic 
glucose phose phosphorylation but it did restore to normal 
the reduced rate of hepatic glucose uptake in the alloxan-
diabetic rat. Goodman (303) reported that the intravenous 
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administration of growth hormone 30-45 minutes before sacri-
fice stimulated the uptake of xylose and a-aminoisobutyrate, 
a non-utilizable amino acid, by the diaphragm. He showed 
[, that this effect could be produced in vitro and that it was 
fi 
t not secondary to lipolysis. If the hormone was injected 3 
~" r: F hours before sacrifice, the uptake of the sugar and the 
~-
[ amino acid was not increased. In addition, the diaphragm 
~~': 
~· was then refractory to the addition of growth hormone in 
vitro. The development of this refractory response was 
blocked in vitro by 10 µg/ml of actinomycin D. This indi-
cates that DNA synthesis was required in order to block 
the stimulatory effect of growth hormone and raised the 
possibility that some of the effects of actinomycin D 
''· in vivo may be due to blockade of this growth hormone ef-
feet. It is important to note that these findings do not 
explain the secondary hyperglycemia obtained when hypophy-
sectomized animals are treated with growth hormone. 
Ottaway (802) showed that the stimulatory effect of 
growth hormone in vitro is inversely related to the fasting 
blood glucose of the hypophysectomized-diabetic rats from 
which the diaphragms are obtained. This is expected if 
the effect of growth hormone is primarily on glucose trans-
port. Glucose transport becomes increasingly rate-limiting 
for glucose uptake as the blood glucose concentration is 
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iowered. 
Milman and Russell (749) reported that alloxan-diabetic 
rats were rendered hyperglycemic by the administration of 
JO mg/kg of purified growth hormone while normal rats were 
not. However, they were if the treatment had been repeated 
2 to 4 hours previously. They also exhibited decreased 
glucose tolerance, depressed respiratory quotients and gly-
cogenesis. These results suggest that alloxan-diabetic rats 
are more sensitive to the effects of growth hormone. 
Effects of Steroids and Related Compounds on the Pancreas 
Lewis and co-workers (659) investigated the influence 
of 178-hydroxy-4-androsten-3-one 17-proprionate and 178-
hydroxy-17a-methyl-4-androsten-3-one on the incidence of 
diabetes in rats after subtotal pancreatectomy and also 
found that the androgens increased the incidence of dia-
betes. Hast (424) has recently reviewed these effects. 
While testosterone caused atrophy, estrogens generally 
exerted a protective or trophic effect. Deoxycorticos-
terone and progesterone had no effect. The estrogen ef-
fect could also be produced with 3,4-bis(p-hydroxyphenyl)-
trans-3-hexene, a synthetic estrogen. This effect may ac-
count for the lower incidence of diabetes in pre-menopausal 
women and the more serious nature of the disease when it 
occurs in post menopausal women. Nonetheless, large .doses 
of estrogens are diabetogenic in spite of their beneficial 
effect on the pancreas. 
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James et al (523) found that 17B-hydroxy-17a-methyl-l, 
4-androstadiene-3-one lowered fasting glucose and impaired 
glucose tolerance by inhibiting ACTH secretion. 
Arginine, leucine, and tris (hydroxymethyl)-amino-
methane stimulate insulin release, but arginine also stim-
. ulates growth hormone release. This action of arginine can 
be used to test the pituitary reserve of growth hormone. 
The mechanism of action of the two amino acids on insulin 
release is different. The effect of leucine is counter-
acted by glucocorticoids, but that of arginine is not. 
Also, since leucine is a ketogenic amino acid, gluconeo-
genesis is not involved. 
L 
Houssay (481) compared the incidence of diabetes in 
95 percent depancreatized male and female rats. He found 
that the incidence was three times greater in male rats. 
The administration of androgens to female rats also in-
creased their incidence of diabetes. On the other hand, 
the administration of 50 µg/day of estradiol or 21-hydroxy-
4-pregnane-3, ll, 20-trione in combination with 150 µg/day 
cortisone initially increased the incidence of diabetes, 
but this initial response was followed by hypertrophy of 
the pancreas with amelioration of the diabetes. Furthermore, 
the glucocorticoids alone at 50 µg/day exerted just a pro-
.· tective effect. Therefore, physiological levels of gluco-
corticoids are not diabetogenic but elevated levels are 
diabetogenic •. 
Renold et al (879) demonstrated that the anti-insulin 
action of growth hormone and cortisol is not due to their 
effect on insulin release. Growth hormone and cortisol 
treatment corrected the weak and slow response of the B 
cells to glucose which is seen in the hypophyse·ctomized 
dog. However, cortisol, as previously noted, also reduced 
the tendency of the insulin response to be prolonged when 
growth hormone alone was administered. Thus, cortisol 
actually prevents B cell exhaustion due to growth hormone. 
However, the ability of cortisol to oppose the stimulatory 
effect of growth hormone on insulin secretion is note-
worthy because serotonin is believed to mediate the effect 
of growth hormone (986, 987). 
Beck (58), Vermeulen et al (1098) and Starup et al 
(1022) have further indicated that 6~chloro-17a-hydroxyl-4, 
6-pregnadiene-3,20-dione acetate (chlormadinone acetate) 
closely resembles glucocorticoids in its effects. This 
compound increased the insulin response to glucose while 
it decreased the glucose response to insulin. It should 
therefore serve as a model compound for future studies of 
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the anti-insulin effects of steroids. The stimulation of 
insulin release by progestins may explain the report of 
Gershberg et al (361) that carbohydrate tolerance was im-
proved in women who had impaired glucose tolerance before 
treatment. It appears that the stimulation of insulin 
response by the pr6gestin in these cases overrides the 
increase in insulin resistance also produced. However, 
the medication is still diabetogenic because it decreases 
glucose response to insulin and leads to pancreatic 
exhaustion. 
Houssay (480) studied the effect of thyroid hormone 
on alloxan diabetes in the rat. He found that pretreat-
ment with thyroid hormone, like estrogen treatment, hyper-
t~ophied the pancreas and made the r~t more resistant to 
alloxan. On the other hand, thyroidectomy proved bene-
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~ · ficial in alloxan-diabetic rats and thyroxine intensified 
> 
their diabetes. This latter effect may be related to in-
hibition of lipoprotein lipase and glutamic dehydrogenase 
and stimulation of adipose tissue lipase produced by the 
hormone. These effects will be discussed in later chapters. 
An endocrine question closely related to the action of 
estrogens concerns the physiological function of fetal 
estriol in pregnancy. On one hand, it is widely held that 
the formation of 36-hydroxy-5-androsten-17-one by the fetal 
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adrenal and its subsequent 16a-hydroxylation by the fetal 
liver are good indications of fetal viability. On the other 
hand, the exact role of fetal estriol in the fetal or ma-
ternal economy has not been determined. Lemon (651) has 
postulated that high estriol levels during pregnancy may 
serve to protect maternal tissues from the tumorigenic po-
tential of estradiol which is also elevated. However, 
other workers (716) have demonstrated increased estriol 
excretion in breast tumor patients thereby casting doubt 
on this hypothesis. The function of fetal estriol may 
be to decrease fetal insulin response to glucose. Diabe-
tic women excrete a lower proportion of total urinary es-
trogens as estriol during pregnancy; they also tend to 
deliver larger infants. The unopposed action of insulin 
appears to be responsible for this effect. Furthermore, 
the inf ants of diabetic women tend to have hyperplastic · 
islets. The decreased formation of estriol by the fetus 
may represent one of the early manifestations ·of the dia-
betic gene. 
Lewis and co-workers (659) investigated the influence 
of 17S-hydroxy-4-androsten-3-one 17-propionate and 17S-
hydroxy-17a-methyl-4-androsten-3-one on the incidence of 
diabetes in rats after subtotal pancreatectomy and also 
found that the androgens increased the incidence of 
diabetes. Hast (213) has recently reviewed these effects. 
While testosterone caused atrophy, estrogens generally ex-
erted a protective or trophic effect. Deoxycorticosterone 
and progesterone had no effect. The estrogen effect could 
also be produced with 3,4-bis(p-hydroxyphenyl)-trans-3-
. 
hexene, non-steroidal estrogen. This effect may account 
for the lower incidence of diabetes in pre-menopausal women 
and the more serious nature of the disease when it occurs 
in post-menopausal women. Notwithstanding, pharmacological 
doses of estrogens are diabetogenic so that this effect. is 
not on the pancreas. 
Lewis and McCullough (322) found that 17B-hydroxy-17a-
methyl-4-androsten-3~one caused hepatic changes which de-
creased glucose tolerance in the rabbit by blocking glyco-
gen formation. Also, the conjugation of bilirubin was 
inhibited producing reversible symptoms of hemolytic 
jaundice reversible when the steroid was withdrawn. These 
effects were not obtained in thyroidectomized animals sug-
gesting that these steroids may affect tpe metabolism of 
thyroxine. James et al (251) found that 17B-hydroxy-17a-
methyl-1,4-androstadien-3-one lowered fasting glucose and 
impaired glucose tolerance while inhibiting ACTH secretion. 
Many efforts have been made to define the effects of 
estrogens on glucose metabolism. McKeins and Bell (691) 
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· found that estrogen treatment stimulated glucose uptake by 
the isolated rat diaphragm. Ecktern and Villes (265) found 
that castration lowered the activities of glucose-6-phos-
phate dehydrogenase, aconitase and isocitrate dehydrogenase 
in rat uterus. The ablation had no effect on the tricar-
boxylic acid cycle, however. 
McKeins and Bell (691) also found that the administra-
tion of 25 µg/day of 3,4-bis(p-hydroxyphenyl)-trans-3-hexene 
increased the activity of the pentose shunt in diaphragm 
muscle, adipose tissue and liver. At 100 µg/day no effect 
on insulin response was observed, but glucose metabolism 
via the pentose shunt was inhibited. The synthetic estro-
gen had no effect on the glucose metabolism of diaphragm 
in vitro at a concentration of 5 µg/ml. 
Villee et al (1104) studied the effects of estradiol-
17S on the transhydrogenation of pyridine nucleotides in 
estrogen dependent tissues. They concluded that estradiol 
may increase the rate of transhydrogenation and thereby 
provide NADP+ necessary for the utilization of glucose-6-
phosphate via the pentose shunt and for the oxidation of 
isocitrate by mitochondrial threo-Ds-Isocitrate: NADP 
oxidoreductase (decarboxylating) (EC 1.1.1.42). The 
,, transhydrogenase, NADPH: NAD oxidoreductase (EC 1. 6. 1. 1) 
is distinct from 17S-hydroxysteroid dehydrogenase, 
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l?S-hydroxysteroid: NAD 178-oxidoreductase (EC 1.1.1.63) and 
from 178-hydroxysteroid: NADP 178-oxidoreductase (EC 1.1.1.64). 
It is possible that estradiol may catalyze transhydrogenation 
·by acting as a coenzyme between these two enzymes. In con-
trast, Warren and Christ (1166) have demonstrated that a 
true estradiol-responsive transhydrogenase is present in 
human placenta. This enzyme combines with estradiol or es-
trone before pyridine nucleotides are bound. Also, the en-
zyme has one binding site which is specific for NAD+ and 
another site which can be occupied by either NADH or NADPH. 
Estradiol does not leave its binding site when it exerts 
its stimulatory effect on transhydrogenation. Apparently, 
the hormone functions more efficiently in this fashion 
rather than as a coenzyme. However, it is not clear 
whether estradiol undergoes oxidoreduction when it is 
bound to the enzyme and the effects of 17a-alkylated es-
trogens on the activity of this enzyme have not been 
reported. 
The adverse effect of estrogens on glucose tolerance 
has rather broad structural specificity. Estradiol-176-
.monobenzoate, bis-3,4-(p-hydroxyphenyl)-trans-3-hexene 
and 17a-ethinyl-17S-hydroxy-5(10)-estren-3-one also pro-
duced the effect. 
Gershberg et al (361) reported that 46 percent of 
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their patients treated with norethynodrel and mestranol had 
elevated two-hour glucose levels during the standard glucose 
tolerance test. Similar results were found by Puchulu ~t al 
i853) who ~ound that the incidence of abnormal glucose tol-
erance curves was increased from 11.1 percent to 66.7 per-
cent if the phenolic C-3 hydroxyl group was methylated. 
Also, the incidence of abnormal tolerance was greater in 
patients who had a family history of diabetes. However, 
Gershberg et al (362) subsequently reported that the ad-
ministration of 0.75 mg/day of mestanol improved the glu-
cose tolerance of diabetic women. Triglyceride levels in-
creased during mestranol treatment in both normal and dia-
betic women. These results suggest that the C-3 phenolic 
hydroxyl group of estrogens is not required for anti-in-
sulin activity. 
Spellacy and Carlson (1007, 1008) found both elevated 
·glucose tolerance curves and elevated plasma insulin levels 
during the glucose tolerance test performed on patients 
receiving 9.85 mg 17a-ethinyl-17B-hydroxy-5(10)estren-3-one 
and 0.15 mg 17a-ethinyl-3-methoxy-l,3,5(10)-estrien-17B-ol 
daily. In contrast, when intravenous glucose tolerance 
tests were performed under similar conditions, Spellacy et 
· !.!. found normal glucose tolerance but two-fold increases 
in plasma insulin levels. 
In similar experiments Yen and Vela (1187) reported no 
changes in either oral or intravenous glucose tolerance but 
noted 3-fold increases in serum growth hormone levels. In-
creased insulin resistance associated with estrogen-stimu-
lated growth hormone release may be the mechanism behind 
this effect. Growth hormone secretion normally occurs in 
response to hypoglycemia and presumably leads to increased 
lipolysis of depot lipid. Apparently, insulin released in 
response to growth hormone does not exacerbate the hy-
poglycemia under these circumstances. This may be due to 
the simultaneous action of glucocorticoids. The failure 
of diabetic women to respond to estrogens with decreased 
glucose tolerance could mean that the anti-insulin effects 
of growth hormone are already manifest in these women. 
Estrogens increase the hepatic synthesis of both 
thyroid binding globulin and corticosteroid-binding glob-
ulin. Indeed, Metcalf and Beaven (736) and Marks et al 
(715) observed 3-fold increases in transcortin during mes-
tranol treatment. Furthermore, Goldman and Ovadia (384) 
confirmed that estrogens increase ACTH secretion in both 
rats and man. However, when estrogens increase ACTH se-
cretion, they also increase trancortin synthesis so that 
most of the increased glucocorticoid output is bound in 
inactive form. Thus, estrogens permit ACTH levels to 
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remain elevated and to exert its effects on adenyl cyclase 
in target tissues. Cross-conjugated steroids such as 17S-
hydroxy-l 7a-methyl-l,4-androstadien-3-one also have this 
effect (1160). 
Plager and Matsui (837) investigated the effects of 
bound and unbound cortisol on the metabolism of glucose 
in slices of mouse ear in vitro. They found that 0.06 µg/ 
ml of cortisol decreased the evolution of 14co2 from glu-
14 14 14 
cose-1- C more than from glucose-6- C or fructose-U- c. 
These results suggest that cortisol decreases glucose oxi-
dation via the pentose shunt. Matsui and Plager also found 
that high doses of estrogens in vivo also depressed the 
oxidation of glucose by mouse ear strips. This result 
confirms the findings of Ingle (515) who demonstrated 
that the administration of 0.5 mg of estradiol per day 
to partially depancreatized rats produced glucosuria 
amounting to 4.0 grams per day. The mechanism of this ef-
feet may be similar to that which decreases glucose tol-
erance in women during estrogen therapy. Overell et al 
(804) were also able to obtain significant inhibitory 
effects on.glucose uptake by mouse skin ~n vitro using 
. 0.01 µg/ml of cortisol or prednisolone. The absence of 
the tricarboxylic acid cycle in mouse skin indicates 
that it is not involved in the steroid effect. 
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Slaunwhite and Sanberg (992) described transcortin, the 
glucocorticoid-binding protein of serum, and methods for its 
isolation. They showed that the level of transcortin was 
elevated during pregnancy •. This elevation had two signifi-
cant effects. First, it decreased the rate of metabolism 
of cortisol. Secondly, it removed non-specifically-bound 
cortisol from albumin binding sites enabling the albumin 
to bind more testosterone. Warren and Salhanick (1115) 
also described some of the properties of transcortin. 
They found that the strength of cortisol binding decreased 
with increasing temperature and advocated the comparison 
of diluted pathologic serum with control serum at 37°C to 
speed the attainment of equilibrium using equilibrium di-
alysis techniques. 
Wira ~t al (1171) have pointed out that the criteria 
that must be met by a hormone receptor include hormone 
specificity, tissue specificity, high affinity and satura-
tion. High-affinity steroid binding sites are generally 
specific sites. In the case of transcortin both the strength 
of binding as well as the total number of binding sites de-
crease with increasing temperature. However, even at con-
stant temperature the equilibrium binding may be affected 
by cooperative ·interactions between binding protein sub-
units as protein concentration varies. Regardless of the 
method chosen to separate free and bound steroids, the pro-
portion graph of Balieu and Raynaud (52} in which the log 
of the fraction of steroid bound is plotted versus the 
total steroid concentration appears to be a simple and 
sensitive indicator of the heterogeneity of binding sites. 
Scholtz and Huther (947} have measured the levels of 
cortisol and corticosterone in normal and diabetic women 
during pregnancy, labor and delivery. They found that 
diabetic women had 42 percent higher levels of cortisol 
and 63 percent higher levels of corticosterone during 
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delivery. The higher levels observed suggest that decreased 
glucocorticoid metabolism in diabetic women is especially 
, evident in times of stress. 
CHAPTER III 
INSULIN INHIBITORS 
!!.uman Insulin Antagonists 
Insulin resistance in man is associated with abnor-
mally high insulin requirements. Baird and Bornstein (38) 
noted that insulin-resistant diabetics were of two types. 
One type had no biologically active insulin in their sera 
and none could be isolated aft~r a lipid solvent extrac-
tion procedure which permitted 85 percent recovery of 
added labeled insulin. On the other hand, the second 
type was characterized by serum insulin which, while not 
active in native serum, could be separated from an in-
hibitory factor by solvent extraction of the inhibitor. 
After separation, the insulin was active. Since the in-
hibitory factor was present in only one type of insulin-
treated diabetic, it does not appear to be an insulin 
antibody. Rather, the insulin inhibitor in these patients 
appears to be a lipid. Furthermore, these observations do 
not eliminate an intracellular site of action for the lipid 
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inhibitor. The factors which cause the rise and decline of 
insulin resistance are important in the management of dia-
betes even though they are not well defined. 
Plotz et al (841) noted that insulin-resistant dia-
betes occurred in 25 percent of all patients with Cushing's 
syndrome. Whether this is a direct glucocorticoid effect 
or is produced by the effect of the pituitary. tumor on glu-
. cocorticoid metabolism is unclear. 
_synalbumin In Vivo and In Vitro 
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Stadie et al (1015) studied the anti-insulin effect of 
growth hormone on rat diaphragm. They found that both pitu-
itary and adrenal factors were necessary for the refractory 
response to insulin. Vallance-Owen et al (1085) studied 
the nature of an insulin.antagonist which they found asso-
ciated with human plasma albumin. They found that it was 
not due to albumin per se since it could be absorbed on 
a cellulose column leaving a non-inhibitory albumin frac-
tion. The factor absorbed to the column was not identified. 
However, in assays of glucose uptake by rat diaphragm incu-
bated in the ~resence of diluted diabetic serum, the depen-
dency of the inhibitor on the pituitary was established. 
Vallance-Owen studied the levels of the synalbumin 
insulin antagonist in the serum of normal, obese and adult 
diabetics. He found that the levels of the antagonist 
were not different in the three cases when the whole serum 
was tested by the rat diaphragm assay. By itself this 
finding casts doubt on the in vivo significance of the an-
tagonist. However, when the albumin fraction of the serum 
was isolated and tested separately, the amount of inhibitor 
bound to albumin was higher in obese and adult diabetics 
than in control groups. Of children who were synalbumin 
positive, 65 percent had at least one synalbumin-positive 
parent, suggesting the dominance of the trait. 
The method used to assay the synalbumin insulin an-
tagonist deserves comment. If the albumin fractions from 
normal and diabetic patients are prepared,. both of these 
fractions inhibit the effects of 1 milliunit of insulin 
on the rat diaphragm. However, if the fractions are di-
luted 4-fold with buffer before the assay, the diabetic 
albumin retains its inhibitor effect while the normal 
albumin loses its inhibitory effect. The final albumin 
concentration in both cases is 1.25 percent. These char-
acteristics appear to indicate that some reversibly bound 
factor is becoming unbound and diluted when the albumin 
is diluted. The denaturation of the albumin by heat ren-
ders the antagonist dialyzable even though the dialyzable 
fraction is partially inactivated by heat. Also, the 
~'- active factor bound to albumin can be removed completely 
l 
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by extraction with boiling ethanol. In contrast, chloroform 
and a mixture of isooctane and acetic acid, known to be ef-
fective in the extraction of fatty acids from albumin, did 
not remove the inhibitor from the albumin. Vallance-Owen 
also noted that the synalbumin inhibitor was inactive on 
adipose tissue. This finding led him to propose that dia-
betics become obese because they are diabetic. 
Alp et al (9} purified the synalbumin antagonist 150-
fold and separated it from albumin. As previously noted, 
they varified that the antagonist could be dialyzed free 
from 0.001 percen~ albumin but not from 0.2-3.0 percent 
albumin solutions. This finding supports the work of 
Vallance-Owen. However, Davidson and Goodner (215) were 
unable to show any physiological effects of the synalbu-
min antagonist in vivo. It did not affect pl~sma insulin, 
nor blood glucose, nor the disposal of a glucose load. 
It even had no effect in partially depancreatized rats~ 
Therefore, the physiological significance of the antag-
onist remains to be determined. 
Vargas et al (1089) reported that an inhibitor of 
glucose uptake in muscle was present in the a 2 and B 
globulin fractions of normal human plasma. Insulin 
activity was associated with the a 1 globulin fraction. 
· ·Taylor et al (1054) showed that growth hormone was required. 
l 
for the production of this inhibitor which reduced glucose 
f uptake in the absence of insulin. Growth hormone alone was 
r· ii 
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t., capable of producing the inhibitor in hypophysectomized rats. 
1 
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It was not removed by passage through a cellulose column. 
It was thought to be identical to the inhibitor of Baird 
and Bornstein. 
The possible role of an insulin inhibitor in the eti-
ology of diabetes has attracted the attention of many in-
vestigators. Park and Krahl (802) initiated studies of 
the effects of hormones on the glucose utilization of the 
isolated rat diaphragm. Using crude pituitary extract, 
they found that the injection of 3 mg/100 gm into intact 
rats three hours before sacrifice led to a depression of 
glucose uptake by the isolated diaphragm. This effect 
did not occur .in hypophysectomized rats unless adrenal 
extract was also administered. The adrenal extract alone 
also intensified the anti-insulin effect in isolated dia-
phra-gms. These experimental results were obtained three 
hours post-injection. Krahl and Cori (612) further in-
vestigated the effect of adrenalectomy on glucose uptake 
of the diaphragm. They found that this operation in-
creased the glucose uptake from 1.38 mg/gm/hr to 2.40 mg/ 
gm/hr. In their work with alloxan-di.abetic rats, these 
authors noted that the 6-hour fasting glucose levels of 
L 
the diabetic rats dropped from 300-800 mg/100 ml before ad-
renalectomy to 200-400 mg/100 ml after adrenalectomy. In 
later work, Krahl (613) studied the effects of crystalline 
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l growth hormone on this same system. He observed the fol-
1\o 
f· 1.. lowing effects: 1) an increase in muscle glycogen, 2) an 
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increase in glucose uptake, 3) a decrease in glycogenolysis, 
4) a decrease in respiratory quotient, 5) a secondary de-
crease in the response to insulin which followed the initial 
stimulation. In addition, he measured the concentration 
of adenosine triphosphate in the diaphragms and found that 
it was the same in ·normal and diabetic diaphragms. Park 
et al (411) confirmed.the biphasic nature of the growth 
hormone response on diaphragm muscle. The initial stimu-
lation of glucose uptake could be obtained by the addition 
of growth hormone in vitro. The secondary inhibitory ef-
feet could be produced by the injection of 2 µg of growth 
hormone and the effect was potentiated by adrenal cortical 
extract. 
Inhibition b:z Beta -Lipoproteins 
In 1953 Bornstein (98) reported that lipoproteins from 
.. 
diabetic rat serum could inhibit the glucose uptake of nor-
mal rat diaphragm. He isolated the lipoproteins both by 
ultracentrifugal flotation and by Meth~d 10 of Cohn et al 
(188). He dialyzed the isolated lipoproteins against 
Krebs-Henseleit bicarbonate buffer for 2-2.5 hours at 21°C 
and then used the lipoprotein in the glucose uptake test. 
He noted that dialysis was associated with instability of 
the lipoprotein inhibitor, as was storage at 0°C. The 
fraction appeared to be most stable when stored undiluted 
and undialyzed at 4-7°C. These observations indicate 
that some type of lipoprotein complex is involved. When 
he tested the lipoproteins thus obtained for their inhib-
itory effects on glucose uptake by rat diaphragm, he added 
the lipoprotein either to 4 percent albumin in buffer or 
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to the lipoprotein-poor serum from which the lipoproteins 
had been removed. This latter serum had also been dialyzed. 
Bornstein reported that initially inhibitory diabetic serum 
became non-inhibitory after the removal of its lipoproteins. 
Addition of lipoprotein·from normal diabetic serum to either 
normal or lipoprotein-free diabetic serum caused inJ;iibition. 
• The lipoproteins obtained from the serum of hypophysecto-
mized-diabetic rats did not display inhibitory activity. 
Bornstein noted that the e1-lipoprotein fraction obtained 
from normal human plasma was not inhibitory, while the 
same fraction III obtained from a patient rendered hypo-
glycemic by insulin was inhibitory. The stimulation of 
growth hormone release in hypoglycemia may explain this 
observation. However, this does not mean that the 
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i. lipoprotein bound factor was growth hormone. Normal rat dia-
• 
·phragms were used for these tests, and, as previously shown, 
these are not sensitive to the direct effects of growth hor-
mone. In hypophysectomized-diabetic rats, Bornstein found 
that glucocorticoids which are inactive alone enhance the 
activity of growth hormone in producing the lipoprotein-bound 
inhibitor. The injection of growth hormone and cortisone in-
to diabetic-hypophysectomized serum donors restored the in-
hibitory capacity of the serum. Injection of either hormone 
alone was ineffective, the serum behaving as normal. These 
hormones, 0.2 mg of growth hormones, and 0.1 mg of corti-
sone were injected interperitoneally for 2 days prior to 
drawing blood. After the production of the inhibitor is 
stimulated by the combined action of these two hormones, 
it continues to be produced for at least one week. The in 
vitro addition of growth hormones and cortisone, 0.1 mg/ml 
and 0.01 mg/ml, respectively, did not significantly affect 
glucose uptake during a one-hour incubation. The magni-
tudes of the in vivo treatments on glucose uptake are 
large. The rate of glucose uptake by diabetic diaphragms 
was 50 percent of normal and ·38 percent of that found in 
hypophysectomized diaphragm. The anti-insulin effect of 
the lipoprotein-bound inhibitor was not completely over-
come by insulin in vitro. Glucose uptake was only 88 
percent normal in the presence of 0.1 unit of insulin per 
ml. Therefore, although growth hormone and glucocorticoids 
may affect glucose transport, they also decrease glucose 
phosphorylation as well. 
Krahl et al (615) carried out additional experiments 
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on the S-lipoprotein-bound inhibitor discovered by Bornstein. 
They succeeded in isolating inhibitory lipoproteins from 
normal rat serum. Every part of their procedure was scru-
.Pulously s~andardized. The keys to the preparation of 
inhibitory lipoproteins from normal rat serum were speed 
and a reduction in the alcohol concentration used in 
Method 6 (187) for the isolation of lipoprotein fractions. 
The fractionation had to start within one hour after the 
blood was drawn. Inhibitory activity of fractions from 
diabetic rat sera was not correlated with protein-bound 
lipid or glucose levels of sera. The fact that the elec-
trophoretic patterns of normal and inhibitory fractions 
were identical rules out the presence of fatty acids as 
the cause for the difference. Fractions prepared from 
fasting normal rats were just as inhibitory as fractions 
from diabeti~ rat sera. Non-inhibitory fractions could 
be obtained if the sera were kept at room temperature 
·for 1 or more hours before fractionation, if the frac-
tion was exposed to 15% ethanol solution for 30 minutes 
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or more, or if individual sera with protein-bound-lipid 
values above 1100 mg/100 ml were included in the serum pool. 
The effect of the alcohol was probably on the lipoprotein 
rather than on the inhibitor itself. An alteration in the 
structure of the lipoprotein could prevent the binding of 
the inhibitor and its transport into rat diaphragm where 
it exerts its effects. The absence of the inhibitor from 
lipoprotein fractions with high lipid contents may indi-
cate that the binding site for the inhibitor was blocked 
by the excess lipids. In contrast to this instability in 
solution, the inhibitory fractions could be stored as 
precipitated protein cakes for 4 days without loss of ac-
tivity. The inhibitory activity of the lipoproteins could 
be enhanced by the intraperitoneal injection of the serum 
donors with 2 mg of g~owth hormone 24 hours prior to the 
experiment. That this effect is not secondary to lipolysis 
produced by growth hormone is indicated by the lack of an 
effect of ACTH and TSH hormones on the activity. The inhib-
itory activity of lipoprotein fraction could be destroyed 
by repeated freezing and thawing. The inhibitory activity 
' 
of the amount of the inhibitor in l ml of fasted or dia-
betic rat serum could counteract 0.0003 units of insulin 
per ml. The significance of this finding can be judged 
when one considers that the normal insulin concentration 
':.,. 
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is approximately 0.0010 units/ml. Thus, the effect could be 
of physiological importance. 
Whitney and Young (1141) confirmed the basic findings 
of Bornstein and Krahl on the hormonal dependence of the 
inhibitor. They found that the inhibitor did not increase 
in concentration in normal rats unless both growth hormone 
and cortisol were administered. The long term treatment 
which they described in order to see the effect may have 
been necessitated by the presence of the pituitary and 
adrenal in their animals. Essentially, they obtained an 
increase in the inhibition rather than an all or none 
effect. Their criterion was an inhibition of glucose µp-
take over a 90 minute incubation of the diaphragm at 37°C. 
Kipnis and Stein (389) have reviewed insulin antag-
onism of all types and have put them into perspective, 
• 
clarifying disputed points by some of their own experi-
mental work. One of the first points they stressed was 
that the defective phosphorylation observed in diabetes 
did not imply a defect in the enzyme hexokinase. This 
will be discussed further in a later section of this 
dissertation. Secondly, glucose transport and utiliza-
tion are decreased in the intact diaphragm of hypophysec-
tomized rats whereas they are increased in the cut dia-
phragm. This statement does not explain the inhibition 
L 
produced by growth hormone and cortisol. However, Kipnis 
reported that growth hormone and cortisol injections into 
intact normal rats decreased the transport of glucose in-
to rat diaphragm. He confirmed that purified albumin has 
a stimulatory effect on glucose uptake •. Also, he was un-
able to verify the presence of bound insulin in serum and 
concluded that growth hormone did not release insulin 
from the pancreas. He observed that the sugar transport 
system is rate limiting at all times in the normal rat, 
even in the presence of insulin. This is not the case in 
the diabetic rat in which phosphorylation can be shown 
to be limiting after insulin administration corrects the 
defect in transport. Summarizing his findings, the defects 
in transport in alloxan-diabetic rats can be corrected 
rapidly by the addition of insulin in vitro. The defect 
in phosphorylation cannot be so corrected and limits glu-
cose uptake in the w:-esence of excess insulin. The mech-
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anism of this decreased phosphorylating activity is unknown. 
In a discussion of Kipnis' results, Bornstein confirmed that 
the lipoprotein inhibitor was not active on adipose tissue. 
The experiments of Bornstein showed that the factor 
bound to lipoproteins was neither cortisone nor growth hor-
mone. It was immediately active on the diaphragm and did 
not require a latent period. One might suppose that the 
L 
factor was cortisol rather than cortisone. In general, it 
has been found that only 11-hydroxy glucocorticoids are ef-
fective in in vitro systems in which protein synthesis me-
diates the glucocorticoid effect. Bornstein did not try 
cortisol in his experiments. However, Antoniades et al 
(15, 17) have shown that glucocorticoids are the steroids 
least strongly bound to the lipoprotein fraction of serum. 
Randle et al (431) have shown that fatty acid oxida-
.tion leads to a decrease in glucose oxidation. For ex-
ample, in the perfused rat heart, octanoate at 0.40 mg/ml 
inhibits glucose uptake 41 percent while 0.70 mg/ml 8-hy-
droxybutyrate inhibits glucose uptake 50 percent. These 
changes are accompanied by an increase in the NADH/NAD+ 
ratio of mitochondria and an elevation in cytoplasmic 
citrate. These changes are somewhat similar to those 
observed during ethanol perfusion. The fact that oxygen 
consumption is not affected indicates that the oxidation 
of pyridine nucleotides is also unef fected by fatty acid 
respiration. In contrast, oxygen consumption is reduced 
by steroids when they produce similar changes in citrate 
and in the reduction potential of mitochondrial pyridine 
nucleotides. 
Mor~an et al (758) reported that glucose phosphoryl-
ation is the rate limiting reaction in glucose uptake by 
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the perfused rat heart at all glucose concentrations over 
2.00 gm/l, even in the presence of 0.1 unit/ml of insulin. 
since insulin secretion is stimulated when glucose phos-
phorylation is inhibited, these results indicate that gly-
colytic inhibitors can be affective insulin antagonists 
under conditions similar to thbse encountered in diabetes 
in vivo. 
The Specificity of Glucocorticoid Effects 
Huisman (494} had observed that adrenalectomy or hypo-
physectomy increased the glucose uptake of the isolated rat 
diaphragm. He found that 0.5-2.5 mg/ml cortisone acetate 
in vitro decreased the glucose uptake of the isolated rat 
diaphragm 30-40 percent. Herman and Ramey (452} reported 
that 0.04 mg/ml cortisol inhibited glucose uptake of the 
diaphragm by 15 percent. At about the same time, Grossman 
and Ryder (205} reported that 0.3 mg/ml (8 x l0- 4M} corti-
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sol decreased the glucose uptake of diaphragm by 32 percent. 
The effect was specific since 2 x 10- 4 Molar cortisone was 
active while twice this concentration of corticosterone 
was inactive. Thus, the 17a-hydroxy group is required 
for this effect. This latter concentration of cortisone 
depressed glucose oxidation by 41 percent. These authors 
also reported that 1.63 µMolar deoxycorticosterone in-
hibited glycogen synthesis 31 percent and accelerated 
. 
> t glycogenolysis while having no effect on either glucose up-
~r· 
l 
take or oxidation. These results with deoxycorticosterone 
have been confirmed by Verzar (577) and will be discussed 
in relation to glycogen metabolism. Rosenkrantz (455), in 
addition to confirming the observations of Grossman and 
Ryder on deox::(corticosterone, also reported that _this 
steroid inhibited yeast hexokinase 60 percent at a concen-
tration of 1.0 mg/ml. The interpretation of this finding 
is difficult because yeast does not contain steroid hor-
manes or insulin. 
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CHAPTER IV 
MINERALCORTICOIDS AND ELECTROLYTE BALANCE 
Problems of Mineralcorticoid Therapy 
At the present time it is not possible to define the 
specificity of the glucocorticoid effect on insulin an-
tagonism by S-lipoprotein. However, some of the effects 
of cortisol on carbohydrate metabolism are non-specific 
in that they may also be produced by other steroids and 
non-steroids (12, 747, 1099). 
In order to study glucocorticoid effects it is neces-
sary to control endogenous cortisol levels. This is best 
done by adrenalectomy which, in addition, increases the 
sensitivity of the experimental animals to minute amounts 
of adrenal hormones. However, adrenalectomy also pro-
duces electrolyte imbalance which may indirectly affect 
carbohydrate metabolism. Therefore, since the amount of 
exogenously administered mineralcorticoid required to main-
tain electrolyte balance is greater than the amount endo-
· genously secreted, the problem of mineralcorticoid therapy 
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is to obtain electrolyte balance without mineralcorticoid 
effects on carbohydrate metabolism. 
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Not all mineralcorticoid effects on carbohydrate metab-
olism are mediated by changes in electrolyte levels. Rather, 
some of these effects may be due to the interaction of the 
mineralcorticoids at glucocorticoid receptor sites. There-
fore, the best mineralcorticoid for this application is 
that which interacts least at glucocorticoid receptor sites. 
Grollman (413, 414) found that most of the deaths from 
adrenal insufficiency in rats occur about 18 days after 
adrenalectomy. Sabatini ·et ·a1 (922) have made a sub-micro-
scopic study of the effect of the pituitary on the adreno-
cortex of the rat. They found that cortical atrophy fol-
lowing hypophysectomy is due to shrinkage of the zona 
fasciculata and zona reticularis. In contrast, the zona 
glomerulosa remained normal two weeks after hypophysectomy. 
ACTH 
ACTH formed in the pituitary stimulates the production 
of glucocorticoids in the adrenal and can produce all glu-
cocorticoid effects when administered to animals with nor-
mal adrenal glands. However, ACTH also has lipolytic ef-
fects which are not mediated by the adrenal glands. In 
Cushing' s Syndrome there is an overproduction o,f ACTH due 
to hyperplasia of the basophil cells of the adenohypophysis. 
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In Addison's disease there is also an overproduction of ACTH, 
but this overproduction is secondary to the decreased corti-
sol production by the adrenal cortex causing decreased corti-
sol feedback of ACTH release. Cox and Hodges (203) also found 
that at least two weeks after adrenalectomy were required be-
fore the pituitary adapts itself to secrete and maintain an 
enormously increased output of ACTH in response to the com-
plete absence of glucocorticoids. 
Although potassium enhances glucose uptake and inhibits 
insulin release from the S cells of the pancreas, changes in 
potassium and other electrolyte effects may be avoided in the 
study of glucocorticoid effects by the use of synthetic gluco-
corticoids which have little or no effect on electrolytes (1195). 
Perhaps the most potent glucocort~coid which still shows low or 
neglible mineralcorticoid effects is 6a,9a-difluoro-11S,17a,21_. 
trihydroxy-16a-methyl-l,4-prenadiene-3,20-dione (Flumethasone). 
In this compound the 16a-methyl counteracts the salt retention 
produced by the 9a-fluorine substitution. A less potent .gluco-
corticoid but one which still possesses minimal mineralcorti-
coid effects is 6a-fluoro-ll13,17a,21-trihydrowy-l,4-pregnadi-
ene-3,20-dione (Fluprednisolone). In addition to the reduction 
in mineralcorticoid activity produced by the introduction of the 
double bond at C-1, the glucocorticoid potency is further en-
hanced by the Ga-fluorine substitution which electronically 
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interferes with the reduction of the double bond at C-4 (887). 
Interestingly, the higher potency of Ga-fluorinated deriva-
tives compared to Ga-methylated derivatives indicates the 
superiority of the electronic block compared to the steric 
block with respect to the specific reductases involved. 
Th~ use of specific glucocorticoids, defined by their 
potency in glycogen deposition, along with specific min-
eralcorticoid therapy in control and experimental adrenal-
ectomized rats simplifies the interpretation of the effects 
observed. But, these specific glucocorticoids may still 
have non-glucocorticoid effects even though they are devoid 
of mineralcorticoid effects. It is hoped that these dis-
tinctions will become clearer to the reader as the disser-
tation progresses. 
In addition to their effect on hepatic glycogen depo-
sition, specific glucocorticoids promote the mobilization 
of phospholipids from the liver while mineralcorticoids 
do not (GS4, 797, 1197). However, the latter steroids 
.have a more potent hypercholesterolemic effect that is not 
generally appreciated, probably because mineralcorticoids 
are not normally in pathological excess (779). 
Adrenal Insufficiency and Diabetes Mellitus 
Adrenalectomized rats cannot be maintained for long 
periods simply by increasing their dietery sodium and 
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restricting their potassium. The pioneering work in this 
particular.area was performed by Grollman (204). He demon-
strated that completely adrenalectomized rats could not 
survive longer than approximately 18 days on sodium chloride 
therapy alone, but could survive if they were also given 
mineralcorticoids such as deoxycorticosterone. However, 
the failure to remove only 5 percent of the adrenal gland 
leads to the survival of the animals without mineralcor-
ticoids due to the hypertrophy of the remaining tissue. 
Grollman also noted that young, untreated adrenalectomized 
animals survived for much .shorter periods than adults, as 
did animals exposed to stress before adrenalectomy. Pro-
longed ether anesthesia during the adrenalectomy reduced 
the survival period from 14 to 7 days. Barbiturate anes-
thesia resulted in better survival rates than ether, but 
high-protein diets and post-operative stress reduced sur-
vival rates. 
Grollman found that body weight loss was the most re-
sponsive non-chemical indicator of adrenal insufficiency 
in adrenalectomized rats. Other indicators have compen-
satory mechanisms which only break down during adrenal 
crisis. Body weight, however, may not be a specific index 
of adrenal insufficiency in alloxan-diabetic-adrenalecto-
mized rats, because insulin deficiency itself causes weight 
r, 
l'~.·.· .. '. 
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1oss and protein depletion. The most sensitive chemical in-
dicator of adrenal insufficiency is blood urea nitrogen (BUN). 
This is especially true when it is measured daily in each 
animal. The blood urea nitrogen will rise in adrenalec-
tomized rats due to hemoconcentration at constant urea pro-
duction and due to reduced urea clearance by the kidney as 
glomerular filtration rate falls. Diabetic-adrenalectomized 
rats will have a higher rate of urea production due to in-
creased protein catabolism, especially if they are main-
tained on a high-protein, low-carbohydrate diet. However, 
the day to day changes in blood urea will still be a valid 
indicator of blood volume, the goal of mineralcorticoid 
therapy, despite the osmotic diuresis caused by glucosuria. 
Although insulin treatment is specifically indicated to 
control the hemoconcentration produced by glucosuria, in-
sulin treatment was not used in these studies for reasons 
already discussed. Therefore, daily glucose determinations 
were not necessary. 
The serum sodium levels in diabetic rats are somewhat 
low. Weisberg {1128) has shown that a reduction in serum 
sodium is a necessary consequence of the increased amounts 
of glucose and urea in blood. A rise of 100 mg/l in serum 
glucose will result in a sodium reduction of 0.28 meg/l 
while the same rise in urea nitrogen will decrease the 
l 
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concentration of serum sodium by 1.8 meq/l. The relative 
amounts of glucose and urea which will displace 1 meq/l of 
sodium are 350 mg/l and 50 mg/l respectively. These results 
indicate that serum sodium levels can be altered by both 
urea and glucose. 
The decreased ability of the adrenalectomized rat to 
excrete potassium is alleviated by the glucosuria of dia-
betes. The resulting high fluid intake effectively dilutes 
the elevated levels of potassium in the adrenalectomized 
rat. The same holds true for the elevat~d magnesium levels 
found in adrenalectomized rats. Potassium and magnesium 
levels in the non-diabetic-adrenalectornized rat are ele-
vated approximately 42 percent and 23 percent respectively. 
Adrenalectomized rats, however, share with diabetic rats 
their tendency toward acidosis. The acidosis of adrenal 
insufficiency is due to the decreased reabsorption of sodium 
ion and increased reabsorption of potassium and hydrogen ions. 
Electrolyte Therapx 
Grollman (414) has shown that adequate replacement ther-
apy of adrenalectomized rats cannot consist of electrolytes 
alone, although the reasons for this are obscure. The oral 
administration of 10 mg/kg daily deoxycorticosterone ace-
tate admixed with the animal's food was found to result in 
adequate replacement therapy. The dose of mineralcorticoid 
could be reduced if additional sodium chloride was also ad-
ministered. McGarack et al (689) showed in humans that the 
dose of mineralcorticoid was inversely related to the total 
dietary sodium. However, it should be noted that the cor-
rect therapy of Addison's disease requires the use of both 
mineralcorticoids and glucocorticoids. 
An example from McGarack et al (689) also illustrates 
the effects which mineralcorticoids can have on carbohy-
drate metabolism. They showed that normal glucose toler-
ance could be obtained in their Addisonian patients on a 
normal diet if 15-20 mg of deoxycorticosterone acetate was 
administered daily. Althauser et al (12) have also shown 
that electrolyte balance in the rat is required for normal 
intestinal absorption of glucose. In adrenalectomized rats 
this function can be almost completely restored by the 
administration of 1 percent sodium chloride as drinking 
fluid. 
In the treatment of alloxan-diabetic-adrenalectomized 
.. 
rats with varying degrees of glucosuria it is advantageous 
to administer the mineralcorticoid in the drinking fluid 
rather than admixed with the solid food for two reasons. 
First, since the bulk of dietary sodium is also in the 
drinking flu.id, the dose of mineralcorticoid is in direct 
proportion to the filtered sodium load in the glomerulus. 
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secondly, the administration of the mineralcorticoid in the 
drinking fluid distributes the total dose throughout the day 
thereby making it more effective than the same total dose 
consumed mainly with solid food according to the nocturnal 
eating habits of the rat. The total dose of hormone admin-
istered is thereby reduced as are the dangers of hyperten~ 
sion, hypokalemia, paralysis, cardiac failure, and myocar-
dial necrosis resulting from overdosage. 
The administration of mineralcorticoids in drinking 
fluid, while eliminating the chance of infection associated 
with daily injections of the hormones, is not without prob-
lems. According to Grollman (414} a 200-gram rat requires 
approximately 2.0 milligrams of oral deoxycorticosterone 
acetate daily. While this requirement may be reduced if 
the hormone is administered in conjunction with 1 percent 
saline, the low solubility of deoxycorticosterone in this 
medium--approximately 17.0 mg/1--could supply about only 
one-third of the required dose. 
This dilemma might be solved by the use of more potent 
mineralcorticoids. Bergstrom and Dodson (69} reported the 
synthesis of 9a-fluoro-21-hydroxy-4-pregnane-3,20-dione 
from corticosterone acetate. They treated the latter 
steroid with 70 percent hydrofluoric acid in anhydrous 
pyridine. Kagawa and Jacobs (553} bioassayed the main 
product and found it to be 12-14 times as poten~ as deoxy-
corticosterone. 
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Aldosterone might also be used to maintain adrenalec-
tomized rats in these studies. Although it is 15 times as 
potent as deoxycorticosterone, Desaulles (230) has esti-
mated that it has 0.5 percent of the glucocorticoid potency 
of cortisol. The ratio of mineralcorticoid to glucocorti-
coid activity in aldosterone might be increased by the in-
troduction of a 9a-fluorine atom. Barton and Beaton (49) 
have describe.a the conversion of corticosterone to aldos-
terone. In this transformation llS-nitrites react photo-
chemically to yield C-18 or C-19 oximes which can be hy-
drolyzed to aldehydes. This reaction applied to 9a-fluoro-
11B ,21-dihydroxy-4-pregnane-3, 20-dione would yield 9a-flu-
oro-11S,21-dihydroxy-3,20-dioxo-4-pregn-18al (11--18) lactol. 
Although intravenous fluid therapy introduces an addi-
tional variable in the maintenance of alloxan-diabetic-
adrenalectomi zed rats, it often saves a rat who has not 
adapted to this state by increasing his saline intake. 
Slow infusion of the following solution often corrects 
the hemoconcentrations and acidosis of these animals in 
this crisis. 
When rats are first rendered alloxan-diabetic, they 
tend to undergo a period of ketosis until their excess 
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TABLE I 
INTRAVENOUS FLUID REPLACEMENT SOLUTION 
,. 
COMPONENT MEQ/L GM/L 
Sodium chloride 103.0 6.020 
~· 
Potassium chloride 4.0 0.298 
Calcium phosphate, dibasic 4.0 0.306 
Sodium bicarbonate 30.0 2.521 
Glucose 1.000 
Fructose 2.000 
~f: 
f. 
"': 
r 
, .. 
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lipid stores are depleted. This is especially true of larger 
rats. The oral hypoglycemic agent 1-phenethylbiguanide 
might be used to enable the animals to get through this per-
iod without resorting to the administration of insulin. 
This particular compound does not act by increasing insulin 
output but by .another mechanism which has not been completely 
elucidated. Superficially, the effects of the compound re-
semble the effects of low concentrations of epinephrine on 
glucose metabolism, but differences no doubt exist. The 
point made here is that the use of this compound may enable 
the animals to get through a period of high mortality and 
thereby improve overall experimental efficiency. 
Large doses of glucocorticoids, 17 mg/kg for 10 days, 
can produce glucosuria similar to that found in alloxan 
qiabetes. This phenomenon is known as steroid diabetes 
(509, 510, 513, 517). Ingle et al (511) compared steroid 
diabetes with pancreatic diabetes in the rat and noted 
that glucocorticoid diabetes was resistant to insulin 
whereas pancreatic diabetes was not. 
Diabetes Mellitus can also occur in patients with 
Addison's disease. This disease is characterized by 
adrenal insufficiency and its associated disturbances in 
mineral and carbohydrate metabolism. Thorn et al (1062) 
demonstrated impairment of the intestinal absorption of 
glucose and an elevated respiratory quotient that is dimin-
ished by cortisol treatment. Althauser et al (12) have 
shown that oral sodium chloride can partially restore the 
defect in the intestinal absorption of glucose. When dia-
• I 
betes complicates adrenal insufficiency, proper management 
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of the patient becomes more complex (1061). If the severity 
of the diabetes corresponds to the degree of glucocorticoid 
deficiency, the patient can often be maintained by mineral-
corticoids alone. In fact, adrenalectomy was used as one 
treatment for diabetes before insulin was discovered. How-
ever, if insulin is needed to control glucosuria, then 
glucocorticoids should be given as protection against hypo-
glycemia. Other considerations of the adrenal in diabetes 
have been reviewed (1063). 
Excessive glucocorticoid treatment in Addison's 
disease may precipitate clinical diabetes (57), generally 
within 3 years. Carbohydrate and mineral balance are best 
maintained separately with cortisol and its 9a-fluoro 
derivative. 
Glycyrrhetic Acid 
If mineralcorticoids produce some glucocorticoid ef-
fects in adrenalectomized rats, what other means are avail-
able to maintain electrolyte balance in these animals? 
Louis and Cohn (678) isolated an electrolyte-active principle 
' . 
from licorice extracts and used this compound to maintain 
adrenalectomized patients before deoxycorticosterone be-
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came readily available. The compound, glycyrrhetic acid, 
was isolated in the form of the ammonium salt of its 3-(2-0-
s-D-glucuronopyranosyl)-a-D-glucuronopyranoside known as 
glycyrrhizin. This glycoside is intensely sweet and has 
been used as an artificial sweetener. The mineralcorti-
coid properties of the licorice glucuronoside are those of 
the parent compound glycyrrhetic acid, often termed gly-
_cyrrhetinic acid. 
Glycyrrhetic acid is a molecule of great theoretical 
interest because it possesses anti-inflammatory and min-
eralcorticoid effects, but not glucocorticoid effects 
(318). The relationship between anti-inflammatory and 
. glucocorticoid potency has been reviewed by Glenn et al 
(371). In general these two potencies parallel each other 
'·· so that the reported separation of these effects . in glycy-
\. 
rrhetic acid by Finney and Somers (318) should be further 
investigated. 
In man the anti-inflammatory dose of licorice extract, 
w~ich constitutes 6-14 percent of the dried rhizone and 
roots of the licorice plast, Glycyrrhizia glabra, is about 
20-25 grams per day. Although this dose is large compared 
to anti-inflammatory steroids, treatment with licorice 
FIGURE III 
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extract and carbonoxalone, the hemi-succinate ester of gly-
cyrrhetic acid, is preferred for the· treatment of peptic 
ulcers which are adversely affected by anti-inflammatory 
steroids. 
Not all commercial samples of glycyrrhetinic acid have 
anti-inflammatory activity because the active 188 form of 
the molecule with a cisD-E ring juncture may be converted 
to the more stable trans form during the acid hydrolysis 
of the glucuronoside glycyrrhizin. This transformation is 
readily explained by the allylic nature of the 186 hydro-
gen due to the presence of the conjugated double bond at 
c-12. Presumably the trans E ring cannot fit the receptor 
site for mineralcorticoid activity while the cis E ring 
can. The active S form of glycyrrhetinic acid crystal-
lized from alcohol has a melting point of 140°, [a]~1=+86° 
(c=O.l in chloroform), while the properties of the inac-
tive a form are 335° and +98° respectively. The pure 
compound has an extinction coefficient of 12,200 at 242 nm 
in ethanol. Additional aspects of the stereochemistry of 
glycyrrhetinic acid have been reported by Beaton and Spring 
(55) • 
The role of the 11-ketone of glycyrrhetic acid in its 
mineral corticoid and anti-inflammatory activity has not 
been determined. However, the related compound, S amyrin, 
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which is identical except for the lack of the 11-ketone and 
c-30 carboxyl groups, also has anti-inflammatory activity 
equal to that of cortisol. Gupta ·et al (418) also found 
that a amyrin had only about one-half the anti-inf lamma-
tory activity of the S isomer. 
The role of the C-11 carbonyl group in the mineral-
corticoid activity of glycyrrhetic acid is unknown but 
could be determined by compariso~ with its 11-deoxy analog. 
Alternately, the mineralcorticoid activity of S amyrin and 
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its C-11 carbonyl derivative could be compared. Such studies 
may clarify the function of the llS-hydroxyl group in aldos-
terone despite its absence in the mineralcorticoid deoxycor-
ticosterone. In addition, it is not known whether the C-11 
ketone in glycyrrhetic ac.id is reduced to an llS- hydroxyl 
group in vivo. However, it is known that the analogous 
reaction with glucocorticoids takes place primarily in the 
liver by the action of the enzyme llS-hydroxysteroid dehy-
drogenase. This enzyme is inactive with SS pregnene deriv-
atives (486) but may or may not be blocked by the 4S-methyl 
group of glycyrrhetic acid. 
Although previous paragraphs have indicated that it is 
feasible to maintain alloxan-diabetic-adrenalectomized rats 
by the administration of a mineralcorticoid in their 
drinking fluid, there are other reasons for not using 
.c 
' . 
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mineralcorticoids for this purpose. Verzar (1099) and Verzar 
and Wenner (1100) have shown that deoxycorticosterone de-
creases muscle glycogen by increasing glycogenolysis. Bart-
lett and Mac Kay (47) and Bartlett et al (48) have confirmed 
these findings in rat diaphragm muscle. Bacila and Baron 
(34) noted that deoxycorticosterone was equal to cortisol 
with respect to its inhibition of the anerobic glycolysis 
of lymphocytes. Interestingly, while cortisol appeared to 
·inhibit only the hexokinase reaction as observed also by 
Ilyin (506) and Ilyin and Titova (507), deoxycorticosterone 
appeared to inhibit other glycolytic reactions as well. 
Blecker (84) and Blecker and White (82, 83) have reviewed 
these effects. They found that 17S-hydroxy-17a-methyl-4-
~· androsten-3-one was as potent as deoxycorticosterone while 
17a-ethyl-17S-hydroxy-4-estren-3-one was three times more 
inhibitory to the glycolysis of lymphoctes. 
Roberts and Nezamis (891) and Russell (917) also ob-
served that deoxycorticosterone could produce some gluco-
corticoid effects in adrenalectomized rats especially when 
hepatic metabolism of the steroid is impaired. Glenn (372) 
similarly noted the local glucocorticoid effects of locally 
administered deoxycorticosterone. To the extent to which 
mineral corticoids produce glucocorticoid effects, mineral-
corticoid maintenance of adrenalectomized rats may reduce 
some glucocorticoid effeets. 
Disputes concerning the efficacy of glycyrrhetic acid 
in the maintenance of adrenalectomized subjects emphasize 
that this molecule has no glucocorticoid activity and can-
not fulfill glucocorticoid requirements. Cristol et al 
(297) reported that glycyrrhetic acid could maintain ad-
renalectomized rats and reduc~ their urinary sodium excre-
tion. In addition, a dose of 300 mg/kg/day caused hyper-
tension in rats similar to that caused by excess deoxycor-
ticosterone. Hudson et al (488) found that adrenalectom-
ized cancer patients could be maintained on a regular diet 
and glycyrrhizin. The dose required was 100 times the 
subcutaneous maintenance dose of deoxycorticosterone. On 
the other hand, Elmadjian et al (282) reported that two 
Addisonian-schizophrenic women could not be maintained by 
the administration of 56 mg/kg/day of ammonium glycyrrhi-
zate in the absence of glucocorticoids. However, this 
dose of the compound reduced their cortisol requirement 
from 25 mg/day to 10 mg/day and maintained the patients 
in excellent electrolyte balance. These results indicate 
that glycyrrhetic acid has no glucocorticoid activity in 
the absence of glucocorticoids but that the compound may 
reduce the rate of metabolism of active glucocorticoids 
when they are also present. 
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Glucocorticoids may exert specific electrolyte effects. 
Mills and Thomas (747) found that cortisol and prednisolone, 
but not deoxycorticosterone stimulated the uptake of inor-· 
~· ganic phosphate by muscle but. not liver. These results sug-
' ~. t gest that the glucocorticoids increased the pool of glycoly-
~· tic intermediate~ in m~scle without affecting the pool size 
g· 
f of these intermediates in liver. The difference in these 
~; 
tissues may be related to the presence of glucose-6-phos-
phatase in liver. A similar increase· in muscle phosphor-
ylated intermediates has been observed by others (759·, 760). 
Block et al· (85) found that a sodium retaining factor 
could be found in the fetal adrenal gland. The intermedi-
ates 4-androstene-3,17-dione and.313-hydroxy-5-androsten-17-
, 
one were also found. The compound 1113-hydroxy-4-androstene-
3,17-dione, normally formed almost exclusively from cortisol 
in the adult, was produced earlier in development than cor-
tisoi. Although the latter 17-ketosteroid has the highest 
anabolic/androgenic ratio of any naturally occurring ster-
oid (737), its effect on fetal carbohydrate metabolism has 
not been studied. The 1113-hydroxyl group reduces its andro-
genie activity to one-fifth that of androsterone. Rosenberg 
and Dorfman (906) also reported that the related steroid 
9a-fluoro-1113-hydroxy-4-androstene-3,17-dione was also de-
void of androgenic activity but that it did have 
r t 96 r mineralcorticoid activity. 
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Effects of Steroids on Blood Pressure 
At least part of the hypotensive effect of some steroids 
may represent an action on glucose utilization in vascular 
muscle. Sturtervant (1037) showed that llS-hydroxy-4-andros-
tene-3,17-dione was the most potent naturally occurring hy-
potensive steroid. It was capable of reducing the blood 
pressure of rats with metacortical hypertension 33-49 mm 
.of mercury for 5.5 hours. In comparison, testosterone and 
1713-hydroxy-4-androstene-3,ll-dione reduced blood pressure 
by 18-22 mm and 4-androstene-3,17-dione and 4-androstene-3, 
11,17-trione reduced it by 9-18 mm. Most surprising was 
the finding that 116,178-dihydroxy-4-androstene-3-one was 
inactive. While these results indicate considerable steroid 
specificity with respect to hypotensive action, additional 
_studies (1038) with synthetic hypotensive steroids based 
on 178-hydroxy-4-estrene-3-one did not confirm such speci-
ficity. Sturtevant found that the parent compound as well 
as its 5(10) unsaturated derivative were inactive. Sub-
stitution in the 17a position with vinyl, allyl, or methyl 
groups resulted in inactive compounds, but the 17a-ethyl 
and 17a-propyl compounds were active. The most potent deriv-
ative was 17S-hydroxy-17a-propyl-58-estren-3-one. Apparently, 
unsaturation at C-4 is not an absolute requirement for 
·~·. 
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physiological activity. Sturtevant did not test llS-hydroxy-
19-nor steroids but, judging from his earlier work, these 
compounds should be even more active. Such derivatives 
might be prepared by microbiological hydroxylation of es-
trenes or from androstenes by the technique of Barton and 
Beaton discussed in conjunction with the synthesis of min-
eralcorticoids. The finding that a long 17a alkyl group 
enhanced hypotensive activity indicates that the mechanism 
involved may be similar to that which operates with some 
progestational steroids. In the rabbit, 17a-(l-butynyl)-
17S-hydroxy-4-estrene-3-one is 83 times as potent as 17a-
ethinyl-17S-hydroxy-4-estrene-3-one by subcutaneous in-
jection but only 63 percent as effective orally. 
The influence of long 17a alkyl groups on hypoten-
sive and progestational activity is reminiscent of 
Selye's (965) finding of increased anesthetic potency in 
a compound which he described as "21-ethylprogesterone" 
(21,25,26,27-tetranor-4-cholestone-3,20-dione) except 
that the alkyl group is in the S rather than in the a po-
~ sition. These results suggest that some C-18 progestens 
~ may have hypotensive effects but additional relations be-
tween the two activities remain to be investigated. How-
ever, the results indicate that hypotensive steroids are 
able to interfere with the action of catecholamines on 
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smooth muscle so that similar interference with the action of 
catecholamines may be found in other tissues. 
The approach to mineralcorticoid replacement therapy 
taken in these experiments has been to administer an elec-
trolyte-active compound in the drinking fluid of the experi-
mental animals. Sodium glycyrrhetinate was the compound 
used. Although this compound contains a C-11 ketone, it 
possesses only mineralcorticoid and not glucocorticoid 
activity. 
The differences between mineralcorticoid and glucocor-
ticoids are generally appreciated, but the effects which 
these types of steroids may have in common are not. It 
seems that 11-deoxy steroids may meet the steric require-
ments of glucocorticoid sites but not vice versa. Glycyr-
rhetic acid is unique in that it has an oxygen at C-11 
but shows only mineralcorticoid activity. It has been 
shown that the presence of the llS-hydroxyl group alters 
the surface activity of the glucocorticoids relative to 
mineralcorticoids. It may also be possible that the C-30 
~'.. carboxyl group in glycyrrhetic acid counteracts the sur-
face effect of the llS-hydroxyl group. In this regard it 
is noteworthy that surface activity was used in determining 
the configuration of the C-30 carboxyl group (55). 
The concern about the possible interaction of 
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f ' ' ~ ~· mineralcorticoids at glucocorticoid sites may seem inordinate 
to the reader. However, the basis of this concern is that 
such mineralcorticoid effects present in all experimental 
animals could mask similar effects produced by glucocorti-
coid derivatives. Unfortunately, while measures were taken 
to eliminate this problem, its actual magnitude was not 
determined. 
CHAPTER V 
GLUCOCORTICOIDS AND HEXOKINASE 
Glycolysis in Muscle Cells and Erythrocytes 
The amelioration of diabetes by hypophysectomy seen in 
the Houssay animal prompted further investigation into the 
effects of pituitary and adrenal extracts on the first re-
action of glucose metabolism. Price et al (833) found that 
.anterior pituitary extracts inhibited muscle hexokinase 
in vitro and that insulin reversed the inhibition in all 
cases. Stadie et al (1016) also reported that exposure 
of the rat diaphragm to pituitary extracts abolished its 
? subsequent response to excess insulin. The factors in-
volved in these observations have not been studied further. 
On the other hand, Price et al (852) found that crude adre-
nal cortical extract, but not crystalline cortisone, cor-
ticosterone or 21-hydroxy-4-pregnene-3,11,20-trione, in-
;; hibited muscle hexokinase. Essentially similar findings 
were reported by Sharma ~t al (974). These reports indi-
.·· .. 
cate that the identity of the active adrenal factor is 
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known. 
Bornstein (100) reported that S lipoproteins from nor-
rats were less inhibitory than S lipoproteins from dia-
betic rats towards muscle hexokinase. Although up to 27 
percent inhibition was observed, other non-glycolytic en-
zymes were also inhibited. Insulin did not reverse the 
inhibition of the enzyme which was attributed to the phos-
phatidyl choline in S lipoprotein. 
Bacila and Baron (34) have studied the effect of glu-
cocorticoids on the anaerobic glycolysis of appendix lym-
phatic cells. Cortisol at a concentration of 50 µg/ml in-
-4 hibited glycolysis 12 percent. At 100 µg/ml (2.8 x 10 ) 
cortisol inhibited glycolysis 40 percent. Mouse diaphragm 
was inhibited 45 percent at a cortisol concentration of 
50 µg/ml in a two-hour incubation in which the glucose 
concentration was 180 mg/ml. Cortisone acetate and de-
oxycorticosterone were as effective as cortisol in eli-
citing this effect. In contrast, the anaerobic glycolysis 
of acites tumor and lymphosarcoma were not affected at 
these steroid concentrations. These results may indicate 
that these tumors have lost their sensitivity to cortisol. 
Human and rabbit erythrocyts glycolysis as well as 
yeast glycolysis were not affected by steroids under these 
,, conditions. A possible explanation for the resistance of 
f 
~' 
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erythrocytes to t.hese steroid effects is suggested by the 
work of Margraf et al (713). These workers found that red 
cells form glucocorticoid C-21 acetates and that 50 percent 
of circulating glticocorticoids are present in this form. 
The key role of red cell glycolysis in the generation of 
its major product, 2,3-diphospho-glycerate, and the role 
of the latter compound in hemoglobin function indicates 
that glycolytic inhibitors could adversely affect oxygen 
transport if their action in red cells was not prevented 
·~ by acetylation. These acetate esters are rapidly hydro-
lyzed in plasma by pseudocholinesterase. 
Effects of Sulfhydr:z=l Compounds and Reagents 
Besides alloxan, both dehydroascorbic acid (693) and 
uric acid (412) deplete insulin storage granules in the B 
cells. These compounds appear to exert their degranula-
tion effect through reaction with glutathione. Indeed, 
alloxan has been used as an analytical reagent in the de-
termination of glutathione. Degranulation is due to the 
f reduction in glutathione levels. Lazarow (644) reported 
that glutathione increased the hyperglycemic response to 
growth hormone and glucocorticoids. However, he.also 
noted that growth hormone and glucocorticoids suppressed 
glutathione levels before these hormones produced gluco-
suria. This observation is another indication that the 
,. 
diabetogenic effects of these hormones are produced in the 
presence of elevated concentrations of insulin. 
Bacila and Baron also observed an insulin-like effect 
of glutathione on the isolated rat diaphragm. They demon-
strated that glutathione could prevent the inhibitory ef-
fect of cortisol on glucose metabolism and postulated that 
glutathione reacted with cortisol to form an inactive de-
rivative. Although C-3 carbonyl group of dihydrosteroids 
had previously been shown to form thiazolidine derivatives 
with cysteine, this reaction is much less facile with con-
jugated C-3 steroid ketones. 
The possibility that sulfhydryl compounds may exert 
an effect on the enzyme hexokinase has been investigated 
by several groups. Lazarus ·et al (645) studied the sulf-
hydryl groups of yeast hexokinase and found that the 
enzyme contained 8 sulfhydryl groups. Four of these re-
acted with methyl mercury iodide in the native enzyme 
f with no loss in activity. However, four additional sulf-
~· t hydryl groups were simultaneously exposed and their sub-
i· 
,. sequent reaction with methyl mercury resulted in dissoci-
l" ~ ation and inactivation of the enzyme. Similar conclu-[ 
fi. sions were reached by Schulze and Colowick (955) in their 
f:', 
~i experiments with methyl mercury nitrate in 5. 4 M guani-
~r . ~ dine hydrochloride and with mercaptoethanol. These 
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findings indicate that simple mercaptide formation does not 
iead to inhibition of yeast hexokinase activity. 
Ilyin (506) and Ilyin and Titova (507) performed some 
interesting experiments relative to the role of hexokinase 
sulfhydryl groups in an effect of glucocorticoids. When 
cortisone acetate was added to rabbit serum B lipoproteins, 
the lipoproteins inhibited yeart hexokinase. This effect 
could be reversed by 0.5 units of insulin in vitro. The 
reversal by insulin required the presence of free sulf-
hydryl groups, but inhibition by cortisol or cortisone 
acetate could still be demonstrated after the enzyme had 
reacted with N-ethylmaleimide or p-chloro-mercuribenzoate. 
Insulin prevented or reversed the binding of the steroid 
to the enzyme which remained active after treatment with 
sulfhydryl reagents. Titova (l067) reported that both 
oxytocin and vasopresson, which have disulfides similar 
to those in the A chain of insulin, could also reverse 
steroid inhibition of the enzyme. Insulin had no effect 
on yeast hexokinase activity in the absence of glucocorti-
coids. The effect appeared to be some what specific since 
insulin did not affect the free sulfhydryl groups of hemo-
globin or the enzyme aldolase. Glucose-6-phosphate dehy-
drogenase, however, was also inhibited by the cortisone 
acetate-a lipoprotein complex. 
,• 
•. t' 
The glucocorticoid effect on the enzyme hexokinase is 
also specific. The phosphorylation of glucose and mannose 
was inhibited, but that of fructose and 2-deoxyglucose was 
t Zinc and silver cations prevented the inhibition of no · 
hexokinase by glucocorticoids as did N-ethylmaleimide. On 
the other hand, p-chloromercuribenzoate reversed glucocor-
ticoid inhibition of the enzyme (506, 507, 1067). Thus, 
p-chloromercuribenzoate had the same effect as the hormone 
insulin. Although these results were obtained in a very 
heterogeneous system, i.e. rabbit B-lipoproteins, bovine 
insulin, and kinase from yeast which lacks both of the 
latter as well as glucocorticoids, the data validly indi-
cate some of the pitfalls in work with hormones in vitro. 
Properties of Hexokinase Isoenzymes 
Schimke and Grosslard (744) studied the distribution 
of hexokinase isoenzymes in animal tissues. They also 
presented detailed kinetic and physiochemical data on 
these enzymes. Hexokinase isoenzymes are enumerated in 
the order in which they migrate during electrophoresis. 
This order is the same as the order in which the enzymes 
are eluted from the ion-exchanger diethylaminoethylcellu-
lose by potassium chloride gradients. Type I hexokinase 
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is found in brain and is the isoenzyme most stable at 45°C 
in the presence of glucose. Both types I and II hexokinase 
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are found in heart muscle and adipose tissue. The type II 
e.nzyme is least stable to heat. Type III hexokinase, which 
is found in liver, is most inhibited by high concentrations 
of glucose and least inhibited by glucose-6-phosphate. 
Kidney contains all three hexokinase isoenzymes. These 
three low km hexokinases have molecular weights of 96,000 
and a similar pH optimum of 7.8-8.8. Glucose, mannose and 
glucosamine have the same km value but that of fructose is 
1000 times greater. However, these substrates and 2-deoxy-
glucose have the same Vmax· Type IV glucokinase in liver 
is very heat labile. It is inactive with fructose and glu-
cosamine but phosphorylates mannose and 2-deoxyglucose in 
addition to glucose. It has a molecular weight of 50,000 
and a more acidic pH optimum of 7.5-8.5. Pilkis et al 
(836) have found that insulin is necessary for the induc-
tion of both glucokinase and hexokinase II. Hypophysec-
tomy decreases hexokinase II but has no effect on gluco-
kinase and this could explain why hypophysectomized rats 
lose muscle glycogen. 
Hanson and Fromm (426) demonstrated that both types 
I and II hexokinase were present in skeletal muscle. 
Using D-fructose as substrate, these makers demonstrated 
that the mechanisms of the type I enzyme was sequential. 
In the sequential mechanism, the Michaelis constant of 
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the variable substrate remains the same or decreases as the 
concentration of the fixed substrate rises. Their proof of 
the sequential mechanism corrects their earlier claim that 
this enzyme followed a ping-pong mechanism. In this latter 
mechanism one of the products is released from the enzyme 
before the second substrate is bound. 
On the other hand, type II hexokinase unlike type I 
hexokinase was found to be inhibited by mannose-6-phos~hate 
and to possess kinetic properties similar to those of yeast 
hexokinase. Since adenosine-5'-triphosphate showed a mixed 
type of inhibition with respect to both glucose and adeno-
sine-5'-triphosphate, the authors concluded that the mechan-
ism of the enzyme was random, i.e. that the binding of either 
substrate influenced the km for the other substrate. 
Glucose-6-phosphate appears to be a mixed inhibitor of 
all rat hexokinase isoenzymes with respect to glucose. The 
decrease in the affinity of the enzymes for glucose pro-
duced by glucose-6-phosphate may decrease glucose transport 
by elevating the intracellular concentration of glucose 
which, in turn, decreases the rate of glucose'transport by 
decreasing the concentration gradient for glucose. Yorke 
(1189) has observed in isolated rat diaphragm that dexa-
methasone simultaneously decreased the concentration of 
sn-3-glycerolphosphate and glucose transport at low steroid 
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concentrations that did not increase lipolysis. These find-
ings could be explained by citrate inhibition of phospho-
fructokinase. 
Effect of Insulin on Isoenzymes 
-
It has been observed that insulin increases the propor-
tion of type II hexokinase in adipose tissue while total 
hexokinase activity remains constant. The mechanism leading 
to this coordinate elevation in one isoenzyme and depres-
sion of another has not been studied. 
Grossbard and Schimke (416) have examined the kinetics 
'· of rat hexokinase isoenzymes. Al though the Michaelis con-
stant of type II hexokinase for glucose if five times greater 
than that of the type I enzyme, the type II enzyme is about 
three times less sensitive to inhibition by complex of mag-
nesium and adenosine-5'-diphosphate. MgATP inhibition of 
the rat isoenzymes appears to be more important that that 
produced by glucose-6-phosphate. It is sensitive to pH 
changes near pH 6.8. Bohnensack and Hofmann (88) have 
found that the Michaelis constant of the enzyme for glucose 
increases with increasing pH. Furthermore, the product in-
hibition of the enzyme seems to decrease with increasing pH. 
Noat et al (787) have determined that the inhibitory effect 
of uncomplexed ATP under certain conditions may ne due to 
an interaction with a yeast hexokinase-glucose complex and 
~-
. 
. l~ 
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that the inhibitor effect of excess magnesium under certain 
conditions may be due to the formation of a Mg 2ATP_ complex 
which decreases the concentration of the substrate MgATP. 
such observations emphasize the importance of the proper 
ratio of magnesium to adenine nucleotides in the control of 
the activity of the enzyme. 
Inhibition by Mg.ADP may be more important in the con-
·trol of the enzyme because it can be removed only by oxi-
dative or substrate phosphorylation of the nucleotide. 
since most of the studies with MgADP have not been carried 
out with an equivalent amount of inorganic phosphate, the 
full regulatory significance of MgADP inhibition of the 
enzyme remains to be determined. However, Blair (80} has 
simulated the hexokinase reaction with the aid of a com-
puter and he concluded that magnesium ion. may act as a 
feedback signal to the enzyme from the adenine nucleo-
tide pool. 
The interactions of magnesium and nucleotides is per-
haps best seen in the complex kinetics of mitochrondrial 
nucleoside diphosphate kinase which has been studied by 
Goffeau et al (378). They also demonstrated that the true 
substrates for this enzyme were magnesium-nucleotide 
complexes: 
MgATP + MgXDP = MgADP + MgXTP 
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The complex MgADP was found to be fifty times more inhibitory 
to the enzyme than excess MgATP. From a study of the kinetic 
behavior of the enzyme, Goffeau et ·a1 concluded that the mech-
EP 
anism was of the order~ping-pong type, i.e. a phosphorylated 
enzyme was an intermediate in the reaction. Furthermore, 
from differences in the pH dependencies of substrates and 
inhibitors of the reaction these workers concluded that the 
enzyme had an allosteric site for MgXDP in addition to the 
substrate site and that the enzyme was a regulatory enzyme 
in metabolism. This conclusion was strengthened by the 
studied of Thompson and Atkinson (1058) who found that the 
activity of the enzyme was regulated by the energy charge 
of the adenine nucleotide pool. Klachko (395) ~as also 
postulated that the mechanism of action of insulin could 
be explained by its activation of the enzyme. Further 
studies are necessary. 
The interpretation of the inhibition patterns of two 
substrate reactions is complex. However, if a reaction 
is ordered, a mixed or non-competitive inhibitor of the 
first substrate will usually appear to be a competitive 
inhibitor with respect to the second substrate. Hanson 
and Fromm (426) as well as Toews (1069) have studied the 
kinetics of rat skeletal muscle hexokinases. 
Toews demonstrated that at pH 8.0 MgADP was a 
: . 
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non-competitive inhibitor of MgATP while glucose-6-phosphate 
was a mixed inhibitor of glucose and a non-competitive inhib-
itor of MgATP. Since a non-competitive inhibitor may be an 
uncompetitive inhibitor, these results are compatible with 
an ordered mechanism for rat skeletal muscle type II hexo-
kinase in which MgATP adds first to the enzyme. It should 
be noted that the above results were observed at low MgADP 
levels. Kosow (609) noted that high levels of MgADP may 
.produce mixed inhibition with respect to MgATP by blocking 
the release of glucose-6-phosphate may produce mixed in-
hibition with respect to MgATP by interacting at an allos-
teric site on the enzyme. These latter effects are similar 
to those which have been observed with nuc.leoside diphos-
phate kinase. 
In contrast to the mechanism of rat type II hexokin-
ase, Noat et al (785) in their study of yeast hexokinase 
noted that the reaction is ordered at pH 8.5 and that glu-
cose adds first to the enzyme. Glucose-6-phosphate inhibi-
tion was found to be competitive with respect to glucose 
at an ionic strength of 0.30 but non-competitive with re-
spect to MgATP. On the other hand, Fromm (343) has demon-
strated mixed inhibition by glucose-6-phosphate with re-
spect to glucose at pH 7.7, 0.05 ionic strength. Other 
workers (88) have confirmed that the non-competitive 
component of this inhibition decreases with increasing pH. 
These results indicate that apparent enzyme mechanisms may 
change with pH. 
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The regulatory significance of the difference in mech-
anism between yeast and type II hexokinase is unclear. How-
ever, while glucose-6-phosphate is generally a competitive 
inhibitor of yeast hexokinase with respect to glucose, glu-
cose-6-phosphate is a competitive inhibitor of the type II 
enzyme with respect to MgATP only at low MgADP levels. The 
main effect of MgADP inhibitiqn in the muscle enzyme appears 
to be to change glucose-6-phosphate inhibition with respect 
to MgATP from a competitive to a mixed type. 
Neat et al (786) obtained good agreement between calcu-
lated and experimentally produced curves of the progress of 
the hexokinase reaction versus time. They have used this 
curve to substantiate their conclusions regarding the mechan-
ism of yeast hexokinase. A similar technique may be used for 
general isoenzyme analysis. It appears that if all isoenzymes 
of a given enzyme have the same mechanism, but different kinet-
ic constants including product inhibition constants, the kinet-
ic constants of the isoenzyme mixture will be a linear combi-
nation of the kinetic constant of the purified isoenzymes. 
Computer analysis of the reaction progress curve should then 
permit calculation of the isoenzyme composition. This approach 
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may be most successful with the five lactic dehydrogenase 
isoenzymes which are of no little clinical importance (956). 
Type II hexokinase is very similar in structure to 
the other mammalian hexokinase isoenzymes with respect to 
molecular weight, number of subunits, pH optimum, and 
other kinetic parameters. It presumably contains both 
type I and type III protein subunits since it migrates 
between types I and III on electrophoresis. On this ba-
sis one would expect type II hexokinase to respond simi-
larly to type III hexokinase under a variety of experi-
mental conditions. 
Shanygina (973) found that glucocorticoid treatment 
decreased heart hexokinase II 60 percent and liver hexo-
kinase II by 73 percent. Although some compensatory in-
crease in hexokinase I activity occurred in both tissues, 
the total hexokinase activity was reduced. Hexokinase II 
is also the isoenzyme which responds to insulin treatment 
which reverses the glucocorticoid effect. The effect of 
cortisol and its blockade by insulin are probably effects 
on the transcription of DNA and different from the in 
vitro effects of these hormones on yeast hexokinase as 
described by Ilyin and Titova (507, 508, 1066, 1067). 
Recently, effects of insulin on metabolism in the ab-
sence of glucose have been demonstrated (897). This implies 
,• 
that insulin has effects other than its effects on glucose 
transport. In a study of the transport of 2-deoxyglucose 
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in muscle, Kipnis and Cori (584) found that insulin in vitro 
could further increase the accumulation of 2-deoxyglucose-6-
phosphate after initial accumulation in the absence of in-
sulin had ceased. 
I" .. . . 
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CHAPTER VI 
GLUCOCORTICOIDS AND CYCLIC ADENYLATE 
~fects on Triglyceride Synthesis and Lipolys·is 
Glucocorticoids inhibit the formation of glyceride gly-
cerol in the absence of epinephrine but enhance its forma-
tion in the presence of epinephrine. These glucocorticoid 
effects may be mediated via citrate inhibition of the phos-
phofructokinase and pyruvate dehydrogenase reactions in 
the absence of cyclic adenylate. The abolition of the in-
hibitory effect of citrate on phosphofructokinase by cyclic 
adenylate, will also be considered. In addition, the mech-
anism by which glucocorticoids may affect citrate levels 
will be discussed. 
~· As in any study of hormonal effects, observations must 
r 
~· begin with those on intact animals. Levin and Farber (653) 
k f r found that adrenalectomized rats could not mobilize fat 
i!.' t to the liver during fasting because glucocorticoids are 
1· ~ i required for the lipolytic effects of growth hormone in 
' 
fasting. Wilhelmi (1150) found that insulin was required 
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for lipogenesis from acetate and carbohydrate. However, cor-
tisone administration inhibited lipogenesis from these 
sources. He noted that growth hormone treatment increased 
fatty acid oxidation and reduced the respiratory quotients 
in the animals and that this action of growth hormone re-
quired the administration of a small amount of cortisone 
which was ineffective when administered alone. At a con-
stant level of administered growth hormone, glucosuria also 
remained constant throughout a 10-f old elevation of adreno-
corticotrophin~ On the other hand, at a constant level of 
administered adrenocorticotrophin, glucosuria was directly 
proportional to the dose of growth hormone. These results 
indicate that the glucocorticoid requirement is saturated 
by relatively small amounts of the hormone while the growth 
hormone requirement is not. 
Welt and Wilhelmi (1133) found that growth hormone and 
adrenocorticotrophin decreased the incorporation of deuter-
iurn into the body fat of the rat while adrenalectomy had 
the opposite effect. The importance of such a decrease is 
.indicated by the observation of Lukens (680) who pointed 
out that the normal rat converted 3 percent of its daily 
intake of carbohydrate to glycogen, 30 percent to fat, and 
67 percent to carbon dioxide. This action of growth hor-
mone and glucocorticoids may also be important in diabetes 
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for, as noted by Chaikoff (166), lipogenesis from glucose 
was much more depressed than glycogen formation in this 
condition. Lukens noted that, although glucocorticoids and 
growth hormone depressed deuterium incorporation into fat, 
normal rats incorporated almost three times as much acetate 
as pyruvate into fatty acids as hypophysectomized rats in-
dicating that inhibition of pyruvate dehydrogenase was a 
major effect of growth hormone and glucocorticoids in nor-
· mal rats. In addition, the fact that adrenalectomized 
rats did not accumulate total body fat in spite of greater 
fat synthesis, indicates that adrenalectomy also increased 
fat oxidation. The mechanism whereby the adrenal inhibits 
fat oxidation is unknown but appears to be related to the 
catabolic effects of glucocorticoids on peripheral tissues 
leading to a sparing of body fat stores. 
I 
Effect of Growth Hormone on Fatty Acid Oxidation 
Although glucorticoids may decrease fat oxidation in 
~' growth hormone treatment leads to increased fatty 
acid oxidation. Greenbaum (407) observed that total body 
fat fell from 40 percent to 20 percent after growth hormone 
administration. Greenbaum and Mc Lean (408) also observed 
increased hepatic fatty acid oxidation between 12 and 24 
hours after growth hormone in rats, but noted that fatty 
acid oxidation was inhibited 6 hours after administration 
~--
.. 
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of the hormone. These findings may indicate that growth hor-
mone does not directly increase fatty acid oxidation in the 
liver, but, rather, that the increased hepatic oxidation is 
secondary to increased lipolysis in the adipose tissue. 
Swislocke and Szego (1043) also observed a reduction in 
serum free fatty acids in dogs within 30-60 minutes of growth 
hormone administration. In contrast, the increase in serum 
free fatty acids which was simultaneous with the increased 
fatty acid oxidation noted above was not observed until 12 
hours due to the requirement of DNA and protein synthesis for 
the lipolytic response (407). Presumably, the protein synthe-
sized under these conditions interacts with glucocorticoids 
and activates adipose tissue lipase. The early reduction of 
serum free fatty acids is believed to be due to a stimula-
tion of insulin secretion by growth hormone. 
·Irifluence of Dietary Carbohydrate 
Goodman (391) found that the effect of growth hormone 
on glucose metabolism in adipose tissue depends on the car-
bohydrate and fat content of the diet. On high-carbohydrate, 
low-fat diets, the effects of growth hormone in hypophysec-
tomized rats is similar to the effects of growth hormone in 
normal rats. Serotonin released by growth hormone may func-
tion as a glucocorticoid under these conditions.· Goodman 
(397) has also found that growth hormone inhibits glucose 
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oxidation and lipogenesis in fed hypophysectomized rats at 
;· concentrations which are not lipolytic. However, the fact 
that the rats used in these experiments had not been hypophy-
sectomized by the author far enough in advance of the experi-
ments to permit cortical atrophy does not eliminate a neces-
sity for glucocorticoids in the effects of growth hormone. 
Growth hormone and glucocorticoids are ineffective in stimu-
lating lipolysis when added in vitro to such a system unless 
.the hypophysectomized rat has been treated with growth hor-
mone for two days prior to the experiment. 
' Toxicity of Growth Hormone 
The accelerating effect of growth hormone on fatty 
acid oxidation may not persist during chronic growth hor-
mone administration. Winkler et al (1166) observed that 
this effect of the hormone could not be observed following 
7 days of continuous treatment. De Bodo and Sinkoff (218) 
also observed this effect and further noted that growth 
hormone was toxic on prolonged administration. ·Glucocor-
ticoids eliminated the toxicity and counteracted growth 
hormone-stimulated insulin release. 
Hypophysectomy greatly reduces the lipolytic effect 
of epinephrine, abolishing the response at low epinephrine 
levels. Part of the effect of hypophysectomy has been at-
tributed to the absence of ACTH-stimulated cortisol synthesis. 
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cyclic adenylate produced in response to epinephrine activates 
phosphofructokinase and enhances the formation of glyceride 
glycerol. In the presence of epinephrine, adipose tissue 
from hypophysectomized rats esterifies 80 percent of the free 
fatty acids hydrolyzed during lipolysis compared to 70 per-
cent in the presence of all pituitary hormones. Glucocorti-
coids alone enhance the effects of low epinephrine levels in 
hypophysectomized rats. However, the effects of high epi-
· nephrine levels are not enhanced. Furthermore, the fact that 
glucocorticoids exert no effects in hypophysectomized rats in 
the absence of epinephrine indicates that the effect of glu-
cocorticoids under these conditions is due to an inhibition 
of the enzyme phosphodiesterase which has been described {969}. 
Role of Phosphodiesterase and Theophylline 
Changes in phosphodiesterase activity cannot explain 
the effects of glucocorticoids in the presence of growth 
hormone because these effects occur with no change in.the 
~- concentration of cyclic adenylate {395}. Fain {299} noted 
~}1!­
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that insulin, nicotinic acid, prostaglandin E1 and 1-phen-
ethylbiquanide inhibited the basal lipolysis of isolated 
fat cells as well as lipolysis caused by catecholamines, 
ACTH, growth hormone and glucocorticoids. 
Weiss et al (1129} were among the first investigators 
to postulate .a role for cyclic adenylate in adipose tissue 
f. 
------------------ --- ----
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lipolysis. They also noted that the 1,3-dimenthylated xan-
thine theophylline and adrenocorticotrophin had lipolytic 
effects. They reported that the maximal response to nore-
pinephrine was only one-third that of theophylline suggest-
ing that theophylline had lipolytic effects which were not 
mediated by cyclic adenylate. Compared with norepinep~rine 
adrenocorticotrophin was 100 times as active on a molar 
basis. Epinephrine and adrenocorticotrophin activate 
adenyl cyclase by different mechanisms (146, 148). 
The single phosphodiesterase enzyme which controls the 
degradation of cyclic adenylate is just as important as 
that which controls the formation of this nucleotide. 
Senft et al (968) noted that the activity of the enzyme was 
decreased in liver and adipose tissue of alloxan-diabetic 
rats thus explaining the increase in cyclic adenylate in 
these organs. Senft et al (969) observed that glucocorti-
coids also depressed the synthesis of phosphodiesterase 
by a mechanism that involved DNA and protein biosynthesis. 
Neither the action of insulin in increasing the synthesis 
of the enzyme nor that of glucocorticoids in decreasing 
enzyme synthesis can account for the lipolytic effects of 
theophylline which do not involve an elevation in cyclic 
adenylate. Bernbaumer et al (137) noted that neither growth 
hormone nor glucocorticoids alone directly affected enzyme 
-. 
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activity. 
·~ N6-2 '-Dibutryl Cyclic Adenylate 
-
Many investigators have used the N6-2'-dibutryl deriv-
ative of cyclic adenylate in their experiments because of 
its more rapid penetration into cells. They have assumed 
that all of the effects of the derivative are due to its 
conversion to cyclic adenylate. However, Solomon et al 
(1002) have shown that the dibutyrl derivative may have 
opposite effects •. The dibutyrl derivative has an inhibi-
tory effect on glucose utilization whereas the unsubsti-
tuted nucleotide stimulates glucose utilization. The 
reason for this difference is not immediately apparent 
but the phenomenon should be kept in mind when interpreting 
the actions of the cyclic adenylate derivative. 
Glucocorticoids have two distinct effects on adipose 
tissue both of which requires the action of growth hor-
mone. The glucocorticoid effect which occurs at lowest 
concentration is only relatively specific in that it can 
also be produced by deoxycorticosterone (293). This ef-
feet is produced by the interaction of these steroids with 
a growth hormone-dependent protein. The steroid-protein 
complex then increases cytoplasmic citrate levels. Higher 
concentrations of glucocorticoids specifically interact 
·With another growth hormone-dependent protein to increase 
the activity of adipose tissue lipase. At 0.01 µg/ml dex-
amethasone, 9a-fluoro-11S,17a,21-trihydroxy-16a-methyl-l, 
4-pregnadiene-3,20-dione, has no significant effect on li-
polysis but decreases palmitate-1-14c incorporation into 
triglycerides from 82 percent to 58 percent of the total 
fatty acids released by lipolysis (370, 371). Similar 
results were reported by Jeanrenaud and Renold (526) and 
are shown in Table II. Glucocorticoids alohe in the ab-
sence of growth hormone also have effects on transcription 
in adipose tissue. For example, Senft et al (969) found 
that glucocorticoids depressed the biosynthesis of the 
enzyme phosphodiesterase in adipose tissue thereby en-
hancing the effects of theophylline, a phosphodiesterase 
inhibitor, on adipose tissue. Butcher et al (146) also 
showed that nicotinic acid could inhibit the enzyme while 
imidazole activated the enzyme, but the biological sig-
nificance of these observations has not been determined. 
Moskowitz and Fain (762) also showed that cyclohexi-
mide inhibits phosphodiesterase and increases cyclic 
adenylate. They found that growth hormone could also in-
crease cyclic adenylate but only after a one-hour lag 
period in which DNA, RNA and protein synthesis was man-
datory. However, their most. surprising finding was that 
1 mM theophylline stimulated lipolysis maximally so that 
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EFFECT OF 9a-FLUORO-llS,17a,21-TRIHYDROXY-16a-METHYL-l,4-PREGNADIENE-3,20-DIONE 
IN VITRO ON GLYCEROL-FFA BALANCE IN ADIPOSE TISSUE FROM FASTED RATS 
Controls 
Glucocorticoid 
0.1 µg/ml 
Total Lip:'.)lysis 
(Net Glycerol x 3) 
30.6 
33.5 
From Jeanrenaud and Renold (526) 
µrroles/gm of wet tissue wt 
Re-Esterif ication 
Net FFA FFA Re- Percent of 
Production Esterif ied Total Lip:'.)lysis 
22.0 8.6 28 
-
30.5 3.0 9 
Incubations carried out for 4 hours in a Krebs-Ringer bicarl:x:mate buffer containing 
5 rrM glurose. 
'· 
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it was not increased by growth hormone and glucocorticoids. 
Furthermore, this effect occurred with no elevation in cyc-
lic adenylate. These results indicate that growth hormone 
and glucocorticoids do not increase lipolysis by increasing 
cyclic adenylate. Rather, these hormones produce an ef-
fect similar to that of theophylline which is also not ac-
tive by virtue of its inhibition of phosphodiesterase. 
The mechanism whereby the combination of the growth hor-
mone-dependent protein and glucocorticoid affects citrate 
levels has not been determined. 
Munk (769) found that deoxycorticosterone in vitro 
could also reverse the effect of adrenalectomy but that 
it was less effective than either corticosterone or cor-
tisol. Inhibitory effects of cortisol on the incorpora-
:{< tion of acyl coenzyme A into triglycerides were observed 
at concentrations of 10-6 Molar during a 2.5 hour incuba-
'i' tion. Fain et al· (299) demonstrated that the lipolytic 
effect of growth hormone appeared immediately if the gluco-
corticoid was added to adipose tissue which had previously 
been incubated for 2.5 hours with growth hormone. The 
fact that deoxycorticosterone can block triglyceride syn-
thesis at higher concentration suggests that other steroids 
and non-steroids may also produce this effect by occupying 
glucocorticoid sites. Although glucocorticoids may have 
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the highest affinity for this site, it is not as specific a 
receptor site as that which leads to the stimulation of hepa-
tic glycogenesis. 
Hepatic Glucocorticoid Receptor Proteins 
-
An example of a specific glucocorticoid effect is seen 
in the work of Beato et al (54) who have isolated a gluco-
corticoid receptor protein from liver which they have im-
plicated in the transport of the cytoplasmic hormone to 
the nucleus where the glucocorticoid inducation of gluco-
neogenic enzymes occurs. On the other hand, an example of 
a non-specific glucocorticoid effect is seen in the study 
of Dugle et al (510) on the diabetogenic action of steroids. 
They found that those steroids with keto groups at C-11 
were more diabetogenic than llS-hydroxy compounds. The com-
pound·4-pregnene-3,ll,20-trione was more diabetogenic than 
llS-hydroxy-4-pregnene-3,20-dione. This observation is 
somewhat similar to observations that have been made con-
cerning the anti-tumor potencies of steroids (369). 
Effect of Triiodothyronine in Hypoehysectomized Rats 
In hypophysectomized rats, triiodothyronine has ef-
fects similar to growth hormone and glucocorticoids. It 
increases the sensitivity of adipose tissue to epinephrine 
after a three-hour incubation and to theophylline after a 
twelve-hour incubation (397). These findings indicate 
' 
' 
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that the hormone has at least two effects, one of which may 
be related to phosphodiesterase activity. 
Norepinephrine is probably responsible for most of 
the glycerol release from adipose tissue. However, when 
the basal.state is altered by epinephrine from the adrenal 
medulla, this catecholamine increases the synthesis of 
cyclic adenylate. Cyclic adenylate activates a specific 
. . 
lipase which non-stereo-specifically hydrolyzes one fatty 
acid from triglyceride substrates. 
The degree to which glycolysis is coupled to pyru-
vate oxidation is determined by the lactic dehydrog-
enase isoenzyme composition in the tissue. Tight coupl-
ing occurs with LDH 1 in heart and the level of NADH is 
more stritctly regulated than it is by LDH 5 in liver so 
that elevated levels of pyruvate and NADH prevail during 
gluconeogenesis. 
Effects of Diabetes on Citrate and Pyruvate Levels 
Dixit et al (238) have reported that a 2-3 fold eleva-
tion in muscle citrate is found in alloxan-diabetic rats. 
More importantly, they found a decreased rate of citrate 
oxidation by muscle but not by liver. These results may 
be due to the more rapid glucocorticoid metabolism of the 
liver in comparison to peripheral tissues. If true, the 
rate of glucocorticoid metabolism could influence diabetes 
. , 
f' 
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by this mechanism. 
Henneman and Bunker (450) reported that human diabetics 
had higher levels of serum pyruvate due to a reduced capa-
city to oxidize pyruvate. This appears to be a direct con-
sequence of the unopposed action of glucocorticoids since 
Haugaard and Haugaard (435) observed the same phenomena in 
alloxan-diabetic rats. 
The degree of inhibition of pyruvate utilization rela-
tive to glycolysis is indicated by the percentage of blood 
glucose carbon which returns to the liver as glycerol or 
lactate to be incorporated into hepatic glycogen. This 
process has been termed recycling. Friedman et al (3~7) 
demonstrated that diabetic rats recycle 2.4 percent of 
their glucose compared to.1.2 percent for normal rats • 
This finding indicates that insulin decreases recycling. 
However, these same workers found that glucocorticoids 
did not affect recycling. This could be interpreted to 
mean that glucocorticoid-induced elevations in .. citrate 
inhibited glycolysis and pyruvate utilization to approxi-
mately the same extent. 
Elevations in muscle citrate in diabetes have been 
demonstrated by Garland et al (358) and by Garland and 
Randle (359). Wieland and Wies (1147) hav:e shown that a 
3-fold elevation in hepatic acetyl coenzyme A occurs in 
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cortisol-treated diabetic rats compared to similar rats 
treated only with insulin. Cahill et al (i51) reported that 
insulin decreased the conversion of glucose to glyceride 
glycerol 5-fold.but that this conversion was increased by 
epinephrine. Epinephrine increases cyclic adenylate which 
decreases the km of phosphofructokinase for fructose-6-
phosphate. Apparently, this effect is sufficient to over-
· come the inhibition of phosphofructokinase by MgATP. In 
addition, the depletion of ATP produced by the activation 
of phosphofructokinase and hexokinase increases the con-
version of triose phosphates to pyruvate. 
Renold et ~l (878) and Phillips ~t ~l (833) reported 
that lipogenesis from pyruvate was reduced 9-fold while 
glucose utilization was reduced only 25 percent by corti-
sol in the presence of 10-4 Molar epinephrine. Deoxycor-
ticosterone in vitro is 50 percent as effective as cortisol 
at a concentration of 30 µg/ml (769). Munk also found that 
lipogenesis was depressed in fat pads from adrenalectomized 
rats by the administration of 2.5 mg/kg cortisol before 
sacrifice. 
Fain et al (299) reported that 0.004 µg/ml dexametha-
sone reduced the glucose uptake of the fat pad from 3.19 
to 1.24 µmoles per 100 mg of tissue while pretreatment of 
the tissue with higher concentrations (0.032 µg/ml) for 
' ' 
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1.5 hours resulted in up to 75 percent inhibition of glucose 
uptake. Goodman and Knobil (389) also noted that glucocor-
ticoid treatment of hypophysectomized rats restored their 
lipolytic response to epinephrine but not to ~rowth hormone. 
This finding is important because it indicates that gluco-
corticoids can enhance the effect of cyclic adenylate quite 
independently of its action with the growth hormone-depen-
dent protein which leads to_ an increase in citrate levels. 
The effect of glucocorticoids on cyclic adenylate in the 
absence of growth hormone appears to be due to the induc-
tion of a glucocorticoid-dependent protein which .inhibits 
the enzyme phosphodiesterase (969). This inducation does 
not explain glucocorticoid effects in the absence of changes 
·in the level of cyclic adenylate. 
Yorke (1189) has found that glucose transport is in-
hibited by low glucocorticoid concentrations which are not 
lipolytic. Citrate inhibition of phosphofructokinase 
raises glucose-6-phosphate which, in turn, may raise the 
km of hexokinase for glucose, thereby reducing enzyme 
activity and the glucose concentration gradient which 
partly determines glucose transport. 
Control of Lipogenesis 
Adipose tissue can respond to both the specific and 
non-specific effects of glucocorticoids. In 1951 Brady 
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~t al (112) observed that cortisone treatment depressed both 
triglyceride and carbon dioxide formation from glucose. 
Landau and Katz (628) estimated that from 11-23 percent of 
glucose in adipose tissue was metabolized via the pentose 
phosphate shunt. However, Wies and Ball (1172) noted that 
most of the NADPH necessary for fatty acid synthesis in 
adipose tissue was formed in the tissue by the operation 
of the malate cycle: 
Pyruvate + co2 +ATP = Oxalacetate +ADP + Pi 
Oxalacetate + H+ + NADH = Malate + NAD+ 
+ Malate + NADP = Pyruvate + co2 + NADPH 
Sum: NADH + NADP+ +ATP.= NAD+ + NADPH +ADP + P. 
1 
The operation of this cycle explains the observations of 
Landau et al (629) that.the amount of NADH'generated during 
fatty acid synthesis was excessive while the rate of opera-
tion of the pentose shunt cou~d not account for all of the 
NADPH required for synthesis. The role of pyruvate carbo-
xylase in this cycle explains ~ts presence in adipose 
tissue in the absence of gluconeogenesis. Furthermore, 
those factors which inhibit the pyruvate dehydrogenase 
reaction may increase the malate cycle. 
Ball (40) determined that epinephrine could activate 
glycolysis in adipose tissue about 24 percent. As men-
tioned earlier this effect is due to an action of cyclic 
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adenylate on phosphofructokinase as well as to an elevation 
of long-chain acyl coenzyme A. 
The anti-insulin effects of growth hormone and gluco-
corticoids occur in isolated adipose tissue and do not re-
quire the presence of B lipoprotein. However, the fact 
that growth hormone and glucocorticoids increase B lipo-
protein insulin inhibition in vivo but not in vitro simply 
reflects the role of the liver in B lipoprotein synthesis. 
Therefore, B lipoproteins may transport the factor which 
mediates the citrate elevation caused by growth hormone 
and glucocorticoids in isolated tissues. Furthermore, 
the B lipoprotein insulin antagonist may be identical 
with the lysolecithin species described by Bolton et al 
(89) which increases the inhibitory effect of ADP on 
platelet metabolism. 
Investigations of the hormonal dependence of the synal-
bumin insulin antagonist by Vallance-Owen et al (1084) in-
dicate that this antagonist is also dependent on both 
growth hormone and glucocorticoids. Although the exact 
nature of the synalbumin antagonist is unknown, its re-
ported properties are not inconsistent with those of a 
polar lipid. Lysolecithin is found in association with 
plasma albumin as is the synalbumin antagonist. If the 
~ synalbumin insulin antagonist is a lysolecithin dependent 
L 
on growth hormone and glucocorticoids, then another lysol-
ecithin species bound to 8 lipoprotein may also be depen-
dent on these two hormones. 
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Winternitz ~t al (1170) showed that the effect of epi-
nephrine on glycogenolysis and glycolysis was enhanced in 
adrenalectomized rats. Epinephrine produced a 62 percent 
fall in muscle glycogen in adrenalectomized rats compared 
to a 34 percent fall in normal rats. In addition, in the 
normal rat the muscle glycogen which disappeared could be 
accounted for as liver glycogen while that in the adrenal-
ectomized rat could not. Thus, it ·appears that glucocor-
ticoids also enhance the gluconeogenic process under these 
conditions. The extent of glycogenolysis in muscle com-
pared to liver depends on the catecholamine used to elicit 
the effect. Isopropyl noradrenaline preferentially in-
creases muscle glycogenolysis and has little or no effect 
on liver glycogen. Glycogenolysis in muscle implies in-
creased glycolysis. The normal response of adrenalec-
tomized rats to epinephrine could be restored by the ad-
ministration of adrenal cortical extract 12 hours prior· 
to the experiment or by the administration of cortisone 
for 24 hours beforehand. In diabetic rats, liver glyco-
gen as well as muscle glycogen falls after epinephrine, 
suggesting that insulin is required for the formation of 
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~ iiver glycogen from glucose synthesized in the liver. The 
·, 
enhanced effect of epinephrine was not seen in adrenalec-
tomi zed-eviscerated rats and this may indicate that the 
liver produces a factor under the influence of glucocorti-
coids which increases the effect of epinephrine. This 
factor may or may not be identical to the anti-insulin 
factor discovered by Bornstein (98) which is transported 
to peripheral tissues as a lipoprotein complex. Winternitz 
has pointed out that the necessity for the liver in the pro-
auction of the epinephrine opposing factor may partially 
explain Russell's (917) finding that there was no differ-
ence in the glucose tolerance of normal eviscerated and 
adrenalectomized-eviscerated rats maintained on deoxycor-
· ticosterone. It would also explain her finding that the 
~·. 
I 
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increased sensitivity of the adrenalectomized rat to in-
sulin is abolished by evisceration. If the primary ef-
feet of the hepatic factor is to decrease the levels of 
cyclic adenylate (290), it may be the same as that of the 
lysolecithin reported by Bolton et al to combine with B 
lipoprotein and increase platelet aggregation. 
Friedman et al (337) have found that ·glucocorticoids 
are required for the effect of hepatic cyclic adenylate 
on gluconeogenesis even though these steroids do not alter 
the concentration of the nucleotide. Bernbaumer et al 
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(137) have also shown that growth hormone and glucocorti-
coids either alone or in combination do not activate adenyl 
cyclase but they do enhance the action of cyclic adenylate 
already formed. 
Scrutton and Utter (960) noted that glucagon and there-
fore cyclic adenylate enhanced pyruvate carboxylase activity 
in liver. Furthermore, Friedman· ·et ·a1 (337) found that the 
rate of gluconeogenesis from lactate was enhanced by gluca-
gon in livers from intact rats but not in livers from ad-
~ renalectomized rats. This response could be restored by 
' 
~· 
the addition of glucocorticoids to the perfused liver. 
Meismann and Segal (730) have noted ·similar behavior in 
the effects of cyclic adenylate on the kinase which acti-
vates hepatic glycogen synthetase. 
Although the induction of gluconeogenic enzymes is 
enhanced by glucocorticoids and opposed by growth hormone,· 
not all of the effects of glucocorticoids on the liver can 
be blocked by inhibitors of DNA and protein synthesis. 
Long et al (676) found that doses of cortisol which have 
no effect on gluconeogenesis from protein have a marked . 
inhibitory effect on glucose utilization in adrenalecto-
mized-diabetic rats. These results suggest that the same 
glucocorticoid-dependent factor formed in the liver in-
hibits glycolysis there and in peripheral ·tissues. 
One of the factors regulating gluconeogenesis is li-
polys is. Williamson et al (1156, 1157) have pointed out 
that none of the steps in the conversion of fatty acids to 
acetyl coenzyme A or to acyl carnitine are rate-limiting 
for fatty acid oxidation. The ratio of NADH to NAD+ is 
increased by fatty acid oxidation and NADH is the main 
source of reducing equivalents for gluconeogenesis. 
Vohainy et al (1107) have similarly commented on the 
failure of added carnitine to enhance palmitate oxidation 
in the perfused rat heart in vitro. On the other hand,· 
carnitine reduced the rate of palmitate oxidation and in-
creased the labeling of the phospholipid fraction. The 
reported enhancement of fatty acid oxidation by carnitine 
in isolated mitochondria may be related to the loss of 
endogenous carnitine during the preparation of the mito-
chondria. 
Effect of Ethanol on Gluconeogenesis 
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Although gluconeogenesis is increased by an increase 
in the reduction potential of the pyridine nucleotides, 
excessive reduction potentials may actually inhibit gluco-
neogenesis as well as peripheral glucose utilization. ·In 
a study of ethanol-induced hypoglycemia Lochner et al (671) 
found that the cause was an inhibition of gluconeogenesis 
in spite of the fact that ethanol inhibited peripheral 
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glucose utilization 25 percent. Both the inhibition of glu-
cose utilization as well as the decrease in gluconeogenesis 
may be attributed to an excessive reduction of pyridine nu-
cleotides. Krebs (618) has shown that NADH depletes hepat-
ic pyruvate by converting it to lactate thereby reducing 
the rate of the pyruvate carboxylase reaction. 
The increase in the reduction potential of the pyri-
dine nucleotides by ethanol depends on the preferential 
utilization of ethanol over other respiratory substrates. 
The conversion of ethanol to acetate does not require the 
utilization of adenosine-5'-triphosphate. On the contrary, 
NADH is generated in the alcohol dehydrogenase and alde-
hyde dehydrogenase steps. Thus, ethanol is oxidized in 
preference to other respiratory substrates because its 
oxidation is associated with a greater free energy decrease 
than the oxidation of other substrates. 
Effects of Clavine Alkaloids 
The fact that theophylline can produce all of the ef-
fects of growth hormone and glucocorticoids indicates the 
possibility that a similar. endogenous compound may be in-
volved in the effects of these hormones. Brek et al (116) 
reported that serotonin was lipolytic in vitro. Hotta et 
~ (477) further demonstrated that dihydroergotamine en-
hanced lipolysis in isolated rat adipose tissue cells. 
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This effect is opposite to that expected from an adrenergic 
blocking agent. In related experiments Harvey et al (432) 
showed that the non-peptide ergot alkaloid ergonovine could 
block the hyperglycemic effect of epinephrine, although the 
dose required was about 40 times higher than that required 
for the same effect with the a-adrenergic blocking agent 
ergotamine. These results suggest that only non-peptide 
ergot alkaloids can block the effects of cyclic adenylate. 
Fain (298) has also shown that the lipolytic effect of di-
hydroergotamine was potentiated by theophylline suggesting 
that the two drugs share a common receptor site. 
Hotta et al (477) reported the lipolytic effects of di-
hydroergotamine on adipose tissue cells. They noted that 
the effect ·in· Vitro was similar to that observed in vivo and 
also noted that insulin could counteract the effect. Prior 
treatment with theophylline and/or growth hormone enhanced 
the effect which was similar to that of glucocorticoids in 
that dihydroergotamine had no effect on lipolysis produced 
by adrenocorticotrophin, thyroid-stimulating hormone, or 
glucagon. These effects were confirmed by Nakano ·et al 
(775) and Fain (208). These results are unrelated to the 
blockade of adrenocorticorophin release by ergotamine ob-
served by Levy and Raney (657) in adrenalectomized rats. 
Northrop and Parks (789) also reported lipolytic effects 
obtained with growth hormone and glucocorticoids. 
In contrast, Efendo and Ostman (271) found that theo-
phylline did not increase the lipolytic effect of dexa-
methasone. They observed that theophylline blocked the 
conversion of glucose to glyceride glycerol without af-
fecting the levels of cyclic adenylate. Butcher and 
Sutherland (145) have reported some properties of phospho-
diesterase including its requirement for magnesium, stim-
ulation by imidazole, and preferential inhibition by 10-2 
M theophylline. The finding that theophylline blocks the 
conversion of glucose to glyeride glycerol could mean that 
theophylline has the same site of action as glucocorti-
coids, i.e. inhibition of triglyceride synthesis. This 
interpretation is born out by the finding that theophyl-
line did not increase the lipolytic effect of glucocor-
ticoids (397). 
Bray and Goodman (115) also found that epinephrine 
increased glycolysis in adipose tissue independently of 
its lipolytic effect indicating that phosphofructokinase 
~- is affected by lower concentrations of cyclic adenylate 
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than the levels required to activate adipose tissue lipase. 
On the other.hand, Karl et al (564) found that when the 
synalbumin insulin antagonist acted on rat diaphragm, the 
concentration of sn-3-glycerophosphate was increased even 
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though glucose uptake was decreased. This indicates that 
the synalbumin antagonist inhibits the glycolysis of D-gly-
ceraldehyde-3-phosphate. 
Flatt (323) has emphasized that insulin-stimulated 
fatty acid synthesis is an energy-yielding process for 
adipose tissue cells. It is therefore limited by the ca-
pacity of the cell to utilize the energy which is produced. 
Because lipolysis in effect functions as an adenosine 
triphosphatase in the metabolism of the cell, the rates of 
fatty acid synthesis in the presence of epinephrine and in-
sulin are greater than the rates in the absence of epineph-
rine. Furthermore, Flatt has shown that fatty acid syn-
thesis is limited by the rate of triglyceride formation. 
Rodbell (897) showed that insulin increased free 
fatty acid uptake by adipose tissue cells in the absence 
of glucose. Larner, however, detected no change in eye-
lie adenylate after insulin. These results suggest that 
insulin decreases lipolysis by a mechanism independent of 
cyclic adenylate. This effect of insulin may explain why 
adipose tissue is more sensitive to insulin than muscle 
(151). 
Anti-Lipolytic Effects of Oral Hypoglycemic Agents 
Brown and Stone (129) observed that tolbutamide (1-
butyl-3-(p-tolylsulfonyl)urea] inhibits the lipolytic 
effect of dexamethasone and growth hormone immediately and 
~oes not require a lag period. Likewise, Stone and Brown 
(1034) determined that phenformin (1-phenethylbiquanide) 
had an anti-lipolytic effect in the absence of glucose. 
The lipolytic effects of DL-arterenol, ACTH, glucagon, and 
theophylline were opposed by phenformin. These results 
suggest that tolbutamide directly opposes the anti-insulin 
effect of glucocorticoids but that phenformin blocks the 
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action of cyclic adenylate as one of its principle effects. 
Phenformin may also lead to inhibition of pyruvic dehydro-
genase. Moorhouse et al (757) observed that the drug de-
creased pyruvate tolerance more in diabetics than in con-
trol subjects. These results suggest that phenformin may 
also enhance citrate inhibition of pyruvate dehydrogenase 
(721) in addition to its effects on cyclic adenylate. 
CHAPTER VII 
METABOLIC EFFECTS OF GLUCOCORTICOIDS 
The non-lipolytic effects of glucocorticoids and 
growth hormone. on glucose metabolism are most important 
in the production of insulin resistance. Unfortunately, 
;·., 
~,. most previous investigators of the anti-insulin action 
~\ 
;, ~ of the hormones have studied them at lipolytic concentra-f 
{_' 
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tions. A second complication of published investigations 
is that they have been done on adipose tissue in which 
the proportion of glucose metabolized via the Embden-
Meyerhof path varies with hormone concentration. 
Effects of Hormones on Glycolysis in Rat Diaphragm 
The effects of insulin and of other hormones on glu-
cose metabolism have been extensively studied with the 
isolated rat diaphragm preparation. This technique was 
introduced by Gemmill who found that insulin increased 
both glucose uptake and glycogen synthesis. Adrenal 
hormone~ have also been studied with this preparation. 
Epinephrine, the first known adrenal hormone, was 
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r 143 f r investigated by Cori et al (200). They found that epineph-
IL:._ . . 
rine decreased glucose utilization. This effect was con-
firmed by Walaas and Walaas (1111) who found that 12 µg/ml 
epinephrine significantly decreased glucose uptake but sig-
nificantly increased lactate output by the rat diaphragm 
preparation. Glycogenolysis also increased so that muscle 
glycogen was depleted within one hour. These results sug-
gest that glucose-6-phosphate formed from glycogen glucose 
can inhibit glucose uptake by causing end-product inhibi-
tion of muscle hexokinase isoenzymes. 
On the other hand, Ingle and Nezamis (518) found that 
the infusion of glucose and epi~ephrine into eviscerated 
rats had no effect on glucose tolerance. Furthermore, 
Bray and Goodman (115) found that epinephrine increases 
glucose uptake in adipose tissue and Williamson (1154) 
found the same effect in rat heart. These latter findings 
suggest that only high concentrations of epinephrine in-
hibit glucose uptake. 
Ingle and Nezamis (514) also examined the effects of 
adrenalectomy on the glucose tolerance of the eviscerated 
rat. They found that adrenalectomy increased the uptake 
of glucose at low levels of glucose and insulin. On the 
other hand, at high levels of glucose and insulin, the 
adrenalectomized rats had higher blood glucose levels at 
,;: 
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the end of the infusion. These results suggest that adrenal 
hormones enhance glycogen formation in extrahepatic tissues 
in the presence of insulin. One possible explanation of 
this effect is that adrenal hormones inhibit glycolysis 
and thereby increase the intracellular concentration of 
glucose-6-phosphate. Another possible explanation is that 
glucocorticoids increase glycogenesis by the kidney. How-
ever, other studies have shown that the kidneys release 
glucose into the blood only during hypoglycemia. Thus, 
, the first explanation is more probable. Additional sup-
L 
port for it is provided by Bowman and Deimer (107) who 
demonstrated that adrenalectomy increases the glycogeno-
lytic effect of epinephrine. 
Kipnis (585) confirmed these results with intact rat 
diaphragm. He noted that adrenalectomy did not affect 
glucose transport, but that it did increase glucose phos-
phorylation in the presence of ,insulin. Hypophysectomy, 
while it decreased basal glucose transport in the absence 
of insulin, also increased glucose phosphorylation in the 
presence of insulin. With the cut·diaphragm, in contrast, 
hypophysectomy increased basal glucose transport but de-
creased glucose phosphorylation in response to insulin. 
·Both adrenal and pituitary hormones decrease glucose phos-
phory],ation in the intact rat. 
.~,,, 
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Kipnis et al (586) also demonstrated intracellular free 
glucose in muscle stimulated with epinephrine. As discussed 
previously, glucose-6-phosphate inhibits muscle hexokinases. 
England and Randle (138) have shown that this mechanism may 
account for over 90 percent of the inhibition of these en-
zymes under certain conditions. However, this mechanism is 
less im~ortant in liver because it contains glucose-6-phos-
phatase. In addition, Ashmore et al (24) have reported 
that the concentration of glucose-6-phosphate in diabetic 
·liver is one-third normal. These results suggest that the 
effect of growth hormone and glucocorticoids on glycolysis 
is more important in muscle and adipose tissue than in the 
liver. Ashmore et al (23) also noted that the rate of glu-
cose phosphorylation was markedly depressed in liver slices 
from alloxan-diabetic rats. 
Effect of Bicarbonate 
Shaw and Stadie (977) first demonstrated the presence 
~ of two identical Embden-Meyerhof pathways in normal rat 
1". 
~· diaphragm. One of these is located on the cell surface, 
f and the other is intracellular. The fact that insulin f is effective in bicarbonate-phosphate buffer but· not in 
f !: phosphate buffer led to the discovery of these pathways. 
"· t 
Only intracellular glycogen formation and glycolysis were 
increased by insulin. On the other hand extracellular 
glycolysis was not responsive to insulin. Apparently, in-
tracellular phosphofructokinase is inactive in the absence 
of bicarbonate according to these workers. Zahnd at al 
(1195) also found that the effect of insulin on glucose 
oxidation in adipose tissue was greater in the presence o.f 
bicarbonate (Table III). Most of these findings were con-
firmed by Landau and Sims (631, 985) using the intact rat 
diaphragm. They carried out all their experiments in bi-
carbonate buffer using either non-labeled or labeled glu-
cose and glucose-6-phosphate. They were, therefore, un-
able to confirm or deny the effect of bicarbonate on in-
tracellular phosphofructokinase. On the other hand, they 
did show that insulin has no effect on the conversion of 
added glucose-6-phosphate into glycogen or lactate. They 
also demonstrated that 11.6 percent of_ the total lactate 
produced in the absence of insulin was produced by the 
extracellular pathway. This percentage was 11.1 percent 
in the presence of insulin, but intracellular glycolysis 
was increased only 5 percent under these conditions. How-
ever, glycogen synthesis was increased 226 percent by 0.1 
unit/ml insulin. 
These results indicate that total glucose uptake is a 
poor measure of glycolysis, especially in the presence of 
insulin. Lactate and carbon dioxide production are better 
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TABLE III 
EFFECT OF BICARBONATE AND PHOSPHATE ON THE RATIO OF 
GLUCOSE CARBON 1 TO GLUCOSE CARBON 6 INCORPORATED 
INTO co2, FATTY ACIDS AND GLYCEROL BY 
ISOLATED EPIDIDYMAL ADIPOSE TISSUE 
Percent of Control 
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Krebs-Henseleit Kreb's Ringer Bicarbonate 
Bicarbonate Phosphate Phosphate 
. OXidation to co2 
·No Horm:me 100.0 123.5 0.810 
Insulin (O.l U/ml) 957.2 246.3 3.89 
Epinephrine 18 µg/ml 72.3 57.8 1.25 
G. H. (100 µg/ml) 65.7 60.2 1.09 
Fatty Acids 
No Honrone 100.0 111.3 0.90 
Insulin 59.7 56.5 1.06 
Epinephrine 125.8 80.7 1.56 
G. H. 75.8 137.1 .55 
Gl::r:cerol 
No Honrone 100.0 53.6 1.87 
Insulin 42.3 53.6 0.79 
Epinephrine 140.2 110.3 1.27 
G. H. 145.4 151.6 0.96 
Zahnd et al (1195) 
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indicators. Also, the fact that the effect of insulin on 
glycolysis is relatively small means that even a slight in-
hibition of its effect may be consequential. The small in-
crease in glycolysis in response to insulin could be second-
arY to insulin-stimulated glycogen formation. As the en-
zyme UTP: a-S-glucose-1-phosphate uridyltransferase [EC 
2.7.7.9] utilizes UTP, it is regenerated from ATP by 
nucleoside diphosphate kinase with depletion of the energy 
charge (one-half the number of pyrophosphate bonds) of the 
adenine nucleotide pool. Glycolysis increases when this 
occurs due to the action of control mechanisms which will 
be discussed later. Furthermore, physiological variations 
in pco 2 may exert significant effects on glycolysis. How-
ever, the effects of bicarbonate buffers on glycolytic en-
zymes have not been thoroughly studied. One other point is 
clear. Since insulin in vitro can reverse the effect of the 
insulin-inhibitor dependent on growth hormone and gluco-
corticoids, it must affect only the ·intracellular glycoly-
tic pathway. 
In their authoritative work on the influence of the 
adrenal cortex on carbohydrate metabolism Long et al (673) 
described several fundamental actions of glucocorticoids. 
They found that in adrenalectomized animals "cortical ex-
tract produces a smaller proportion of glucose oxidation 
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} and a larger deposition of the absorbed glucose as liver 
l t glycogen, while the muscle glycogen level is not increased." 
t· l . 
In contrast to liver glycogen which can be increased in the 
fasted rat by glucocorticoid administration, muscle glyco-
gen cannot be increased by glucocorticoids unless the ani-
mals are fed (676, 768). 
Herring and Crans (453) noted that low doses of cor-
tisol were much more effective in hypophysectomized rats 
in maintaining muscle glycogen than in maintaining liver 
glycogen. Villee and Hastings (1103) confirmed these 
findings using the isolated rat diaphragm and also demon-
strated that part of the drop in muscle glycogen could be 
attributed to increased glucose utilization following 
adrenalectomy. The greater effect on muscle glycogen com-
pared to liver glycogen indicates that gluconeogenesis is 
not involved in this effect. 
Long et al {674) further studied the effect of corti-
sol on the glucose tolerance of the eviscerated rat. They 
found that the infusion of 0.2 mg of cortisol per hour at 
2, 3 or 5 hours before glucose administration or during 
glucose administration did not decrease the glucose tol-
erance of the rat. However, these tests were performed 
without insulin so that glucose transport rather than glu-
cose phosphorylation was limiting for glucose utilization. 
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t 
ce the fact that glucose phosphorylation is limiting 
the conditions of the normal glucose tolerance test, 
results are often cited as evidence for the lack of 
feet of glucocorticoids on peripheral glucose utiliza-
t 
E c on Peripheral Glucose Utilization 
~vidence that glucocorticoids do depress the extra-
h: LC utilization of glucose has been provided by Boutwell 
a: iiang (102). In experiments with mice they noted that 
t' ,irnover time of glucose was increased 50 percent while 
tl lte of glucose utilization was decreased to 65 percent 
o:: > control value 4-6 hours after the administration of 
l c)f cortisone. Also, Lecoco 'et al (648) administered 
a 3e priming dose of 33 mg of cortisol to dogs prior to 
t~ Jntinuous infusion of 1.3 mg of cortisol per minute. 
T ~ound that a 38 percent decrease in hepatic glucose 
o t within 30 minutes with little change in blood glu-
e Frawley (328) also showed that cortisol eliminated 
l rmptoms of hypoglycemia before any changes in blood 
g, 3e occurred. 
C ~s in Hepatic Glycolytic Intermediates 
,ecoco et al (648) attributed the glycogen formation 
F; they observed to an increase in the hepatic concen-
t an of glucose-6-phosphate, an activator of glycogen 
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synthesis. However, Hornbrook et al (476) observed a fall 
in hepatic glucose-6-phosphate and uridine diphosphate glu-
cose after cortisol administration. Furthermore, the he-
patic concentrations of a number of other glycolytic in-
termediates did not change after cortisol. Munk and Koritz 
(768) observed that an elevation in blood glucose always 
preceded the increase in liver glycogen by at least 30 min-
utes. It appears that glucose-6-phosphatase is also acti-
vated under these conditions (22). 
One reason for these discrepancies may be the diff i-
culty involved in measuring small significant changes in 
blood glucose. However, it appears that the activation of 
glycogen synthetase cannot explain the increased glucose 
output by the liver. This can only pe explained by acti-
vation of glucose-6-phosphatase. Furthermore, the explan-
ation that the initial increase in hepatic glycogen syn-
thesis is not secondary to glucose-stimulated insulin re-
lease is supported by the fact that muscle glycogen rises 
1 hour after both blood glucose and liver glycogen are 
elevated. If hepatic glycogen synthesis was caused by 
insulin, it should have coincided with insulin-stimulated 
muscle glycogen formation. 
The Catabolic Effect of Cortisol 
Long et al (676) also observed that glucose synthesis 
was not a consequence of protein catabolism. Dur1ng the 
first 4 hours following cortisol the total carbohydrate 
content of the fasted rat increased 250 mg/kg with no in-
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crease in blood urea nitrogen. The catabolic effect of glu-
cocorticoids appears to be due to an inhibition of amino 
acid transport in peripheral tissues. Tilton and Torralla 
(1065) showed that the administration of cortisone acetate 
to adrenalectomized-eviscerated rats accelerated the rate 
of rise of plasma amino acids under all of the conditions 
which they studied. This finding has been confirmed in 
eviscerated-adrenalectomized-alloxan-diabetic rats by Smith 
and Long (997). Kostyo {610) showed that the effect of cor-
,... tisol, corticosterone, deoxycorticosterone, and 17a,21-di-
hydroxy-4-pregnene-3,20-dione occured after a three-hour 
induction period at l0-7M concentration. 
. Effects of Steroids on Glycogen 
Shortly after the total synthesis of the adrenal ster-
oids the effects of these hormones on glycogen formation 
in rat diaphragm was determined. Bartlett et al (48) used 
labeled glucose to show that corticosterone was less potent 
than deoxycorticosterone at 10 µg/ml in inhibiting glycogen 
formation, thus confirming the earlier findings of Bartlett 
and MacKay (41). Verzar and Wenner (1099) further observed 
that 5-10 mg/100 ml deoxycorticosterone increased. 
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glycogenolysis while completely inhibiting glycogen synthe-
sis caused by 10 milliunit/ml insulin. In a subsequent 
study Verzar and Wenner (1100) compared various hormones 
in the inhibition of glycogen synthesis. They found that 
the order of potency was 3,4-bis(p-hydroxyphenyl)-trans-3-
hexene>progesterone>deoxycorticosterone>corticosterone. 
This order of hormones is not correlated with hormone action 
but is the order of decreasing polarity of the hormones, sug-
gesting that they interact at a hydrophobic site. 
Control of Gluconeogenesis and Gly~ogenesis 
Seubert et al (970) found that gluconeogenesis does 
not require de novo enzyme biosynthesis. However, the ac-
tion of pyruvate carbon dioxide ligase (ADP) (EC 6.4.1.1) 
and GTP: oxalacetate carboxy-lyase (transphosphorylating) 
(EC 4.1.1.32) require the expenditure of four moles of high 
energy phosphate in addition to those derived from glycoly-
sis in order to reverse this process. Also, the activity 
of pyruvate kinase, ATP: pyruvate phosphotransferase 
(EC 2.7.1.40), is so much greater than that of the latter 
enzyme that no reversal of glycolysis could occur unless 
pyruvate kinase were inhibited •. Shrago et al (982) found 
an elevation of phosphoenolpyruvate carboxykinase activ-
ity in alloxan-diabetes and following glucocorticoid 
treatment. 
154 
The low activity of fructose-1,6-diphosphate 1-phospho-
hydrolase (EC 3.1.3.11} in muscle prevents gluconeogenesis 
in this tissue. This enzyme is inhibited by high concen-
trations of its substrate and also by its product fructose-
6-phosphate (752). This means that the enzyme cannot func-
tion unless phosphofructokinase is inhibited. Inhibition 
of phosphofructokinase is also important because hepatic 
pyruvate kinase is also activated by fructose-1,6-diphos-
.Phate. The required inhibition of this enzyme is produced 
by elevated levels of ATP and citrate. Martin and Silbert 
(721} found that citrate also inhibits pyruvate dehydro-
genase. The effect was significant at 1 mM citrate and 
maximal at 12 mM citrate. 
Larner investigated the mechanism by which insulin 
activates liver glycogen synthetase. He found that the 
activation of the enzyme by insulin is mediated by an 
inhibition of the protein kinase which phosphorylates 
[. the I form of the enzyme to the D form (636}. Insulin 
decreases the affinity of Transferase I kinase for cyclic 
adenylate which increases the affinity of the kinase for 
ATP (637). Since the activity of the D form of the en-
zyme is dependent on the concentration of glucose-6-phos-
phate while the activity of the I form is not, a decrease 
in the phosphorylation of the I form increases the activity 
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of glycogen synthetase. Glucose-6-phosphate increases the 
affinity of glycogen synthetase D for its substrate uridine 
diphosphate glucose. However, the synthesis of uridine di-
phosphate glucose is not affected by this activation mech-
anism. Epinephrine increases the concentration of cyclic 
adenylate and thereby promotes the conversion of glycogen 
synthetase to its active D form. On the other hand, glu-
cocorticoids may increase glycogen synthesis by interfer-
ing with the action of this nucleotide (204). 
Vardanis {1088) found that both glucose-6-phosphate 
and inorganic phosphate activated mammalian liver glyco-
gen synthetase by increasing the affinity of the enzyme 
for glycogen 50 fold. The concentration of inorganic 
phosphate required for half-maximal activation was 7.75 
x l0-4M, well within the physiological range. Steiner 
et al (1027) also determined that the enzyme could be ac-
tivated by fructose-6-phosphate. 
Stetten et al (1029) reported that the rate of oxida-
tion of glucose to carbon dioxide was one-third normal in 
alloxan-diabetic rats. In more severely diabetic depan-
creatized dogs Feller (310) found the rate of glucose 
oxidation to be one-fifth normal. However, Chernick and 
Chaikoff (178) found that the oxida~ion of fructose and 
acetate to carbon dioxide was not impaired in the absence 
of insulin, indicating that the block in glucose metab-
olism is at the phosphofructokinase reaction. This block 
is surmounted when fructose-1-phosphate is split to form 
o-glyceraldehyde-3-phosphate. In addition, Chaikoff (166) 
reported that lipogenesis from glucose was reduced to 10 
r percent of normal in the diabetic animal. These findings 
were confirmed by Feller (310) as well as by Stetten· ·~ 
al (1029) who concluded that lipogenesis from glucose was 
depressed more than glucose oxidation. Diabetic liver 
slices, for example, incorporate virtually no glucose in-
to fatty acids compared to the 0.8 percent incorporated 
by normal liver slices. 
The influence of insulin on the formation of pyruvate 
and glycogen in rat diaphragm has been studied by Villee 
et al (1104). They found that insulin increased the per-
centage of pyruvate formed from glucose more than it in-
creased pyruvate oxidation. Diaphragms from adrenalec-
tomized rats synthesized less glycogen than normal but 
more of it from glucose. The marked inhibitory effect of 
the pituitary on glycogen synthesis is shown in Table II. 
Adrenalectomy of diabetic rats restores glycolysis more 
than glycogenesis. 
Cori (199) compared the rates of glycogen formation 
from glucose, fructose and galactose. Although glucose 
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was absorbed from the intestine twice as fast as fructose, 
both hexoses formed liver glycogen equally well and more 
rapidly than galactose. Galactose is probably a poor gly-
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~ cogen precursor because the conversion of uridine diphos-
pha te galactose to uridine diphosphate glucose by UTP-
glucose-4-epimerase (EC 5.1.3.2) depends on the concentra-
+ tion of NAD Peak glycogen values are obtained four hours 
after galactose administration. Cori also noted that 39 
percent of fructose administered to rats was converted to 
liver glycogen compared to 17 percent in the case of glu-
cose. These results indicate that fructose rather than 
glucose is more rapidly converted to liver glycogen. 
Re·gulation· of Fructolysis 
The metabolism of fructose illustrates several impor-
tant aspects of glycolytic control mechanisms. Fructose 
can be phosphorylated by all of the low km hexokinases, 
but its affinity for these enzymes is one-tenth of its 
affinity for a specific ATP: D-fructose 1-phosphotrans-
ferase (EC 2.7.1.3) in liver. This latter enzyme is as 
important as glucokinase in sucrose metabolism. In addi-
tion, the incorporation of fructose into glycogen is one-
sixth normal in alloxan-diabetes (23). Since gluconeo-
genesis is increased in this disorder, this finding sug-
gests that glycerolkinase or triokinase may be depressed 
this condition. 
Liver, muscle and adipose tissue contain fructokinase 
isoenzymes. Hers and Kusaka (454, 455) have described 
.some of the differences between the hepatic and muscle en-
zymes. The muscle isoenzyme has a low affinity for fruc-
tose compared to the hepatic isoenzyme Michaelis constant 
of 5 x l0- 4Molar. However, the hepatic isoenzyme is ex-
ceptionally sensitive to competitive inhibition by ADP. 
This inhibition may involve the ribose moiety of the nu-
cleotide. Gromora (415) has shown that the fructokinase 
present in adipose tissue decreases during fasting. This 
isoenzyme is probably different from the low km forms 
found in intestinal mucosa and liver. 
The f~uctose-1-phosphate formed by the above kinases 
has two fates. In muscle it is further phosphorylated 
by ATP: D-fructose-1-phosphate 6-phosphotransferase (EC 
2.7.1) which has not been extensively studied since its 
discovery by Slein et al (995). In liver, fructose-1-
phosphate is split to form D-glyceraldehyde and dihydroxy-
~ acetone phosphate by aldolase B, an isoenzyme of ketose-1-
phosphate aldehyde lyase {EC 4.1.2.7). When saturated, 
this enzyme can split fructose-1-phosphate and fructose-
1,6-diphosphate at the same rate. Liver aldolase B has 
both a lower km and higher maximum velocity with fructose-
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!-phosphate compared to the muscle isoenzyme. Aldolase A, 
, however, has a maximum velocity with fructose-1,6-diphos-f ~~ f phate which is over 12 times that of the hepatic enzyme. 
~: 
~ Phosphoglucokinase may also be an important regula-
~-
tory enzyme because its product a-D-glucose-1,6-diphos-
phate, in addition to its catalysis of glucose-6-phosphate 
utilization via the phosphoglucoseisomerase reaction, is 
equally potent as this glycolytic intermediate in causing 
end-product inhibition of hexokinase isoenzymes (609). 
Fructose metabolism in liver can proceed by a path-
way which bypasses the reaction catalyzed by the regula-
tory enzyme ATP: D-fructose-6-phosphate 1-phosphotrans-
ferase (EC 2.1.1.11) because liver contains glycerol-
kinase, ATP: D-glycerol-phosphotransferase (EC 2.7.1.30), 
and triokinase, ATP: D-glyceraldehyde 3-phosphotrans-
ferase (EC 2.7.1.28). In contrast, neither muscle nor 
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adipose tissue contain significant amounts of these enzymes. 
D-glyceraldehyde arising from peripheral fructose 
metabolism may be reduced to glycerol by alcohol dehydro-
genase rather than being transported unchanged to the 
liver. Landau and Merlevede (626) found extensive label-
ing in positions 3 and 4 as well as in positions 1 and 6 
of liver glycogen glucose following the administration 
of D-glyceraldehyde-3-14c. However, their conclusion 
L
I! . 
. 
that this could have resulted from the intermediate forma-
tion of glycerol does not appear to be justified in view 
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of the asymmetric nature of glycerol phosphorylation. Gly-
cerol formed in peripheral tissues may serve the function 
of lactate in transferring reducing equivalents from the 
pituitary to the liver. 
~ff ects on Sugar Tran·sport 
Cori and Cori (200} compared the utilization of three 
hexoses in eviscerated rats in the presence and absence of 
insulin. They found that fructose was utilized 5.3 times 
as fast as glucose while mannose was utilized 4.3 times as 
fast in the absence of insulin. However, in the presence 
of insulin fructose and mannose disappeared at the same 
rate but only 38 percent as fast as glucose. The more 
rapid rates of fructose and mannose disappearance in the 
absence of insulin cannot be explained by the km values 
of hexokinase for these hexoses. Since mannose and glu-
cose are transported by different.membrane carriers, in-
sulin apparently decreases the k of the carrier for glu-
m 
cose more than the km of the carrier for mannose. 
The use of fructose in the diet of the alloxan-dia-
betic rats has been reviewed by Sarett and Snipper (935}. 
Since the liver converts fructose to glucose, they found 
no decrease in glucosuria when fructose constituted 60 
. I 
percent of the diet. Only 5 percent of the dietary fruc-
tose was excreted as fructose. However, many of the rats 
fed fructose recovered from their diabetic symptoms and 
excreted less urine than the rats fed glucose. These re-
sults suggest that a significant fraction of the ingested 
fructose is metabolized directly by peripheral tissues in 
the absence of insulin via the f ructokinase reaction which 
bypasses the citrate-inhibited phosphofructokinase reac-
tion. 
In rat heart Battaglia and Randle (50) showed that 
insulin stimulated the transport of glucose, mannose, D-
3-0-methylglucose, 2-deoxyglucose, D-xylose, D-arabinose, 
D-lyxose and L-arabinose by one mechanism and the trans-
port of fructose and galactose by another. Mackler and 
Guest (696) also showed that the increased utilization 
of fructose by diaphragm in the presence of insulin could 
be counteracted by glucose. This implies that fructose 
in the absence of glucose is phosphorylated mainly by 
hexokinase and only by f ructokinase when hexokinase is 
saturated. 
It has been shown that fructose re-feeding restored 
the glucose tolerance 6f the fasted rat more effectively 
than isocaloric sucrose re-feeding, despite the fact that 
the fructose re-fed rats had lower hepatic glucokinase 
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activity. This result indicates that the latter enzyme does 
not influence glucose tolerance in the rat. 
Burch ~t ~l (132) found that fructose feeding increased 
hepatic glucose and glucose-6-phosphate without increasing 
hepatic glycogen synthesis. They attributed the lack of 
glycogen synthesis to a decrease in uridine diphosphate 
glucose secondary to a decrease in ino!ganic phosphate due 
to its incorporation into fr~ctose-1-phosphate. The activ-
ity of liver aldolase becomes rate-limiting for oxidative 
phosphorylation under these conditions. Therefore, fruc-
tose may be a tool for decreasing hepatic ATP. The pos-
sibility that fructose-1-phosphate directly inhibited UTP: 
a-D-glucose-1-phosphate uridyl transfer~se (EC 2.7.7.9) 
was not investigated. 
Fructose is converted to glucose by the intestinal 
mucosa during its absorption. This transformation is 
catalyzed by ketose reductase and aldose reductase with 
sorbitol as an intermediate. This process results in the 
transhydrogenation of NADH to NADPH which is required for 
the synthesis of fatty acids from carbohydrate. The ex-
tent to which this process contributes to carbohydrate-
induced lipemia following sucrose ingestion has not been 
determined. 
Although Wick et al (143) observed that fructose 
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was but poorly utilized in eviscerated rabbits in the pres-
ence of glucose, Miller et al (744) found that intravenous 
fructose disappeared faster than glucose in normal and dia-
betic subjects. Furthermore, Pearson and Rimer (820) ob-
.served that a patient unable to utilize glycogen because 
of phosphorylase deficiency (type V glycogen disease) 
could perform on a treadmill when plasma fructose was main-
tained at 0.10 mg/l. In contrast, a glucose level of 1.60 
gm/l was required for this activity. These findings in-
dicate that peripheral fructose utilization becomes more 
~· significant when glucose utilization is blocked. There-~'. 
~. l fore, the metabolic significance of fructokinase in peri-
l• 
~:· ~ pheral tissues under normal conditions remains obscure. 
~,,, 
Papper et al (806) studied the effect of cortisone 
on the fructose and glucose tolerance of normal man. An 
oral dose of 200 mg of cortisone acetate decreased glu-
~ cose tolerance of normal men. An oral dose of 200 mg 
of cortisone acetate decreased glucose tolerance but 
did not impair fructose tolerance. This result suggests 
that most of the fructose is metabolized by the liver 
under the conditions of the test. On the other hand, 
Frawley et al (328) observed that glucocorticoids could 
reduce the dis.appearance of fructose from the serum at 
low glucose concentrations possibly because some fructose 
is phosphorylated by hexokinase urider these conditions. 
Frawley also noted_that the cortisol effect could not be 
produced by corticosterone administration, indicating ·the 
necessity of the 17a.-hydroxyl group in the effect of cor-
tisol. Sprague et al (1013) al?o demonstrated that 11-
dehydrocorticosterone had little effect on carbohydrate 
metabolism in Addison's disease. 
The key role of triokinase and glycerolkinase in 
fructose metabolism suggests that f~uctose metabolism 
will be impaired when the activity of these kinases is 
reduced. For example, Glenn et al (370) reported that 
cortisol decreased the oxidation of glycerol to carbon 
dioxide. The extent to which the inhibition of these en-
zymes is due to the direct interaction of the dihydroxy-
acetone side chain of the glucocorticoid with the enzymes 
has not been determined. Nor has the effect of growth 
hormone in triokinase activity been reported. 
Randle ~t al (861, 863) have attributed the reduced 
glycolysis of diabetic rat heart to the increased lipoly-
sis which occurs in these tissues. They have termed their 
hypothesis the "glucose-fatty acid cycle." According to 
this hypothesis fatty acids are utilized in preference to 
glucose when they are present as respiratory substrates. 
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Lipolysis in muscle as well as in adipose tissue is in-
creased by insulin deficiency. This effect is believed to 
be due ~o an increase in cyclic adenylate formation which 
is normally prevented by insulin. Since the rate at which 
' fatty acids are oxidized is proportional to fatty acid con-
centration (341), lipolysis tends to increase the ratio of 
+ NADH to NAD as well as the ratio of acyl coenzyme A to 
coenzyme A. 
The ratio of NADH to NAD+ in cytoplasm has been esti-
mated from the ratio of lactate to pyruvate or from the 
ratio of sn-3-glycerolphosphate to dihydroxyacetone phos-
-" phate. Insulin deficiency reduces the lactate/pyruvate 
ratio to 54 percent of its control value in heart and to 
74 percent of its control value in diaphragm. On the 
other hand, the ratio of sn-3-glycerolphosphate to dihy~ 
droxyacetone phosphate was reduced to 50 percent of its 
.,. t control value in heart and to 57 percent of its control 
~· 
~; 
:; value in diaphragm. In contrast, this ratio was unchanged 
in diabetic hepatic cytoplasm. These.cytoplasmic ratio 
changes are opposite to those expected in mitochondria 
where fatty acid oxidation occurs. 
Glycolysis is inhibited by citrate in extrahepatic 
tis.sues in diabetes even though the ratio of NADH to NAD+ 
is decreased. Garland and Randle (359) have found that 
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that the citrate concentration was 53 µmoles/100 gm in dia-
betic rat heart compared to 22 µmoles/100 gm in normal rat 
heart. Garland et al (358) also determined that 1 mmolar 
citrate reduced the rate of the phosphofructokinase reac-
' tion by 23 percent in diabetic rat heart. These results 
were confirmed by Beatty and Peterson (56) who found that 
the excretion of citrate was increased in alloxan-diabetic 
and in depancreatized rats. Given the inhibition of phos-
phofructokinase by citrate in diabetes, the reversal of 
this inhibition by the reduction of citrate levels is a 
key to the mechanism of acti9n of insulin. Although in-
sulin may ipcrease isocitrate oxidation in mitochondria, 
an action of insulin on isolated mitochondria has 'not 
been conclusively demonstrated. Also, since the NADH/ 
NAD+ ratio is one of the factors which controls mitochon-
driql isocitrate oxidation, insulin may act by changing 
this ratio. 
Garland and Randle (359) found that the ratio of 
acetyl coenzyme A to coenzyme A was increased 3-fold in 
diabetic rat heart. In addition, the free fatty acid 
concentration was increased 2.3-fold in diabetic heart 
and 1.8-fold in diabetic diaphragm. The output of gly-
cerol was increased 2.3-fold in heart, 1.6-fold in. dia-
phragm and 1.7-fold in adipose tissue. In muscle the 
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increase in the ratio of acetyl coenzyme A to coenzyme A 
ieads to a 30 percent inhibition of pyruvate oxidation. 
However, in liver it leads to increased formation of ketone 
bodies. 
Newsholme et al (781) also found that pyruvate per-
fusion inhibits glycolysis in muscle but not in liver. In 
muscle pyruvate inhibits the pyruvate kinase reaction. How-
ever, in liver pyruvate may enter the citric acid cycle as 
oxalacetate. This reaction is catalyzed by pyruvate: car-
bon-dioxide ligase (ADP) (EC 6.4.1.1) and is more endergonic 
than the entry of pyruvate into the cycle vta the pyruvate 
dehydrogenase reaction. 
The fatty acids released during lipolysis are acti-
vated to acyl coenzyme A derivatives. However, Garland 
and Randle (359} observed that the concentration of acyl 
coenzyme A in diabetic rat heart was only 66 percent of 
normal. This finding suggests that the incorporation of 
acyl coenzyme A into triglycerides is increased. Denton 
and Randle (227) have shown that the incorporation of 
sn-3-glycerolphosphate into glyceride glycerol increases 
in diabetic rat heart and epididymal adipose tissue as 
expected. However, the mechanism of this effect is obscure 
even though Denton and Ran~le indicated that it was depen-
dent on growth hormone and glucocorticoids. 
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Lipogenesis and Ketosis 
-
Denton and Halperin (228) studied the factors which con-
trol triglyceride formation and found that the rate did not 
correlate with either the concentration of sn-3-glycerol-
phosphate nor with the concentration of acyl coenzyme A. 
Therefore, the mechanism whereby triglyceride synthesis is 
increased in diabetes has not been determined. 
Jungas and Ball (551) have calculated that 40 percent 
of the oxygen consumption of fat cells from fed rats is 
related to the energy requirements of triglyceride syn-
thesis. Triglyceride synthesis is virtuall¥ absent in 
3-day fasted rats; inhibition of triglyceride synthesis 
thus is important to the conservation of glucose during 
fasting. 
Flatt (323) has shown that fatty acid synthesis is 
increased in adipose tissue when triglyceride synthesis 
is increased because acyl coenzyme A inhibits acetyl co-
enzyme A carboxylase. Fatty acid synthesis in this tis-
r sue is limited by the ability of the cell to utilize ap-
!'. proximately 1. 8 moles of high energy phosphate per acetyl 
~~ 
• ~ coenzyme A unit from glucose incorporated into fatty acids. 
r 
~. ~ Therefore, at any level of tissue respiration, the total 
"" ~ ATP derived from fatty acid synthesis and fatty acid oxi-
·~ 
dation is constant. Consequently, the control of the rate 
]'. 
·~·-
of fatty acid oxidation by control of the rate of actyl 
· coenzyme A incorporation into triglycerides represents an 
important control point for glucocorticoid action. 
Scow et ·a1 (957) studied ketosis in pancreatectomized 
rats. They found that either hypophysectomy or adrenal-
ectomy abolished the ketosis. They also found that the 
administration of growth hormone alone to hypophysectom-
ized-pancreatectomized rats had no effect on blood glu-
cose or ketone bodies. On the other hand, cortisone 
alone at a dose of 2 mg/day killed 50 percent of the ani-
mals in 48 hours. Deoxycorticosterone had no effect 
under these conditions. The glucocorticoid also increased 
glycerides in the liver under these conditions. These re-
sults demonstrate that glucocorticoids alone accelerate 
ketosis and that growth hormone enhances this action. 
Scow and Chernik (958) also showed that dexametha-
sone was very ketogenic in hypophysectomized-depancrea-
tized rats but that growth hormone and glucocorticoids 
produced no change in body fat unless the rats were 
stressed. These results ~uggest that the major effect 
of glucocorticoids may be to enhance the effect of epin-
ephrine. Growth hormone alone again had no effect but 
increased lipolysis in response to dexamethasone and 
theophylline. These results suggest that glucocorticoids 
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and theophylline share a common mechanism of action and that 
not all of the lipolytic effect of theophylline is due to 
its inhibition of phosphodiesterase. Fain (294) also ob-
served that growth hormone alone was not lipolytic in adi-
pose tissue but that it enhanced the effects of glucocorti-
coids. Uroguoti et al (1080) reached the same conclusion 
studying ketotic dogs. 
The glycogenic effect of glucocorticoids depends upon 
their inhibition of pyruvic dehydrogenase, while its ke-
togenic effect is due to its enhancement of the lipolytic 
effect of cyclic adenylate. Renold et al (818) deter-
mined that cortisone depressed glucose uptake 25 percent 
while it depressed lipogenesis from pyruvate 89 percent. 
There are many other reports of decreased pyruvate tol-
erance following glucocorticoid administration (328, 450, 
451). However, it is not clear whether an increase in 
the ratio of acetyi coenzyme A to coenzyme A is the mech-
anism whereby glucocorticoids inhibit pyruvic dehydrog-
enase. 
Welt and Wilhelmi (1133) found that adrenalectomy 
increased hepatic lipogenesis. However, the inhibitory 
effect of gluco.corticoids on hepatic lipogenesis may be 
masked by the mobilization of lipid to the liver from 
1 peripheral tissues. Hill and Drake (460) found an 
I 
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increase in hepatic triglycerides but not phospholipids fol-
the administration of cortisone acetate. However, although 
the enzyme which activates fatty acids to their acyl coen-
zyme A derivatives was increased 2-fold, triglyceride syn-
thesis was increased only 30 percent. These results sug-
gest that triglyceride synthesis is primarily inhibited by 
glucocorticoids. Similarly, Hazzard et al (441) noted that 
the rise in plasma triglycerides during estrogen therapy 
was accompanied by a relative inhibition of triglyceride 
synthesis. 
The fact that adrenalectomy restores lipogensis in 
liver but not in isolated adipose tissue suggests that 
glucocorticoids may influence enzymes unique to liver such 
as glycerolkinase. Ashmore et al (25) found that gluco-
corticoids had no effect on the incorporation of glycerol 
into glucose. On the other hand, Glenn et al (368) have 
,, shown that glucoco.rticoids depress glycerol oxidation. 
These results suggest that glycerol phosphorylation is not 
rate-limiting for gluconeogenesis from glycerol. 
In this discussion of the effects of glucocorticoids 
on glycolytic regulation glycolytic oscillations have been 
neglected. However, an understanding of such oscillations 
appears essential for the complete understanding of gly-
\· 
~.· colytic regulation. Betz and Chance (75) have summarized 
~ 
their findings concerning the causes of glycolytic oscil-
lations: 
"If our hypothesis is true, the following 
points are responsible for the oscillations: (a) 
the limited activity of pyruvate decarboxylase, 
responsible for the accumulation of reduced pyri-
dine nucleotide, pyruvate, fructose-1,6-diphos-
phate, dihydroxyacetone phosphate, and glyceral-
dehyde-3-phosphate; (b) the kinetics of phospho-
fructokinase, which is inhibited by its substrate, 
adenosine-5'-triphosphate; and activated by the 
products, fructose-1,6-diphosphate, and adenosine-
5'-diphosphate; (c) the kinetics of glyceraldehyde-
3-phosphate dehydrogenase, which is inhibited not 
only by its products, reduced pyridine nucleotide 
and 1,3-phosphoglycerate, but also by its substrate, 
blyceraldehyde-3-phosphate; (d) the intimate connec-
tion between different parts of the glycolytic path-
way, by the adenosine-5'-triphosphate and reduced 
pyridine nucleotide feedback systems, which brings 
an accumulation of glyceraldehyde-3-phosphate just 
at the moment when glyceraldehyde-3-phosphate de-
hydrogenase is inhibited by its products, thus 
producing the inversion." 
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Effects of Hormon·es on Adipose Tissue 
-
The best indications of the sites of hormone action 
have come from the study of the metabolism of specifically 
radiolabeled glucose in hormone-sensitive tissues such as 
adipose tissue. As a result of such studies the general 
site of action ot several hormones can be outlined. Insu-
lin, the hormone of primary interest in diabetes, appears 
to primarily increase fatty acid synt
1
hesis from pyruvate. 
All of its other actions appear to be secondary to its 
lipogenic effect. In accord with this proposed action 
those tissues in which lipogenesis is prominent are the 
~- tissues most sensitive to insulin. On the other hand, 
'. 
the heart is less affected by diabetes in comparison to 
other tissues because of its low rate of lipogenesis. 
The main reactions affected by growth hormone, epin-
ephrine, and glucocorticoids are less clear. Both growth 
hormone and epinephrine are lipolytic as well as anti-
lipogenic. ·However, the action of these hormones may 
overlap to some extent. For example, insulin increases 
the lipolytic action of epinephrine while growth hormone 
and epinephrine may increase the formation of sn-3-gly-
cerolphosphate from glucose. 
Perhaps the most striking effect of insulin is the 
apparent increase in the efficiency of glucose utilization 
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that it produces. In particular, the low rate of glyceride 
glycerol synthesis necessary for the high rate of fatty acid 
synthesis indicates how much of the energy of glucose is 
wasted in glyceride glycerol synthesis in response to lipo-
lytic hormones. 
In fasted-refed rats the most marked effect of growth 
hormone is its depression of all phases of glucose metab-
olism. These effects are due to the increased utilization 
of endogenous triglycerides for oxidation. Also, growth 
hormone inhibits ~riglyceride synthesis under these condi-
tions. In rats fed ad libitum growth hormone increases 
pyruvate oxidation less than insulin but increases trigly-
ceride synthesis and citrate oxidation more than insulin. 
Additionally, growth hormone increases lipogenesis while 
epinephrine decreases lipogenesis. This latter effect of 
epinephrine is clearly opposite to that of insulin. 
There appears to be a reasonable correlation between 
Kreb's cycle activity and glyceride glycerol snythesis. 
This indicates that when a molecule of D-glyceraldehyde-
3-phosphate is used for triglyceride synthesis another 
molecule of pyruvate must be oxidized via the Kreb's cycle 
to keep the total oxidizable substrate approximately con-
stant. 
The low rate of glyceride glycerol synthesis plus the 
TABLE IV 
EFFECT OF DIET AND HORMONES ON DISTRIBUTION OF GLUCOSE CARBON IN FAT PADS 
Pentose Kreb's 
Glucose Cycle Pyruvate Cycle Total Fatty Glyceride 
Treatment Uptake co2 co2 co2 co2 Acid Glycerol Lactate 
Relative Glucose Carbon Yield 
Fasted-
Ref ed 460 59.8 101.2 13.8 174.8 193.2 32.2 59.8 
Fed-
ad libitum 100 8.0 13.0 8.0 29.0 21.0 20.0 30.0 
Percent Difference Fran Control Fasted-Ref ed Rats 
Insulin 67.4 54.4 82.6 11.6 67.4 79.3 19.5 54.4 
Growth 
Honrone -28.2 -66.8 -54.3 -330.6 -28.2 -67.4 -104.8 -27.1 
Percent Difference From Control Fed Ad Libitum Rats 
Insulin 140 230.0 269.2 -10.0 181.5 311.3 32.0 51.9 
Growth 
Honrone 151 25.0 218.4 351.1 201.8 100.9 441.0 -55.6 
Epinephrine 150 -6.3 92.3 431.3 158.7 -16.7 400.0 91.6 
I-' 
......i 
From Katz et al (568) U1 
TABLE V 
IN VITRO UTILIZATION OF U-14c-LABELED GLUCOSE BY 
RAT DIAPHRAGM WITH 0.5 UNIT/ML INSULIN 
Adrenal-
Diabetic ectornized/ 
Adrenal- Adrenal- Hypophy- Hypophy-
Nonnal Diabetic ectarnized ectomized sectanized sectanized 
Glucose Utilized 
rrg/gm/hr 2.87 2.17 3.91 5.20 4.42 6.11 
Utilized Glucose 
Metabolized to co2 
0.22 0.11 0.29 0.44 mg/gm/hr 0.18 0.27 
percent 7.7 5.1 7.4 3.5 6.1 7.2 
Medium Glucose 
Metabolized to co2 percent 16.3 9.2 25.3 15.9 28.5 33.9 
Utilized Glucose 
Metabolized to Glycogen 
rrg/gm/hr 0.62 0.61 0.54 0.71 1. 71 2.23 
percent 21.6 28.1 13.8 13.6 38.7 36.5 
Utilized Glucose 
..... Unaccounted for 
-..] . 
rrg/gm/hr 2.03 1.45 3.03 4.31 2.44 3.44 °' 
Fran Villee and Hastings (1103) 
. . 
' 
•. 
iow (25 percent) maximal contribution of the pentose cycle 
suggests that the concentration of triose phosphates is 
depressed due to their rapid utilization by D-glyceralde-
hyde-3-phosphate dehydrogenase and that the activity of 
the pentose cycle is closely tied to the activity of pyru-
vate dehydrogenase so that the inhibition of D-glyceralde-
hyde-3-phosphate dehydrogenase by NADH is not significant 
when its other product 1,3-diphosphoglycerate is depleted. 
Also, the additional ATP converved when glucose is metab-
olized via the pentose cycle and bypasses the exergonic 
phosphofructokinase reaction of the Embden-Meyerhof path-
way is sufficient to convert one of the acetyl coenzyme 
A units derived from the hexose into malonyl coenzyme A. 
The decrease in the pentose shunt in the refed rat 
treated with insulin is due to the diversion of glucose-
6-phosphate to glycogen synthesis. The increase in gly-
colysis during glycogenesis provides the energy for that 
process through the formation of UTP via the nucleoside 
diphosphate kinase reaction. The high k of D-glucose-
m 
6-phosphate: NADP oxidoreductase (EC 1.1.1.49) for its 
substrate reduces its activity when glucose-6-phosphate 
is converted to glycogen. 
The activation of acetyl CoA carboxylase following 
insulin may also be responsible for the decrease in 
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cytoplasmic citrate via citrate cleavage to acetyl coenzyme 
A and oxalacetate. 
In general, the higher the net rate of dihydroxyace-
tone phosphate utilization, either by its conversion to D-
glyceraldehyde-3-phosphate or to sn-3-glycerolphosphate the 
lower the extent of equilibration expected in the triose 
phosphate. There is almost complete isotopic equilibra-
tion in the insulin-treated fat pad because most of the 
n-glyceraldehyde-3-phosphate is formed via the pentose 
cycle as shown in the accompanying diagram. The non-
isotopic equilibration of triose phosphates in methods 
which assume equilibration results in a decrease in the 
14 . 14 
ratio of glucose-I- C to glucose-6- C incorporated into 
14 
acetyl CoA and an increase in the ratio of glucose-1- C 
14 to glucose-6- C incorporated into glyceride glycerol. 
Using their method which corrects for the non-equi-
librium of triose phosphates under various hormonal con-
ditions, Katz et al (568) obtained the data in Table IV 
relative to the effects of insulin, growth hormone and 
epinephrine on metabolism. In fasted-refed rats, which 
are similar to diabetic-refed rats, insulin increases 
pyruvate oxidation and fatty acid synthesis much more 
than glucose utilization. Isocitrate oxidation and gly-
ceride glycerol synthesis, on the other hand, are 
selectively decreased. In fed animals, these effects are 
even greater. The decrease in isocitrate oxidation can be 
explained by the elevation of NADH relative to NAD+ pro-
duced by the pyruvate dehydrogenase reaction. However, 
the conversion of dihydroxyacetone phosphate to sn-3-gly-
cerolphosphate is not increased, indicating that insulin 
increases the synthesis of glyceride fatty acids but not 
of glyceride glycerol. 
Landau et al '(629) have pointed out that although the 
activity of the enzyme D-glyceraldehyde-3-phosphate ketol-
isomerase (EC 5.3.1.1) is not rate-limiting for glycoly-
sis, the activity of the enzyme is not sufficient to com-
pletely equilibrate a label in C-3 of its substrates. 
This limitation is important in all studies with speci-
fically-labeled glucose, especially in studies of glycoly-
sis. For example, the percent of randomization in C-3 of 
the triose phosphates was 12 in control fat pads, 22 fol-
lowing insulin, 8 following growth hormone, 4 after thy-
rotrophin and 10 after epinephrine treatment. 
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Katz ~t al (568) investigated the effect of the triose 
phosphate isomerase reaction on the estimation of the pen-
tose cycle contribution to glucose metabolism using glu-
14 14 14 . 
cose-1- C, glucose-6- C and glucose-U- C and measuring 
incorporation into glyceride glycerol and fatty acids. 
FIGURE IV 
D-GLYCERALDEHYDE-3-PHOSPHATE FORMATION VIA 
THE PENTOSE CYCLE 
D-GLYCERALDEHYDE-3-,HOS,HATE FORMATION VIA THE ,ENTOSE CYCLE 
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14 TheY compared their method using glucose-2- C to·those which 
·14 14 
use only glucose-1- C and glucose-6- C and assume complete 
isotopic equilibration in D-glyceraldehyde-3-phosphate-3-14c 
14 
·and dihydroxyacetone phosphate-1- C. In comparison to the 
2 14c · · h · h · · 1 · b · glucose- - experiments in w ic isotope ·equi i ration 
need not be assumed, the latter methods give good results 
in control and insulin-treated fat pads, but not in growth 
hormone and epinephrine-treated fat pads. The percent of 
glucose metabolized by the pentose pathway.was 14 in con-
trol fat pads, 25 following insulin, 11 after either growth 
hormone or thyrotrophin and 7 after epinephrine-treatment. 
The ketogenic effect of glucocorticoids appears to 
be due to an enhancement of the effects of cyclic adenyl-
ate. DeBodo and Altszuler (219) demonstrated that hypo-
physectomized-adrenalectomized dogs were insensitive to 
epinephrine •. Hypophysectomy also reduced gluconeoge:nesis 
by decreasing the supply of 'fatty acids for respiration. 
Senft et al (969) found that a glucocorticoid-dependent 
protein also decreased the activity of the enzyme phos-
phodiesterase in adipose tissue thereby decreasing the 
hydrolysis· of cyclic adenylate. The significance of. this 
effect is uncertain because glucocorticoids enhance the 
effect of cyclic adenylate without ?hanging its concen-
tration (307). Engel et al (285) noted that the barbiturate 
nembutal markedly enhanced the ketogenic effect of ACTH. 
Whether this effect is due to an inhibition of phosphodi-
esterase activity has not been determined. However, such 
reports stress the necessity to control barbiturate anes-
thesia in glucocorticoid studies and to use other anes-
thetics when possible. 
Apparently, Kreb's cycle activity reaches a maximum 
in the presence of epinephrine but does not keep pace 
with lactate production ~n adipose tissue. The degree 
to which glycolysis is coupled to pyruvate oxidation is 
determined by the lactic dehydrogenase isoenzyme compo-
sition in the tissue. Tight coupling occurs with LDH1 
in heart and the level of NADH level i.s more strictly 
regulated than it is by LDH 5 in liver so that elevated 
levels of pyruvate and NADH prevail during gluconeo-
genesis. 
On the other hand, Denton and Randle (226) have 
demonstrated that the concentration of acyl coenzyme A 
is decreased in diabetic rat qeart during the increased 
triglyceride synthesis which occurs when growth hormone 
and glucocorticoids increase lipolysis •. This indicates 
that a mechanism other than lipolysis increases trigly-
ceride synthesis during lipolysis. · 
Leboeuf et al (647) (Table VI) found tha~ cortisol 
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TABLE VI 
THE EFFECTS OF CORTISOL ON GLUCOSE METABOLISM 
BY RAT EPIDIDYMAL ADIPOSE TISSUE IN VITRO 
Honrones Total Glyceride Fatty 
Added co2 Glycerol Acids Glycogen 
Percent Difference F:rom Control 
Insulin 
(O. l unit/ml) 386 37.6 534 385 
Epinephrine 
(lo-4 M) 185 175 54.7 73.1 
Cortisol 
c10-4 M) 
-18.l -12.2 -22.4 -28.0 
,i~ ' Percent Difference From Honrone Minus Cortisol 
Insulin 
and Cortisol 3.68 4.97 8.10 -33.1 
,, Epinephrine f' and Cortisol ,. (Nonnal Rats) -27.1 ,, -22.0 -35.6 • 
' !·' 
Epinephrine 
and Cortisol 
(Adrenalecto-
mi.zed Rats) -41.3 -50.5 -4.48 -55.2 
LebOeuf et al (647) 
~· 
l 
reduced glycogen synthesis 30% in the presence of insulin 
indicating that its effect is not on transport. Also, the 
decrease in glyceride glycerol synthesis by cortisol could 
be the basis of its ketogenic effect. Epinephrine, which 
increased glycogen formation, enhanced the inhibitory ef-
feet of cortisol. These results suggest that cortisol 
modifies the effects of cyclic adenylate. 
Jungas and Ball (551) found that 0.1 µg/ml epineph-
rine increased the output of free fatty acids and gly-
cerol by adipose tissue. Insulin addition increased gly-
cerol release 3-fold but decreased free fatty acid levels 
to low values. The oxygen consumption rose several fold 
during treatment. The effect of insulin in decreasing 
free fatty acid release and increasing glycerol release 
in the presence of epinephrine is dependent on glucose, 
although insulin itself in the absence of epinephrine is 
capable of suppressing lipolysis. 
When glucose is the sole substrate of adipose tissue, 
it can furnish only 63 percent of the reduced nicotinamide 
adenine dinucleotide phosphate required for the observed 
conversion of glucose to fatty acids. The rest of the 
requirement must come from the oxidation of other sub-
strates and through the transhydrogenation of NADH to 
NADPH. This finding is not unusual since Williamson and 
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Krebs have observed that glucose alone even in the presence 
of insulin can account for only 57 percent of the respira-
tion of rat heart. In the absence of insulin the propor-
tion falls to 24 percent. The preferred substrate for 
heart is acetoacetate which contributes 73-82 percent of 
the respiratory fuel in the absence of insulin and 51-64 
percent in the presence of insulin. In contrast, liver 
can form but cannot oxidize acetoacetate, readily. The 
low utilization of acetoacetate by liver and its high 
utilization by heart has been attributed to the difference 
in Succinyl-CoA: 3-oxoacid CoA-transferase (EC 2.8.3.5) 
catalyzing the reaction: 
0 0 
- " " -O-CCH2CH 2C-O 
The enzyme is normally present intramitochondrially in 
most tissues except liver. Heart has 2.5 times the intra-
mitochondrial activity of skeletal muscle. In addition, 
heart muscle is unique in that it contains 20 times the 
extramitochondrial activity of skeletal muscle. The pro-
duction of large amounts of succinate by this reaction is 
not without significance. Krebs has shown that succinate 
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is the preferred substrate of mitochondria. In the presence 
of succinate the oxidation of reduced nicotinamide adenine 
dinucleotide is decreased and the high energy phosphate 
.·associated with reduced NAD: (ubiquinone) oxidoreductase 
(EC 1.6.99.3) is reconverted to reduced NAD. This process 
has been termed reversed electron flow. With glucose in 
the absence of insulin, the heart preferentially utilizes 
its own energy stores in preference to the available glu-
cose and this behavior persists even with insulin. These 
results tend to enforce the idea that the body treats glu-
cose as if its only function were to provide the oxalace-
tate needed to catalyze the respiration of other substrates. 
Flatt and Ball (322) have found that the rate limiting 
factor in the operation of the pentose cycle is the rate 
of regeneration of NADP+ from NADPH. According to this 
view it is the rate of fatty acid synthesis which regu-
lates the operation of the pentose cycle and not vice 
versa as is commonly thought to be the case. Acetate 
metabolism provides the minimum amount of reducing equiv-
alents not derived from the tricarboxylic cycle. There-
fore, when acetate is provided as fuel, more of the cell's 
requirements for reducing equivalents is met by transhy-
drogenation from NADPH to NADH. This frees more NADP+ 
!"· . 
l for the pentose cycle and as a result, almost all of the 
r· 
' ' 
glucose metabolized is metabolized via the pentose cycle 
and almost all of the glyceraldehyde-3-phosphate formed 
via this cycle is converted to fatty acids. Since glycol-
ysis is more exergonic due to the phosphof ructokinase re-
action, some mechanism must operate to inhibit glycolysis. 
citrate has been shown to be able to serve this function. 
When mitochondria are getting all their energy from ace-
tate, the increase in the pentose cycle provides 95 per-
cent of the reducing equivalents required for the observed 
acetate conversion to fatty acids. Flatt and Ball (322) 
found that acetate increases the pentose cycle 83 percent, 
the conversion of glucose to fatty acids by 16 percent, 
and total fatty acid synthesis by 60 percent. The in-
crease in the pentose phosphate pathway that occurs on 
the addition of acetate illustrates some of the mechan-
isms which normally limit the operation of the cycle. 
Acetate enters the mitochondrion and is oxidized in pref-
erence to pyruvate because of the exergonic nature of the 
acetate CoA ligase (AMP) (EC 6.2.1.1) reaction: 
0 
" - -4 c~3c-o + CoA + ATP 
0 
= CH ~-S-CoA + AMP- 2 + PP- 3 3 
Because acetate is oxidized in preference to pyruvate, the 
pyruvate is available for reduction in the cytoplasm by 
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(1) 
malic enzyme, L-malate: NADP oxidoreductase (decarboxylating) 
~ .. 
' 
'· 
~ . 
'· .' 
(EC 1.1. l. 40) : 
00 
1111 + CH 3CCO- + NADPH + H + 
0 
II 
Hco; = co 
HO-~-H + NADP+ + H2o 
H-C-H 
I -
co 
II 
0 
Although the equilibrium constant for the above reaction 
+ lies far to the left, the ratio of NADPH to NADP and the 
·elevated pyruvate drives the reaction. The malate then 
diffuses into mitochondria where it undergoes conversion 
to oxalacetate by L-malate: NAO oxidoreductase (EC 1.1. 
1.37): 
0 0 II 
- II CH 
-
I co 
NAO+ + 
HOCH 
H+ 
= NADH + 0 = c + 
HCH I HCH I 
- I co 
II co 
0 II 0 
The oxalacetate formed is condensed with acetyl CoA to 
citrate by citrate oxalacetate lyase (CoA-acetylating) 
(EC 4. 1. 3. 7) : 
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(2) 
(3) 
. -2 3 + 
oxalacetate + acetyl-S-CoA = citrate- + CoA-SH + H 
(4) 
The citrate so produced diffuses _out of the mitochondria and 
is cleaved by ATP: citrate oxalacetate-lyase (CoA-acetyl-
ating and ATP-dephosphorylating) (EC 4.1.3.B): 
citrate- 3 + ATP- 4 + CoA = 
oxalacetate- 2 + acetyl-S-CoA + ADP- 3 + P.- 2 
1 
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(5) 
The acetyl CoA produced is used for fatty acid synthesis in 
the cytoplasm and the oxalacetate is converted to phospho-
enolpyruvate: 
phosphoenolpyruvate- 3 + Hco;1 + IDP- 3 + H+ (6) 
The phosphoenolpyruvate so produced is then available for 
the regeneration of inosine-5'-triphosphate and pyruvate by 
the reaction catalyzed by ATP: pyruvate phosphotransferase 
(EC 2.7.1.40): 
H+ + phosphoenolpyruvate- 3 + IDP- 3 = pyruvate-l + ITP- 4 
(7) 
For every two cycles of reactions 1-4, one citrate molecule 
diffuses out of the mitochondria leaving behind a reduced 
NADH equivalent. This NADH equivalent was formed at the ex-
pense of NADPH ir the cytoplasm and represents a transhydrog-
enation and transfer of reducing equivalents into the mito-
chondria. 
The transfer of reduced NADH equivalents into mitochondria 
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normally occurs by reversal of reaction 3 in the cytoplasm, 
the oxalacetate required being provided by the L-aspartate: 
2-oxoglutarate aminotransferase (EC 2.6.1.1) reaction: 
0 0 0 
It 
-
II 
-
II 
-co co 0 C-0 
I I II 
-
I 
H N-C-H + c ---> c-o + H N-C-H 3 I <--- I 3 I I 
H-C-H H-C-H H-C-H H-C-H 
II 
-
I I I 
co H.-C-H H-C-H H-C-H 
I 
-
I 
-
I 
-co c-o c-o 
II 11 II 
0 0 0 (8) 
After the malate and glutamate diffuse into the mitochon-
dria, reaction 3 occurs as well as the reverse of reaction 
8. The a-ketoglutarate and aspartate then diffuse out of 
the mitochondria into the cytoplasm to complete the cycle. 
Harding et al (427) found that adrenal steroids, testo-
sterone propionate, and growth hormone were without effect 
on the above enzyme. They found, however, that glucocorti-
coids increased the activity of L-alanine: 2-oxoglutarate 
aminotransferase and that deoxycorticosterone depressed 
this enzyme. The other hormones were without effect. 
Role of Glutamic Dehydro·genase in· Gluconeogenesis 
The mitochondrial enzyme L-glutamic: NAD(P) oxido-
reductase (deaminating) (EC 1. 4 .1. 3) must be considered 
as a regulatory enzyme essential for gluconeogenesis. 
This enzyme catalyzes the reaction: 
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NH 4+ + 2-ketoglutarate-
2 + NAD(P)H + H+ (10) 
ouring gluconeogenesis from amino acids there is a net pro-
auction of glutamate by transaminase enzymes. This gluta-
mate must be oxidized if gluconeogenesis is to proceed •. 
Frieden (335) has reviewed some of the regulatory aspects 
of glutamic dehydrogenase. The active enzyme is composed 
of inactive subunits which associate in the presence of the 
amino acids L-methionine, L-leucine and L-isoleucine as well 
;t + 
as NAD • At moderate concentrations of GTP, the enzyme is 
very sensitive to activation by ADP even though neither 
nucleotide is a reactant. The enzyme is also sensitive 
to product inhibition. Equimolar 2-ketoglutarate inhibits 
the enzyme 43 percent. 
Although Yielding and Tomkins (1188) have described 
the non-specific inhibition of this enzyme by a number of 
steroids, no steroid was as inhibitory as thyroxine which 
was found by Winslow et al (1167) to inhibit the reaction 
51 percent at 1.3 x l0- 5Molar. However, the inhibitory 
action of thyroxine on the enzyme appears superficially 
to be contrary to the increased contribution of amino acids 
to basal metabolism in hyperthyroidism. 
Williamson· et ·a1 (1157) have shown that glutamate 
192 
exerts a catalytic influence on the transport of extramito-
chondrial NADH reducing equivalents into mitochondria. There-
fore, when mitochondrial ADP rises glutamic dehydrogenase is 
activated leading to glutamate oxidation. On the other hand, 
if GTP is depressed during protein biosynthesis the effect 
of ADP on glutamate oxidation is attenuated. An increase 
in glutamate oxidation reduces the transport of extramito-
chondrial reducing equivalents into the mitochondrion. As 
a result glycolysis is reduced. Thus, glutamic dehydrog-
enase increases cytoplasmic NADH when it converts the amino 
acid glutamate to the oxalacetate precursor 2-ketoglutarate. 
Villee (1105) reported that l0- 6Molar corticosterone 
increased NAD+ reduction 75 percent indicates that the ef-
feet is not even relatively specific for glucocorticoids. 
Krebs (617) has shown that the ratio of NAD+ to NADH 
in diabetic liver is decreased extramitochondrially but 
increased intramitochondrially. The ratio fell from 7.25 
to 2.08 in the cytoplasm and increased 7.3 to 10.8 in the 
mitochondrial matrix. The cytoplasm is thus in a more 
reduced state while the mitochondrial matrix is in a more 
oxidized state. This situation basically reflects a lack 
of transfer of reducing equivalent from the cytoplasm into 
the mitochondria. 
The pyruvate that is not converted to acetyl CoA 
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TABLE VII 
INFLUENCE OF HORMONES ON THE NICOTINAMIDE 
NUCLEOTIDE COENZYMES OF RAT EPIDIDYMAL FAT PAD 
Treabrent NAD+ NADH NADP+ NADPH NAD+/NADH 
(µg/nq tissue protein) 
Control 1.30 0.40 0.14 0.46 3.25 
HypOphysectanized 1.14 0.29 0.17 0.25 3.93 
~ .. 
Hypophysectomized 
+ Growth Horrrone 0.90 0.27 0.09 0.21 3.33 
Control 0.75 0.21 0.39 3.57 
Alloxan-Diabetic 0.88 0.22 0.13 4.00 
McLean et al (693) 
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because of the inhibition of pyruvate dehydrogenase by the 
elevated ratio of acetyl CoA/CoA is converted to oxalace-
tate by pyruvate: carbon dioxide ligase (ADP) (EC 6.4.1.1): 
ADP- 3 + P.- 2 +HO+ 
1 3 
-2 
oxalacetate + 
A portion of the oxalacetate formed in this reaction con-
denses with acetyl CoA to form citrate which diffuses out 
into the cytoplasm to inhibit phosphofructokinase. How-
ever, some of the oxalacetate is reduced to malate. The 
increase in mitochondrial malate effectively prevents the 
(11) 
transfer of cytoplasmic reducing equivalents into the mito-
chondrion by abolishing the malate concentration gradient. 
As a result the hepatic ratio of NADH/NAD+ rises leading 
to gluconeogenesis. The malate concentration is increased 
so much that oxalacetate formation occurs in spite of the 
lower NADH/NAD+ ratio present in mitochondria. This is 
possible only because oxalacetate is also elevated. A 
possible reason for the failure of lipogenesis during glu-
coneogenesis is that higher concentrations of fructose-1, 
6-diphosphate are required for lipogenesis than for glu-
coneogenesis. Plate et al (439) found that fructose-1, 
6-diphosphate decreases the Michaelis constant of fatty 
acid synthetase for NADPH. Furthermore, low citrate 
' 
I
f 
. 
. 
. 
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levels slightly increase the level of fructose-1,6-diphos-
phate and increase the activity of fructose diphosphatase. 
Higher levels of citrate further increase the concentration 
of the diphosphate which inhibits the diphosphatase and 
further channels glyceraldehyde-3-phosphate to glycerol 
glyceride formation. 
CHAPTER VIII 
STRUCTURAL ASPECTS OF LIPOPROTEINS 
£_omparison of Human and Rat Beta Lipoproteins 
Both human and rat S lipoproteins have approximately 
the same molecular weight of about 2 million and both are 
composed of approximately 10 subunits. However, while 
these subunits are identical in the rat molecule, Shore 
and Shore (980) found three types of subunits in human 
S lipoprotein. The fact that delipidated rat S lipopro-
teins form insoluble aggregates less rapidly than human 
s lipoproteins means that protein-protein interactions 
which must be overcome during lipid binding are weaker 
in rat molecules. The function of the multiple peptide 
chains in the human molecule may be to provide coopera-
tive interactions so that protein-protein interactions 
become weaker, and protein-lipid interactions stronger 
as more lipid is bound. 
Cooperative Interactions in Beta Lipoproteins 
In contrast to the findings of Gotto ~t al (402) 
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that no cooperative interactions between lipid and protein 
existed in S lipoprotein, Camejo et al {157) found that the 
binding of phospholipids to apoalphalipoprotein exposed pep-
tide bonds to the solvent with exchange of amide hydrogens. 
Phospholipids also appear to be important in insulin inhib-
ition by S lipoprotein. The fact that phospholipases at-
tack a lipoprotein indicate that the phosphoiipids are lo-
cated on the surface of the molecule. 
Granada and Scanu {405) have investigated the effects 
of lipid extraction on lipoprotein structure.; Following 
the extraction procedure, two components of S lipoprotein 
with sedimentation constants of 10.9 S and 15.5 S were 
produced. Lipid extraction following succinylation of 
the available amino groups in the molecule resulted in a 
single 7.2 S subunit. This disassociation phenomena is 
similar to that reported by Shore and Shore {981) who 
found a moelcular weight of 2.8-3.0 x 10 6 for the intact 
a lipoprotein molecule and 6.4 x 10 4 for each of the ten 
postulated subunits. 
Gotto et al {402) have described a technique for the 
preparation of delipidated a lipoprotein subunits free of 
detergent mole.cules. This procedure takes advantage of 
subtle differences in physical chemistry between dodecyl 
sulfate and decyl sulfate. Decyl sulfate can be reversibly 
bound to the subunit while dodecyl sulfate cannot be com-
pletely removed by dialysis after lipid extraction. 
Gotto et al (403) further investigated the structure 
of the delipidated apolipoprotein by infrared analysis. 
They found the molecule to contain S-pleated sheet struc-
ture which did not change appreciably on delipidation. 
These findings are in basic agreement with those of Scanu 
(942) from circular dichroism measurements and indicate 
.that there is little or no cooperative interaction between 
the apolipoprotein and its lipids. Camejo et al (157) 
have, however, found that the delipidated high density 
lipoprotein molecules do have two unique characteristics. 
First, it was able to penetrate lipid films at pressures 
above the collapse pressure of the protein, and secondly, 
the protein itself could form a film even at low salt 
concentrations. This latter characteristic was ascribed 
to the absence of disulfide bridges in the molecule. 
These findings indicate that modification of the apolipo-
proteins by introduction of cross-links may provide some 
additional information about the.function of the molecule 
(431, 462). 
Chapman (172) and Colacicco (189) have described 
methods applicable to the interaction of apolipoproteins 
with lipid monolayers. These techniques generally involve 
198 
199 
the introduction of the apolipoprotein under a lipid mono-
layer followed by observations of the changes produced in 
surface tension. This technique has provided more informa-
tion than circular dichroism studies. A similar technique 
might be used to study the action of lipoprotein lipase. 
For example, the enzyme along with a apolipoprotein and 
acceptor albumin might be introduced into the bulk phase 
under the lipid substrate monolayer. 
The possibility that polyunsaturated cholesterol es-
ters may be involved in intermolecular bonding of lipopro-
tein subunl.ts is.indicated by Lindgren et al (667) who 
found that dialysis of sf 0-20 s lipoproteins in the ab-
sence of chelating agents to prevent metal catalysis of 
air oxidation results in Sf 0-2 fragments which resembled 
HDL1 • Authentic HDL1 (immunochemical identification) has 
density properties similar to the B lipoproteins in rats 
and man but has not been further studied. 
Abnormal Beta LiJ?oproteins 
Alterations in S lipoprotein structure are not unique 
to the s lipoprotein insulin antagonist but are also found 
in other disorders of lipid metabolism. Swit2er (1044) 
noted that an immunochemically distinct S lipoprotein, 
lipoprotein X, was formed in, and hence could not be used 
to test for the presence of, biliary obstruction. 
Lipoprotein X contains lecithin as its main phospholipid 
~omponent, only traces of triglycerides and cholesterol 
esters, but large amounts of f~ee cholesterol. In con-
trast, Gardner et al (357) observed that serum cholesterol 
esters were reduced in viral hepatitis. Eder et al (268) 
were among the first to use percent cholesterol esterifi-
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cation as a chemical means of differentiating between viral 
hepatitis and obstructive jaundice. 
In contrast Hezzard et al (442) noted that the abnor-
mal 8 lipoprotein which migrates electrophoretically as 
· a broad bend in Type III hyper-8-lipoproteinemis has an 
increased content of esterified cholesterol. Most of the 
individuals with this disorder develop Xanthoma tuberosum, 
·characteristic cholesterol deposits in the skin, indica-
However, individuals with Type II hypercholesterolemia 
may also be distinguished from Type III individuals by 
the presence of Xanthoma tendinosum instead of Xanthe-
· ma ·tuberosum. Unfortunately, the appearance of these sub-
cutaneous cholesterol deposits is also indicative of com-
parable cholesterol deposition in arterial plaques. 
CHAPTER IX 
STEROID EFFECTS ON SERUM LIPOPROTEINS 
Etiology of Atherosclerosis 
Both dietary cholesterol and saturated fatty acids 
.can contribute to the development of atherosclerosis in 
predisposed individuals. The main predisposition is an 
elevation in blood catecholamines due to environmental 
stress which increases not only fasting serum triglycer-
ides but also post-prandial hyperlipemia. Afflicted in-
dividuals can be detected by their elevated catechola-
mine excretion when exposed to occupational stress (338). 
However, excretion patterns may be normal after the sub-
ject has been hospitalized. 
The rise in norepinephrine secretion in such indi-
viduals frequently leads to an elevation in blood pres-
sure so that the latter is associated with a three-fold 
increase in the chance of myocardial infarction (558). 
In another study Yater et al (1183) observed a 4-fold 
increased risk. It is not clear how hypertension 
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increases the risk but an effect of pressure on the disposi-
tion of lipids from S lipoproteins has not been excluded. 
Increased mechanical trauma to the vessel is also a possi-
ble explanati'on of the blood pressure effect. Elevations 
in epinephrine, on the other hand, may lead to enhanced 
platelet aggregation as well as to the previously described 
lipolytic effects. Past-prandial hyperlipemia may be re-
sponsible for the 20 percent reduction in coronary blood 
. flow and the failure of collateral. circulation in some 
cardiovascular patients. Friedman et al (338) have also 
observed the sludging of erythrocytes 3-9 hours following 
food ingestion in patients prone to atherosclerosis. 
Rane et al (864) have shown that dietary factors 
alone could not account for the difference in athero-
sclerosis in two similar groups of East and West Finnish 
farmers indicating that diet alone is not the primary de-
terminant of the disease. However, that high blood cho-
lesterol levels accelerate the disease process is well 
known (558). In addition, S lipoprotein levels do not 
correlate better with the progression of the disease than 
do total serum cholesterol levels (380). It appears, how-
ever, that total cholesterol levels are related to the 
tendency for cholesterol to deposit in arterial fissures 
during the healing process which is constantly occurring. 
platelet aggregates play an important role in this process 
because these lipid-rich cells are phagocytized by macro-
phages which are then converted to foam cells which are 
responsible for the release of cholesterol in the vicinity 
of the arterial lesion. 
Although men have a higher total cholesterol and 
higher ratio of e to a lipoprotein compared to women, re-
cent studies have indicated that these differences cannot 
account completely for the sex differences in atheroscler-
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osis. Rosenman and Friedman (910) have indicated that dif-
ferences in behavior and occupational stress may be at 
least partly responsible. Women in the professions, for 
example, have a 5-fold increased incidence of athero-
sclerosis compared to women with less stressful occupa-
tions. However, these results do not rule out the im-
portance of hormonal factors in the control of serum li-
pids. For example, atherosclerosis is more frequent 
among men with a mesomorphic or muscular physique. Such 
findings may indicate that both physical stature and ag-
gressiveness may reflect patterns of testoserone produc-
·· tion and target tissue responses and may provide a basis 
l
t 
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for the belief that atherosclerosis begins to develop in 
man at about the age of puberty. 
Saturated fatty acids in the diet increase the 
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incidence of atherosclerosis by increasing the level of cho-
lesterol. Apparently, there is a limit on the ratio of sa-
turated to unsaturated fatty acids that may be present in 8 
lipoprotein. Ways et al (1120) have suggested that exces-
sive oxidation of linoleic acid may be an etiologic factor 
in acanthcytosis and pointed to their observation that ery-
throcyte linoleic acid was only 25 percent of normal in 
this disorder. Philips and Dodge (832) also confirmed the 
.low levels of essential fatty acids in a-8-lipoproteinemia. 
These results are puzzling because a lipoproteins normally 
transport essential fatty acids as cholesterol esters. In 
the genetic absence of a lipoproteins which occurs in 
Tangiers disease cholesterol esters accumulate in the re-
ticuloendothelial system, but unesterif ied cholesterol is 
normal~ Furthermore, low levels of carotene leading to 
pigmentary retinitis are observed even though the bulk of 
carotene is transported by B lipoprotein. Jepsco et al 
(529) also observed that a deficiency of cholesterol es-
ters occurred in Xanthoma tuberosum characteristic of 
Type III hyper-S-lipoproteinemia in which an abnormally 
less dense lipoprotein is produced. The heterogeneous 
nature of this molecule is further indicated by the 
broad B band which it forms on electrophoresis. In con-
trast, high unesterified cholesterol levels characterize 
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xanthoma tendinosum seen in Type II hyper-B-lipoproteinemia. 
These results indicate the importance of polyunsaturated 
fatty acids. 
Function of Cholesterol 
Saturated fatty acids may elevate serum cholesterol 
by forming lecithin-cholesterol complexes which increase 
the total number of cholesterol binding sites in the B 
lipoprotein molecule. An increase in total cholesterol 
and saturated lecithins, for example, is seen during high-
dosage estrogen therapy. Recently, Ladbrooke et al (625) 
have shown that cholesterol forms a 1:1 molecular com-
plex with dipalmitoyl phosphatidyl choline that abolishes 
the mesomorphic phase transition of the phospholipid. 
Apparently, cholesterol functions to reduce the random 
motion of the hydrocarbon tail of the saturated fatty 
acid. Polyunsaturated fatty acids, on the other hand, 
have greater rigidity than their saturated counterparts 
because of their double bonds. The presence of this in-
creased rigidity is not disproven by the generally lower 
melting points of the polyunsaturated fatty acids because 
the crystal lattice energy, as evidenced by the heat of 
fusion, is lower for the polyunsaturated fatty acids. 
The important role of polyunsaturated fatty acids 
in preventing the elevation of B lipoprotein levels is 
,.., ... 
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seen in the results of a clinical study by Vergrassen et al 
(1094). They showed that when dietary fat was 50 percent 
of total calories, the isocaloric substitution of safflower 
oil for olive oil in the diet reduced cholesterol levels by 
17 percent. Such an effect is equivalent to that obtained 
with hypocholesterolemic drugs such as 2-(p-chlorophenoxy)-
2-:-methylproprionic acid and lipod.iactic steroids. Further-
more, Peifer and Holman (826) have shown that total unsa-
turation rather than essential unsaturation at carbons 12 
and 15 determines the cholesterol-lowering effect of poly-
unsaturated fatty acids, indicating that physical proper-
ties are the main consideration. However, for other rea-
l 
sons related to platelet function, diets rich in the es-
sential fatty acid linolenate are preferable to catalyti-
cally dehydrogenated polyunsaturated fatty acids for the 
prevention of myocardial infarction. Besides the mechan-
ism outlined above, Lewis (660) has shown that polyunsat-
urated fatty acids also increase the conversion of choles-
terol to bile acids and lower cholesterol levels by this 
means. On the other hand, patients with Type II hyper-
cholesterolemia have been shown to be resistant to this 
latter effect. 
Another puzzling aspect of lipid metabolism was re-
ported by Setsuda and O'Kabe in reference to the low levels 
of linoleic acid in diabetes._ They reported that insulin, 
but not sulfonylurea drugs could restore normal levels of 
linoleate. Since the sulfonylureas stimulate insulin re-
lease, it appears that they also antagnoize this effect of 
insulin. 
The effects of glucocorticoids on serum lipids were 
discussed previously. Generally, these effects include an 
increase in phospholipids with lesser increases in choles-
terol and triglycerides. These effects are generally fav-
orable provided that the pancreas can produce sufficient 
insulin to overcome the lipolytic effects produced by the 
glucocorticoid. As discussed elsewhere in this disserta-
tion, at least part of this glucocorticoid effect appears 
to be due to an action on the liver that is not dependent 
on protein biosynthesis. 
Sex Differences in the Subunit Structure of HDL 
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In men S~ 20-100 and 100-400 pre-S-lipoproteins show 
an upward trend_ in the third decade and even steeper upward 
trends in the fourth decade up to the fifth decade and then 
a decline occurs. In women the S~ 100-400 pre-S-lipopro~ 
teins are approximately one-third the level in men in the 
third decad~. The S~ 20-100 pre-S-lipoproteins increase 
with age in women starting with the fifth decade. Between 
the third and fifth decades, mean HDL 2 a lipoproteins are 
l 
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twice as high in women as in men. The other a lipoproteins, 
HDL
3 
and HDL1 , do not change. These findings suggest that 
the estriene effect is not on the synthesis of the apo-a-
lipoprotein subunit, but rather that it promotes the con-
version of HDL 3 lipoprotein (M. W. 175,000) to HDL 2 lipo-
protein (M. W. 360,000) by promoting a subunit rearrange-
ment in which another high density apolipoprotein subunit 
of M. W. 40,000 and a phospholipid-cholesterol complex of 
145,000 are added. Shore and Shore (981) have recently re-
viewed the structural aspects of the serum lipoproteins. 
They have noted that the peptide composition of HDL2 is 
more heteroge~eous than that of HDL 3 • Whereas both lipo-
protein species contain the two major carboxyl terminal 
glutamine and threonine peptides, HDL 2 also contains an-
other peptide which is rich in serine, glutamic acid and 
glycine and which is believed to end in carboxy terminal 
alanine. All of these peptides contain methionine but 
the alanine containing peptide unique to HDL 2 is devoid 
of trytophane. It appears that HDL 3 contains six poly-
peptide subunits of 15,000 molecular weight while HDL2 
contains eight. Although the exact role of the two major 
peptides is unknown, there presence in all high density 
lipoprotein species suggests that they form a dimer which 
then binds lipid as in the 40,000 M~ W. fragment involved 
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in the structure of HDL 2 • 
Peefers and Blaton (825) have also identified four pep-
tides in human HDL 2 by isoelectric fodusing which have pI's 
of 9.16, 8.97, 6.36 and 5.38. The peptides which pI's of 
s.97 and 6.36 correspond to the carboxy terminal threonine 
and glutamine peptides. The study of these peptides is 
complicated by the presence of polymorphic forms which sep-
arate on DEAE cellulose but electrophrese identically in 
polyacrylamide with 8 M urea. 
Reciprocal Effect of Estrogens 
Estriene effects on atherosclerosis offer the greatest 
hope for preventing the disorder by natural regulatory mech-
anisms. The terms androstane and estriene emphasize that 
these effects are distinct from those of endogenous hormones. 
Changes in S lipoprotein occur in a reciprocal fashion in 
response to steroid-induced a lipoprotein changes in 50 per-
cent of human subjects. However, the net change in choles-
terol levels will depend on the relative changes in lipopro-
tein species and their cholesterol contents. In man eleva-
tion in a lipoprotein is generally followed by a larger re-
duction in S lipoprotein so that total cholesterol levels 
are reduced. In the dog and especially in the rat, a lipo-
proteins predominate over S lipoprotein so that an elevation 
in a lipoprotein increases total cholesterol. The basic 
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effects of steroids on the lipoprotein distributions in both 
animals, however, is similar. 
Studies by Bowers and Schally (105), Fillias (316), 
o'Key et al (794), Lyman ·et ·a1 (684) and Kritchersky ·et al 
(619) have shown that low-dosage estrogen therapy raises 
the level of cholesterol arachidonate in the rat. The in-
corporation of arachidonate and stearate into hepatic phos-
pholipids is also increased. On the other hand, Aftergood 
· et al (6) reported that the cholesterol esters of arachi-
donate and linoleate were markedly reduced and replaced by 
those of palmitoleate, oleate, and stearate when the human 
estrogen dose was administered. These effects appear to 
be secondary to effects on hepatic phospholipid synthesis. 
Ramey and Baron (858) observed that the estriene 3,17S-di-
hydroxy-l,3,5 (10)-estriene-16-one increases the incorpora-
tion of acetate and inorganic phosphate into hepatic phos-
pholipids. 
The effect of glucocorticoids on serum lipids parallels 
its effects on lipid metabolism. Kobernich and More (602) 
showed that the administration of 20 mg of cortisone per day 
to rabbits elevated serum cholesterol and unesterified fatty 
acids at the time that steroid diabetes ensued. Brady ·et 
~ (112) showed that the elevation in serum fatty acids was 
accompanied by reduced fatty acid synthesis from pyruvate 
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2-6 hours after glucocorticoid treatment when gluconeogenesis 
from pyruvate was increasing. 
Adrenalectomized dogs maintained on deoxycorticosterone 
acetate show a 75 percent drop in total serum lipids over a 
three week period (238). However, this drop is not accom-
panied by changes in phosphlipid concentration in the liver, 
kidney, small intesting, muscle or lung; and the half-life 
of plasma phospholipids is not altered. In contrast to 
these results in the dog Migeon (740) found that liver li-
pids increased in the adrenalectomized rat maintained on 
deoxycorticosterone acetate. Treatment with cortisone re-
stored the liver lipids to normal but did not elevate serum 
cholesterol. The increased mobilization of lipid stores in 
the adrenalectomized rat was also reported by Tracht ·et al 
(1074). It is probably the result of the lipolytic activ-
ity of ACTH which increases after adrenalectomy. The sup-
presion of ACTH release described by Levy and Ramey (657) 
will be discussed later in conjunction with the other ef-
fects of ergotamine. 
Comparison of Cortisone and Prednisone 
Furman et al (349) showed that the administration of 
500 carbohydrate calories could prevent the elevation of 
cholesterol and phopholipids associated with the adminis-
tration of 30 mg of prednisolone to men. It is not clear, 
TABLE VIII 
EFFECTS OF 20 DAYS OF GLUCOCORTICOID TREATMENT 
ON THE PLASMA LIPIDS OF THE RABBIT 
Percent Difference Fram Control Period 
Glucocorticoid Neutral Total Unesterif ied Esterif ied Total 
Administered Lipids Phospholipids Cholesterol Cholesterol Lipids 
Cortisol +53.5 +46.6 +100 -28.6 +47.5 
Cortisone +482 +89.3 +186 -29.3 +256 
17a,21-dihydroxy-
1,4-pregnadiene-3, 
11,20-trione +380 +126 +207 +14.3 +259 
Adlersberg ( 4) 
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however, whether the suppression of free fatty acid mobili-
zation was due to the glucose or to the insulin which it re-
leased. Lever et al (654) found that glucocorticoids in-
creased a lipoprotein cholesterol and phospholipids to ab-
normally high values in man. Similar results were obtained 
by Adlersberg et al (4) in the rabbit and a~e shown in 
Table VIII. Especially prominent is the highly significant 
decrease in esterified cholesterol. Este.rified cholesterol 
was increased by prednisone but decreased by cortisone. 
This difference may be related to the metabolism of the 
two steroids. The decreased esterification seen with endo-
genous glucocorticoids is similar to the effect produced 
by estrogens. 
The metabolic effect of predniso~e is almost the same 
as that of cortisone even though the total 17-ketosteroid 
excretion is depressed via the effect of the synthetic glu-
cocorticoid on adrenocorticotrophin production. In addi-
k tion, Howard et al (483) found that part of the effect of 
prednisolone in raising a lipoprotein concentration could 
be attributed to a decrease· in adrenal androgen production. 
Glucocorticoids seem to exert their effects on phos-
pholipids. Allersberg et al (5) found that cortisol in-
creased serum phospholipids 24 percent, cholesterol esters 
23 percent, and cholesterol 19 percent. Triglycerides 
were decreased by this hormone. Oliver and Boyd (797} and 
Lever et al (654) confirmed these findings. The latter 
group found increases in a lipoprotein phospholipids and 
cholesterol in 7 out of 8 patients. Unexpectedly, deoxy-
corticosterone acetate, when given at 2.5 percent of the 
dose of cortisone acetate, produced a 48 percent rise in 
a lipoprotein cholesterol and 10 percent decrease in 8 li-
poprotein cholesterol in one-half the time. Despite the 
greater nagnitude of the mineralcorticoid effect, the im-
portance of the glucocorticoid effect is not minimized be-
cause the factors which regulate mineralcorticoid release 
are largely independent of those which regulate glucocor-
ticoid secretion and vice versa. However, at least part 
of the effect of the adrenal gland on serum cholesterol 
is mediated by mineralcorticoids. 
Clinical Effects of Free and Sulfate Conjugated Estrienes 
Estrogens increase the output of the lipolytic hor-
mone ACTH by the pituitary. Also, ACTH is sufficient to 
produce an increase in cortisol output by the adrenal 
cortex. However, the increased cortisol is not all in the 
free form and in fact is partially inactivated by being 
bound to transcortin which is also increased following es-
trogen treatment. 
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The decreased circulating linoleate seen during estrogen 
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therapy is partly attributable to enhanced mitochondrial 
chain elongation of this fatty acid to arachidonate (4w6). 
Furthermore, increased amounts of eicosatrienoic acid (4w9) 
are also formed from oleic acid, indicating that chain 
elongation may be increased generally (403). This process 
per se does not seem to be the cause of the insulin resist-
ance seen during estrogen therapy, unless the substrate 
specificity of the enzymes which incorporate long-chain 
acyl coenzyme A derivatives into triglycerides is such 
that chain elongation results in a decreased rate of this 
reaction. 
A basic difference exists between the effects of es-
trogens on serum cholesterol and the effects of glucocor-
ticoids on hepatic enzyme induction. Steinberg (1025) 
has shown that growth hormone is required for the estro-
gen effect. In contrast, both Csanyi and Greengard {208) 
and Liberti et al (661) have shown that growth hormone sup-
presses glucocorticoid induction of tyrosine aminotrans-
ferase and tryptophane oxygenase. The suppression of cor-
tisol-dependent enzyme induction by growth hormone is op-
posite to the synergistic anti-insulin action of these 
hormones. 
Several attempts have been made to synthesize estriene 
steroids which would have an estrogen effect on serum lipids 
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but not the other effects associated with estrogen therapy. 
such steroids have been termed "lipodiactic" steroids, and 
many compounds of this type are designed so that the ratio 
of lipid lowering effect to estrogenic effect is maximal. 
For example, Roussel (patent number 3,032,563) has intro-
duced the steroid 16a-ethinyl-11S,16S-dihydroxy-l,4-andro-
stadien-3-one. This compound possesses a number of the 
structural features usually associated with estrogens, 
anabolic steroids, and glucocorticoids. Particularly note-
worthy is the displacement of the hydroxyl and ethinyl 
groups in ring D. Also, while the function of the 11 -hy-
droxyl group in this compound has not been determined, its 
primary effect may be to decrease the conversion of the 
compound to the corresponding phenolic derivative (417). 
Perhaps the most interesting lipodiactic steroid so 
far developed is 16,16-difluoro-17a-ethinyl-3-methoxy-l, 
3,5 (10)-estrien-l 7S-ol. Except for the fluorine subs ti tu-
tions, this compound is identical to the estrogen which 
causes the most pronounced elevations in serum triglycer-
ides. This close similarity in structure suggests that D 
ring binding is necessary for the triglyceride effect, 
while A ring binding facillitates the binding of D ring. 
Humber et al (496) have reported that this compound inhib-
its cholesterol synthesis 36 percent at l0- 4Molar. 
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Arnold et al (20) reported that the lipodiactic/estro-
genic ratio for the steroid 17-(3-hydroxy-l-propynyl)-3-
methoxy-l,3,5(10)-estrien-17S-ol was 1300 times that of 
equine estrogen sulfates and 3300 times that of estrone. 
The enhancement produced by the 17a side chain is especially 
noteworthy. A similar enhancement of anesthetic steroid ef-
fects was observed by Selye and is also found in progesta-
tional steroids. 
Several clinical trials have outlined the effects of 
estrogen therapy on serum lipids. In 1957 Furman and 
Howard (349) studied the effects of estrone sulfate on a 
and B lipoproteins. In addition to the gynecomastia asso-
ciated with the therapy, they noted that predictable changes 
in 8 lipoproteins could be produced in only about 56 percent 
of all their subjects. In 1962 these scientists reported 
similar findings in hyperlipemic subjects (350). 
In 1962 Marmasten et al (717) reported the results of 
lipodiactic therapy following myocardial infarction. They 
found no correlation between serum lipids and survival. 
Fu~thermore, while equine estrogen s~lfates significantly 
improved survival rates, no such improvement could be dem-
onstrated for the pen-conjugated steroids 17a-ethinyl-l,3, 
5(10)-estriene-3,178-diol and 3-methoxy-16a-methyl-l,3,5{10)-
estriene-16S,17B-diol {895). The conclusion of such studies 
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appears to be that only conjugated lipodiactic steroids are 
able to improve post-infarction survival by a mechanism un-
related to serum lipid levels. Further studies are necessary 
to confirm the conjugate effect. 
Two additional lipodiactic steroids merit consideration 
from a structure-function standpoint. The first is the pat-
ented adrenal androgen analogue 17a-ethinyl-3-ethoxy-3,5-
androstadiene-11S,17B-diol which is hydrolyzed in vivo to 
17a-ethinyl-11S,17S-dihydroxy-4-androsten-3-one. This par-
ticular compound is similar to the endogenous cortisol me-
tabolite 11S,17B-dihydroxy-4-androsten-3-one. In addition, 
this steroid is quite similar to the endogenous hypotensive 
steroids reported by Sturtevant (1037). 
The second lipodiactic steroid that should be consid-
ered is that described by Gordon ·et al ( 400) as having good 
separation of lipid and estrogenic effects. The compound 
2-methoxy-l,3,5(10)-estriene-3,16a,17S-triol is an endo-
genous steroid in man and its production is increased by 
thyroxine. Gallagher et al (355) found that the formation 
of this particular steroid was reduced in breast tumor 
patients. The relation between its lipodiactic effect and 
possible anti-tumor effect should be further investigated. 
Estrogen Conjugates 
The superiority of estrogen sulfates in lipodiactic 
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therapy may be explained by the finding of Fishman· et al 
(319) that these conjugates are intermediates in the forma-
tion of 2-methoxy estrogens. Therefore, although previous 
studies have been disappointing, these considerations sug-
gest that 16,16-difluoro-17a-ethinyl-2-methoxy-l,3,5(10)-
estriene-3,118,17S-triol may merit clinical trial as a 
lipodiactic drug. 
Conjugated equine estrogens (Premarin) have generally 
been preferred to the use of non-conjugated estrogens due 
to their lower estrogenic side effects. Approximately 50 
percent of myocardial infarction patients experience a max-
imal decrease in serum cholesterol of 10 percent during the 
administration of 4.0 mg/day of conjugated equine estrogens 
over a three-month period (1021). Those patients who do 
not respond to this dose may respond to the maximum dose of 
10.0 mg/day. However, not all patients respond to the larg-
er dose and there seems to be an increase in death rate from 
2 to 8 percent associated with the maximum dose. 
Oliver and Boyd (796) have demonstrated that 17a-ethin-
yl-l,3,5(10)-estriene-3,17B-diol at a dose of only 0.10 mg/ 
day produces ch.olesterol lowering effects equivalent to 4. O 
mg/day of conjugated estrogens. Moreover, 0.20 mg/day can 
lower cholesterol levels 25 percent in normal subjects and 
35 percent in subjects with Type II hypercholesterolemia 
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a three-month period. These studies stress the differ-
ence in individual responses to drugs. Ideally, each pa-
tient should be titrated with the drug until side effects 
occur (895). 
In 1963 Stamler et al (1021) further raised doubts 
about the efficacy of estrien therapy following myocardial 
infarction by showing that the commencement of therapy 
within three months following the infarction actually in-
creased patient mortality. This occurred despite the fact 
that five-year mortality was reduced 50 percent. The early 
· increase in deaths was one of the first indications of the 
risks associated with estrien therapy.· While this finding 
has not been explained, it could have been due to enhanced 
p1latelet aggregation secondary to the estriene at a time 
when factors related to tissue damage were also actively 
promoting coagulation. 
In order to compare the results of estrogen therapy 
with other treatments the data.of Huninghak et al (497) 
may be cited as typical of long-term Atromid-S therapy. 
They reported that at least 50 percent of their patients 
experienced cholesterol reductions of at least 15 percent. 
If it is assumed that death rate is approximately propor-
tional to cholesterol and that all other factors were sim-
ilar, estriene therapy seems to be at least as beneficial 
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other hyperlipidemic drugs. 
Besides their effects on lipid biosynthesis, estrienes 
may also differ with respect to their effects on lipopro-
tein lipase activity. Keeping estriene inhibition of the 
enzyme to a minimum should be a goal in any series of struc-
tural alterations. This effect has apparently not been con-
sidered in the previous studies and may have contributed to 
individual variability if the lipids were not measured in 
the fasting state. 
1.·· .. ·.·. 
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CHAPTER X 
LIPOPROTEIN LIPASE AND THE LIPOPROTEIN INSULIN AN'l1AGONIST 
!iipoprotein Lipase Activity: Effect of Insulin, Ethanol, 
catecholamines and Cyclic Adenylate 
Lipoprotein lipase may be involved in the degradation 
of the lipoprotein insulin antagonist. Lipoprotein lipase 
activity is decreased in diabetes (578). The sulfated poly-
saccharide heparin is required for enzyme activity and in-
sulin may increase enzyme act~vity by increasing heparin 
synthesis by mast cells in the arterial wall. Schiller 
and Dorfman (943) have demonstrated decreased incorpora-
tion of radioactive sulfate into heparin in diabetes. The 
key role of heparin in the action of the enzyme was shown 
by Korn (606) who inactivated it by treatment with heparin-
ase. Heparin is synthesized in lung, liver, muscle and 
intestine but has not been recovered from normal plasma; 
its presence there is due to its escape from perfused 
tissues. 
Insulin may also affect the synthesis of the enzyme 
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protein. Kessler (578) found that diabetes reduced the hep-
arin-releasable lipoprotein lipase from adipose tissue but 
increased the release of the enzyme from myocardial tissue. 
Kessler also investigated the activities of the myocardial 
and diaphragm enzymes during fasting where the activity in-
creased and decreased respectively following glucose admin-
istration. The decrease in activity following glucose is 
, probably related to the suppression of growth hormone re-
lease by glucose. 
~ .. 
Mallov and Cera (703) found that heart lipoprotein 
lipase was increased by ethanol intoxication, catechola-
mines, and ether anesthesia. The ethanol stimulation of 
the enzyme did not occur in adrenalectomized rats or in 
puromycin-treated rats indicating that glucocorticoid-de-
pendent protein synthesis may be required. 
Wing and Robinson (1164, 1165) observed that serum 
lipoprotein lipase from fed animals had a shorter half-
·life than the enzyme from fasted animals. They also noted 
that actinomycin blockade of DNA synthesis produced an in-
crease in the stable form of the enzyme. This effect of 
actinomycin could be reversed by catecholamines or adreno-
corticotrophin, agents which increase cyclic adenylate. 
! . Huttunen and Steinberg (501) have shown that cyclic adeny-
late activates adipose tissue lipase via a phosphorylation 
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of the enzyme mediated by a specific protein kinase. A sim-
ilar enzyme phosphorylation may be involved in the conver-
sion of lipoprotein lipase to its unstable form. Catechola-
mine stimulation of this reaction may be.of particular im-
portance in carbohydrate-induced lipemia which is charac-
terized by a primary elevation in sf 20-400 pre-S-lipopro-
teins (7, 76). 
Phospholipase A and Lipoprotein Structure 
Although Dbrzaki and Zieve .(253) have shown that lipo-
protein lipase is not stereospecific in its hydrolysis of 
triglycerides, they did show that the enzyme also possesses 
phospholipase A activity. Vogel and Bierman (1106) have 
confirmed the phospholipase activity in vivo. Dorzaki and 
Zieve studied this phospholipase activity in vitro and 
found that it was more susceptible to the micellular state 
of the substrate as influenced by salts and other agents 
than was the lipase activity of the enzyme. Chylomicrons 
contain phosphatidyl ethanolamine which is released as 
l chylomicrons are degraded. If factors which prevent the 
i degradation of this phospholipid a~e present, then its 
t' f · relative concentration in blood may increase under these 
~:. t conditions. Marinetti (714) studied the effect of phos-
"'· r· pholipase A action on S-lipoproteins. Although he found 
t\ 
no change in molecular weight or in other molecular 
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parameters, the effect of phospholipid hydrolysis may be dif-
ferent when triglycerides are also being hydrolysed. Simi-
larly, Banaszak and McDonald (41) reported that treatment 
of s-lipoprote~n with proteolytic enzymes did not dramati-
cally alter the clarity of lipoprotein solutions. Although 
it.might be argued that some lipoprotein peptide bonds were 
buried and not exposed to the attack of the enzyme, these 
results do not rule out the importance of lipid-lipid in-
teractions in holding lipoprotein subunits together. In 
contrast, the subunits of de-lipidated S-lipoprotein form 
insoluble aggregates. 
Effects of Nicotinic Acid, Thyroxine, Atrornid, Polyunsaturated 
Acids, Androsterone Estrienes and Cholinesterase Inhibitors 
Many drugs affect the activity of lipoprotein lipase. 
Nicotinic acid, which inhibits adipose tissue lipase, was 
used by Molnar et al (753) in an attempt to reduce lipoly-
sis in diabetes. Although the drug initially reduced free 
· · fatty acid levels, it also had a stimulatory effect on li-
poprotein lipase which persisted at a drug level at which 
inhibition of adipose tissue lipase did not occur. The 
net effect of the drug was to raise fatty acid levels and 
to exacerbate the diabetes. Nicotinic acid also produces 
hypotension. 
Porte et al (847) also found that thyroxine increased 
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lipoprotein lipase activity. However, the increase in myo-
. cardial metabolism also produced by the hormone may produce 
angina pectoris in patients with narrowed coronary arteries. 
Oliver and Boyd (798} have investigated the effect of D-thy-
roxine in the treatment of hypercholesterolemia. Although 
type III hypercholesterolemia was unaffected by the drug, a 
mean decrease of 16 percent in ser.um cholesterol was ob-
served after 6 months of therapy with 7.5 mg of D-thyroxine 
per day. At this dose level 35 percent of the patients ex-
perienced angina. Furthermore, although no significant in-
creases in basal metabolic rate were observed, most patients 
lost weight during therapy. An escape phenomena was noted 
with the drug, i.e~ the drug became less effective with 
time. One possible explanation of this finding is that 
D-thyroxine displaces L--thyroxine from thyroid-binding 
globulin so that the hormone inhibits TSH release from the 
pituitary. An escape phenomena has also been observed with 
2-(p-chlorophenoxy}-2-methyl-propionic acid (clofibrate} 
which may exert this effect by the same mechanism. 
·Atromid-S (clofibrate} is often prescribed for the 
treatment of type II hypercholesterolernia. However, Japson 
and James (530} reported that the drug produced only a tran-
sitory 9 percent reduction in cholesterol in this disorder. 
On the other hand, Hood et al (475} observed that the drug 
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caused a significant improvement in hypertriglyceridemia due 
to its activation of lipoprotein lipase. This result was 
best observed when activity was expressed per milligram of 
a-lipoprotein protein. The enzyme is normally associated 
with the lipoprotein and this fact has been used to advan-
tage in its purification by floatation. Fielding (314) 
has purified the enzyme from rat plasma 500-fold. He ob-
served that the optimum temperature of the enzyme was 37°C, 
the optimum pH 8.5, and that the enzyme lost 10-15 percent 
of its activity per day even at 0°C. The molecular weight 
of the enzyme was found to be 72,600. These results indi-
cate that Atromid-S may be an effective drug for the treat-
ment- of hypertriglyceridernia but that D-thyroxine is a 
better treatment for type II hypercholesterolemia in those 
'.;:· patients who do not experience angina. 
"'. 
Types I and V hypertriglyceridemia may represent me-
tabolic defects in the activation of lipoprotein lipase. 
The proposed conversion of the stable form of the enzyme 
to the less stable form by the action of cyclic adenylate 
and the ability of glucocorticoids to enhance the action 
of the nucleotide may explain the reports by Bagdade· et ·a1 
(35) of a reduction of lipoprotein lipase activity during 
glucocorticoid-induced lipemia. Similar decreases in 
enzyme activity may occur in patients with diabetic 
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retinopathy. Ianacone and Kornerup (503) reported elevations 
in serum lipids in this condition. A decrease in the enzymes 
sulfating heparin may be partly responsible. Yde (1186) 
found that these enzymes were reduced in diabetes. In fact, 
a negative correlation exists between the fasting levels of 
serum sulfation factor and serum glucose. 
Rosenman et al (909) found that not all of the hypo-
lipidemic effect of thyroxine could be explained by its 
activation of lipoprotein lipase. They found that thyrox-
ine decreases serum cholesterol by increasing the rate of 
bile acid formation, even though it also increases the rate 
of cholesterol synthesis. Estrogens also increase bile 
acid formation but have a lesser effect on cholesterol syn-
thesis. These results indicate that drug effects on the 
rate of bile acid formation can dominate effects on choles-
terol synthesis and that drugs which can reduce the rate 
of the former process without affecting the latter may be 
valuable hypocholesterolemic agents. Polyunsaturated 
fatty acids also promote bile acid formation and they, 
in conjunction with estrienes may be the most effective 
treatment for type II hypercholesterolemia (659, 796, 1021, 
1094). Dayton et al (217) have.shown that when dietary fat 
con~titutes 40 percent of calories a diet containing 38 per-
cent of this fat as linoleic acid resulted in 48 deaths 
over an 8-year study compared to 70 deaths for a diet con-
taining only 10 percent of its fat as linoleic acid. This 
dietary treatment of a lipid disorder is similar to the 
dietary restriction of carbohydrate found by Kuo (622) to 
aid type IV hyperpre-S-lipoproteinemia. 
Non-aromatic steroids may also affect lipoprotein 
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lipase activity. Laron and Kowadlo (638) have demonstrated 
marked increases in plasma free fatty acids following the 
administration of 10 mg/kg of testosterone propionate to 
two-day fasted female rats. 'A 78 percent rise occurred in 
the treated animals versus a 5 percent rise in the controls. 
Although this rise was attributed to fat mobilization from 
depot lipid, it could pot be produced in one day-fasted 
animals. Since S-lipoproteins begin to rise after approxi-
mately 48 hours of ·fasting due to lipolysis in adipose tis-
sue, an activation of lipoprotein lipase by the steroid 
could also explain the findings. 
Androsterone exerts a hypocholesterolemic effect in 
normal subjects that has not been explained (446). Signif-
icant reductions can be obtained by the intramuscular ad-
ministration of 50 mg/kg of the steroid per day. In rats 
Abdell and Mosbach (1) have reported that 17S-hydroxy-17a-
methyl-4-androsten-3-one and its metabolite 17a-methyl-5a-
androstane-3S,17S-dibl lowered serum cholesterol. The 
effect of the metabolite appears to be similar to that ob-
served with androsterone in man. However, the effect of 
the testosterone derivative in the rat is opposite to that 
observed in man because a-lipoproteins are the predominant 
cholesterol-bearing lipoproteins in the rat. 
Although androsterone exerts a hypocholesterolemic 
·effect in normal men, certain 17a-alkylated C-18 and C-19 
steroids appear to exert this effect only in hypertri-
glyceridemic individuals. Sachs and Wolfman (923) demon-
strated that 17~-hydroxy-17a-methyl-2-oxa-5a-androstan-3-
one produced a 38 percent reduction in cholesterol, a 40 
percent drop in phospholipid, and an 81 percent drop in 
triglycerides in subjects with hypertriglyceridemia. On 
the other hand, the same compound produced typical an-' 
drogenic effects in normal individuals, namely, changes 
of +7 percent, -1 percent, and +65 percent in these same 
respective lipids. Furman and Howard (349) demonstrated 
the hypocholesterolemic effect of 17S-hydroxy-17a-methyl-
4-androsten-3-one in type II hypercholesterolemia and 
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Gluek et al (375) obtained similar effects with 17a-ethinyl-
17S-hydroxy-4-estren-3-one in four patients with familial 
type V hypertriglyceridemia. ·In fact, a 2-10 fold reduc~ 
tion in plasma triglycerides was the major effect of the 
therapy. These reports represent a significant advance 
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in the treatment of this disorder. Acute abdominal pain is 
characteristic of type V hyperlipemia. Many of the symptoms 
resemble those of pancreatitis, including elevations of 
serum amylase and serum lipase normally used in the labora-
tory diagnosis of pancreatitis. However, the administra-
tion of heparin or the withholding of long-chain trigly-
cerides from the diet lessens the abdominal pain associated 
with this disorder bu~ not that associated with pancreatitis. 
Hazzard et al (441) and Fabian et al (292) have shown 
that lipoprotein lipase is inhibited by aromatic steroids. 
Although estrienes inhibit lipoprotein lipase in normal 
and hyperlipidemic subjects, the mechanism of the effect 
is unknown. In contrast, Szensikowski et al (1045) have 
shown that eserine blocks 50 percent, and tetraisopropyl 
phosphoramide 93 percent of the post-absorptive lipolytic 
activity in the rat. The mechanism of this effect appears 
to be similar to that involved in the inhibition of the 
enzyme by protamine. The phosphramide may therefore be 
valuable in lipoprotein lipase studies. 
Effects of Lipids on Platelet Aggregation and Fib!inolysis 
Platelet aggregation is one of the initial events in 
:, myocardial infarction and (3-lipoproteins have been shown 
to affect this process. While fatty acids can cause the 
~ reversible aggregation of platelets, the aggregate is real ~\ 
l 
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and can momentarily block circulation in small capillaries. 
If this process leads to anoxic damage in the capillary, tis-
sue thromboplastin is released into the circulation and some 
thrombin is formed. Since platelets are irreversibly aggre-
gated by low levels of thrombin, those factors which control 
reversible platelet aggregation also control irreversible 
platelet aggregation. 
The process of ADP-induced platelet aggregation may 
be viewed as a result of depressed cyclic adenylate levels 
in the platelet. As such it represents an effect of cyclic 
adenylate on cell surface charge that has not yet been re-
ported for other types of cells. The mechanism whereby 
cyclic adenylate affects surf ace charge appears to be more 
closely related to electrolyte metabolism than to glucose 
metabolism. 
Glucocorticoids also enhance platelet aggregation but 
the mechanism is not clear. Generally, platelet aggre-
gates are formed in narrow pulmonary vessels following the 
administration of large doses of glucocorticoids. Appar-
ently, platelet serotonin, which is releasa:lduring the ir-
reversible phase of platelet aggregation, causes the con-
striction of bronchioles and may enhance the anoxic effect 
of platelet aggregates. 
High levels of free fatty acids in plasma promote 
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platelet aggregation. Hoak et al (465) found that both sa-
turated and polyunsaturated fatty acids had this effect. 
However, whereas the polyunsaturated fatty acids produced 
only microscopic aggregates, saturated fatty acids produced 
visible clumps. According to Goloff et al (386) these ef-
fects are best seen in the vasculature of the wing of an 
unanesthesized bat where as little as 0.01 cc of a 0.01 per-
cent suspension of sodium stearate produces vasoconstriction 
and thrombogenic effects that cannot be duplicated by larger 
doses of oleic or linoleic salts. This type of aggregation 
is not inhibited by heparin and is different from irreversi-
ble platelet aggregation induced by thrombin. However, 
Glynn et al (376) found that even reversible platelet ag-
gregation within the microcirculation could produce anoxic 
damage in the arterioles and microcirculation. 
Many cardiac patients have partially occluded coronary 
arteries. These patients are often treated with heparin 
to lessen the chance of intravascular clotting leading to 
complete occlusion. Since lipoprotein lipase is activated 
by this treatment, meals high in saturated fat may cause 
abnormal increases in saturated free fatty acids which pro-
mote reversible platelet aggregation as described above. 
This consideration emphasizes the role of diet in the con-
trol of atherosclerosis. 
' . 
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Kerr et al (573) found that platelet aggregation by sa-
turated fatty acids was inhibited by the 18w3 fatty acid 
lirolenate but not by the 18w6 fatty acid linoleate. Thompson 
(1059) found increased platelet adhesion in multiple scle-
rosis and noted that circulating cholesterol linoleate was 
depressed in the active stages of the disease. Since this 
ester is synthesized from a linoleate-containing lecithin, 
its depression in these stages might be explained by the 
presence of phospholipase A activity in the circulation of 
these patients. Bolton and Phillipson {92) presented evi-
dence supporting the presence of an abnormal lysolecithin 
in multiple sclerosis that tends to support the above hy-
pothesis. This lysolecithin increases in the chronic 
phases of the disease resulting in increased platelet sen-
sitivity to ADP-induced aggregation. The abnormal lyso-
lecithin is believed to be formed by the action of phos-
pholipase A on an abnormal lecithin of n.eural origin. How-
ever, a similar lecithin species has been demonstrated in 
patients with vascular disease. Although the phospholipase 
A activity in vascular disease is released from erythro-
cytes by centrifugation, little is known about this enzyme 
nor about the enzyme active in multiple sclerosis. Platelet 
aggregation in response to ADP appears to be more frequent 
in venous regions of low turbulance so that these regions 
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are more susceptible to thrombosis. 
Prostaglandin PGE1 inhibits lipolysis and platelet ag-
gregation. Karim and Sharma (563) found that ethanol could 
abolish uterine contractions produced by the oral adminis-
tration of PGE 2 to gravid women at term. This finding sug-
gests that a decrease in the cytoplasmic ratio of NADH to 
NAD+ is one of the effects of the lipid. The possibility 
I 
that prostaglandins exert some of their effects following 
their conversion to coenzyme A derivatives and the incor-
poration of the latter into phosphatidic acid and trigly-
cerides has not been investigated. 
The role of stress in atherosclerosis has already 
been discussed. Delong et al (225) showed that the whole 
blood clotting times of stressed rats was decreased rela-
tive to non-stressed controls. These results are consis-
tent with the known affect of epinephrine on platelet ag-
gregation. This action is not mediated by cyclic adenyl-
ate. Indeed, Marquis et al (719) have shown.that cyclic 
adenylate decreases platelet aggregation in response to 
adenosine-5'-diphosphate, ADP. Therefore, any factor 
which decreases the cyclic nucleotide will increase 
platelet aggregation in response to ADP. While prosta-
glandin E1 decreases the levels of cyclic adenylate in 
adipose tissue (146, 297), it increases the levels of the 
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cyclic nucleotide in platelets. In addition, it is inter-
esting to note that although the prostaglandin is the most 
potent inhibitor of platelet aggregation yet discovered, it 
cannot be used therapeutically because of the hypotension 
which it also produces. This action appears to be opposite 
to the action which the prostaglandin has on uterine smooth 
muscle. 
The arterial intima is continually being injured and 
repaired. The basis of the effect of serum lipids on 
thrombus formation is illustrated by the results of Bang 
et al (76). These workers found that chylomicrons and 
pre-S-lipoproteins were incorporated into the fibrin clot 
and that once incorporated the lipoprotein inhibited fi-
brinolysis of the thrombus. 
The prostaglandins have an important role in modify-
ing the actions of cyclic adenylate in adipose tissue. 
First, the mode of transport of prostaglandins does not 
seem to have been studied, especially with respect to their 
possible transport by lipoproteins. Bergstrom (70) noted 
that these lipids inhibited the lipolytic action of cate-
cholamines but not their effects on heart or on glucose 
metabolism. Fain (297) reported that PGE1 also inhibited 
the lipolytic action of growth hormone and glucocorticoids. 
Thus, prostaglandins may directly oppose the interaction of 
~·· 
' 
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glucocorticoids with the postulated growth hormone-dependent 
protein. However, PGE1 may increase cyclic adenylate levels 
in some tissues. These results suggest that both PGE1 and 
growth hormone along with glucocorticoids affect lipolysis 
independently of cyclic adenylate levels. 
Effects of Aldosterone Antagonists 
Glucocorticoids may act to decrease triglyceride syn-
thesis. Danowski et al (212) noted that the aldosterone 
antagonist 3-(3-keto-7-a-acetylthio-17s-hydroxy-4-andros-
ten-17a-yl)-propionic· acid gamma lactone, like glycyr~ 
rhetic acid, could enhance the 'inhibition of triglyceride 
synthesis by cortisol. 
Sequelle of Initial Myocardial Infarction 
The arterial damage resulting from an initial myocar-
dial infarction results in the release of tissue thrombo-
plastinsand higher steady-state levels of plasma thrombin. 
Since thrombin preferentially accelerates platelet aggre-
gation, an initial infarction increases the probability of 
a subsequent infarction. Thrombin acts by exposing platelet 
factor 3, a platelet membrane lipoprotein which contains 
phospholipids active in blood coagulation. 
The elevation in S-lipoprotein which occurs following 
an infarction and persists for approximately two months 
thereafter appears to be due to an inhibition of lipoprotein 
238 
lipase activity that may be caused by the presence of hep-
arin-neutralizing factors. However, the significance of the 
decrease in sf 12-20 lipoproteins following infarction, first 
reported by Dodds and Mills (246) remains obscure. 
McDonald and Edgall (688) have verified the hypercoagu-
lability of the blood of patients with angina pectoris or 
actual myocardial infarction due to the presence of tissue 
thromboplastin as mentioned above. Agents which increase 
platelet aggregation in response to ADP in vitro may also 
increase secondary platelet aggregation in response to ADP 
released from platelets primarily aggregated by long chain 
saturated fatty acids. 
The main result of the increased ADP concentration in 
platelets is that processes which maintain the repulsive 
surface charge on the platelet are reduced so that platelets 
show increased adhesiveness to each other and to glass. This 
change in surface charge is reflected by changes in the elec-
trophorectic mobility of the platelet. 
French (330) has noted that low levels of thrombin pref-
erentially accelerate platelet aggregation. After this ini-
tial aggregation which is an irreversible process, the plate-
lets release a lipoprotein, platelet factor 3, which in-
creases the rate of thrombin formation. It is this second 
,. 
,'~ 
l 
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surge of thrombin formation which clots fibrinogen. How-
ever, although platelets are irreversibly aggregated, throm-
bus formation is still reversible at this stage. The irre-
versible stage in thrombus formation appears to be the ab-
sorption of certain plasma glycoproteins by the developing 
thrombus ( 131) • 
Role of Phospholipids 
The increase in B-lipoprotein which follows myocar-
dial infarction has been investigated by Hampton and Mitchell 
(425) and by Bolton et al (89). They found that the lipopro-
tein in this instance contained an abnormal lecithin which 
was converted to a lysolecithin by the action of an enzyme 
found to be of red cell origin. Although the exact nature 
of the abnormal lecithin has not been determined, it is be-
lieved to be a symmetrical lecithin containing only mono-
enoic or saturated fatty acids. A similar type of lecithin 
has been shown by Bplton et al (91) to be present in women 
taking estrogen-progestin combinations. The effect was at-
tributed to the estrogen component because the progestin 
6-chloro-17a-hydroxy-l,4-pregnadiene-3,20-dione 17 acetate 
was without effect when administered alone (843). The es-
trogen effect under these conditions appears to be due to 
an increase in lecithin saturation (423). An additional 
direct effect of estrogens on B-lipoprotein is not ruled 
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Indeed, Roberts and Szego (892) have reported the 
presence of covalently bound estrogen activity in the S-li-
poproteins of human plasma. The estrogen activity was pres-. 
ent in a hydrophilic esterified form equivalent to 18 µg/l 
of estriol. 
Although the effects of estrogens on blood coagulation 
are complex, their enhancement of ADP-induced platelet ag-
gregation appears to be due to an increase in the hepatic 
synthesis of monounsaturated lecithins. For example, 
Bolton et al (91) observed that platelet electrophoretic 
mobility, a measure of the repulsive negative charges be-
tween platelets, was increased by estrogen therapy. In 
addition, the platelets became much more sensitive to the 
reduction in their mobility normally caused by 0.05 µg/ml 
of ADP.· For instance, an anurism of the left middle cere-
bral artery was observed in a patient whose platelet mo-
bility was decreased 12 percent by 0.005 µg/ml ADP, the 
( highest sensitivity observed during the study. 
l 
.. 
. 
Hampton and Mitchell (425) have reported that the 
lecithin precursor of the platelet-active lysolecithin, 
alt.hough present in normal plasma, is increased 5-fold 
following myocardial infarction. The hydrolysis of this 
lecithin to the active lysolecithin was inhibited by cya-
nide and fluoroacetate anions. The phospholipase enzyme 
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responsible for the transformation seemed to be specific for 
lecithin bound to B-lipoprotein. Bolton at al (89) noted 
that the active lysolecithin was not formed if the lipopro-
tein had been frozen and thawed and thereby denatured. The 
phospholipase, therefore, shows substrate specificity simi-
lar to that shown by lipoprotein lipase. The function of 
the lipoprotein may be to bind the lecithin in an asymmet-
rical manner for Attwood et al (32) noted that asymmetrical 
micelles were more rapidly hydrolyzed by phospholipase A. 
The phospholipase as well as its lysolecithin product are 
destroyed when incubated in plasma for 1 hour at room tern-
perature. The lysolecithin appears to be destroyed by a 
separate lysolecithinase of wide distribution. On the 
other hand, the lecithinase is destroyed if the plasma 
comes in contact with glass. This latter inactivation 
does not appear to be caused by the proteolytic enzymes 
involved in blood coagulation which are surface-activated, 
but rather to an instability to glass surfaces similar to 
that observed with lipoprotein lipase (314). The condi-
tions which affect the formation of the lysolecithin are 
also similar to those which have been reported for the 8-
lipoprotein insulin inhibitor by Bornstein (100). 
Several questions related to the beneficial effects 
of estriene therapy on coronary thrombosis remain unanswered. 
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Although Ask-Upmark (29) and Tausk (1053} have reviewed per-
tinent findings relative to the relationship between estro-
gens and arterial damage, the fact that estrienes are not 
beneficial by virtue of their effects on serum lipoproteins 
nor by virtue of their effects on thrombus formation means 
that the actual basis of the long-term improvement in post-
infarction survival is still unknown. Furthermore, the 
superiority of conjugated estrogens compared to non-con-
·_jugated estrogens in this type of therapy must be confirmed. 
comparison of Estrogen and Cortisol Effects on Platelet 
A~gregation and Glucose Tolerance 
Egeberg and Owren (273} observed elevations in two 
hemostatic lipoproteins, platelet cofactor I and Factor V 
during estrogen therapy. Platelet cofactor I (Factor VIII} 
was also elevated in diabetic patients, patients with 
Cushing's disease, and during pregnancy. It is noteworthy 
that glucose intolerance has also been noted in each of 
these conditions. 
Little is known about the biochemistry of Factor VIII. 
A deficiency of the activity of this factor produces Bemo-
philia A in males. It is known, however; that Factor VIII 
stimulates blood coagulation in response to tissue thrombo-
plastins as well as in response to surface contact. Its 
action is closely related to that of another lipoprotein, 
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platelet factor 3 •. The complex of Factor VIII and platelet 
~ factor 3 has been termed "threone" and it accelerates the 
generation of thrombin by acting as a catalyst for the rapid 
interaction of other clotting factors leading to thrombin 
formation. Therefore, at least part of the estrogen effect 
on blood coagulation is due to an increased formation of 
Factor VIII, which increases the concentration of threone 
in blood. According to Hemker and Kahn (448), threone pro-
motes the interaction of Factor VII with Factor IX as well 
as the interaction of Factors V and X. 
Although the membrane lipoprotein platelet factor 3 
is not required for the anti-insulin effect of B-lipopro-
teins, some of its properties will be described since they 
may be confused with the lysolecithin species which is be-
lieved to be required for insulin antagonism. The lipid 
portion of platelet factor 3 lipoprotein is active in cer-
tain coagulation tests such as the thromboplastin genera-
tion test and in the Stypven-time deternination. The exact 
nature of this lipid portion of the molecule has not been 
determined. However, it is known that the active componcmt 
is a phospholipid which can be formed from sn-1,2-dioleoyl-
phosphatidyl ethanolamine (844). The active phospholipid 
is found in most crude cephalin preparations. Its in vivo 
significance is seen in the results of Marciniak et al (710) 
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·who showed that the simultaneous injection of the cephalin 
fraction with autoprothrombin C (Factor X) was lethal while 
the injection of either factor alone was not lethal. 
Platelet aggregation is prevented normally by the ac-
tion of a membrane bound kinase which introduces negatively 
charged phosphate groups into the platelet membrane and 
thereby generates repulsive platelet charges. ATP is the 
phosphate donor for this reaction and the process is in-
hibited by ADP. This scheme was proposed by Salzman (928). 
However, the source of extracellular ATP for the reaction 
has not been specified. It appears that some mechanism 
exists by which intracellular ATP equivalents are trans-
ported through the membrane and subsequently converted to 
extracellular ATP because nucleotides do not penetrate the 
platelet membrane. Furthermore, the high levels of acid 
phosphatase contained in platelets may be involved in the 
removal of the membrane phosphate groups thereby neces-
sitating their continuous replacement. Although ATP in-
hibits ADP-induced platelet aggregation, ATP does not 
inhibit platelet aggregation produced by thrombin. Both 
ADP and serotonin are known to be stored in platelet gran-
ules that are irreversibly disrupted during thrombin ag-
gregation. This effect of thrombin·on platelet granules 
may be related to its effect on platelet phospholipid 
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synthesis. Majewus ·et al (699) have shown that platelet 
phospholipid synthesis can be increased 7-f old by thrornbin 
within 2 minutes and that this effect is accompanied by the 
reduction in the molecular weight of a platelet membrane 
protein from 190,000 to 107,000. 
The Mechanism of Steroid Effects 
Jederkin and White (527), White (1138), and Wade and 
Jones (1109) have reported that 6 x l0- 4Molar 3,4-bis (p-
hydroxyphenyl)-trans-3-hexene,4,16-prenadiene-3,20-dione, 
progesterone, and 17a-ethyl-17S-hydroxy-4-estren-3-one in-
creased mitochondrial ATP utilization and inhibited the 
rate of oxygen consumption. The first non-steroid was 
about 26 times as potent as the first steroid listed. 
The chemical progesterone precursor, in turn, was about 
3 times as potent as the latter two steroids ·which were 
approximately equal in effect, but 3 times as potent as 
deoxycorticosterone which was equal to 17S-hydroxy-17a-
methyl-4-androsten-3-one in potency. Their data also in-
dicate that the 3-fold difference in activity between the 
latter steroid and 17a-ethyl-17S-hydroxy-4-estren-3-one is 
due to the difference in the C-17 and not the C-10 substi-
tuents (492). The high activity of 4,16-pregnadien-3,20-
dione also suggests that other flat polycyclic molecules 
such as 3-methylcholanthrene and ergolanes may also 
be able to produce these effects. On a molar basis these 
inhibitory effects were greater than those of dicumarol, 
dinitrophenol, methylene blue, sodium azide or sodium cya-
nide. Essentially similar findings were reported by Jones 
and Wade (535) and by Hochster and Quastel (467). 
Gordon et al (398, 399) attributed the increased uti-
lization of extramitochondrial ATP to a steroid block in 
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the reduction of mitochondrial cytochrome C by NADH. Since 
the steroids were effective in the presence of amytal (5-
ethyl-5-isoamyl-barbituric acid) which inhibits electron 
transport at cytochrome C but did block reduction of coen-
zyme Q (ubiquinone), the steroids were believed to inhibit 
electron transfer between coenzyme Q and cytochrome b or 
between the latter and cytochrome c. Gordon et al (398) 
reached similar conclusions. Jedeikin and White (527} 
f also found that 10- 4Molar deoxycorticosterone inhibited 
~··· the oxidation of pyruvate and succinate and that NAD + 
could overcome this inhibition. 
Gallagher (352) also found that cortisol inhibited the 
oxidation of NADH. However, he found that the inhibition 
could be reversed-by glutathione and acetyl coenzyme A and 
.that the effect could be abolished by preparing mitochondria 
in water rather than in 0.25 Molar sucrose. These results 
emphasize the importance of mitochondrial integrity in the 
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effect of the steroids. 
Blecher (84) further studied the effect of glucocorti-
coids on lymphatic cells and found that they inhibited gly-
colysis rather than glycogen formation. White and Makman 
(1139) reported that the effects of glucocorticoids on thy-
mocytes required the presence of an energy source and in-
tact cellular protein and nucleic acid synthetic capacities. 
These results suggest that the effects of glucocorticoids 
are much more specific than that of the other steroids men-
tioned above. That this specific glucocorticoid effect may 
be mediated by the S-lipoprotein glycolytic inhibitor is in-
dicated by the findings of Hofert and White {468) demon-
strating a major role of the liver in the systemic action 
of glucocorticoids in the involution of lymphoid cells. 
Jones and Wakil (936) observed that NADH-cytochrome C 
reductase in microsomes has an absolute requirement for ly-
soleci thin and lecithin. They postulated that these lipids 
combined to form micelles of distinctive structure. This 
effect is similar to that reported for the lipid portion of 
platelet factor 3. It was also reported that a similar 
type of micelle could be formed by 2-butyryl-3-olelyl-sn-l-
glycerophosphoryl-choline. The possibility that certain 
steroids disrupt the structure of these micelles should be 
investigated. 
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Selye (965) first observed the anesthetic effects of 
steroids in mice. He found that female mice were much more 
sensitive to anesthesia than .males. Using 135 gm mice, he 
found that as little as 5 mg of deoxycorticosterone or 15 
mg of progesterone produced marked anesthesia in females. 
The anesthesia was further prolonged by the administration 
of 50 mg of androsterone. The male mice, however, were 
hardly affected by 40 mg of deoxycorticosterone. Winter 
(1169) confirmed these findings and showed that the anes-
thesia could be reversed by glucose. 
Gordon (399) reported that 17a.-ethyl-1713-hydr0xy-4-
androsten-3-one produced anesthesia while estradiol did 
not. However, Wade and Jones (1109) reported that estra-
diol was about as effective as 513-pregnane-3a.,2013-diol and 
testosterone. The use of non-hormonal steroids as anes-
thetics eliminates side effects such as salt-retention by 
deoxycorticosterone. For example, 21-hydroxy-513-pregnene-3, 
20-dione 21-hemisuccinate has been used as a clinical anes-
thetic. The administration of 1.5 gm of the compound 
(Viadril) to men produces surgical anesthesia sometimes ac-
companied by profuse salivation which can be eliminated by 
atropine (dl-hyoscyamine), an anti-cholinergic belladonna 
alkaloid. In view of the fact that Viadril produces anes-
thesia more readily than analgesia, the substitution of 
scopolamine (hyoscine), a parasympatholytic agent which is 
a precursor of atropine, for atropine, should depress the 
central nervous system and enable the effective dose and 
thrornbophlebities associated with the hemisuccinate ester 
to be reduced. Pedersen (823) reported that the adminis-
tration of 0.5 mg of scopolamine to men produced sedation 
in 88.4 percent of them with no excitation or respiratory 
depression. Bradycardia, nausea and vomiting occurred in 
20 percent. These results suggest that the combination of 
scopolamine and a more potent anesthetic which is water 
soluble may be a clinically useful agent in man. Scopola-
mine may also be used to treat the pyloric spasm which 
occurs in alloxan-diabetic rats, thus improving their 
survival. 
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The llS-hydroxyl group dramatically changes the sur-
face activity of steroids. Munk (766) found that cortisol 
laid on edge at the heptane-water interface while deoxy-
corticosterone and progesterone took up parallel positions. 
Weissman (1130) noted that cortisol counteracted the re-
lease of acid hydrolases from liver lysosomes by deoxycor-
ticosterone and progesterone as well as the release of 
salts and glucose from synthetic micelles by the latter 
steroids. These findings suggest that glucocorticoids 
have specific surface effects. 
·. 
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Effects of Other Compounds 
·- Mills and Roberts (745) as well as O'Brien (793) have 
shown that a number of clinically used drugs reduce the AOP-
sensi ti vi ty of platelets. One of the more interesting is 
thorazine [2-chloro-10-(3-dimethyiaminopropyl)-phenothiazine] 
' 
which is also known as chlorpromazine. Several seemingly 
unrelated effects of this drug are of interest in light of 
the hyperglycemic effect of the drug. Reckless and Hopkin 
(869) demonstrated synergism in anesthetic effect of the 
phenothiazine and morphine; anesthetic steroids have also 
been described. Although chlorpromazine alone decreases 
respiratory rate, it also counteracts respiratory depres-
sion due to morphine (869); glucocorticoids have the same 
effect. Furthermore, the phenothiazine opposes the emetic 
effect of serotonin and apomorphine; both of the latter 
compounds have hyperglycemic effects (180, 987). Chlor-
promazine also accelerates the clearing of hyperlipidemic 
serum (471) but inhibits ethanol metabolism (118). 
While the above observations do not suggest a common 
mechanism, reports that an abnormal lecithin molecule 
transported by B-lipoprotein following its conversion to 
lysolecithin, increases platelet ADP-sensitivity, suggests 
that a specific lecithin may mediate glycolytic inhibition 
by steroids (573, 720, 928). Furthermore, since Hughes 
, . 
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·and Tonks have shown that glucocorticoids enhance platelet 
aggregation (493), they may exert this effect by increasing 
the synthesis of the abnormal lecithin in the liver. Growth 
hormone or estrogens may also affect the synthesis of this 
lecithin species. 
A platelet membrane lipoprotein, platelet cofactor 3, 
is exposed during irreversible platelet aggregation when it 
accelerates thrombin formation. This factor is described 
. because it also contains an essential phosphatidyl ethanol-
amine derivative but is not concerned with reversible plate-
let aggregation. On the other hand, Factor XII, Hageman 
factor, which is a proteolytic enzyme responsible for the 
reduced clotting time of blood exposed to hydrophilic 
(glass) surfaces, has been shown by Harmison and Mammen 
(429) to increase platelet ADP-sensitivity. These workers 
also found that purified Hageman factor along with purified 
~, platelet cofactor 3 could activate ·purified prothrombin to 
r 
thrombin. 
Chlorpromazine, phentolamine (2-[N-(m-hydroxyphenyl)-
p-toluidinomethyl]-imidazoline), and diphenyldiamine (2-
diphenylmethoxy-N,N-dimethylethylamine) inhibit ADP-induced 
platelet aggregation (213, 1199). These drugs are very 
similar structurally. In addition to these platelet effects, 
Charaton and Bartlett produced hyperglycemia in dogs by the 
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administration of 50 mg of chlorpromazine. Dobkin et al 
:· (241) also produced hyperglycemia in man by the intravenous 
administration of 1.5 mg/kg of the drug. Furthermore, Hiles 
(457) noted that patients with a family history of diabetes 
were most prone to chlorpromazine hyperglycemia. The ef-
feet of chlorpromazine on glucose utilization is similar 
to that of cortisol. 
Chakrelarte et al (167) found that the combination of 
the synthetic steroid 17a-ethyl-4-estren-17S-ol and the 
oral hypoglycemic agent phenethylbiquanide inhibited ADP-
induced platelet aggregation. A reduction in platelet ad-
hesiveness was produced in most patients by the administra-
tion of 50 mg of phenethylbiquanide and 4 mg of the steroid 
per day. Phenethylbiquanide inhibits oxidative phosphoryla-
tion, depresses cytoplasmic ATP, and therefore accelerates 
glycolysis by its anaerobic effect. However, if this were 
its only action, phenethylbiquanide would promote platelet 
aggregation. The inhibitory effect of this compound could 
be due to inhibition of platelet phosphodiesterase with 
.resulting elevation in platelet cyclic adenylate which has 
been shown to have this effect. If the steroid also 
inhibits platelet aggregation by reducing cyclic adenyl-
ate levels, then it appears to have an effect opposite to 
that of glucocorticoids which enhance the effects of this 
l 
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n~cleotide. However, since platelets are capable of gluco-
neogenesis, the role of protein synthesis in these effects 
cannot be determined from present data. 
zucher and Peterson (1198) reported that a single dose 
of aspirin irreversibly reduced platelet aggregation in re-
sponse to epinephrine for the platelet life-span of 9-11 
days. Hemostasis was still satisfactory, however~ The 
molecular reaction involved is believed to be the transfer 
of the phenolic acetyl group of aspirin to a protein amino 
group. Furthermore, al-Mondhiry et a1· (754) determined 
that acetic anhydride could also produce the aspirin effect 
whereas sodium acetate could not, even though total ace-
tate incorporation was about the same as with the anhydride. 
Apparently, these workers did not distinguish between coval-
ent and non-covalent acetyl groups. Also, although these 
workers were working with whole platelets, only one of many 
acetylatable proteins is involved in the ADP-induced aggre-
gation. 
In summary, the phenomenon of ADP-induced platelet ag-
gregation provides a model system in which the action of a 
unique species of lysolecithin associated with S-lipopro-
tein may be studied. The identity of this lipoprotein fac-
tor with the insulin inhibitor cannot yet be made with cer-
tainty since the mechanism by which ADP exerts its effect 
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is not known. However, a reduction in platelet ATP is one 
of the effects of ADP so that some aspect of platelet metab-
olism is blocked by B-lipoprotein. If the insulin antagonist 
enhances platelet aggregation, then insulin should counteract 
its effect. 
Sirek et al (987) and Feldman and Lebowitz (309) fur-
ther demonstrated that serotonin antagonists could block 
the hyperglycemic effect of serotonin. These latter workers 
also showed that the adrenergic blocking agent phentolamine 
also had this effect even though it did not block insulin 
release by epinephrine. In additional experiments Sirek 
et al (987) showed that 2-bromolysergic acid diethylamide 
inhibited the rise in blood pressure following the trans-
fusion of blood from normal dogs treated with growth hor-
/mone. These results suggest that growth hormone releases 
serotonin into the blood. The serotonin, in turn, releases 
adrenal epinephrine. In perhaps their most interesting re-
port Sirek (986)showed that dihydroergotamine treatment 
abolished the early increase in glucose utilization fol-
lowing the injection of growth hormone into hypophysecto-
mized dogs. This hypoglycemic effect of serotonin has been 
observed by others and may be due to the displacement of 
cortisol from some of its binding sites. In related ex-
periments Levine et al (656) found that serotonin at a 
r 
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concentration of 4 x 10 M produced glycogenolysis, hypergly-
cemia, and increased phosphorylase activity independently of 
the vasomotor effects of the amine on the liver. These ef-
fects could be. blocked by the serotonin antagonist Nl-methyl-
ergonovine. 
Adrenalectomized rats are more sensitive to serotonin, 
serotonin toxicity and intravenous serotonin hyperglycemia. 
Adrenalectomy also decreases blood serotonin, -the induction 
of trytophan pyrolase. by serotonin, and the block in sero-
tonin hyperglycemia by dihydroergotamine. Serotonin de-
# creases thyroxine release and increases prolactin release. 
:'~· Serotonin induces hypertrophy of the n1anunary gland wi tl1 
hyperplasia of the ducts and lobular differentiation in 
most ovarectomized rats, but not in hypophysectomized rats. 
Serotonin decreases. gluconeogenesis and lowers muscle gly-
cogen but stimulates the growth of Walker carcinocarcinoma. 
Growth hormone increases the urinary excretion of 5-hydroxy-
indoleacetic acid. 
Brand et al (113} reported that chlorpromazine could 
block the emetic effects of apomorphine, morphine, and di-
hydrogenated ergot alkaloids. Ansell and Marshall (14} 
reported that chlorpromazine inhibits phospholipid synthe-
sis and Greig and Gibbons (11} have shown that the pre-
servative effect which the phenothiazine has on red cells 
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in stored blood is due to the inhibition of a red cell lec-
ithinase by the drug. These results suggest that chlorpro-
mazine may bind to alkaloid as well as to phospholipid bind-
ing sites. 
Gey and Pletscher (364) have shown that serotonin 
raises blood pyruvate and lactate levels suggesting that 
serotonin may interact with the growth hormone dependent 
protein which elevates cytoplasmic citrate levels. 
Since ergot alkaloids and phenothiazines are not en-
dogenous metabolites, if they are found to compete for 
some glucocorticoid-binding sites, this would indicate 
that some glucocorticoid effects are due to binding at 
non-specific sites and that certain drugs also exert their 
effects by binding to these sites. Furthermore, if ergot 
derivatives are found to have the highest binding affinities, 
the results may mean that related compounds could be imper-
tant drugs capable of producing the non-specific but not 
the specific effects of glucocorticoids. The anti-inflam-
matory effects and anti-glycolytic effects of the steroid 
are believed to be in this latter category. 
In conclusion, the ability of S-lipoprotein lysolec-
ithin to enhance (89, 425) platelet aggregation by adeno-
sine-5'-diphosphate may provide a convenient assay system 
with which to further study the phenomenon on a molecular 
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basis. With such an assay the factors which regulate the 
hepatic synthesis of the lecithin precursor of the lysolec-
ithin may be studied. In particular, the roles of non-glu-
cocorticoids, phenothiazines, serotonin, and serotonin an-
tagonists in the effect can be determined. Furthermore, 
the hypothesis that such effects are related to a block 
in the conversion of diglycerides to triglycerides can be 
evaluated. 
Role of Growth Hormone in Estrogen Effects 
Steinberg (1025) has shown that the effects of estro-
gens on serum lipids in female hypophysectomized rats re-
quires growth hormone. In addition, it appears that the 
deleterious effect of high-dosage estrogen therapy is also 
mediated by a growth hormone-dependent mechanism. Further-
more, both the effects of glucocorticoids on glucose up-
take in adipose tissue (397) as well as the effects of 
this hormone on the production of the S-lipoprotein insulin 
inhibitor have been shown to be dependent upon growth hor-
mone (98). 
Bala et ·a1 (39) have shown that estrogens enhance 
growth hormone release while progestational steroids such 
as 17a-hydroxy-6a-methyl-4-pregnene-3,20-dione suppress 
·growth hormone release in response to insulin or arginine. 
These results may indicate that the effects of the estrogen 
~> 
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and progestin components on growth hormone release may cancel 
each other to some extent, depending on their relative poten-
cies and the ratio in which they are present in the medica-
tion. In many cases net effects on growth hormone levels 
are observed. Spellacy et al (1010, 1011) found elevations 
in growth hormone following the administration of 0.075 mg 
17a-ethinyl-3-methoxy-l,3,5(10)-estrien-17S-ol and 5.0 mg 
17a-ethinyl-17S-hydroxy-5(10)-estren-3-one. Since most com-
binations contain 0.05 mg of estrogen but 5.0 mg of proges-
tin, the nature of the latter may determine the growth hor-
mane effect of the various combinations. On the other hand, 
the sequential use of 0.10 mg of estrogen, double the above 
dose, may elevate growth hormone levels more frequently. 
Several groups have reported the effects of estrogens 
and progestins in clinical studies. Svandborg and Vikrol 
(1041) reported that the percentage of lecithin increased 
while that of cholesterol and lysolecithin decreased fol-
lowing estradiol benzoate •. The lipid pattern observed is 
somewhat similar to that which occurs in multiple sclero-
sis. Wynn et ·a1 (1179) showed that 31 percent of women 
taking estrogen-progestin combinations had fasting trigly-
ceride levels higher than the upper limit of normal. Also, 
approximately, 15 percent of these same subjects had ab-
normal glucose tolerance tests. These changes were not 
due to the progestin component because they could be pro-
duced by the estrogen component alone. 
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The most pronounced change in serum lipids with estro-
gen-progestin combinations is an approximately 160 percent 
rise in the level of pre-B-lipoproteins. Other increases 
found by Wynn ·et al (1179) expressed as the percentage of 
pre-medication values include: triglycerides, 51.5; cho-
lesterol, 7.3; sf 0-12 lipoproteins, 15.9; sf 20-100 lipo-
proteins 56.2. Although no change occurred in Sf 12-20 
lipoproteins, the atherosclerotic index was elevated 25 
~· percent because of the pre-B-lipoprotein rise. The over-
all picture closely resembles that seen in type IV carbo-
hydrate-induced hyperpre-B-lipoproteinemia. The relatively 
slight elevation in cholesterol cannot explain the in-
creased incidence of thrombophlebitis nor the changes in 
glucose tolerance. Other studies, however, in which in-
dividual phospholipids were deternined have helped to ex-
plain this result. 
Brody et ·a1 (20) found that C-18 and C-21 progestins 
had different effects in estrogen combinations. The C-21 
progestins partially counteracted the estrogen-induced in-
crease in triglycerides as well as the decrease. in phos--
phatidyl ethanolamine. These results suggest that C-21 pro-
.gestins may inhibit the incorporation of sn-1,2-diglycerides 
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into triglycerides. Di Paola ~t al (35) have indicated that 
the 3-methyl ether of 17a-ethinyl-l,3,5(10) estriene-3,178-
diol more adversely affects glucose tolerance than the parent 
steroid, indicating that the CJ-hydroxyl group is not re-
quired when administered for this effect. 
Larsson-Cohn ~~ al (640) studied the effects of the 
combination of 0.1 mg of the ether and 3 mg of 17-acetoxy-
6-chloro-4,6-pregnadiene-3,20-dione on serum lipids. They 
found the following percent changes: triglycerides, + 139; 
lecithin, + 46; sphingomyelin, + 12. Phosphatidyl ethanol-
amine was slightly increased, free fatty acids slightly re-
duced, and lysolecithin unchanged. These observations, how-
ever, do not permit a distinction between increased rates 
of lipid biosynthesis and decreased rates of lipid degrada-
tion. 
The above effects on serum lipids are similar to those 
f produced by glucocorticoids as observed by Sherbe (978) in 
~' 
?, 
women prior to adrenalectomy. Furthermore, the results sug-
gest that the 118 and C-21 hydroxyl groups are not abso-
lutely required for this effect even though they enhance it. 
Since the progestin component is usually present at 100 times 
the level of the estrogen component on a weight basis, ef-
fects that go unnoticed at physiologic progesterone levels 
,. may become significant at these higher levels. 
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Jeurand and Oliver (531) found that growth hormone 
treatment increased the saturation of serum triglycerides. 
Hagopian and Robinson (423) also found that estrogen treat-
ment increased triglyceride saturation. This effect was 
found to occur during the synthesis of phosphatidic acid 
which has been shown to occur in mitochondria. Although 
triglyceride and phospholipid synthesis from diglycerides 
occurs extramitochondrially, factors regulating the trans-
port of phosphatidic acid from mitochondria have not been 
completely elucidated. Greenbaum and Mc Lean (408) noted 
that diglycerides accumulate in the liver of rats follow-
ing growth hormone treatment. Steinberg (1025) has also 
noted that growth hormone is required for estrogen-,induced 
hypocholesterolemia in rats. These observations suggest 
that growth hormone and steroid effects on triglyceride 
synthesis occur extramitochondrially. 
Phosphatidic Acid Synthesis 
The enzymes of phosphaditic acid synthesis have been 
studied by several groups. O'Kuyama et al (795) found 
that oleic acid was esterified faster than stearic acid. 
Eloison et al (283) observed that 90 percent of palmitic 
acid was esterified at the sn-1 position while only 10 per-
cent was esterified at the sn-2 position. Similar findings 
have been observed with oleic and palmitic acids. It thus 
: , 
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appears that phospholipid composition is a function of hepat-
ic acyl coenzyme A concentrations. 
Since the enzyme involved in the acylation of the sn-2 
position is much more active than the enzyme acylating sn-1 
position with :i;:almi toyl coenzyme A. A similar situation also 
exists with respect to the enzymes catalyzing acyl transfer 
reactions with lysophosphatides. De Tomas and Renner (231) 
observed that unsaturated acyl coenzyme A was incorporated 
faster into lysophosphatidyl ethanolamine than into lyso-
phosphatidyl choline. In addition, Akesson et al· (8) 
noted that the enzyme which esterifies palmitoyl coenzyme 
A at sn-1 functions best with tetraenoic 2-acyl-sn-glycerol-
3-phosphorylcholine and ethanolamines, incorporating 90 per-
cent of added palmitate into these species within 5 seconds 
after its addition. Both the specificity in the formation 
of phosphatidic acid as well as the specificity in the 
acylation of lysophosphatides results in the formation of 
unsaturated phosphatidyl ethanolamine and the expense of 
saturated phosphatidyl cholines. 
The further metabolism of phosphatidic acid does not 
appear to take place in mitochondria. The enzymes required 
for the addition of acyl coenzyme A to diglycerides appears 
to be in the cytoplasm while the enzymes which catalyze the 
formation of phospholipids from diglycerides are found in 
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hepatic microsomes. Recent studies by Reiser et al (876) in-
dicate that triglycerides formed in the cytoplasm may serve 
as phospholipid precursors under certain conditions. 
Besides being incorporated into phosphatidic acid, long-
chain acyl coenzyme A derivatives may have several other 
fates. They may be converted to carnitine esters by an en-
zyme which has been found to be increased in the alloxan-
diabetic rat. However, it should be noted that this reac-
\ tion is not rate limiting for fatty acid oxidation (1107, 
1156). If the fate of the acyl coenzyme A is to be oxi-
dized, Huixtable and Wakil (463) have determined that the 
rate of this oxidation will decrease with increasing unsa-
turation except for linolenate, which is oxidized faster 
than linoleate. These studies also indicate that effi-
cient incorporation of linoleyl coenzyme A into complex 
lipids is necessary to conserve this essential fatty acid 
from rapid oxidation. 
Another possible fate of long-chain acyl coenzyme A 
is chain elongation. The chain elongation of saturated acyl 
coenzyme A such as _palmitoyl coenzyme A occurs to a greater 
extent in females than in males (423). On the other hand, 
there is no difference in the chain elongation of linoleyl 
coenzyme A to arachidonyl coenzyme A. While these results 
suggest that separate enzymes may be involved in the chain 
elongation of saturated and unsaturated coenzyme A deriva-
tives with only the former under hormonal control, female 
rats do have higher serum arachidonate levels than males 
50 that the degradation of arachidonate may also be hor-
monally controlled. This appears to be the case since un-
saturation decreases fatty acid oxidation. 
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Not only is arachidonate less readily oxidized than 
other fatty acids, it is also less readily incorporated in-
to the sn-2 position of phospholipids. Akesson (8) found 
that most of the label in linoleoyl coenzyme A was not in-
corporated unchanged or after conversion to arachidonyl co-
enzyme A, but that 60-80 percent of the linoleoyl label was 
incorporated as 18w6,9,12 octadecatrienoyl coenzyme A or as 
20w6,9,12 eicosatrienoyl coenzyme A. This indicates that 
there is an optimal substrate unsaturation for this reac-
tion ( 8). 
In addition to the existence of optimal unsaturation 
in the formation of phosphatidic acid, there is also an op-
timal concentration of each acyl coenzyme A. Husbands and 
Lands (500) have shown that optimal incorporation occurs at 
50 µM concentration with substrate inhibition at 60 µM. 
This finding suggests that an increase in acyl coenzyme A 
produced by lipolysis cannot increase triglyceride synthe-
, sis unless the formation of sn-3-glycerophosphate is also 
t. 
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increased. However, an elevation in acyl coenzyme A renders 
these derivatives more available for oxidation, desaturation 
or chain elongation. 
The tendency for estrogens to decrease phospholipid un-
saturation is enhanced by stimulation of the methylation of 
phosphatidyl ethanolamine to phosphatidyl choline (684). 
Merkl and _Lands (735) and Lands and Hart (633) have shown 
that hepatic enzymes catalyze exchange reactions between 
saturated diacylphosphoglycerides and unsaturated acyl co-
enzyme A. When the concentration of phosphatidyl ethanol-
amine is depressed by increased methylation, one of these 
enzymes can no longer catalyze the unsaturation of phos-
phatidyl ethanolamine prior to its methylation to phos-
phatidyl choline. Estrogens thus enhance the rate of syn-
thesis of saturated lecithins. Ramey and Baron (858) also 
found that the estrogen analogue 17s-hydroxy-3-methoxy-l, 
3,5(10)-estriene-16-one increased the incorporation of in-
organic phosphate and acetate into phospholipids. The ex-
tent to which estrogen-dependent chain elongation of sa-
turated fatty acids depletes hepatic acetyl coenzyme A and 
regenerates coenzyme A remains to be determined. 
The net decrease in esterified cholesterol during hy-
perestrogenic therapy is a direct consequence of the altera-
tions in the composition of phosphatidyl choline which 
donates the acyl group from its sn-2 position and of the 
rigid specificity of cholesterol: lecithin acyl transfer-
ase (373, 849) which has been found to produce cholesterol 
esters characteristic of the serum from which it is ob-
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tained within the limits of the composition of the lecithin 
substrates present. 
As previously noted, estrogens promote the conversion 
of phosphatidyl ethanolamine to phosphatidyl cholines. Fur-
thermore, phosphatidyl ethanolamines, in the course of their 
synthesis incorporate more highly unsaturated fatty acids 
into the sn-2 position and therefore, more highly saturated 
fatty acids in the sn-1 position. Therefore, the lysolec-
ithins derived from these methylated phosphatidyl ethanol-
amines will also contain more highly unsaturated acids in 
the sn-1 position. 
Regardless of the mechanism by which estrogens in-
crease the methylation of phosphatidyl ethanolamine to phos-
phatidyl choline, the fact that ethanol administration which 
increases the NADH/NAD+ ratio al~o increases the methyla-
_tion reaction, suggests that other agents which increase the 
reduction potential of the pyridine nucleotides will also 
increase the methylation reaction. Glucocorticoids have just 
that effect and may therefore produce changes in hepatic 
phospholipids similar to those produced by estrogens. For 
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example, an abnormal species of phosphatidyl choline is pro-
duced during high dosage estrogen therapy. This lecithin is 
converted to an abnormal lysolecithin which enhances plate-
let aggregation in response to adenosine-5'-diphosphate~ 
This lysolecithin may function by specifically blocking the 
incorporation of long-chain saturated acyl coenzyme A into 
phosphatidic acid. 
Cosgriff (202) has reported that glucocorticoid treat-
ment enhances blood coagulation, but did not elucidate the 
·mechanism by which this occurs. Therefore, an effect on 
phospholipid metabolism similar to that caused by estrogens 
~· has not been ruled out. On the other hand, glucocorticoids 
are known to promote the mobilization of phospholipids from 
the liver (1197). Furthermore, the effects of estrogens on 
the formation of high-density a-lipoproteins may be medi-
ated by their effects on phospholipids. The cooperative 
nature of the interaction between phospholipids and high-
density lipoproteins lends support to such a conclusion. 
As noted earlier, any factor which increases the con-
centration of acyl coenzyme A will increase the ratio of 
NADH to NAD+. At present, the extent to which inhibition 
of the incorporation of these derivatives into triglycer-
ides--a non-specific glucocorticoid effect--can account for 
this change is unknown as is the mechanism whereby 
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glucocorticoids decrease such incorporation. 
In conclusion, the non-glucocorticoid effects of gluco-
corticoids have been reviewed with respect to their role in 
insulin antagonism and glycolytic inhibition. From consider-
ations of the action of 8-lipoprotein lecithins on platelet 
aggregation it appears that the same or similar lecithin 
molecule may, after its conversion to lysolecithin, affect 
the concentration of acyl coenzyme A in other cells by 
blocking the incorporation of these derivatives into phos-
phatidic acid. 
Like estrogens, growth hormone also increases the per-
cent saturation of triglycerides. However, the mechanism 
is somewhat different. As noted previously, both trigly-
cerides and phospholipids are synthesized from diglycerides. 
However, the specificities of the enzymes involved are such 
that saturated diglycerides are directed towards trigly-
ceride synthesis while unsaturated diglycerides are directed 
towards phospholipid synthesis via cytidine diphosphate cho-
line and cytidine diphosphate ethanolamine. Growth hormone 
appears to exert its effects by decreasing the maximum ve-
locity of triglyceride formation from saturated diglycerides. 
Leal and Greenbaum (646) observed that growth hormone 
treatment depressed hepatic triglycerides 83 percent. Di-
glycerides, however, were increased 40 percent as was 
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phosphate incorporation into phospholipids. Acetate incor-
poration into phospholipids was decreased as a result of the 
increased diglyceride pool. Furthermore, because of the in-
creased substrate pool and reduced maximal rate of trigly-
ceride formation, more time is permitted for a better match-
ing of the available substrates to the active site of the 
enzyme. These factors combine to increase triglyceride sa-
turation. In addition, the increased pool size of phospho-
lipids and the resulting exchange reactions which they un-
dergo, further increase the saturation of the hepatic acyl 
coenzyme A pool from which triglycerides are synthesized. 
Ethanol administration, which increases the reduction 
potential of the pyridine nucleotide pool, also has an ef-
fect on phospholipid synthesis. Fallon et al (304) re-
ported that the administration of 20 percent ethanol in-
creases the methylation of phosphatidyl ethanolamine, an 
effect also produced by estrogens. Furthermore, Medenhall 
et al (732) observed that ethanol administration, like 
growth hormone administration, increased triglyceride sa-
turation, but not lecithin or cephalin saturation. These 
~ 
results confirm the specificity of the phospholipid syn-
thesis. On the other hand, if the saturation of the di-
glyceride pool is increased, the same specificity may lead 
to a reduction in total phospholipid synthesis and to the 
; 
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development of fatty infiltration of the liver. 
Although estrogens may impair carbohydrate tolerance by 
increasing acyl coenzyme A concentration, this does not ap-
pear to be the mechanism by which estrogens affect glucose 
tolerance. Rather, the fact that estrogens produce the same 
effects as ethanol indicates that estrogens may increase lee-
ithin unsaturation and decrease glucose tolerance by decreas-
ing the oxidation of mitochondrial NADH. 
L 
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CHAPTER XI 
STEROID EFFECTS IN BREAST TUMOR THERAPY 
Steroid hormones have long been employed in the treat-
ment of breast cancer. Androgens, estrogens, progestins, 
and combinations of these hormones have been used without 
a complete understanding of how they exert their effects. 
The interpretation of the results of these treatments has 
been complicated because pharmacological steroid doses 
have been employed, because of the complex hormonal depen-
dency of the tissue, and because of steroid metabolism 
elsewhere in the body. 
Clinical findings in the hormonal treatment of breast 
~' 
cancer may be summarized as follows (76). First, tumors 
are generally more responsive to steroids if the tumor is 
hormone-dependent. This is the prime reason for early 
treatment. Secondly, low doses of estrogens promote tumor 
growth. The quantity of estrogens required for this ef-
feet may be produced in ovarectomized women from androgens 
formed in the adrenal gland. Thirdly, both oophorectomy 
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and adrenalectorny reduce estrogen production. Fourthly, and 
most importantly, high doses of estrogens have been shown to 
inhibit tumor growth more effectively than high doses of an-
drogens. The fact that this latter estrogen effect is ex-
actly opposite to its hormonal effect on the same tissue 
merits further research, especially because this disorder 
affects 5 percent of American women and because mortality 
from the disease has not decreased in recent decades. Fur-
therrnore, these steroid effects may be related to glucocor-
ticoid effects. 
Mechanism of Steroid Action 
Pharmacological doses of estrogens inhibit mammary 
tumor growth more than similar doses of androgens. With 
both treatments there is maximal stimulation of the gland 
by estrogens. Treatment of an estrogen-dependent tumor 
with natural androgens which are converted to estrogens 
(417) is, in effect, a useless treatment because the basis 
of the androgen treatment is purported to be to counteract 
the stimulation of the hormone-dependent gland by low es-
trogen levels. This does not mean that androgens are corn-
~ pletely ineffective in treating the disorder. Androgens 
~ 
may inhibit tumor growth by an~anti-pituitary effect. How-
ever, the beneficial effects of androgens could be improved 
" by the use of synthetic analogues which cannot be converted 
l 
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to estrogens in vivo. This same reservation applies to glu-
cocorticoids used to treat the disease. 
The mechanisms described above cannot account for all 
of the greater effects of estrogens. There are several doc-
umented cases of both subjective and objective remissions of 
breast tumors with synthetic androgens in completely hypo-
physectomized patients (60). Since these patients were de-
void of gonadotrophin secretion, the steroid effect was not 
mediated by the pituitary but must have been directly on 
the tumor tissue. 
Experiments with synthetic steroids in the treatment 
of breast cancer in animals and women have indicated that 
the total effect observed is the summation of endocrine 
and non-endocrine effects. Endocrine effects include 
anabolic, anti-estrogenic, and anti-pituitary effects. 
Non-endocrine effects include a direct anti-glycolytic ef-
' 
~ feet on the tumor. Thus, the most effective anti-tumor 
' 
steroid for a given patient may depend on the relative hor-
monal dependence of the tumor which may change with time. 
Obviously, species differences in these influences may be 
considerable so that potency in the rat may differ sub-
stantially from that found in clinical trials. Still, 
there is reason to believe that the present cure rate of 
approximately 25 percent with steroid hormone therapy 
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could be doubled to 50 percent or higher by the judicious 
use of synthetic anti-tumor steroids which are not estrogen 
precursors. 
In order to determine the non-endocrine anti-glycolytic 
effects of steroid hormones against breast tumors, studies 
would have to be carried out in hypophysectomized, oophor-
ectomized, adrenalectomized tumor-bearing animals treated 
with growth hormone free of prolactin. Although such 
studies have not been reported, the structure-function re-
lationships for anti-tumor activity may be discerned from 
studies already reported. Clinically, testosterone pro-
pionate has been used with favorable regressions in about 
20 percent of patients who are less than 5 years postmeno-
pausal. In patients who are more than 5 years postmeno-
pausal, the stimulatory effect of physiological amounts of 
estrogens no longer counteracts the inhibitory effects of 
., these compounds in pharmacological doses. It is important 
;'j; 
to note that these recommendations are based on the limited 
comparison of natural estrogens with testosterone propi-
onate, an estrogen precursor. It is important, also, to 
recognize that most of the anti-tumor activity is pharma-
cological rather than hormonal. Therefore, although the 
net anti-tumor effects of estrogens is less than that of 
" 
testosterone propionate in premenopausal women, synthetic 
~; 
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anti-tumor steroids can be made which are not estrogen pre-
cursors and which do not stimulate estrogen-dependent tumor 
tissue. Synthetic anti~tumor steroids have effects which 
are over 2.5 times that of testosterone propionate. This 
increase in potency does more than offset the 1.4 fold 
greater effect that natural estrogens have relative to nat-
ural androgens in patients who are more than 5 years post-
menopausal. Thus synthetic anti-tumor steroids should emerge 
as the preferred hormonal treatment in all cases of breast 
i. cancer. 
' 
1· ~· 
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Results of Endocrine Ablation 
The importance of estrogens in estrogen-dependent tumors 
and the production of adrenal androgens which are estrogen 
precursors has led to adrenalectomy as a form of therapy for 
breast cancer. Generally, oophorectomy is the first endo-
crine ablative procedure used following mastectomy. A fav-
orable response to oophorectomy is obtained in 30 percent 
of pre-menopausal women. Approximately 40 percent of soft 
tissue, pleural, or skeletal metastases respond compared 
to 18 percent of liver, lung or CNS metastases. If the 
response to oophorectomy is favorable, this is an indica-
tion that the tumor is estrogen dependent and that the re-
moval of adrenal estrogens may provide additional remission. 
Although adrenalectomy subsequent to oophorectomy does not 
~-
result in remission in all cases, it does not present the 
possibility of damage to optic and olefactory nerves asso-
ciated with hypophysectomy. 
use of Steroid Discriminants 
The adrenal gland also appears to be the source of 
anti-tumor activity which parallels the urinary excretion 
of 17-hydroxycorticoids as measured by the Porter-Silber 
reaction. Bulbrook (30, 130) recognized this and devised 
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a discriminant function based on the excretion of 3a-hydroxy-
se-androstan-17-one relative to 17-hydroxycorticoids: 
80-80 x mg 170HCS/24 hrs + 
µg 3 -hydroxy-Ss-androsten-17-one/24 hrs 
When this discriminant is used, a number of greater than 
zero is associated with remission following adrenalectomy 
and vice-versa. In the initial study a positive discrim-
inant was associated with remission 93 percent of the 
time and a negative discriminant with non-remission 85 
percent of the time. Although the causative role of each 
discriminant factor need not be known for it to be valid, 
such a discriminant will best fit the population data 
from which it is derived. 
Since the determination of Bulbrook's discriminant 
function involved· the determination of 3a-hydroxy-5B-an-
drostan-l 7-one by chromatographic techniques which were 
l 
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unsuitable for many laboratories, other workers have devised 
discriminants that convey essentially the same information. 
Although inherently less specific because it measures groups 
of steroids, the simplest discriminant is the ratio of 11-
deoxy-17-ketosteroids to 17 hydroxycorticoids excreted. If 
this ratio is less than 0.13 the discriminant is consid-
ered negative; if the ratio is greater than 0.16, the dis-
criminant is considered positive. This determination is 
practical in the laboratory because the ll-deoxy-17-keto-
steroids can be separated as a group by chromatography on 
Sephadex LH-20 and quantitated by the Zimmerman reaction. 
It should be noted here that this same information can be 
obtained after the conversion of 17 hydroxycorticoids to 
C-19 steroids by a method already described in detail. 
To understand why these discriminant functions ac-
curately predict the response to adrenalectomy in premeno-
pausal patients it is helpful to assume that anti-tumor 
activity is associated with 17 hydroxycorticoids and that 
ring A reduced C-19 steroids of adrenal origin excreted 
in the urine reflect the formation of the estrogen precur-
sor 4-androstene-3,17-dione by the adrenal gland. Accord-
ing to these assumptions a high production of estrogen pre-
cursors relative to anti-tumor steroids is associated with 
a favorable response to adrenalectomy. On the other hand, 
280 
a low production of estrogen precursors relative to anti-
• tumor steroids is associated with an unfavorable response 
<:'·. 
;. 
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to adrenalectomy. Empirically, the anti-tumor activity of 
the adrenal is associated with the excretion of 17-hydroxy-
corticoids while the excretion of ll-deoxy-17-ketosteroids 
· provides an index of the adrenal as a source of estrogens. 
The pituitary gland is necessary for the induction of 
mammary cancer by carcinogenic hydrocarbons such as 3-me-
thylcholanthrene. Presumably the carcinogen can only cause 
a mutation when mitosis is stimulated by pituitary hormones. 
Alternately, the carcinogen may interact with a receptor 
protein produced in response to growth hormone or prolactin. 
This finding indicates that the response to carcinogens de-
pends on growth hormone, prolactin, or both. 
Peerlman (818) reported that cancerous persons excrete 
significantly less 17-ketosteroids than non-cancerous per-
sons. Moreover, Sokal et al (1000) noted that patients 
with malignant conditions generally show marked increases 
in 17-ketosteroid excretion during the administration of 
300 mg of cortisone acetate per day. A clear demarcation 
with little overlap was observed in cancerous and non-can-
cerous subjects. These results suggest that reduced glu-
cocorticoid production with increased conversion of glu-
cocorticoids to 17-ketosteroids is characteristic of 
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malignant states. 
Function of Estriol 
Lemon (552) has recently examined the relationship be-
tween breast cancer and estriol excretion. He found subnor-
mal excretion of estriol relative to estrone and estradiol 
in fibrocystic disease, in fibrocystic disease complicating 
mammary cancer, and in premenopausal and postmenopausal mam-
mary cancer patients. Hyperthyroidism was the only non-neo-
plastic syndrome with a similar excretion pattern, but up 
to one-fifth of euthyroid premenopausal women without mam-
1 
mary disease had similar excretion patterns. Marmaston et 
al (717) also measured estriol excretion in breast cancer 
~ 
patients and found that both pre- and postmenopausal pa-
tients had significantly increased estriol excretion. 
These results do not support an anti-tumor effect of estriol. 
Saxema and Emerson (941) have found that estrogens pro-
duced in the adrenal gland may exacerbate mammary tumors. 
Postmenopausal mammary tumor patients who improved follow-
ing adrenalectomy excreted 0.88 µg estrone per day before 
and 3.36 µg estrone per day (340 ~ 196%) after ACTH treat-
ment. On the other hand, the negative responders excreted 
1.51 µg estrone per day before and 2.25 µg estrone per day 
(66 ~ 38%) after ACTH. Apparently, adrenal estrogen syn-
thesis is more sensitive to ACTH in the patients who respond 
L 
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to adrenalectomy even though they have lower basal estrogen 
excretion. This may indicate that the responders have lower 
endogenous ACTH secretion and also lower glucocorticoid 
levels. These findings further suggest that determination 
of the change in the ratio of total urinary estrogens to 
total urinary 17-hydroxycorticoids after ACTH treatment 
may provide a more precise predicator of the response to 
adrenalectomy. These determinations are available in most 
laboratories via the Kober and Porter-Silber reactions re-
spectively. The optimal age for response to adrenalectomy 
following oophorectomy is 50-59 with a remission rate of 
56 percent compared to a 29 percent remission rate for the 
40-49 age group. 
Gallagher et al (355) also reported that male breast 
cancer is associated with increased estriol production. 
The rise in estriol excretion in this disorder is asso-
ciated with myxedema and a reduced formation of 2-methoxy 
estriol. This latter steroid has been shown to be the 
natural steroid which has the highest lipodiactic/estro-
genie ratio. Decreased production of this steroid in 
hypothroidism may explain the elevation of B-lipoproteins 
in this disorder. In female breast cancer, Barclay et al 
(45) have confirmed that the pre-B-lipoproteins are de-
creased secondary to a drop in high-density lipoprotein 
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.". phospholipid. Despite these changes a marked drop in plasma 
triglycerides is the most significant change in plasma lipids. 
Effects.of Thyroid and Growth Hormones on Steroid Metabolism 
-
Liechty et al (666) and Bulbrook et al (130) have re-
ported that the incidence of breast cancer is greater in 
.. hypothyroid than in euthyroid women. The reason for this 
difference may be related to the effects of thyroxine on 
~' 
L 
glucocorticoid metabolism. 
Bradlow et al (111) found that triiodothyronine in-
creased the activities of mitochondrial 4,Sa:-reductases 
for a number of steroids thereby increasing the excretion 
of andros.terone and decreasing the excretion of 3a:-hydroxy-
Ss-androstan-17-one, its 58 diastereoisomer. In contrast, 
thyroid hormone has no effect on the 4,Ss-reductases in the 
cytoplasm. The decreased excretion of 3a:-hydroxy-Ss-andro-
stan-17-one simply reflects the relative competition of the 
mitochondrial and cytoplasmic enzymes for available 4-andro-
stene-3,17-dione. Yates et al (1184) have also found that 
thyroxine increases the conversion of cortisone to 17a:,21-
dihydroxy-5a:-pregnene-3,ll,20-trione by rat liver mitochondria. 
Gallagher et al (355) reported that the reduction of llS-
hydroxy-4-androsten-3, l 7-dione to llS-hydroxy-Sa:-androstane-3, 
17-dione was increased by thyroid hormone. The more rapid 
formation of the Sa: metabolite resulted in decreased formation 
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of 3a,11S-dihydroxy-4-androsten-17-one. In myxedema, the 
conversion of cortisol to 3a,11S,17a,21-tetrahydroxy-5S-
pregnan-20-one is doubled and its conversion to 3a,17a,21-
trihydroxy-5B-pregnane-ll,20-dione is halved. The reverse 
changes are seen in hyperthyroidism. The formation of 3a, 
11S,17a,21-tetrahydroxy-5a-pregnane-20-one was unaffected 
by thyroid hormone. Although Koerner and Hellman (604) 
reported that thyroxine administration reduced the activity 
of llS-hydroxy dehydrogenase in rat liver but not in rat 
kidney, thyroi9 hormone treatment results in an overall in-
crease in 11-keto glucocorticoid metabolites due to the 
peripheral metabolism of the steroid (447). 
In myxedemia, the increase in Sa steroid reduction and 
decrease in lls-hydroxy dehydrogenase activity results in 
increased formation of 3a,11S-dihydroxy-4-androstan-17-one 
and its 3s-epimer in approximately equal amounts (355). 
The 3S-epimer is similar to 3S,11S-dihydroxy-5a-androstan-
17-one. Kemp et al (575) found that this latter steroid 
was somewhat unusual in that it formed an 11 monoacetate 
preferentially when esterified with acetic anhydride and 
pyridine at room temperature. This behavior is very dif-
ferent from that of other llS-hydroxylated steroids which 
form such a derivative only when heated. The possible role 
of the allylic alcohol in the hyper-S-lipoproteinemia of 
L 
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myxedema has not been determined. 
Triiodothyronine promotes the conversion of cortisol to 
cortisone as well as the Sa reduction of cortisone. The hor-
mone, however, does not promote the Sa reduction of cortisol. 
i (1184) . Other steroids may exert the same effect in differ-
, ent ways. For example, Schriefers et al (9S3) reported that t, 
17S-hydroxy-l-methyl-l-androsten-3-one decreased.both adrenal 
weight and corticosterone production rate. In contrast, 17a-
.ethinyl-178-hydroxy-4-estren-3-one decreased corticosterone 
production without affecting adrenal weight. 
Not all of the effects of hypophysectomy on the Sa re-
auction of steroids can be attributed to the lack of thy-
roid hormone. Forchielli et al (327) found that the Sa re-
ductase for androstene-3,17-dione could be restored to SO 
percent of prehypophysectomy levels by the administration 
of 10 I U/day of adrenocorticotrophic hormone or by 10 µg/ 
day of growth hormone. These results suggest that this re-
duction may be catalyzed by two distinct enzymes under dif-
ferent hormonal control. 
There has been some controversy about the identity of 
human growth hormone and human prolactin. Apparently, these 
two hormones are very similar so that they cannot be readily 
separated. However, that the two hormones may be distinct 
entities is suggested by the lack of a constant ratio of 
" ~L·, 
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growth hormone to prolactin activities in different prepara-
tions. Furthermore, Brauman et al (114) used tissue cul-
tures from human anterior hypophysis removed from hypothal-
mic influences to show that prolactin secretion could in-
crease while growth hormone secretion decreased and vice 
versa on the addition of hypothalamic extracts, indicating 
distinct hormones. 
The exact relationship between growth hormone and pro-
lactin is especially important in the treatment of breast 
cancer by pituitary stalk section. This procedure decreases 
the output of growth hormone but increases the output of 
prolactin. Since prolactin has a stimulatory effect on 
breast tumors, complete hypophysectomy is preferable to 
pituitary stalk section. 
In the intact rat prolactin may play an important role 
in the induction of mammary tumors by estrogens. Low con-
centrations of estrogens increase prolactin secretion. Pro-
lactin, in turn, stimulates progesterone production by the 
. corpus luteum, and the progesterone, in turn, further stimu-
lates prolactin output so that a state of pseudopregnancy 
is produced. During this state DNA synthesis is greatly 
increased in the mammary gland and this event alone may in-
crease the possibility of gene mutation. Indeed, a number 
of enzymes are induced during the development of lactation 
287 
these inductions may provide a good biochemical model 
.. for the study of the interaction of many hormones in the reg-
ulation of metabolism. For example, Howanitz and Levy (482) 
observed large increases in citrate cleavage enzyme and sim-
ilar increases have been observed in the enzymes of the pen-
tose cycle following parturition. The interaction of growth 
hormone, insulin, ACTH, glucocorticoids, estrogens and pro-
lactin in the metabolism of the gland should provide more 
metabolic insight than similar studies of adipose tissue 
have provided. 
As mentioned previously, the formation of some cortisol 
metabolites is influenced by many other hormones so that the 
level of the metabolite actually excreted may be an indica-
tion of the hormone output that effects the production of 
these metabolites. For example, the excretion of 3a,118-
dihydroxy-Ss-androstan-17-one is increased in myxedema not 
only because of the reduced conversion of cortisol to cor-
tisone, but also because the Sa reductases for these gluco-
corticoids are also decreased. The close association of 
this steroid with rnyxedema and of the latter with cancer 
incidence may explain the results of Dobriner et al (242-
245) who reported that levels of this steroid had prognos-
tic value in breast cancer (242) and in cancer of the pros-
tate (818). If abnormally elevated levels of this steroid 
f 
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are found in the course of urinary steroid excretion studies, 
they should be followed up with more modern and definitive 
thyroid function studies and with specific prostatic acid 
phosphatase determinations. 
Another type of steroid metabolite characteristic of 
myxedema is the allylic alcohol 3a,11S-dihydroxy-4-androsten-
17-one. In contrast to the reduction of the double bond, the 
reduction of the 3 ketone is not diminished by hypothyroid-
• 
ism. Ringold (887) has shown that the major metabolites of 
6a-fluoro-17S-hydroxy-4-androsten-3-one are 6a-fluoro-5S-
androstane-3,17-dione and 6a-fluoro-4-androstene-3a,17S-diol. 
The 6a-f luorine decreases Sa enzymatic reduction as well as 
the rate of oxidation of the 178 hydroxyl group. 
The previous considerations of the effects of estrogens 
and progestins on mammary tumor induction may not apply to 
established tumors. For example, Crawley and Mac Donald 
f (205) obtained a 35 percent remission rate in the treatment 
v 
t [ of mammary carcinoma in postmenopausal women with estrogens 
alone. However, in estrogen-resistant patients, the simul-
taneous administration of 17a-hydroxyprogesterone caproate 
increased their remission rate to 50 percent. The additional 
benefit produced by 17a-hydroxyprogesterone may be due to 
inhibition of growth hormone release which has been demon-
strated in acromegalics but inconsistently in normal subjects 
2.89 
(627). However, as noted previously, therapy with estrogens 
or estrogen precursors is inexcusable in view of 'the avail-
ability of synthetic steroids which are just as effective 
but are not estrogen precursors. 
Recently, Lemon (650) has advocated the use of synthetic 
glucocorticoids such as prednisone as an alternative to ad-
renalectomy for the treatment of estrogen-sensitive breast 
tumors in oophorectomized patients. Prior oophorectomy is 
required because glucocorticoids stimulate the release of 
follicle-stimulating hormone which increases estrogen pro-
duction. In addition, prednisone suppresses the release of 
ACTH and the production of endogenous cortisol which is a 
F' better estrogen precursor than prednisone. Since predni-
sone also suppresses thyroid function, triiodothyronine 
supplementation was employed. .Calcium salts were admin-
istered to counteract the catabolic effect of the gluco-
corticoid on bone. However, if these were the only mech-
anisms by which the glucocorticoid acted, the treatment 
would be no better than oophorectomy alone. In contrast, 
Lemon found that 48 percent of his patients benefited 
from prednisone therapy even though one-third of these 
had previously failed to respond to cortisone. This per-
centage is high compared to the 23 percent remission rate 
of bone metastases produced by androgens or estrogens and 
LL~·. 
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compared to the 44 percent remission of soft tissue involve-
ment produced by estrogens. Symptoms of Cushing's disease 
including weight gain, truncal obesity, peptic ulcer and 
osteoporesis were prominent side-effects of this medication. 
struct.ure-Function Studies on Anti-Tumor Compounds 
The prednisone remission rates are high compared to the 
figure of 25 percent reported for 17a-hydroxy-6a-methyl-4-
pregnene-3,20-dione and the figure of 26 percent reported 
for 9a-fluoro-11S,17a-dihydroxy-6a-methyl-l,4-pregnadiene-
3,20-dione. However, since results for other compounds 
such as 6-chloro-9a-fluoro-17a-hydroxy-l,4-pregnadiene-3, 
11,20-trione, which should have higher activity on the 
basis of previous considerations, were not reported, an 
assessment of the role of the C-21 hydroxyl group in these 
effects cannot be made. However, Lemon noted that the glu-
cocorticoids seemed to have an inherent anti-tumor activity. 
Glenn et al (368) have determined the relative anti-
tumor and androgenic activities of several synthetic anti-
tumor steroids. Using their data which is recorded in 
Table IX and assuming that the factors by which structural 
modifications enhance activity can be multiplied, it is 
possible to calculate that the approximate anti-tumor ac-
tivity of 17S-hydroxy-2a-methyl-5a-estrane-3,ll-dione would 
be 2.2 times that of llS-hydroxy-Sa-estrane-3,11-dione which, 
L 
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TABLE IX 
RELATIVE EFFECTIVENESS OF STEROIDS AGAINST BREAST CANCER 
steroid Activities Expressed as Percentage of Testosterone Propionate 
ga-fluoro-17B-hydroxy-17a-methyl-4-androstene-3,ll-dione •••••••••••• 255 
A-nortestosterone proprionate •.••••••••••••••••••••••••••••••••••••• 131 
2a-fluoro-17B-hydroxy-4-androsten-3-one 17 proprionate ••••••••••••••• 53 
11B,17B-dihydroxy-17 -methyl-4-androsten-3-one ••••••••••••••••••••••• 39 
11S,17S-dihydroxy-17 -methyl-1,4-androstadien-3-one •••••••••••••••••• 30 
17S-hydroxy-17a-methyl-4,6-androstadien-3-one •••••••••••••••••••••••• 20 
17a-ethinyl-17B-hydroxy-4-androsten-3-one ••••••••••••••••••••••••••••• O 
17B-hydroxy-6S-methyl-5a-androstan-3-one propionate ••••••••••••••••• 205 
9a-fluoro-11B, 17B-dihydroxy-17a-methyl-5B-androstan-3-one •••••••••• 119 
17B-hydroxy-17a-methyl-5a-androstane-3,ll-dione •••.•••••••.•••••••••• 89 
~; Sa-androstan-17 S-ol propionate . ................... • ................... 32 
17B-hydroxy-17a-methyl-5B-androstan-3-one ••••••••••••••••••••••••••••• O 
17a-ethinyl-17S-hydroxy-4-estren-3-one •••.•••.••••••••••••••••••••••• 96 
17B-hydroxy-17a-methyl-4-estren-3-one •••••••••••••••••••••••••••••••• 76 
17a-ethinyl-17B-hydroxy-5(10)-estren-3-one •••••.••••••••••••••••••••• 65 
17B~hydroxy-2a-methyl-4-estrene-3-one •••.•.•••••••••••••••••••••••••• 41 
Segaloff (962) 
f.... 
. L
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in turn, is twice that of testosterone propionate. Studies 
by Gallagher et al {355) suggest that the estradiol metab-
olite 3-hydroxy-2-methoxy-1,3,5(10)-estren-17-one which is 
formed in response to thyroid hormone may be an active anti-
tumor agent. 
Segaloff {962) has reported the oral activities of sev-
eral anti-tumor steroids which are presented in Table IX. 
These data indicate that A-nortestosterone propionate is 
more active than testosterone propionate and that the 9a-
chloro-118, l 7S-dihydroxy-l 7a-methyl-4-androstene-3-one 
has the same anti-tumor activity as its 9a-fluorine analog 
but only one-tenth of its androgenic activity. Also~ 6a-
fluorination reduces anti-tumor activity even though Kincl 
and Dorfman {581) found that this substitution increased 
pituitary gonadotrophin inhibitory activity. 
Rooks et al {902) showed that the introduction of an 
11-ketone enhanced the potency of 17S-hydroxy-2a,17a-di-
methyl-l, {5a)-androstan-3-one in inhibiting the incorpora-
tion of glycine into rat tumor protein. A similar inhibi-
tion of the incorporation of glycine into protein was also 
observed by Bornstein (98) in his work on lipoprotein in-
sulin antagonism. 
Anti-tumor activity is also distinct from anabolic 
activity. The latter activity appears to require both the 
L 
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18 methyl group and a pi type molecular orbital at position 
2 or 3 in the steroid nucleus. Wolf ~t al (1173) demon-
strated that 2a,3a-epoxy-5a-androstan-17S-ol has the same 
anabolic effect as testosterone propionate, while 2a,3a-
epithio-5a-androstan-17S-ol is a potent anti-estrogen as 
well. Kincl and Dorfman (582) reported that 2(5a)-andro-
sten-17s-ol was 60 percent more myotropic and 60 percent 
less androgenic than testosterone. The dichloroacetate 
was its most potent ester. Later, Nutting et ·a1 (791) con-
firmed these findings and, in addition, showed that the la-
methyl group further increased its oral anabolic-androgenic 
ratio. Edgren (270) extended these findings and demon-
strated that ethyl groups at the 13S and 17a positions of 
4-gonen-3-one greatly increased its anabolic activity but 
not its androgenic activity. The 17S-hydroxyl group 
lowered the anabolic-androgenic ratio. Also, androgenic 
activity appeared to be associated with a certain conforma-
tion of the non-conjugated 3-ketone that was favored by 
the presence of the 19-methyl group. Fang et al (305) have 
isolated a receptor protein for androgens which has a higher 
affinity for 5a-androstan-3,17-dione than it has for test-
osterone. Although the 6S methyl group markedly enhances 
activity, the reduction in activity by 6a-fluorine substi-
tution and the abolishment of activity by the 6a-chlorine 
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substitution indicates that steric factors are important at 
this position in the steroid nucleus.· In contrast to these 
steric effects the presence of a vinylic chlorine in the C-6 
position as in 6-chloro-17-hydroxy-4,6-pregnadiene-3,20-dione 
acetate may actually enhance anti-tumor activity. 
Rooks et al (902) also found that the 6a m~thyl as well 
as Ga-fluorine substitutions reduced anti-tumor activity in 
the steroid 17B-hydroxy-2a,17a-dimethyl-5a-androstan-3-one 
while unsaturation at carbon 1 increased activity. On the 
other hand, both 11$-hydroxy-6a-methyl-4-pregnane-3,20-dione 
as well as 9a-fluoro-11B-17a-dihydroxy-6a-methyl-l,4-pregna-
diene-3,20-dione 17 acetate are active against testosterone 
propionate-resistant tumors. In these compounds the 6a-methyl 
group reduces the salt retention caused by the 9a-fluorine 
substitution. 
Glenn et al (367) found that 17B-hydroxy-2a-methyl-5a-
androstene-3,ll-dione was a potent anti-tumor steroid. They 
showed that the shift of the C-19-methyl group to the 2a 
position enhanced activity. Also, the 11$-hydroxy deriva-
tive of this compound was somewhat less active than the 11-
ketone but was preferred because of its lesser side effects. 
Segaloff (962) also found that 11-ketones were more active 
than the corresponding 118-hydroxy compounds while the re-
verse is true for anti-glycolytic effects (293). 
l 
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The influence of methyl substitution in ring A on anti-
tumor activity has also been investigated. De Marco· et al 
(224) found that 4,17S-dihydroxy-17a-methyl-4-estren-3-one 
was over twice as active as testosterone in inhibiting the 
growth of Ehrlick carcinoma in rats. Furthermore, both 17s-
hydroxy-2a~methyl-Sa-androstan-3-one and 17S-hydroxy-4a-
methyl-5a-androstan-.3-one are highly active against mammary 
tumors (902). Although an analogous methyl group is present 
in all ergot alkaloids, anti-tumor activity in these compounds 
has not been thoroughly studied. 
Kim et al (980) have described an anti-tumor triterter-
pene from Wallenia yunguenis (Myrsinaceae) which was ·active 
against Walker 256 I M carcinosarcoma. This compound, known 
as myrsine-saponin (3s,27a-dihydroxyolean-12-ene-28-oic acid), 
has a structure similar to glycyrrhetinic acid which has been 
shown to have anti-inflammatory but not glucocorticoid ef-
fects (318, 418). The C-27a hydroxyl group in this compound 
is in a position similar to that of the N1 nitrogen in cla-
vine alkaloids. 
Other factors which may influence the potency of anti-
tumor steroids are their solubilities in physiological fluids 
and their conjugation rates prior to excretion. Protein 
binding, especially as influenced by other drugs or endo-
genous metabolites, is also an important factor in activity. 
296 
Since Glenn et al (371) and Frawley (328) have shown 
that glucocorticoids inhibit pyruvate oxidation, it has been 
assumed that inhibition of glucose utilization is secondary 
to the inhibition of pyruvate oxidation. The basis of the 
block in pyruvate oxidation is the increase in long-chain 
fatty acyl coenzyme A which promotes fatty acid oxidation 
and an increase in the ratio of acetyl coenzyme A to free 
coenzyme A. The increase in acetyl coenzyme A not only in-
hibits pyruvate dehydrogenase but also increases the forma-
tion of cytoplasmic citrate which blocks glycolysis at the 
phosphofructokinase step. 
Besides glucocorticoids, other non-steroid compounds 
have also been shown to inhibit pyruvate oxidation. Sarker 
(936) found that the alkaloid sanguinarine produced by 
S-anguinaria canadensis inhibited pyruvate oxidation by 
pigeon brain mitochondria 35 percent at a concentration of 
-5 4.1 x 10 M. Sublethal doses have been used to produce ex-
perimental glaucoma in animals. Furthermore, the compound 
is also a potent oxytoxic, 0.5 mg/kg produces prompt uterine 
contractions. 
The inhibition of pyruvate oxidation by sanguinarine 
can be abolished by prior addition of mercaptoethanol to 
the suspension of pigeon brain mitochondria. A covalent 
sanguinarine derivative was formed but was not identified. 
FIGURE VII 
STRUCTURE OF S.Ai.~GUINARINE 
SANGUINARINE 
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~lthough sanguinarine contains pentavalent nitrogen, the ex-
tensive conjugation delocalizes the charge in the nucleus of 
the molecule. Furthermore, the base exists in two polymor-
phic crystalline forms and its quaternary salts are reddish 
in color. These properties suggest that labeled sanguinarine 
may find use in the affinity labeling of non-specific gluco-
corticoid sites of the type under discussion here. The thiol 
effect mentioned above is similar to that reported to occur 
~ in the glucocorticoid inhibition of yeast hexokinase (507, 
508). In the latter case, treatment of the enzyme with N-
ethylamaleimide prevents the reversal of glucocorticoid inhib-
i tion by insulin ·in vitro. 
Hartwell (433) has reported that sanguinarine and its 
analogue chelerythrine have a necrotizing activity against 
sarcoma 37 in mice. The specificity of this effect has not 
been investigated but there are reports that Cherokee Indians 
used the bloodroot (Sanguinaria canadensis) for the treatment 
of warts and polyps as early as 1817 and for the treatment 
of breast cancer as early as 1857. 
The total synthesis of sanguinarine has not been des-
cribed and the best source of the compound is probably 
argemone oil as described by Sarkar (936). 
The enhanced anti-mammary tumor activities of 6a-methyl-
~ ated progesterones appears to be due to the effects which 
L 
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these compounds have on the pituitary. Glenn et al (368) 
concluded that both adrenal and gonadal functions were mark-
edly inhibited by 6ct-methylated steroids. This inhibition 
occurred in spite of the fact that the compounds had little 
or no effect on bone growth. These findings are similar to 
the results of a comparative study reported by Laron and 
Pertzelan (639). In fact, the suppressive effects of 6a-
methylated hormones on pituitary function were so great 
that they persisted for approximately two weeks after the 
cessation of steroid administration. Liddle (663) observed 
that the 6a-methyl substitution increased the activity of 
cortisol and 11$-hydroxy-4-pregnene-3,20-dione, while it 
decreased the activity of 9a-fluoro-11S,17a,21-trihydroxy-l, 
4-pregnadiene-3,20-dione. In aggrement with previous studies 
Liddle found that llS-hydroxy-4-pregnene-3,20-dione increased 
the excretion of 17-hydroxycorticoids perhaps by competing 
with cortisol for feedback inhibition receptors which reg-
ulate ACTH release in the pituitary. Kleeman et al (596) 
also observed that the non-glucocorticoid 9a-fluoro-1113,17a-
dihydroxy-6a-methyl-l,4-pregnadiene-3,20-dione had no effect 
on nitrogen excretion or eosinophiles but that it suppressed 
ACTH secretion and exacerbated diabetes at a dose of 30-80 
mg per day. Lipsett and Bergenstal (669) treated Addisonian 
patients with 9a-fluoro-11S,17a-dihydroxy-6a-methyl-l, 
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4-pregnadiene-3,20-dione and found that the steroid had life-
maintaining activity equal to that of cortisol. 
In contrast to the adverse effects on the induction of 
mammary tumors, carcinogenic hydrocarbons have been shown 
to enhance the effects of anti-tumor steroids. Both Huggins 
et al (492) as well as Glenn et al (366) reported that 3-
methyl-cholanthrene acted synergistically with anti-tumor 
steroids. Furthermore, Huggins et al found that only those 
steroids which promoted the growth of the normal mammary 
gland acted synergistically with 3-methylcholanthrene. 
Alone, the latter compound was catabolic. Its structure 
is shown in Figure VIII. 
A 17a-alkyl group may enhance anti-tumor activity in 
a rather specific manner. Whereas progestational activity 
is enhanced by 17a-(l-butynyl) groups, saturated alkyl 
groups larger than ethyl and ethinyl groups reduce anti-
tumor activity. For example, 17a-ethyl-17B-hydroxy-4-
estren-3-one is a powerful inhibitor of tumor growth while 
its 17a-ethinyl analog actually promotes tumor growth. The 
17a-propyl group abolished activity. These findings may be 
related to those of Drill and Riegel (256) who found that 
17a-ethinyl-17B-hydroxy-4-estrene-3-one had only 1 percent 
of the anabolic activity of the 17a-ethyl analog. The marked 
dependency of anti-tumor activity on the nature of the 
r 
FIGURE VIII 
STRUCTURE OF 3-METHYLCHOLANTHRENE 
3-METHYLCHOLANTHRENE 
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17a-alkyl group suggests that the ethyl group can conform by 
free rotation to the requirements of the receptor but that 
the more rigid ethinyl and larger propyl groups cannot. 
At this point it may be helpful to clarify the effect 
of steroid substitutions on androgenic, anabolic, anti-
pituitary and anti-tumor activity. The steroid 17S-hydroxy-
6S-methyl-4-androsten-3-one has the highest reported andro-
genic/anabolic ratio. The C-3 carbonyl oxygen, C-4 double 
bond, and C-19 methyl groups increase androgenic activity. 
In contrast, the 17a-ethyl group reduces androgenic activity 
6-fold, and the C-11 carbonyl oxygen 5-fold. On the other 
hand, the androstane derivative with the highest anti-pitui-
tary/androgenic activity is a 2-formyl-2(5a)-androsten-17S-
ol (582). The steroid with the highest anabolic/androgenic 
activity ratio is 17a-ethyl-17S-hydroxy-1(5a)-estrene-3,ll-
dione. The 17a-ethyl group increases anabolic activity and 
decreases androgenic activity. Unsaturated 17a-alkyl groups, 
such as the 17a-ethinyl group, decrease both activities. 
The evaluation of anti-tumor steroids in vitro may not 
reflect therapeutic results because of the absence of the 
effect of the steroid on the pituitary. Inhibition of the 
release of pituitary hormones, especially prolactin and 
growth hormone, is important in anti-tumor activity. Pitui-
tary inhibition would result in decreased prolactin output. 
L 
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since breast tumors in adrenalectomized-oophorectomized pa-
tients may be dependent on pituitary prolactin, reduction of 
prolactin secretion, in addition to glycolytic inhibition, ap-
pears to be the main action of anti-tumor steroids in ~hese 
patients. In contrast, tumors which reactivate following an 
~nitial remission in response to steroids may be less depen-
dent on prolactin so that steroids with a higher ratio of 
anti-glycolytic to anti-prolactin activity may be more ef-
fective against these reactivated tumors. 
Although hypophysectomy eliminates prolactin output, 
growth hormone secretion, which appears to be important in 
the anti-glycolytic activity of steroids, is also abolished. 
The fact that hypophysectomy removes both tumor-stimulating 
as well as tumor-inhibiting factors may explain the lack of 
an effect of hypophysectomy in these patients. The recent 
availability of human growth hormone for substitution therapy 
may lead to increased use of hypophysectomy to eliminate pro-
lactin output. 
Dorfman (251) has shown that the efficacy of anti-tumor 
steroids is not related solely to pituitary inhibition. 
Dorfman's results are limited by the fact that he evaluated 
the parental activ~ty of only those derivatives known to 
be orally active. He found that 17S-hydroxy-17~-methyl-4-
androstene-3,ll-dione was the most potent anti-tumor steroid 
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investigated even though it has no anti-estrogen activity. 
from other studies it appears that 4-chloro-17a-hydroxy-2a-
methyl-19-nor-4-pregnene-3,ll-20-trione 17-acetate may have 
higher activity since some anti-tumor activity is sacrificed 
in order to obtain oral activity. 
The 17a-alkyl group is not the only structural modifi-
cation that enhances.oral activity by blocking the oxida-
tion of the 17S-hydroxyl group. For example, 17S-hydroxy-
2a-methyl-l, (Sa)-androsten-3-one (stenbolone) has been pat-
ented as a potent, orally active anabolic agent. The find-
ing that structural modifications in ring A influence en-
zymatic reactions in ring D and vice-versa indicates that 
the overall structure of the molecule and its metabolic 
reactions must be considered in the design of steroid drugs. 
Such findings raise the possibility of eliminating the he-
patic changes associated with 17a-alkylated steroids. 
Dorfman (251) has demonstrated that anti-estrogen ac-
tivity as measured by the action of the compound in inhib-
iting the effects of estrogens on mouse uterus is not re-
quired for anti-tumor activity. For example, 17S-hydroxy-
17a-methyl-l,4-androstadiene-3,ll-dione was very active 
against testosterone-propionate-resistant tumors yet had 
no detectable anti-estrogen effect. Other C-4 unsat-
urated steroids shared this property. On the other hand, 
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Sa-reduction resulted in compounds which had high anti-es-
trogen activity in addition to undiminished anti-tumor ac-
tivity. Therefore, the structural requirements for anti-
tumor activity are less stringent than those for anti-es-
trogen activity. Fluorine substitution in the 9a position 
increases anti-estrogen activity (1090) while 2a-f luorine 
substitution increases anti-pituitary activity (582). 
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Antoniades· ·et ·a1 (15} have shown that human plasma frac-
tions II and III which contain the S-lipoprotein and S- and 
· y-globulins respectively, preferentially bind the unconju-
gated steroids corticosterone, llS-hydroxy-4-androstene-3, 
17-dione, and cortisol in that order (Table X). However, 
since most of the glucocorticoids in plasma are specifically 
bound by transcortin in fraction IV-I, the S-lipoprotein 
fraction is the fraction which contains most if not all of 
the llS-hydroxy-4-androstene-3,17-dione in plasma. 
Sandberg and Slaunwhite (931) further investigated the 
metabolism of this steroid and found that it existed in two 
pools which were cleared with half-lives of 30 and 80 min-
utes. Conjugates of the steroid, although rapidly formed, 
were slowly cleared. Approximately 61 percent of the ex-
creted radioactivity from the steroid was excreted in con-
jugated form and this fraction had a half-life of 98 min-
utes. Furthermore, 14 percent of the conjugate fraction 
TABLE X 
PERCENT DISTRIBUTION OF ADRENAL STEROIDS IN 
HUMAN PLASMA FRACTIONS VERSUS 
TIME AFTER AN INTRAVENOUS TRACER DOSE 
llS-Hydro:xy-4-Andro- 11$,21-Dihydro:xy-4- 11S,17a,21-Trihydro:xy-
Stene-3,17-Dione Pregnene-3,20-Dione 4-Pregnene-3,20-Dione 
10 Minutes 20 Minutes 120 Minutes 
Time Interval 
PlaSI'(la Fraction Con ju- Non-Con- Con ju- Non-Con- Con ju- Non-Con-
(Method 6) gated jugated gated jugated gated jugated 
I 6.4 5.4 3.9 3.8 3.7 4.9 
II + III 16.0 39.1 4.2 23.0 14.4 22.5 
IV-1 6.5 13.00 52.0 55.5 27.6 31.1 
IV-4 11.2 4.4 8.5 3.5 4.6 4.5 
v 60.0 38.1 31.4 15.2 49.7 37.0 
Antoniades et al (15} 
w 
0 
O"I 
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could not be accounted for as either sulfate or glucuronide 
conjugates. This 14 percent, however, could be hydrolyzed 
with hot acid. These results suggest that at least one glu-
~· 
r cocorticoid metabolite may be associated with S-lipoprotein [' 
r and may form unusual conjugates. Both the identity of the 
:;. 
conjugated steroids and their role in insulin inhibition re-
main to be determined. 
The steroid llS-hydroxy-4-androstene-3,17-dione is 
formed from cortisol in a reaction that is promoted by 
estrogens (222). Also, thyroid hormone appears to increase 
the conversion of this steroid to 17$-hydroxy-Sa-androstene-
3,11-dione by promoting its Sa-reduction and 11$-hydroxy 
dehydrogenation (111). All of the intermediates in this 
process have been isolated from rat urine by Schubert and 
Wehrberger (954). In euthyroid subjects llS-hydroxy-4-
androstene-3,17-dione is metabolized as follows: 60 per-
cent is converted to 3a,11S-dihydroxy-5a-androstan-17-one; 
10 percent is converted to 3a,11S-dihydroxy-5s-androstan-
17-one; 6 percent to 3a,11S-dihydroxy-5s-androstan-17-one; 
and 3 percent to 3a-hydroxy-5a-androstene-ll,17-dione. In 
myxedema, more 3a-hydroxy-5S-androstene-ll,17-dione is 
formed from 4-androstene-3,11,17-trione, indicating that 
the Sa-reductase for the latter steroid as well as that 
for its 11$-hydroxy analog is also depressed. The extent 
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to which any of these alterations are involved in the hyper-
s-lipoproteinemia of myxedema is unknown. 
Distinct enzymes appear to be involved in the metabolism 
of each steroid. Tomkin (1070) observed that the enzyme which 
catalyzed the 58 reduction of cortisone to be inactive with 
cortisol and llB-hydroxy-4-androstene-3,17-dione. The in-
troduction of a double bond at C-1 completely blocks the 
reduction of cortisol but not the reduction of cortisone. 
This unsaturation, however, does not block the conversion 
~ of prednisolone to prednisone. This latter reaction is en-
hanced by 4-androstene-3,11,17-tione in which the lla hydro-
gen of cortisol is transferred to the lla position of the 
trione (257, 1194). The double bond in position 1 is re-
duced in vivo (1078), but it may be reduced after the 
double bond in the 4 position in some cases. Thus, the 
presence of the 1 double bond may enhance androgenicity 
in the androstene series while it decreases sodium reten-
tion in the pregnane series. Also, Slaunwhite and Sandberg 
(990) have found that the presence of the 1 double bond in 
glucocorticoids decreases their conversion to 17 ketoster-
oids. Similarly, Langecker (634) found that substituents 
in ring A influenced the rate of oxidation of the 178-hy-
droxyl group in the androstene series. In order of de-
creasing rates of oxidation, the order is testosterone, 
L 
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17s-hydroxy-5a-androstan-3-one, 176-hydroxy-l, (Sa)-androstan-
3-one, and 178-hydroxy-l-methyl-l, (Sa)-androstan-3-one. In 
addition, Ringold (888) has pointed out that the opposite 
situation may occur, i.e. substituents in the 16 position 
can markedly alter the rate of oxidation of the 3a-hydroxy 
group by 3a-hydroxysteroid dehydrogenase. Clearly, these 
examples indicate that caution should be observed in ex-
trapolating the metabolism of one steroid ·to that of another. 
Further complicating steroid metabolism are the effects which 
one steroid may have on the metabolism of another steroid. 
For example, Hagen and Troop (422) found that testosterone 
depressed the ring A reduction while accelerating the C-20 
reduction of cortisone in both males and females. Corti-
sone acetate, on the other hand, depressed ring A reduc-
tion of cortisone only in males while it depressed C-20 re-
duction in both males and females. With cortisol Deckx et 
·a1 (222) obtained more C-20 reduction in males and rela-
tively more 4,Sa reduction and 17-ketosteroid formation 
with females. Yates· ·et ·a1 (1184) confirmed these findings, 
showing that female rats had from 3 to 10 times the rate 
of ring A reduction of cortisol as males had. The inves-
tigators Schrief ers and Wassmuth (951) have shown that 
most of the increase in ring A reduction in females for 
cortisone is of the 4,Sa type. Balieu and Maurais-Jaurvis 
--
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(51), however, reported that the ratio of Sa to 58 reduction 
products of 17-ketosteroids depended on the oxidation of the 
substituent at position 17. Thus, the ratio was higher in 
women with the 17S-hydroxy derivatives and higher in men with 
the 17-keto derivatives. If one assumes that the same en-
zymes carry out the transformations in either sex, then the 
sexes must differ in the ratio of the enzymes which act on 
the 178 hydroxyl and 17 keto steroids. The rate of ring A 
reduction is important because this is the rate-limiting 
reaction in steroid metabolism (952). Female rat liver has 
also been shown to convert more cortisol to 118-hydroxy-4-
androstene-3,17-dione (222). 
Although it is possible to determine the extent to 
which any of these steroids bind to purified s-lipoprotein 
using the technique of equilibrium dialysis, it is unlikely 
that these studies alone will uncover the mechanism of anti-
insulin effect of the lipoproteins. Bornstein (98) found 
that the addition of cortisone to lipoproteins in vitro did 
not result in insulin antagonism like that produced when 
cortisone was injected into the rat before blood lipopro-
teins were isolated. 
Effects of Clavine and Morphine Alkaloids 
Clavine alkaloids are formed by the fungus Claviceps 
purpurea which is parasitic on Elymus mollis (rye) or on 
.. 
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£_ennisetium typhohordeum. The hormone-like potency of d-
lysergic acid diethylamide has prompted research on these 
alkaloids in an effort to find other active compounds. For 
example, ergonovine, more correctly termed ergometrine [N-
(a- (hydroxymethyl)-ethyl)-d-lysergamide], is derived from 
the naturally occurring compound ergotamine. Ergotamine 
has the same nucleus as ergonovine (d-lysergic acid) , but 
also has a cyclic polypeptide side chain which is derived 
from the amino acids alanine, phenylalanine, and praline. 
The polypeptide side chain is required for a-adrenergic 
blocking activity which is characteristic of ergotamine 
and dihydroergotamine. Thus, ergotamine will block epi~ 
nephrine-induced contractions of the isolated rabbit uterus, 
but ergonovine will not. The C-9 double bond enhances the 
vasoconstrictive and oxytoxic actions of ergonovine. This 
double bond may be shifted to C-8 as in argoclavine with 
retention of both properties. The structures of ergono-
vine and argoclavine are shown on the following page (948, 
1019). In addition, the structure of elymoclavine is shown 
because it is also an important naturally occurring clavine 
alkaloid. 
Yanai and Nagasawa (1182) have shown that 2-brominated 
ergot alkaloids suppress mammary lobulo-alveolar formation 
and decrease the frequency of mammary pre-cancerous 
FIGURE IX 
STRUCTURE OF ERGONOVINE 
HOCH2CHCH3NHCCf° 
. 
• .
3 
ERGONOVINE 
-FIGURE X 
STRUCTURES OF AGROCLAVINE AND ELYMOCLAVINE 
• 
H 
R•C~ •AGROCLAVINE 
R•C~l+ELYMOCLAVINE 
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r TABLE XI 
PHYSICAL PROPERTIES OF CLAVINE ALKALOIDS RELATED TO STEROIDS 
CO!mon N~ Configuration Melting Point 8pecif ic Rotation 
Agroclavine (Sex) , 8--Methyl-8-Ene 20S-206 -182 
Costaclavine (S8), 8a.-Methyl 182 +44 
Elyrroclavine (Sa.) , 8--Hydroxyrnethyl-8-Ene 248-2S2 -S9 
Festuclavine (Sa.) , 8a.-Methyl 203-204 -90 
Isolysergine (Sa.) , 8(3-Methyl-9-Ene 134-137 +203 
Lysergine (Sa.) , 8a.-Methyl-9-Ene 288-289 +64 
Lysergene (Sa.) , 8--Methylene-9-Ene 244-24S +407 
Pyroclavine (Sa.) , 88-Methyl 243-244 -109 
Ultraviolet Absorption Maxima (run) 
Unconjugated ••••••••••• 22S, 284, 293, 
Conjugated ••••••••••••• 22S, 240, 284, 293, 31S, 
Lysergene •••••••••••••• 22S, 243, 263, 33S 
,•·,o··~. 
' ' ' ' ' ~ 
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hyperplastic aleovolar nodules by decreasing prolactin out-
put from the pituitary. Knew-Hseung et al (599) have also 
suggested that ergocornine directly blocks estrogen-stim-
ulated prolactin release. These effects resemble the in-
hibition of prolactin release by high levels of estrogens. 
The enhancement of anti-tumor activity by 4-methyla-
tion and 2a-formylation in the steroid series has been pre-
viously noted (251, 902). The analogous modifications in 
the clavine alkaloids are ~6-methylation (present in all 
ergolanes) and 8a-formylation. Another important modifi-
cation is the introduction of bromine in the C-2 position. 
Savine (939) found that the 2-brominated derivative of d-
lysergic acid diethylamide was a more potent antagnoist 
of serotonin and catecholamines even though it was devoid 
of vasoconstrictive and psychomimetic effects. Berde (66) 
has reviewed the comparative effects of these compounds. 
These effects are of interest because Gay and Pletscher 
(364) have reported that serotonin elevates blood pyruvate 
and lactate when administered systemically. 
Elymoclavine, 8-hydroxymethyl-8-ergolene, or its N1-
methyl or 2-bromo derivative may show some anti-tumor ac-
tivity. This should be increased by the oxidation of the 
primary hydroxyl group to the aldehyde with dicycloheximide 
and dimethylsulfoxide yielding 8-formyl-6-methyl-8-ergolene: 
J 
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Elymoclavine is 8-hydroxymethyl-6-methyl-8-ergolane. The 
corresponding saturated derivative might be prepared by the 
hydroboration of agroclavine. Brown et al (124, 125) have 
described the conversion of a-pinene to S-pinene in 54 per-
cent yield via hydroboration. This result suggests that 
the endocyclic C-8 double bond of agroclavine may be hydro-
borated with diisocampheylborane, and the product either 
oxidized to 8a-hydroxymethyl-6-ergolane or hydrolyzed with 
acetic acid to festuclavine. The same compound might also 
be made from dihydroergotamine following hydrolysis and re-
duction of the carboxyl group. 
The preparation of ergonovine from ergotamine via the 
hydrazide is accompanied by racemization to isolysergic 
acid hydrazide due to the acidic hydrogen at C-8. The pos-
sibility of preventing this racemization by protecting the 
--
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c-9 double bond does not seem to have been investigated. 
This double bond might be protected by the formation of its 
cis glycol with hydrogen peroxide using osmium tetroxide as 
catalyst. Following the formation and reaction of hydra-
zide intermediates the double bond can be regenerated by the 
procedure of Corey and Winter (197). This procedure in-
volves the reaction of the glycol with N,N'-thiocarbonyl-
imidazole to form the cyclic thiocarbonate. The carbonate 
is then treated with trimethyl phosphate to regenerate the 
double bond with the formation of trimethylthiophosphate 
and carbon dioxide. 
Kornfield et al (608) have described the total synthe-
sis of 2,3-dihydro-6-methyl-9-ergolen-8-one [9-keto-7-methyl-
4,5,5a,6,6a,7,8,9-octahydroindolo-(4,3-f,g)-guinoline]. The 
keto group in the above compound may be replaced by a me-
thylene group by the use of the Wittig reagent methylene 
diphenylphosphorane. The ethyl reagent has been used to 
introduce the side chain into 17 ketosteroids.' The result-
ing lysergene derivative can be converted to the Ba-methyl 
or 8a-hydroxymethyl compound by the method of Brown et al 
(124). This, in turn, can be directly converted to the C-12 
hydroxy indole with potassium nitrodisulfonate as described 
by Stadler et al (1020). The corresponding C-12 hydroxy 
ergot alkaloids are not found in nature because the enzyme 
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involved in the initial biosynthetic step cannot utilize 5-
t: hydroxytryptophan in place of tryptophan. 
1· f On the other hand, Jacobs and Gould (520) have reported 
the total synthesis of racemic 6,8-dimethylergolane by a me-
thod that can be modified to permit the synthesis of the 12-
hydroxy derivative. However, they did not compare the par-
ticular diastereomer which they isolated with authentic fes-
tuclavine and the optical rotation which they reported indi-
.cates that their product was contaminated by other diastereo-
isomers. Esterification of the C-12 hydroxyl group with an 
optically active acid such as that derived from 8-pinene 
by hydroboration offers the possibility of asymmetric in-
auction in the subsequent reductive steps. 
Ergot alkaloids have been shown to block hepatic gly-
cogenolysis in response to cyclic adenylate (432). Ergo-
novine may act as a glucocorticoid analog in adrenalec-
tomized rats because it is able to block ACTH release.· 
Rezabeck et al (882) have shown that 8a-cyanomethyl-6-
methyl-ergolane has hormone-like activity. When adminis-
tered at a dose of 1 mg/kg daily, the compound prevented 
conception. When administered at 10 mg/kg daily, the com-
pound caused abortion up to the 7th day after copulation. 
The structure of the alkaloid is similar to 2a-cyano-17S-
hydroxy-4,4,17a-trimethyl-5-androsten-3-one, an inhibitor 
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of pituitary function and steroidogenesis in the rat (582). 
Related ergolanes may also be active against mammary tumors. 
Structure-function studies have indicated that other 
modifications besides 2-bromination may decrease the action 
of clavine alkaloids on smooth muscle. In particular, methyl 
ation of the adjacent N-1 nitrogen significantly reduces the 
oxytoxic and vasoconstrictive actions of these compounds. 
The best known compound of this type is Sansert [N-(hydroxy-
methyl)propyl]-1-methyl-d(+)-lysergamide. This compound has 
found application in the treatment of migraine headache (983). 
Migraine headache is believed to be caused by a genetic 
deficiency of monamine oxidase in the brain which results in 
the accumulation of tyramine and 5-hydroxyindoleacetic acid 
formed from serotonin. The vasodilation produced by the 
latter compound induces the headache. Sansert is believed 
to act by inhibiting the formation of 5-hydroxyindoleacetic 
acid and it does not share the vasoconstrictive properties 
of other clavine alkaloids (66). 
Although the treatment of migraine with Sansert is 
effective, the treatment can produce a condition known as 
retroperitoneal fibrosis in about 1 out of 10,000 patients 
taking the drug. Retroperitoneal fibrosis is a disease in 
which pulmonary and aortic complications resemble those 
seen in rheumatoid disorders. This is not surprising 
--
FIGURE XI 
SUGGESTED SYNTHESIS OF 6,8- DIMETHYLERGOLAN-12-ol 
PART I 
SYNTHESIS OF 6,8-DIMETttYLERIOLAN-12-0L 
OOH 
< 
> H > 
Ht't 
320 
FIGURE XII 
SUGGESTED SYNTHESIS OF 6,8-DIMETHYLERGOLAN-12-ol 
PART II 
SYNTHESIS OF 6,8-DIMETHYLERGOLAN-12-0L(CON'T) 
r<:'i __ ~·· 
H 
CH 
~ 
H 
H 
321 
322 
since serotonin is believed to be involved in the inf lamma-
tion reaction. Graham (404) has also reported endocardial 
lesions resembling those found in the carcinoid syndrome. 
Although these changes are partially reversed when the drug 
is withdrawn, some changes persist. 
Changes of particular interest during retroperitoneal 
fibrosis include thrombophlebites and fibrotic obstruction 
in the great vessels and lymphatics as well as in the ureters 
and bowel. These early lesions involve the infiltration of 
fat by lymphocytes followed by plasma cells and then f ibro-
sis. These changes can lead to pleural thickening in the 
lung causing friction rub. The great vessel changes appear 
grossly similar to the changes that take place during 
atherosclerosis. 
A similar type of cystic degeneration and its rela-
tion to mammary cancer has been described by Davis et al 
(216). They showed that women with cystic disease have 
26 times more cancer of the breast than do women in gen-
eral. Moreover, biopsy tissue removed during surgery 
revealed an 18 percent incidence of malignant degeneration. 
The chance of developing lesions in the breast remaining 
after partial mastectomy is about 20 percent. For this 
reason, a complete mastectomy is often done initially. 
The important point is that the superficially normal 
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breast removed during the complete operation affords an oppor-
tunity to study those biochemical and histological changes 
associated with the precancerous state. The fact that ergot 
' 
t' r alkaloids can produce similar and somewhat reversible changes 
similar to those found in cystic disease suggests that the 
alkaloid may be mimicking the effect of an endogenous metab-
olite. 
Other similarities appear to exist between ergot alka-
loids and steroids. Zellwige ~t al {1196) have described 
the teratogenic effect of lysergic acid diethylamide in a 
single case of unilateral fibular aplastic syndrome in a 
child born to parents who had taken the drug. Chromatid 
breaks were observed in the white cells of mother, father 
and child. The relationship between these breaks and the 
production of retroperitoneal fibrosis during migraine 
therapy with Sansert [N-{hydroxymethyl)-propyl-1-methyl-
d{+)-lysergamide] is not clear. 
Takano et al {1047) observed more fetal malformations 
in pregnant rabbits given 1 mg/kg chlormadinone acetate 
than in those given 1 percent mestranol in norethisterone. 
Also, Carr (160) has described a higher incidence of spon-
taneous abortions with progestins due to the formation of 
triploid chromosomes. However, only 2.5 percent of XO 
abnormalities came to term as female infants with Turner's 
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syndrome. 
While these and other findings may possibly explain the 
recent withdrawal of chlormadinone acetate from the market, 
genetic effects do not appear to be involved in the anti-
insulin effects of these compounds. 
Bergen ~t al (67) also found that glucocorticoids may 
compete with lysergic acid diethylamide for some binding 
sites. Cortisol, cortisone, corticosterone, deoxycorti-
costerone and progesterone at l0-7Molar inhibited the metab-
olism of the alkaloid by 88,88,73,62 and 20 percent respec-
tively. 
Morphine may also share some receptor sites with sero-
tonin, glucocorticoids and estrogens. Gaddum and Picarelli 
(351) described two types of serotonin receptors in intes-
tine. The M receptors could be blocked by morphine and 
were .mainly found in nerves. The D receptors, on the other 
hand, were blocked by dihydroergotamine and were found 
mainly in muscle. The anesthetic, muscle-relaxant, and res-
piratory depression produced by morphine may be due to in-
hibition of serotonin. 
Pee Ping and Walsh (824) found that morphine increased 
glucose uptake in diaphragms from normal rats but decreased 
glucose uptake in diaphragms from morphinized rats. Corti-
sol antagonized the effect of morphine. On the other hand, 
L 
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morphine antagonized cortisol-stimulated respiration but en-
hanced the effect of cortisol on glycogenesis. 
In further studies Ng and Walsh (783) found that either 
epinephrine or cortisol reduced glucose uptake by rat dia-
phragm. When epinephrine was added first, the secondary ad-
dition of cortisol increased glucose uptake. However, if 
the diaphragms were from chronically morphinized rats, the 
addition of epinephrine had no effect and cortisol increased 
glucose uptake. This effect of cortisol alone was abolished 
if epinephrine was also added. In addition, these workers 
(784) found that the block in glucose uptake by epinephrine 
in normal diaphragm was restored to morphinized diaphragm 
in the presence of morphine. These results indicate that 
cortisol and morphine have similar effects on normal and 
morphinized diaphragms respectively. Further analysis of 
the results suggests that morphine antagonizes the inhibi-
tory effect of cortisol upon glucose transport. Also, most 
glucocorticoid sites in morphinized tissue, including that 
of the growth hormone-dependent protein which acts as a 
glucocorticoid receptor and leads to citrate elevation, 
is occupied by morphine in morphinized tissues. Further-
more, the morphine-protein complex appears to be more 
effective than the glucocorticoid-protein complex in in-
creasing cytoplasmic citrate. Therefore, when cortisol 
' L 
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displaces morphine, citrate is lowered and glucose uptake is 
increased. These results suggest that citrate elevation in 
response to morphine is dependent on growth hormone and may 
be abolished by hypophysectomy. 
Levy and Ramey (657) have shown that ergotamine, like 
morphine, inhibits ACTH release and fat mobilization in 
adrenalectomized rats. On the other hand, Harvey et al 
(432) showed that ergonovine inhibits epinephrine-induced 
hyperglycemia and that dihydroergotamine treatment actually 
increased hepatic glucose upta~e in response to cyclic 
adenylate. These results suggest that clavine alkaloids 
block the effects of cyclic adenylate on phosphorylase b 
kinase and on trasferase I kinase. These latter effects 
are directly opposite to the enhancement of cyclic adenyl-
ate effects by cortisol. Therefore, it appears that clavine 
alkaloids block the effects of cortisol at specific receptor 
sites but not at relatively non-specific sites. 
Anti-tumor activity appears to be closely related to but 
distinct from progestational activity. Rooks et ·a1 (902) 
have observed that 9a-fluoro-6a-methyl-11S,17a-dihydroxy-
4-pregnene-3,20-dione 17-acetate caused little or no in-
hibition of glycine uptake in fibroadenoma in rats. Glenn 
et ·a1 (368) made similar observations with the correspond-
ing C-1 unsaturated analog but also observed that it 
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produced a 73 percent inhibition of a testosterone propionate-
resistant fibroadenoma. Dorfman (251) observed an 87 percent 
inhibition of an adenocarcinoma with the C-1 unsaturated ana-
, 
log. He further noted that 11S-hydroxy-6a-methyl-4-pregnene-
3,20-dione caused a 48 percent inhibition of fibroadenoma 
while Glenn et al (368) reported that 17a-hydroxy-6a-methyl-
4-pregnene-3,20-dione 17 acetate inhibited fibroadenoma po-
tently but actually stimulated a testosterone propionate-
resistant fibroadenoma. In summary, these findings indicate 
that an oxygen at carbon 11 is _required for the inhibition 
of testosterone propionate-resistant tumors. Apparently, 
the oxygen at C-11 blocks the conversion of testosterone 
to estradiol by these resistant tumors. The 9a-fluorine 
substitution abolishes inhibition of fibroadenomas. The 
fact that the 2a-methyl substitution abolishes progesta-
tional activity suggests that 17-acetoxy-2a-methyl-19-nor-
4-pregnene-3,11,20-trione may show anti-tumor activity. 
The metabolism of 2a-methyl steroids, especially C-11 oxy-
genated glucocorticoids, has been discussed by Bush and 
Mahesh (142). 
As shown in Table XII, the steroid 9a-bromo-4-preg-
nene-3,11,20-trione is a C-11 oxygenated steroid with a 
high ratio of progestational to glucocorticoid activity. 
It is noteworthy that Huggins et al (490) found that this 
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TABLE XII 
GLUCOCORTICOID AND PROGESTATIONAL 
AC~IVITIES OF SUBSTITUTED PROGESTERONES 
Progesta- Gluoo-
Substituted Progesterone tional* Cortiooid** Ratio 
9a-Br, 11 -OH 0.12-0.18 0.08 1.5-2.3 
9a-Cl, 11 -OH 0.06 0.35 0.16 
9a-Fl, 11 -OH 0.18-0.30 0.85 0.22-0.36 
9a-Br, 11-=0 0.18-0.30 0.03 6.0-10.0 
9a-Cl, 11-=0 0.06 0.15 0.60 
9a-Fl, 11-=0 0.12-0.18 1.10 0.10-0.16 
9a-Br-11B-OH-17a-CXXX::H *** 3 1. 75-3.50 5.0**** 
6a-CH3, 17a-CXXX::H3 10 20 **** 
l 7a-cx:ncH3 0.07-0.15 0.2**** 
*Oral Clauberg Assay. 17a-ethinyl-17B-hydroxy-4-estren-3-one = 1.0 
Miyake and Rooks (751) 
**Liver Glycogen Deposition. Cortisol = 1.0 
Fried and Borman (333) 
***Bergstrom and Nicholson (68) 
****Subcutaneous Clauberg Assay. Progesterone = 1.0 
steroid markedly enhanced the anti-tumor effects of estro-
gens as well as the carcinogenic and catabolic effects of 
3-methylcholanthrene. These results are in agreement with 
clinical studies in which 17a-hydroxyprogesterone caproate 
was found to enhance the anti-tumor activity of pharmaco-
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l logical doses of estrogens (490). It appears that estrogens ~ 
~ 
~· should always be administered in combination with progestins ~· 
for maximal anti-tumor activity. 
In summary, it appears that the anti-tumor effect of 
9a-bromo-4-pregnene-3,ll,20-trione is greater in combination 
with estrogens. While it is unknown whether C-19 progestins 
are also synergistic with estrogens, it appears that the 
function of the C-11 oxygen is not to prevent the progestin 
from acting as an estrogen precursor. Finally, further work 
will be needed to elucidate the mechanism of the direct 
anti-tumor effects of steroids which are independent of 
other hormones. 
L 
CHAPTER XII 
MATERIALS AND METHODS 
Tables XIII and XIV list the major chemicals used ac-
cording to their sources. Other chemicals used but not 
specifically listed were of reagent grade. Solutions were 
prepared in deionized, glass-distilled water. The melting 
points listed were determined between cover glasses using 
a Fisher melting point apparatus and are uncorrected. 
Since one of the main purposes of this work was to 
compare the effects of fluprednisolone and 20B-hydroxy-
fluprednisolone, it was necessary for the author to syn-
thesize the latter compound from the former. Norymberski 
and Woods (790) have described a technique for the selec-
tive reduction of steroid C-20 carbonyl groups which em-
ploys a 1.5 molar excess of sodium borohydride at 0°C for 
1 hour. Their technique was employed to synthesize the 
6a-fluoro-11S,17a,20S,21-tetrahydroxy-l,4-pregnadien-3-
one used in this study. The reduced steroid was separated 
from fluprednisolone by preparative thin-layer chromatography 
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TABLE XIII 
CHEMICALS 
Abbott LabOratories 
R Pentbrane (methoxy flurane) - 2,2-dichloro-1,1-difluoroethyl methyl ether, 
List No. 6864 
Amersharn/Searle 
o-Glucose-6-14c, 52.4 rrCi/mrole, Number CFA 351, Lot 10 
Hexadecane-1-14c, 2220 df!I1/rrg 
Cal-Atomic 
14 D-Glucose-6- C, 10 rrCi/rmole, Lot 78101 
International Chemical Company 
4-androstene-3,11,17-trione, Lot 439211 
3a-hydroxy-5a.-androstene-ll,17-dione, Lot 19(3-0330 
3(3-hydroxy-5(3-androstene-11,17-dione, Lot 198-1580 
3B-hydroxy-5a.-androsten-17-one, Lot 578-0480 
3(3-hydroxy-ll-oxoolean-12-ene-30-oic acid (glycyrrhetic acid), 
mp 155-161°C 
21-hydroxy-4-pregnene-3,20-dione acetate, Lot 4097, mp 137°C 
llf3,17a,20a.,21-tetrahydroxy-4-pregnen-3-one 21 acetate, Lot 023199 
Mann Research Laboratories 
17a,21-dihydroxy-5f3-pregnene-3,ll,20-trione, Lot T207 
118,17a,21-trihydroxy-4-pregnene-3,20-dione, Lot T3305 
llf3,17a.,21-trihydroxy-58-pregnene-3,20-dione, Lot Tl828 
L 
TABLE XIV 
CHEMICALS 
Nutritional Biochemical Company 
Diabetic Rat Diet, Lot TD-68580, Composition: 
3% Sodium-free salt mixture 
5% Safflower oil 
1% Vitamin fortification mixture, corrplete 
55% Casein, high protein 
5% Non-nutritive fiber 
21% D-fructose 
10% Sodium succinate .6 H20 
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Sigma Chemical Company 
17a,21-dihydroxy-5s-pregnene-3,ll,20-trione 21 acetate, Lot 95S-2390-l 
3a-hydroxy-5a-androstan-17-one, Lot 28S-2430 
3a-hydroxy-5S-anqrostan-17-one, 98%, Lot 127S-2500 
3S-hydroxy-5S-androsten-17-one, Lot 97S-0330 
313-hydroxy-5-androsten-17-one, Lot 18S-3030 
t!pjohn Pharmaceuticals 
6a-fluoro-11S,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione 
(fluprednisolone), Lot WA 701, mp 206-208°C, acetate, 
m p 235-238°C 
r 
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on 20 cm x 20 cm glass plates coated with silica gel G-254 
and fluorescent indicator (Brinkman Instruments). Several 
solvent systems were satisfactory for this purpose. Among 
these were the upper phase of tertiary amyl alcohol, ani-
sole, water (190/600/10, Rf 0.12 and Rf 0.42 respectively); 
the system 1,8-epoxy-p-menthane, n-propanol, water (100/20/5, 
Rf 0.23 and Rf 0.59 respectively) and the system methylcyclo-
hexane, n-propanol-water (75/25/5) where the separation was 
equivalent. It should be noted that this latter solvent 
system is similar to the ternary minimum boiling azeotrope 
' 
of methylcyclohexane, ethanol, water (66/24/10, b p 66°C). 
The reduced 206-hydroxyl derivative was detected by its 
quenching of the fluorescence of the phosphor in the silica 
gel. Therefore, if reduction of the conjugated C-3 ketone 
occurred, the resulting compound would not have been de-
tected. As expected, the more polar 20B-hydroxyl deriva-
tive migrated slower than the parent steroid. Zones which 
contained the steroids were located under ultraviolet light 
and scraped from the plate into a beaker containing methanol. 
After thorough mixing, the methanol was passed through a 
fine sintered glass filter and flash evaported to dryness 
under reduced pressure. Recrystalized 20S-hydroxyflu-
prednisolone had a melting point of 188-192°C compared to 
206-208°C for fluprednisolone. The diacetate of the 
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reduced derivative was also prepared with acetic anhydride 
and pyridine and it had a melting point of 210°C. As far as 
the author could determine, the melting points for these re-
i duced derivatives have not been reported. 
While on the subject of steroid chromatography, it 
should be noted that cortisol and f luprednisolone migrate 
I· together in such solvent systems at t-amyl alcohol, chloro-
f f benzene, water (150/590/10, Rf 0.18), 95 percent ethanol-
~.· [ water saturated with cyclohexane (Rf 0.227); in 95 percent 
'· ~· t ethanol-water, benzotrifluoride water (115,360,25, Rf 0.226), 
.... 
and in cyclopentanol, dibromomethane water (10/10/1, Rf 0.81). 
Thus, these steroids and possibly their metabolites would be 
most difficult to separate in studies of the metabolism of 
the labeled hormones. Other considerations suggest that 
these steroids may be separated as C-21 esters in the ternary 
azeotrope of cyclooctane, n-propanol-water. 
Inf rared spectra were recorded using a double-beam 
Perkin-Elmer 337 grating spectrophotometer. The resolution 
obtained with this instrument is better than that in spectra 
found in the literature so that direct comparisons are not 
possible. The steroid spectra were recorded using redis-
tilled carbon disulfide (odorless) as solvent in 2.0 mm 
sodium chloride cavity cells manufactured by Barnes Engineer-
ing, Inc. Solvent evaporation was excessive when the 
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flexible plastic stoppers supplied with these cells were 
used. They were replaced with solid teflon stoppers ground 
from a teflon rod with the aid of a pencil sharpener. How-
ever, since excessive sealing pressure on-the stoppers re-
sulted in the splitting of the cavity cells, solvent eva-
poration during the recording of spectra had to be routinely 
monitored and sealing pressure increased slightly if neces-
sary. 
Infrared spectra were recorded on transmittance paper 
so that the transmittance of the solvent could be subtracted 
from that of the solvent plus solute in the longer path 
length cell. That is, the blank cell did not completely 
compensate for the infrared absorption of the solvent. 
Still, there were negative absorbance regions due to the 
displacement of solvent by solute in regions of high solvent 
absorption. The same set of cells was used for all spectra 
in the 1300-400 cm-l region. The cells cleaned with methyl-
ene chloride and carbon disulfide and air-dried before use. 
The scanning time was 72 minutes and the slit program was 
one-tenth normal slit width. Melting points were determined 
between cover glasses on a Fisher melting point apparatus 
and are uncorrected. The solution spectroscopy of steroid 
esters was chosen because it eliminates hydrogen bonding 
and polymorphism associated with the spectra of solid 
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hydroxylic steroids. Although steroid acetates are suitable 
for this purpose, steroid benzoates have better chromate-
[ graphic properties (121). Furthermore, the ultraviolet ab-
f ~ sorption of the benzoyl group facilitates the collection of 
" 
--
chromatographically separated steroid peaks. 
Krahl et ·a1 (365) have demonstrated the effect of the 
rat S-lipoprotein insulin antagonist in vitro on rat dia-
phragm but no one has yet evaluated its action in vivo. 
A very sensitive in vivo assay of insulin in fasting al-
loxan-diabetic adrenalectomized rats has been described 
by Bornstein and Trewhella (95). However, it is a two-
point assay based on the drop in blood glucose produced 
by insulin in exactly one hour at 37°C. Insulin antago-
nism counteracts the drop in blood glucose. In order to 
overcome the limitations of the two-point assay, multi-
point assays have been devised in which the specific ac-
tivity of expired co 2 is measured at intervals during the 
infusion of labeled glucose (220, 311, 1029). Since the 
specific activity of expired co2 approaches that of the 
infused glucose in approximately 4 hours, all measurements 
must be made in this interval. Demonstration of glucocor-
ticoid-dependent insulin inhibition by lipoproteins in vivo 
is essential to the concept of inherited insulin antagonism 
in diabetes mellitus. 
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In these experiments S-lipoproteins isolated from the 
sera of steroid-treated donor rats are administered to re-
cipient rats and the effect of the lipoprotein on the oxida-
tion of glucose-6-14c to carbon dioxide is measured. Steroid 
contamination was minimized by withholding steroid treatment 
for 6 hours before lipoprotein isolation as well as by the 
washing step applied to the precipitated lipoprotein during 
its isolation. 
Male Sprague-Dawley rats weighing approximately 175 
grams were obtained locally. The following procedure was 
used to produce alloxan-diabetes. First, the rats were 
fasted about 24 hours to deplete hepatic glycogen. Sec-
ondly, a solution of 65 mg/ml of alloxan monohydrate in 
saline was injected intravenously at a dose of 1.0 ml/kg. 
The animals were then given food ad libitum. Approximately 
two-thirds of the rats developed a 24-hour fasting glucose 
in excess of 2.0 gm/l within 2 days after alloxan adminis-
tration. However, one-half of the diabetic animals died 
and one-third of the original number of rats did not be-
come diabetic according to the above criterion. Insulin 
and electrolyte therapy were not used because such treat-
ment would have increased the variation between rats. All 
rats having fasting glucose levels less than 2.0 gm/l were 
recycled and subsequently received 1.5 ml/kg of alloxan. 
--· 
338 
The wide variation in the response of individual rats to the 
standard dose of alloxan remains unexplained. However, the 
dose of 65 mg/kg appeared optimal with respect to the yield 
of viable alloxan-diabetic rats. 
Acidosis was associated with obesity in the alloxan-di-
abetic rats. Also, growth was self-limiting in the diabetic 
rats in that it tended to exacerbate the insulin deficiency. 
However, those alloxan-diabetic rats that remained alive for 
at least one week were adrenalectomized under pentobarbital 
anesthesia. An abdominal approach was used in which both 
kidneys and adrenals were clearly visible. This approach 
insured complete adrenalectomy. All rats were injected with 
10 mg/kg of 6a-fluoro-11B,17a,21-trihydroxy-l,4-pregnadiene-
3,20-dione to prevent hypoglycemia during the immediate post-
operative period. Also, the rats were transferred to a low 
glucose diet high in fructose and protein with glycyrrhe-
tinic acid in saline as drinking fluid. This diet is des-
cribed in detail on page 332. 
Adrenalectomy produces an approximate reduction of 50 
percent in serum glucose. That is, the severity of diabe-
tes is reduced by this amount. Afterwards it is possible 
to further reduce insulin secretory capacity by adminis-
tering additional alloxan to raise the glucose levels to 
pre-adrenalectomy levels. Those adrenalectomized rats 
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f t who had fasting glucose levels less than 400% mg prior to 
'c t~ 
, adrenalectomy were again given the standard dose of 65 mg/kg 
-
of alloxan intravenously. Then the fasting serum glucose 
was again determined to select those rats having 6-hour fast-
ing glucose levels of at least 200% mg when maintained on the 
low-glucose diet. These rats could not be fasted for more 
than 6 hours without risk of death from spontaneous hypogly-
cemia. This procedure is listed stepwise on the following 
pages. It results in the preparation of severely diabetic 
rats without insulin treatment. 
Experimental Procedure 
1. Obtain 180-gram male Sprague-Dawley rats locally and 
maintain them on a standard laboratory diet for 2 days. 
2. Fast all rats for 24 hours, then inject 65 mg/kg of 
alloxan monohydrate in saline into the tail vein. 
3. Feed all rats ad libitum for 2 days. 
4. Fast all rats again for 24 hours. 
5. Anesthetize the rats with 20 mg/kg sodium pentobarbital 
and obtain 400 µl samples of tail blood. 
6. Measure serum glucose with a glucose oxidase method. 
7. Reject as non-diabetic all rats with serum glucose less 
than 2. 0 gm/l. 
8. Feed the remaining diabetic rats ad libitum for at 
least 1 week. 
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9. Adrenalectomize all surviving diabetic rats. 
10. Inject adrenalectomized rats with 10 mg/kg flupredniso-
lone post-operatively and then transfer them to the low 
glucose diet and the saline-glycyrrhetinate drinking 
fluid. 
11. Allow at least 1 week for recovery from adrenalectomy. 
12. Fast rats having pre-adrenalectomy glucose values be-
tween 2.0 and 4.0 gm/l for 6 hours and then inject 65 
mg/kg of alloxan monohydrate as previously described. 
13. Feed all rats ad libitum for 2 days. 
14. Fast all rats for 6 hours and measure serum glucose as 
previously described. 
15. Reject as non-diabetic all rats having serum glucose 
levels less than 2.0 gm/l. 
16. Group the diabetic rats in pairs on the basis of weight 
and fasting serum glucose. Designate the heavier of 
the pair the donor rat and the lighter the recipient 
rat. 
17. Inject the donor rat with 10 mg/kg of either 6a-fluoro-
11S,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione or 6a-
fluoro-11S,17a,20S,21-tetrahydroxy-l,4-pregnadiene-3-
one in propylene glycol subcutaneously at 48, 24 and 
6 hours before exsanguination via the abdominal aorta. 
18. Fast the donor rat for 6 hours prior to exsanguination. 
--
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9 Exsanguinate the donor rats under methoxyf lurane anes-1 • 
thesia. At the same time begin to fast the recipient 
rat for 6 hours. 
2o. Transfer the blood from a 10 cc syringe to a 25 ml plas-
tic International centrifuge (PR-2) tube and centrifuge 
for 10 minutes at 8,000 x g at 0°C using the high speed 
attachment and head number 298. 
21. Remove the serum from the clot with a clean calibrated 
syringe and needle. 
22. Precipitate the serum S-lipoproteins with dextran sul-
fate and calcium chloride as described in the text. 
23. Wash the S-lipoprotein precipitate with calcium acetate. 
24. Dissolve the precipitate in 1.0 ml of tris(hydroxy-
methyl)-aminomethane-EDTA buffer, pH 9.1 that has been 
saturated with blue dextran. 
25. Equilibrate Bio-Gel DM-100 {a polyacrylamide sieving 
gel containing diethylaminoethyl anion exchange groups) 
with isotonic tris(hydroxymethyl)aminomethane-HCl buf-
fer, pH 7.40 at 37°C and pack it into a column 2.0 x 
30 cm. 
26. Apply the blue lipoprotein solution in a narrow zone 
at the top of the above column and elute it with the 
isotonic buffer which has a pH of 7.8 at 0-4°C. 
27. Collect 0.5 ml fractions and pool the 4 fractions 
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having the highest concentration of blue dextran and 
hence of the S-lipoprotein which is excluded from the 
gel with it. 
28. Inject 2.0 ml of the S-lipoprotein solution intraperi-
toneally into the recipient rat anesthetized with pen-
thrane. 
29. Inject the recipient rat with a priming dose of 50 
14 µCi/kg of glucose-6- c. Then follow with a constant 
infusion of insulin and glucose-6-14c {0.05 µCi/mmole) 
as described in the text. 
30. Collect 5 samples of 14co2 of 45-minutes duration each 
directly in scintillation vials as described in the 
text. 
31. Terminate the experiment after 225 minutes in one of 
32. 
--
two ways: 1) Place the rat in a cage under a labora-
tory hood for 1 week so that the rat may return to 
background radioactivity levels prior to receiving 
lipoproteins from rats treated with other steroids; 
2) Following the second experiment with the recipient 
rat place him in liquid nitrogen in preparation for 
liver and muscle glycogen analysis. 
Measure the specific activity of the expired 14co 2 
with a liquid scintillation counter using an open 
window. 
33. 
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Plot the specific activity of the 14co2 versus time and 
fit the best straight line to these points which also 
passes through the origin. The slope of this regression 
line is then taken as a measure of the rate of glucose 
oxidation. The details of the statistical treatment 
have been described by Sokal and Rohlf (1001) • 
Serum glucose was determined with a commercial glucose 
oxidase reagent (Glucostat Regular, Worthington Biochemical 
I corporation). The lyophilized reagent was reconstituted in 
30 ml of 0.10 M tris(hydroxymethyl)aminomethane-maleate buf-
fer, pH 6.9, instead of 83 ml of water in order to provide a 
greater excess of enzyme for glucose determinations in the 
diabetic range. This added buffer strength necessitated the 
use of twice the volume of 5.0 N HCl to stop the reaction. 
Also, the reaction time was reduced from the recommended 15 
minutes to 5-10 minutes to increase the linearity of the 
reaction. The glucose oxidase-peroxidase reagent was stored 
frozen and it was filtered through Whatman 50 filter paper 
immediately before use to remove pigment. Glucose standards 
were preserved with benzoic acid and the actual determina-
tions were carried out at ambient temperature using an ul-
tramicro technique. The reagent described above loses ac-
tivity during prolonged use at ambient temperature. 
When the method described in step 31 is used for 
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~ reducing the radioactivity of expired co2 to background lev-
t ~. els. Arrangements should be made to insure that the hood 
ventilating system is not shut down during the procedure. 
Ideally, the radioactive rat should be maintained in a large 
metabolic cage. The room air could first be bubbled through 
sodium hydroxide and then through a constant humidity solu-
tion in order to maintain a comfortable environment for the 
rat during the week. This would result in the production of 
about 225 grams of barium carbonate for disposal. The dis-
advantage of this procedure is that it requires a separate 
metabolic cage for each rat to avoid cross contamination. 
In the absence of the necessary equipment the author thought 
14 that it would be safer to vent the co2 directly into the 
atmosphere rather than into the sewage system where it may 
have come into contact with acid without the benefit of a 
hood. 
Rats were anesthetized with the inhalation anesthetic 
2,2-dichloro-1,1-difluoroethyl methyl ether (Penthrane, 
methoxyflurane) or with 2-chloro-1,1,2-trifluoroethyl ethyl 
ether. Poznak and Artersio (850) compared several deriv-
atives of 1,1-difluoroethyl methyl ether as anesthetic 
agents and found that the 2,2-dichloro compound was both 
a potent anesthetic as well as non-flammable in the con-
centrations required for anesthesia. The vapor pressure 
[' 
" i 
-
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of the anesthetic in inspired air was regulated by bubbling 
room air first through sodium hydroxide to absorb carbon di-
oxide and then through a gas trap containing the anesthetic 
at a temperature approaching -21.1°C which was maintained by 
surrounding the trap with frozen sodium chloride eutectic 
(23.3 percent NaCl). Although the use of a single tempera-
ture limits precise control of the depth of anesthesia, this 
can be accomplished by controlling the flow rate of carbon-
qioxide-free air through the vaporization trap. Faster flow 
rates reduce the concentration of the anesthetic agent in 
inspired air (Figure XIII). 
In early experiments the S-lipoprotein fraction of rat 
serum was isolated by a modification of the ethanol precipi-
tation technique described by Krahl et al (306). The modi-
fication was that manipulations other than centrifugation 
at -5°C were conducted at 0°C. The precipitation reagent 
was composed of the following ingredients: 
38 ml absolute ethanol 
0.6 ml of 0.8 M HOAc-NaOAc buffer, pH 4.0 
4.0 ml of 0.06 M NaCl 
0.42 ml of 1.0 M HOAc 
H2o to 200 ml 
The precipitation reagent was cooled to 0°C. Approximately 
2.0 ml of donor rat serum was slowly added with continuous 
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by 1.0 ml of 0.4847 M tris(hydroxymethyl)aminomethane(58.783 
gm/1)-0.0810 M ethylenediaminetetraacetic acid (3.946 gm/l) 
buffer, pH 9.2. The suspended precipitate and crystals were 
shaken in the cold room for approximately 30 minutes and then 
centrifuged.as previously described. The resulting solution, 
saturated with blue dextran marker, was applied to an ion ex-
change-gel exclusion column consisting of diethylaminoethyl 
groups on a polyacrylamide matrix (Bio-gel DM-100). This 
gel excludes protein having molecular weights in excess of 
100,000. The column, 20 mm x 300 mm, was equilibrated with 
the isotonic tris-HCl buffer, pH 7.8 at 0°C (pH 7.40 at 
37°C) described above. Both the blue dextran and the S-li-
poprotein were excluded from the gel and emerged from the 
column with the void volume of approximately 16.6 ml. The 
dextran sulfate and EDTA anions were exchanged for chlor-
ide ions while chelated calcium and protein contaminants 
entered the gel. The four bluest o.s ml eluant fractions 
were pooled and administered to recipient rats. Since the 
concentration of blue dextran and tris buffer administered 
to each recipient rat was the same, these agents should 
not affect the results. The dextran sulfate precipitation 
procedure is superior to the ethanol precipitation pro-
cedure because it avoids solvent denaturation and removes 
low molecular weight phospholipases which may be present. 
l 
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However, it employs high pH, 9.2, and may result in the loss 
of dializable lipoprotein constituents during passage through 
the gel exclusion column. These potential limitations have 
not been evaluated but should be kept in mind when the tech-
nique is used. 
Following the administration of the B-lipoprotein frac-
tion from the steroid-treated donor rats to the anesthetized 
recipient rat, a continuous infusion of glucose and insulin 
was initiated. The composition of this solution is shown 
in Table XV. The specific activity of the glucose infusion 
solution was measured by counting a weighed sample of glu-
cose 2,5-dichloro-phenylhydrazone, mp 152-152.5 (lit 160°C) 
which was prepared as described by Mandl and Newberg (708). 
The derivative was formed in anhydrous n-propanol and re-
crystallized from 1,1,2-trichloroethane. For example, a 
solution diluted to contain 0.05 µCi/mmole according to 
manufacturer's specifications was found to contain 0.0676 
µCi/mmole by the above technique. The discrepancy between 
calculated and experimentally determined glucose infusion 
rates is attributed to the viscosity of the 27 percent 
glucose solution. 
14 An ethanolic solution of glucose-6- C was diluted 
to contain 5.0 µCi/ml and used as such to prime the body 
glucose pool of the rat. This solution was administered 
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TABLE XV 
GLUCOSE INFUSION SOLUTION 
,, 
Canponent Concentration Infusion·Rate 
Glucose 272.11 mg/l 83.3 mg/hr 
Sodium heparin O.Olmg/l 0.003 mg/hr 
Phenobarbital 0.54 mg/l 0.17 mg/hr 
Insulin 0.02 mg/l 0.14 units/hr 
Infusion Rate = 0.3 ml/hr 
l 
to the rat at a dose of 1.0 ml/kg in order to raise the spe-
cific activity of the body glucose pool to that of the glu-
cose infusion solution, i.e. 0.05 µCi/mmole. At this level 
of radioactivity approximately 10.1 µCi of radioactivity 
was required per 200 gm rat. 
In preliminary experiments the respiratory carbon diox-
ide was isolated as barium carbonate and counted at in-
finite thickness (20 mg/cm2) in an end window planchet 
counter. These experiments indicated that the specific 
activity of the carbon dioxide reached a plateau after 
about 4 hours of infusion. In another series of experi-
ments an attempt was made to increase counting efficiency 
and to by-pass the plating procedure associated with plan-
chet counting by converting barium carbonate to quaternary 
ammonium carbonate in toluene prior to homogeneous liquid 
scintillation counting. Finely divided barium carbonate 
was mechanically shaken for 24 hours at ambient tempera-
ture with quaternary ammonium tosylate in toluene for re-
action according to the equation: 
The fact that carbonate is isolated as its barium salt is 
somewhat disadvantageous because the barium salts of or-
ganic sulfonates are among the most soluble sulfonate salts. 
Since the equilibrium in the above reaction depends on the 
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~ relative solubilities of barium carbonate and barium sul-
fonate, the forward reaction may be enhanced by using sul-
fonates which form barium salts that are relatively insolu-
ble in toluene, i.e. barium methanesulfonate. In order to 
be competitive to the direct trapping of carbon dioxide in 
quaternary ammonium hydroxide, a method described below, 
the above reaction would have to proceed almost to comple-
tion. The solubility of cesium carbonate in 2-propanol 
(.025 M) was determined in order to test the feasibility 
of related reactions employing different metal carbonates. 
All steroid comparisons are based on the direct trap-
ping of respiratory carbon dioxide in a 0.5 molar solution 
of quaternary ammonium hydroxide in toluene. A special· 
gas trapping device was constructed which permitted the use 
of standard liquid scintillation vials. Its construction 
is shown in Figure XIV. Since the device was constructed 
of several pieces, it was necessary to use vacuum grease 
on crevices and threads to prevent gas leaks. With the 
exception of the tef lon coupling a similar single-piece 
device may be constructed entirely of glass thus greatly 
reducing the possibility of leakage. 
Collection vials were changed at 45-minute intervals 
up to 225 minutes. Then the anesthetized rat was removed 
from the metabolic cage and either placed in a cage under 
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a fume hood to allow expired radioactivity to return to back-
ground levels or placed in liquid nitrogen for subsequent 
muscle and hepatic glycogen analysis following the second li-
poprotein treatment administered to the rat. This protocol 
allowed both steroid treatments to be compared in the same 
rat. Following freezing in liquid nitrogen the rat carcas-
ses were stored at 120°C in a deep freeze. For glycogen 
analysis the carcasses were removed and warmed in a cold 
room at 0°C, the limbs were removed and the digits and skin 
were disgarded in the appropriate manner with the rest of 
the radioactive carcass with the exception of the liver. 
The resulting mass of tissue was weighed and digested in 
hot KOH. When cooled, the digestion mixture was decanted 
from the bones and filtered through alkali-resistant fiber 
glass. The bones were then dried and their weight was 
subtracted from the total weight of the tissue. The glyco-
gen was then precipitated with ethanol according to the 
technique of Good et al (367). However, despite the ad-
ministration of glucose and insulin, only traces of glyco-
gen were found in some experiments. 
CHAPTER XIII 
RESULTS 
Part I: Infrared Studies 
For convenience in confirming the identity of commer-
cial steroids, the melting points and specific rotations 
of some endogenous 3-hydroxy-17-ketosteroids and their 
acetates can be found in Table XVI. Note that these pa-
rameters are not very definitive. Exceptions include the 
low melting point and high specific rotation of 3a-hydroxy-
5$-androstan-17-one, the high melting point of its llS-
hydroxyl derivative, and the high specific rotation of the 
latter's dehydration product. In contrast, 3$-hydroxy-5-
androsten-17-one has a low specific rotation. In general, 
5a-epimerization and ester formation lower specific rota-
tion with the exception of uncertain entries which are 
underlined. 
The infrared spectra of these 3-hydroxy-17-ketoster-
oids are more definitive. Note that, from the data of 
Jones et al (538-547) in Table XVII, C-11, C-17, and 
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TABLE XVI 
MELTING POINTS AND POSITIVE SPECIFIC ROTATIONS OF 
MAJOR 17-KETOSTEROIDS AND THEIR ACETATES 
17-Ketosteroid Alcohol Acetate 
3a-hydroxy-5a-androstan-17-one 184-185, 94.6° 160-161, 77° 
3a-hydroxy-5S-androstan-17-one 143-144, 111° 151-155, 98.4° 
3a-hydroxy-9(11), (5a)-androstan-17-one 187-188, 136° 190-192, 135° 
3a-hydroxy-9(11), (5S)-androstan-17-one 169-170, 151° 86-88 
3a,11S-dihydroxy-5a-androstan-17-one 199-200, 98.4° 240-242 
3a,11S-dihydroxy-5S-androstan-17-one 237-238, 96° 
3a-hydroxy-5a-androstane-ll,17-dione 153-155, 127° 184-185, 113° 
3a-hydroxy-5S-androstane-ll,17-dione 188-189, 95.8° 163-164, 145° 
3S-hydroxy-5a-androstan-17-one 178-179, 87.5° 96-97, 68° 
3S-hydroxy-5--androstan-17-one 152-153, 11° 171-172, 3.9° 
3S-hydroxy-5S-androstan-17-one 154-155, ago 157-158, 82° 
w 
Ul 
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TABLE XVII 
INFRARED ABSORPTION MAXIMA OF STEROID KETONES 
Ketone -1 (an ) (CE14) 
-1 (an ) (CHC13) 
C-3 1717-1713. 1711-1706 
61-C-3 1680-1684 1670 
64-C-3 1674-1678 1666 
61,4-C-3 1666-1663 
64,6-C-3 1669-1666 
C-11 1712-1706 1705-1698 
C-17 1745-1743 1736-1733 
C-20 1709-1706 1707-1694 
616-c-20 1666-1670 1652-1662 
17a-OH-C-20 1706-1710 1698-1702 
17a-OH-C-20-21-oAc 1708, 1693 1723-1728 
C-20-21-oAc 1720-1727 
C-3,11 1713 
61-C-3,17 1719, 1745 
C-3,20 1719, 1710 
C-11,17 1719-1714, 1754 
C-11,20 1713 1711 
17a-OH-C-3,ll,20 1705, 1685 
Jones et al (538 - 547) 
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c-11,17 ketones can be readily distinguished. However, C-3 
acetate esters in chloroform absorbing at 1739-1735 cm-l 
-1 
mask C-17 ketones absorbing at 1736-1733 cm Likewise, 
c-3 benzoates in chloroform absorbing at 1724-1717 cm-l mask 
c-11 ketones in 17-ketosteroids absorbing at 1719-1714 cm- 1 • 
Unfortunately, the absorption shift of C-3 o~chlorobenzoates 
to lower frequencies is not quite large enough to eliminate 
this masking. 
To test the feasibility of the infrared analysis of 
mixtures of these 17-ketosteroids, a unique absorption peak 
was found which characterized each compound in the mixture. 
Then the absorption coefficient of each compound at each 
wave length was.determined. It was assumed that the absor-
bence at all other frequencies is proportional to its absor-
bence at its unique frequency. However, it should be noted 
that all compounds absorb at the unique frequency of any 
particular compound. It is possible to consider the ob-
served spectrum of a mixture of these pure compounds as a 
linear summation of the spectra of the individual compounds. 
That is, the absorbence at each unique frequency of the 
spectrum of the mixture is given by: 
A f = bB f + cC f + dD f + dE f + •••••••••• 
where the lower case letter represent the proportion of 
each compound in the mixture. When the total number of 
l_• 
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FIGURE XXI 
3a-HYDROXY-5S-ANDROSTANE-ll,17-DIONE 
100 ~ 
80 
·-
1300 1200 1100 1000 900 800 700 600 
)a-Hydro.xy-5(3-androstane-ll,17-d1onem.p.185FREQUENCY (CM -') 2.0 mg./ml., 2.0 l'lllllo 
TABLE XVIII 
INFRARED ABSORPTION CHARACTERISTICS OF 17-KETOSTEROIDS 
IN CARBON DISULFIDE SOLUTION 
17-Ketosteroid Extinction Coefficients (0 • 2% I 
-1 Frequency cm ·105g 1034 994 988 955 
3a-hydroxy-5a-androstan-17-one 0.049 0.027 0.301 0.061 0.003 
3a-hydroxy-5S-androstan-17-one 0.220 0.270 0.115 0.088 0.022 
3S-hydroxy-5a-androstan-17-one 0.079 0.387 0.042 0.042 0.022 
3S-hydroxy-5S-androstan-17-one 0.099 0.027 0.028 0.032 0.085 
3S-hydroxy-5-androstan-17-one 0.069. 0.076 0.062 0.042 0.036 
3a-hydroxy-5a-androstane-11,17-dione 0.024 0.062 0.081 0.237 0.015 
3a-hydroxy-5S-androstane-ll,17-dione 0.046 0.155 0.054 0.016 0.024 
0.2 cm) 
932 
0.028 
0.015 
0.044 
0.009 
0.022 
0.015 
0.073 
802 
0.007 
0.000 
0.009 
0.007 
0.066 
0.012 
0.012 
w 
°' 
°' 
367 
compounds in a mixture is unknown, the criteria for including 
another compound in the summation is that its inclusion de-
creases the deviation of the summated from the observed 
spectrum. 
While only obviously unique frequencies have been 
treated here, each compound has a definite absorption at 
each frequency. Using computerized methods, the summation 
-1 process may be repeated at 1 cm intervals or less, depend-
_ing on the slit width program of the instrument. Such a 
procedure would necessitate the direct recording of infra-
red spectra on magnetic tape or disc. 
The infrared results in Table XVIII indicate that there 
is little difficulty in distinguishing pairs of C-5 epi-
meric steroid alcohols. Note that the absorbences which 
are underlined are not necessarily at the best frequencies 
for this particular purpose. The resolution of the spec-
trometer is a key factor in the analysis of complex mix-
tures of these steroids at the selected frequencies. For 
example, the absorption of 3a-hydroxy-5s-androstan-17-one 
-1 
at 1034 cm occurs as a trough between two peaks and may 
decrease with better resolution thus making this frequency 
more specific for 38-hydroxy-Sa-androstan-17-one. 
Although it was necessary to scan the entire finger 
print region in carbon disulfide in order to determine 
368 
characteristic frequencies, the fact that these frequencies 
-1 
are between 1058 and 802 cm means that less volatile sol-
vents which produce greater concentration accuracy can be 
used if they have an infrared window in the region. Bromo-
form, which has an absorbence relative to air of less than 
0.36 between 1050 and 900 cm-l in a 2.0 mm cell is almost 
adequate for this purpose. Deuterated bromoform should also 
be investigated in this use. It is possible that the 802 
-1 
cm frequency may be replaced by another frequency which 
is masked in the 835-900 cm-l region of carbon disulfide 
absorption. The melting points that were determined for 
3a-hydroxy-5s-androstan-17-one and 3S-hydroxy-5a-androstan-
17-one are somewhat lower than previously reported values 
suggesting contamination by 3S-hydroxy-5-androstan-17-one. 
However, the infrared analysis does not support that ex-
planation. 
The inf rared spectra of the corresponding o-chloro-
benzoates are much less distinctive. This is expected 
since all these derivatives share the absorptions of the 
o-chlorobenzoate group including peaks at 1280, 1240 and 
-1 745 cm However, characteristic frequencies do exist 
for the 11-deoxy derivatives which are markedly different 
from the characteristic frequencies in the corresponding 
-1 
steroid alcohols. The frequency (700 cm ) appears to 
I 100 
80 
20 
0 
FIGURE XXII 
3a-HYDROXY-Sa-ANDROSTAN-17-0NE 3-o-CHLOROBENZOATE 
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FIGURE XXIII 
3a-HYDROXY-58-ANDROSTAN-17-0NE 3-o-CHLOROBENZOATE 
1300 1200 1100 
Ja-H7drox7-5~-androstan-17-one 
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FIGURE XXIV 
3S-HYDROXY-s~-ANDROSTAN-17-0NE 3-o-CHLOROBENZOATE 
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FIGURE XXV 
38-HYDROXY-58-ANDROSTAN-17-0NE 3-o-CHLOROBENZOATE 
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-FIGURE XXVI 
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FIGURE XXVII 
3a-HYDROXY-5S-ANDROSTANE-ll,17-DIONE 3-o-CHLOROBENZOAT~ 
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be associated with the C-3 hydrogen. This vibration is in-
f luenced by the conformation of the ester group as well as 
by the nature of the A-B ring juncture and the presence of 
the C-11 ketone. This is hard to explain and may be further 
investigated by comparison with the.spectra of the meta-
and para-chloro-substituted benzoyl esters. 
The C-11 oxygenated steroid esters seem to be devoid 
of characteristic frequencies. However, these frequencies 
may be present in a region of solvent absorption as dis-
cussed previously. This disadvantage is partially offset 
by the fact that C-11 ketonic and non-ketonic steroids are 
much more easily separated as C-3 esters rather than alco-
hols. The wide melting point range of 3a-hydroxy-5S-andro-
stan-17-one 3-o-chlorobenzoate confirms the presence of im-
purities noted in the alcohol which are difficult to sep-
arate chromatographically. Also noteworthy is the fact 
that the ester of 3S-hydroxy-5a-androstan-17-one had a 
melting point close to that of the parent steroid. The un-
corrected exteinction coefficients of the 17-ketosteroid 
3-o-chlorobenzoates are shown in Table XIX. The same data 
has been recalculated to correct for differences in con-
centration caused by the evaporation of carbon disulfide. 
This was done by assuming that the absorbence at 1050 cm-l 
was 0.300 in the spectrum of all esters. The main effect 
TABLE XIX 
INFRARED ABSORPTION CHARACTERISTICS OF 17-KETOSTEROID 
3-o-CHLOROBENZOATES IN SOLUTION 
3-o-chlorobenzoate Extinction Coefficients (0.2%, 0.2 cm) 
Frequency cm-l 1025 1015 1005 970 795 700 
3a-hydroxy-5a-androstan-17-one 0.059 0.079 0.090 0.176 0.030 0.032 
3a-hydroxy-5S-androstan-17-one 0.056 0.052 0.057 0.038 0.086 0.125 
3S-hydroxy-5a-androstan-17-one 0.046 0.046 0.159 0.032 0.004 0.022 
3S-hydroxy-5S-androstan-17-one 0.079 0.203 0.139 0.076 0.071 0.114 
3S-hydroxy-5-androstan-17-one 0.176 0.079 0.127 0.013 0.000 0.602 
3a-hydroxy-5a-androstane-ll,17-dione 0.052 0.052 0.052 0.028 0.031 0.194 
3a-hydroxy-5S-androstane-ll,17-dione 0.038 0.036 0.067 0.024 0.036 0.796 
w 
-...J 
0\ 
TABLE XX 
INFRARED ABSORPTION CHARACTERISTICS OF 17-KETOSTEROID 
3-o-CHLOROBENZOATES IN SOLUTION NORMALIZED TO AN 
EXTINCTION COEFFICIENT OF 0.300 AT 1050 cm-l 
3-o-Chlorobenzoate 
-1 Frequency cm 
3a-hydroxy-Sa-androstan-17-one 
3a-hydroxy-5s-androstan-17-one 
3S-hydroxy-5a-androstan-17-one 
3s-hydroxy-ss-androstan-17-one 
3e-hydroxy-5-androstan-17-one 
3a-hydroxy-5a-androstane-11,17-dione 
3~-hydroxy-5s-androstane-11,17-dione 
Extinction Coefficients (0. 2%, 0 ~ 2 cm) 
1025 1015 1005 970 795 700 
0.055 0.076 0.085 0.168 0.029 0.031 
0.052 0.048 0.053 0.035 0.079 0.115 
0.046 0.046 0.159 0.032 0.004 0.022 
0.051 0.130 0.089 0.048 0.045 0.073 
0.186 0.084 0.134 0.014 0.000 0.636 
0.057 0.057 0.057 0.031 0~034 0.213 
0.062 0.058 0.109 0.039 0.059 1.129 
of this approximation is to reduce the extinction coef f i-
cients of 3a-hydroxy-5$-androstan-17-one. Otherwise, the 
qualitative interpretation of the data is the same. The 
corrected data is shown in Table XX. 
Part II: Rat Maintenance 
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The second important experimental result is also qual-
itative. It was found possible to maintain alloxan-dia-
betic adrenalectomized rats on the specially compounded 
diet shown on page 332 of Chapter XII. This diet was admin-
istered in conjunction with a saturated solution of sodium 
glycyrrhetate in saline at pH 8.0. The solubility of so-
dium glycyrrhetate in 0.9 percent saline was found to be 
0.213 gm/l at this pH. Rats maintained on the solid low-
carbohydrate diet remained hyperglycemic. No deficiencies 
were noted in the diet during prolonged feeding. The diet 
was palatable to the rats and it served its purpose of 
maintaining healthy diabetic-adrenalectomized animals in 
the absence of insulin injections. 
A minor result of these investigations is the veri-
fication of the effect of the halogenated anesthetic 2-
chloro-1,1,2-trifluoroethyl ethyl ether on fasting serum 
glucose. Although it is important to be aware of this 
effect, it does not appear to be an important factor in 
these experiments because they were carried out during 
TABLE XXI 
The Effect of 2-Chloro-1,1-2-trifluoroethyl Ethyl 
Ether on Blood Glucose of Fasting (4 Hours) Rats. 
Non-anesthetized 
1.10 grn/l 
0.99 grn/l 
0.93 grn/l 
1.01 grn/l Means 
Anesthetized 
1.31 grn/l 
1.13 grn/l 
1.20 grn/l 
1.21 grn/l 
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an infusion of glucose at a level of approximately 500 mg 
per 100 ml. Furthermore, the effect of the anesthetic was 
constant in all experimental treatments so that it should 
not be a factor in differences between treatments. 
Although the focus of the experimental approach has 
been on the transport of steroid-dependent anti-insulin 
factors by 8-lipoproteins, some experiments were also per-
formed to test direct steroid effects. Of course, gluco-
corticoids cannot be tested directly because of their glu-
coneogenic effects on the liver. However, other steroids 
may be tested for their effect on glucose oxidation. Per-
haps the best way to do this is to administer the steroid 
treatment to a diabetic-adrenalectomized rat prior to the 
administration of labeled glucose and the measurement of 
glucose oxidation in a metabolic cage. 
A somewhat simpler approach consists of the measure-
ment of the effects of such steroids on the survival time 
of adrenalectomized rats following the administration of 
glucose and excess insulin. The results from this type 
of study are shown in Table XXII. Although the results 
indicate that so-called anesthetic steroids have anti-
insulin effects, the variable length of time between the 
onset of hyperglycemic convulsions and hypoglycemic death 
made the latter event unsatisfactory as an experimental 
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TABLE XXII 
The Effect of Pretreatment with 2.1 mg of the Anesthetic 
Steroid 17a,21-Dihydroxy-5B-Pregnane-3,ll,20-Trione 21-
Acetate on the Onset of Hypoglycemic Death Following the 
Injection of 1 ml of 44 Percent Glucose and 1 unit of In-
sulin Into 6-Hour Fasted Alloxan-Diabetic Adrenalectanized 
Rats. 
Survival Times (Minutes) 
Control 
195 
284 
193 
223 Means 
Steroid-Treated 
309 
410 
387 
369 
381 
endpoint. 
Part II: Research on the Me·asurement of C02 Specific 
Activity by Liquid Scintillation Techniques 
382 
A method was designed for the homogeneous liquid scin-
tillation counting of barium carbonate as quaternary ammo-
nium carbonate following its reaction with quaternary ammo-
nium tosylate. This method was found to be less sensitive 
than the measurement of relative specific activity by plan-
chet counting at infinite thickness. The cause of the re-
duced sensitivity was not the efficiency of liquid scin-
tillation counting which was high, but the low percentage 
conversion of the reaction forming quaternary ammonium 
carbonate. Solubility considerations suggest that the 
percentage conversion may be increased by reaction with 
quaternary ammonium mesylate. The plot of efficiency versus 
external standard ratio employing quaternary ammonium tosyl-
ate is shown in Figure XXVIII. 
The method of determination of specific activity of 
co2 actually used in these experiments is based on the di-
rect trapping of the gas by a quaternary ammonium hydroxide 
dissolved in toluene. The specially designed and con-
structed apparatus used by the author for this purpose is 
shown in Figure XIV, page 353. The efficiency plot for this 
method of counting is shown in Figure XXIX. Since the 
FIGURE XXVIII 
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TABLE XXIII 
EFFICIENCY VERSUS EXTERNAL STANDARD RATIO FOR 0.5 MOLAR QUATERNARY AMMONIUM 
BICARBONATE IN TOLUENE CONTAINING 6.0 GRAMS/LITER 2,5-DIPHENYLOXAZOLE 
External 
Standard 
Ratio 
0.323 
0.360 
+Hexadecane-1-14c 3026.1 
. 14 
-Hexadecane-1- C 61.1 
Net .•.•••...•••••• 2965.0 
+Hexadecane-1-14c 6575.3 
-Hexadecane-1-14c 453.3 
Net ••••••••••••••• 6122.0 
Vial Weight 
14278.8 mg 
14277.3 mg 
14 Hexadecane-1- C 
Specific 
Activity Efficiency 
2965 cpm 
---= 89.0% 
3330 dpn 
1.5 mg x 2220 dpn/mg = 3330 dpn 
16765.8 mg 
16762.9 mg 
6122 cpm 
---= 95.1% 
6438 dpn 
2. 9 mg x 2220 dpn/mg = 6438 dp:n 
FIGURE XXIX 
EFFICIENCY VERSUS EXTERNAL STANDARD RATIO FOR 
0. 5 MOLAR QUATERNARY AMMONIUM BICARBONA'rE IN rrOLUENE 
E'"CIENOY VERSUS EXTERNAL '1'ANDARD RATIO fOR o.9 
MOLAR QUATERNARY ""8NONIUM llCARIONATE IN TOLUENE 
CONTAINUf8 8.0 8RAMS/LIT!R t.1·D11tHENYLOXAZCiL! 
EXTERNAL STANDARD RATIO 
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combining capacity of the organic base must be saturated in 
order to calculate specific activities by this method, the 
low efficiency of co2 collection (approximately 50 percent) 
and the low rate of co2 production by the rat combine to 
limit the frequency of specific activity measurements. 
Another liquid scintillation method for the determina-
tion of specific activity was devised with the hope of in-
creasing the efficiency of co2 collection. However, the 
method was not tested because it requires temperature-con-
trol led counting. In the method an aqueous cesium hydrox-
ide solution is saturated with co2 • Cesium bicarbonate 
and primary fluor are then precipitated by the addition 
of 2-phenoxyethanol saturated with primary fluor, thereby 
forming a four-phase invariant system at constant temper-
ature and pressure. After equilibration below ambient 
temperature, the organic phenoxyethanol phase containing 
cesium bicarbonate, water and primary fluor should remain 
homogeneous for counting at ambient temperature. Studies 
were carried out to determined the comparative counting 
efficiencies of a number of organic solvents. As seen 
in Table XXIV, the efficiency of phenoxyethanol is 76.7 
percent, or approximately 85 percent of the efficiency 
of toluene. The same solvent phenoxyethanol was also 
used to determine the specific activity of the glucose 
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TABLE XXIV 
EFFICIENCIES OF SCINTILLATION SOLVENTS CONTAINING 
6.0 GMS/LITER DIPHENYLOXAZOLE AS PRIMARY FLUOR AS 
DETERMINED WITH HEXADECANE-l-c14 (2220 DPM/MG) 
Activity (gm) 
Spike ••• 35126.6 
Bkg •••••••• 98.0 
Net ••••• 35028.6 
Spike •••• 8747 .1 
Bkg •••••••• 69.l 
Net •••••• 8878.0 
Spike •••• 9784.5 
Bkg •••••••• 75.2 
Net •••••• 9709.3 
Spike ••• 13096.5 
Bkg ••••••• 129.4 
Net ••••• 12967.1 
Spike •••• 3863.l 
Bkg .... ~ ••• 73.5 
Net •••••• 3789.6 
Hexadecane .. Efficiency 
Toluene 
16674.4 mg 
16656.7 m::; 351028 •6 cp:n = 89.1% 
17.7 mg x 2220 dµn/mg = 39,284.0 dp:n 
Benzyl Alcahol 
16485.6 mg 
16478.2 mg 81878 •0 cp:n = 54.0% 
7.4 mg x 2220 dµn/mg = 16,428.0 dp:n 
Phenoxyethanol 
16472.8 mg 
16467.1 mg 91709 •0 cpn = 76.7% 
5.7 mg x 2220 dpn/ItB = 12,654.0 dp:n 
Anisole 
17081.8 mg 
17075.3 m::; 121967•0 cp:n = 89.9% 
6.5 mg x 2220 dµn/mg = 14,430.0 dp:n 
Dioxane 
16666.4 mg 
16659.3 mg 31789 •0 cpn = 24.0% 
7.1 mg x 2220 dµn/mg = 15,762.0 dp:n 
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infusion solution. Glucose was isolated from the solution 
and counted as its 2,5-dichlorophenylhydrazone. It is appro-
priate to note that labeled 2,5-dichlorophenylhydrazine may 
be synthesized from chlorine-36 labeled p-dichlorobenzene 
of known specific activity so that glucose specific activity 
may be determined solely from radioactivity measurements. 
An additional advantage of 2,5-dichlorophenylhydrazones over 
nitrophenylhydrazones as derivatives is that they are not 
colored and therefore they are less quenching to the liquid 
scintillation process. The specific activity of glycogen 
glucose can also be determined by this method following 
hydrolysis with sulfuric acid and neutralization with bar-
ium carbonate. 
Despite the fact that excess insulin and glucose were 
infused in these experiments and despite the fact that all 
limb muscles were taken for the isolation of muscle glyco-
gen, sufficient muscle glycogen could not be recovered 
from enough rats to make valid comparisons between steroid 
treatments. It is doubtful that significant muscle glyco-
genolysis occurred during freezing in liquid nitrogen be-
cause one would expect the limbs to freeze rapidly. 
Part III: Effects of Steroid Treatments 
Results from the best executed series of comparisons 
of f luprednisolone and 20S-hydroxyfluprednisolone treatments 
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is shown in Table XXV and plotted in Figure XXX. In these 
experiments the effects of S-lipoproteins from rats receiv-
ing each of the steroid treatments were determined in dif-
ferent recipient rats because only a limited number of ex-
periments were completed by the proposed method in which a 
single recipient rat received S-lipoproteins from both types 
of steroid-treated rats. It appears that the second use of 
a recipient is more critical than the first in that the rat 
is more susceptible to respiratory depression and respira-
tory arrest. 
The slope of the regression line for each set of ob-
servations was determined by the regression analysis in 
Table XXVI. The assumption that the regression line passes 
through the origin is theoretically correct and provides 
more meaningful regression slopes than those obtained by 
treating the origin as just another data point. The sta-
tistical treatment was simplified by treating the indepen-
dent variable time in units of 45 minutes. However, the 
slope, b, so obtained must be divided by 45; hence the b/45 
term in Table XXVI. Random variations in the rates of glu-
cose oxidation were greater than those due to steroid treat-
ments. The greatest variation was uncontrolled respiratory 
depression and anoxia produced by the anesthetic and the 
deficits of carbon dioxide and oxygen in the inspired air. 
TABLE XXV 
GLUCOSE OXIDATION AFTER LIPOPROTEINS FROM FLUPREDNISOLONE 
AND 208-HYDROXYFLUPREDNISOLONE TREATMENTS 
Regression Experimental Fasting Counts Per Minute 
Line Weight Glucose Per Microrrole C02 Symbol GMS GMS/L 
45 Min 90 Min 135 Min 
6a-fluoro-11S,17a,20S,21-tetrahydroxy-l,4-pregnadiene-3-one 
A 330 1.96 39.1 268.4 417.9 
B 329 1.96 76.7 151.9 389.0 
E 358 4.88 14.8 46.9 179.3 
F 429 2.02 16.2 73.9 165.4 
6a-fluoro-11S,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione 
c 323 3.16 25.0 145.1 202.6 
D 401 2.99 12.8 83.5 184.8 
\ . 
G 386 4.67 14.3 55.7 98.9 
H 314 3.69 15.0 42.8 84.6 
w 
\,0 
0 
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FIGURE XXX 
GLUCOSE OXIDATION AFTER LIPOPROTEINS FROM FLUPREDNISOLONE 
AND 208-HYDROXYFLUPREDNISOLONE TREATMENTS 
FIGURE XI GLUCOSE OXIDATION AFTER LIP,PROTEINS FROM 
fLUPREDNISOLONE AND 208-HYDROXYFLUPREDNISOLONE TREATMENTS 
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TABLE XXVI 
REGRESSION STATISTICS 
s = Specific Activity, T = Time, I = Interval Time 
I = T/45, S = bI, ::E! I= 6, ::E:I2 = 14, (::E! I 2)/4 = 9, [::E:I2-(~ I) 2/4] = 5 
Regression ~s ::E:S2 ::E!IS [::E:S2-(::E:IS) 2/::E:I2] [::E!IS-::E!I::E!S/4] b/45 
6a-fluoro-11B,17a,20B,21-tetrahlaroxy-l,4-pregnadiene-3-one 
A 725.4 526,205.16 1,829.6 287,094.74 741.50 2.904 
B 617.6 180,277.50 1,547.7 9,178.26 459.60 2.456 
E 255.5 33,080.81 I 646.5 30,095.37 263.25 1.026 
F 241.0 34,567.14 546.5 13,324.12 185.00 0.867 
339,602.49 1649.35 1.813 + 1.019 
6a-fluoro-11B,17a,21-trihydro~-l,4-Eregnadiene-3,20-dione 
c 372.7 62,725.77 923.0 2,588.00 363.95 1.465 
D 281.1 41,287.13 734.2 2,783.58 312.55 1.165 
G 168.9 13,088.19 422.4 343.78 169.05 0.672 
H 142.4 9,214.00 354.4 242.67 140.80 0.563 
5,958.03 986.35 0.966 + 0.424 
Totals: 2804.6 900,445.70 7,004.3 345,560.52 2635.70 
Critical Sum of Squares= F. 90 [7.7] x ::E!d~i/3 = 2.78 x 345,560.52/3 = 320,219.42 
. 2 
Sum of Squares Arrong All Slopes= 345,560.52 - (2635.70) /8 x 5 = 171,877.66 
Since 171,877.66<<320,219.42, the slopes are not significantly different at the 
90 percent confidence level. In contrast, a Student's t value of 1.535 for the 
difference between the mean slopes of steroid treatments is greater than t. 90fGl 
w 
\,0 
N 
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This variation and that in infusion rates could be eliminated 
by the use of a mechanical respirator and positive displace-
ment infusion pump. 
In order to demonstrate significant differences between 
steroid treatments the specific activity of the glucose ad-
ministered to the rat will have to be increased 5-10 fold 
and more frequent specific activity measurements will have 
to be made. Provided that 20B-hydroxyfluprednisolone does 
not stimulate glucose oxidation, then the demonstration that 
the rate of glucose oxidation is lower with the fluprednis-
olone treatment than with the 20B-hydroxyfluprednisolone 
treatment proves that the effect of f luprednisolone is sig-
nificant in vivo. The possibility that 20B-hydroxyflupred-
nisolone does stimulate glucose oxidation may be eliminated 
by comparing both steroid treatments with the basal glucose 
oxidation rate. To do this one must be able to predict.the 
latter portions of the specific activity versus time curve 
from measurements of its initial portion. Each recipient 
rat could be subjected to a control peiiod and then to an 
experimental period after lipoprotein administration. Dif-
ferences between the experimentally determined and calcu-
lated specific activity curves could then be observed. 
~ . 
CHAPTER XIV 
DISCUSSION 
The purpose of this dissertation is to evaluate in-
sulin inhibition by glucocorticoids in vivo. It includes 
an evaluation of the specificity of the effect. For the 
purposes of this discussion the author defines a specific 
glucocorticoid effect as one which requires all of the 
functional groups present in cortisol. If insulin inhib-
ition by glucocorticoids is non-specific, then 20S-hydroxy 
glucocorticoids should produce insulin antagonism in vivo. 
On the other hand, if insulin inhibition by glucocorticoids 
is specific, it should not be produced by the 20S-hydroxy 
glucocorticoids in vivo because these metabolites are 
formed irreversibly from glucocorticoids in the rat (486) 
and thus are not precursors of glucocorticoids. 
If the anti-insulin effect of fluprednisolone is sig-
nificantly greater than that of 20S-hydroxy flupredniso-
lone, what are possible explanations of this specificity? 
One explanation is that the C-20 ketone interacts with a 
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receptor protein through anil formation. It is unlikely that 
differences in hydrogen bonding between the C-20 ketone and 
c-20 hydroxyl group could account for the differences in the 
observed effects. On the other hand, the C-21 deoxy deriva-
tive which may be formed from the C-21 mesylate, could be 
used to evaluate the effect of hydrogen bonding on the glu-
cocorticoid effect. For example, Munk (766) has shown that 
the llS-hydroxyl group markedly alters the surface activity 
.of steroids. 
The following tentative sequence of events is thought 
to occur during glycolytic inhibition by glucocorticoids. 
First, the glucocorticoid combines with a growth hormone 
dependent protein and the resulting steroid-protein complex 
causes a decrease in triglyceride synthesis which leads to 
an increase in the synthesis of saturated lecithins which 
are transported to peripheral tissues by s-lipoproteins. 
Enzymes of red cell origin hydrolyze the lecithin to an ac-
tive lysolecithin species which inhibits oxidative phos-
phorylation in mitochondria perhaps by displacing the essen-
tial phospholipids of cytochrome C. Thus, the specificity 
of the phospholipid effect is due mainly to the protein and 
not to any special properties of the lysolecithin itself. 
However, since the mitochondria contain an enzyme which 
normally converts the lysolecithin species back to lecithin, 
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the lysolecithin which affects the activity of the mitochon-
dria is probably resistant to this conversion and derived 
from non-mitochondrial species of lecithin {633). 
The hypothesis that these steroid effects are caused 
by species of S-lipoprotein lysolecithin can be investigated 
by correlating S-lipoprotein lysolecithin composition with 
the magnitude of inhibition of glucose oxidation. Lysolec-
ithin species may be characterized following hydrolysis 
with lysolecithinase and gas chromatography of the methyl 
esters of the resulting fatty acids. 
Since S-lipoproteins are synthesized in the liver, and 
since the liver has been implicated in the anti-insulin ef-
fect of glucocorticoids, the possibility that the time 
course of the synthesis of the inhibitor parallels the in-
duction of gluconeogenic enzymes such as tryptophane pyrol-
ase and ty~osine transaminase {208, 661) should be deter-
mined. Experiments with actinomycin D may not decide whe-
ther protein synthesis is required for the anti-insulin ef-
fect because this inhibitor of DNA synthesis may also block 
the synthesis of the S-lipoprotein necessary to transport 
the inhibitor. On the other hand, considerations ~n pre-
ceeding chapters suggest that growth hormone is required 
for the anti-insulin effect of glucocorticoids because it 
is necessary for the production of a particular receptor 
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protein for the glucocorticoid. This particular receptor 
protein might be detected by comparing the hepatic cortisol 
binding proteins of hypophysectomized rats before and after 
growth hormone treatment. 
The specificity of the insulin antagonism by glucocor-
ticoids is its most interesting and critical aspect. As 
previously noted, many polycyclic compounds such as estro-
gens and chlorpromazine produce hyperglycemic effects which 
appear to be mechanistically similar to that of glucocorti-
coids. Therefore, the possibility that must be eliminated 
is that pharmacological doses of these synthetic compounds 
exert their hyperglycemic effect by interacting with the 
growth hormone dependent receptor protein. 
Serotonin is a hyperglycemic compound released in re-
sponse to growth hormone treatment. Since the hyperglyce-
mic effect- of serotonin is caused by its release of adrenal 
epinephrine, the effect of serotonin should not be impor-
tant in adrenalectomized rats. However, the effect of sero-
tonin and serotonin antagonists may be significant modi-. 
fiers of insulin inhibition by endogenous glucocorticoids 
in intact animals. For example, some serotonin antagonists 
can suppress ACTH ~elease in addition to displacing sero-
tonin from its binding sites. 
The mechanism of the enhanced platelet aggregation 
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which is found in diabetes mellitus and which contributes to 
diabetic retinopathy by blocking blood flow in the stagnant 
regions of the venous circulation of the retina may be sim-
ilar to the mechanism of glycolytic inhibition by glucocor-
ticoids. For example, it is known that platelet glycolysis 
is necessary to maintain the repulsive electrical charges 
between platelets. Furthermore, platelets are capable of 
triglyceride and phospholipid synthesis so that they are 
susceptible to factors which affect these processes. The 
importance of platelet function in the pathology of dia-
betes mellitus is evident from the fact that 60 percent 
of patients with diabetes for more than 10 years have 
retinal hemmorhages and from the fact that 69.4 percent 
with diabetes for over 15 years die of atherosclerosis. 
Fructose overcomes glycolytic inhibition by glucocor-
ticoids in. liver and adipose tissue. Although fructolysis 
bypasses the inhibition of phosphofructokinase by citrate 
in insulin deficient tissues, it is not clear how fructose 
reverses the inhibition of lipogenesis which is the cause 
of the elevated citrate levels. It appears that fructose 
or fructose-1-phosphate has a direct effect on triglycer-
ide synthesis in mitochondria which counteracts the inhib-
ition of this process postulated to be produced by a com-
plex of glucocorticoids with a growth hormone-dependent 
r ~ 399 
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r. protein. Thus, the effect of fructose is similar to that of 
insulin under these circumstances. However, the presence of 
fructose or its esters in mitochondria has not been reported. 
In multiple sclerosis the phospholipase A which forms 
the B-lipoprotein lysolecithin species that enhances plate-
let aggregation is released from damaged nervous tissue 
(92). The phospholipase A activity of lipoprotein lipase 
appears to be more specific in that it is not responsible 
for the formation of the insulin-inhibitory lysolecithin 
species. Indeed, since insulin resistance is associated 
with diabetic lipemia, the insulin inhibitory lysolecithin 
species may block the activity of lipoprotein lipase. Ap-
parently, this reduction in lipoprotein lipase activity ob-
scures the inhibition of triglyceride synthesis in diabetes. 
Hill et al (460} have shown that triglyceride synthesis is 
impaired by glucocorticoids even though the activities of 
triglyceride-synthesizing enzymes in tissue extracts is 
increased (439). Hazzard et al (441} also noted a relative 
inhibition of triglyceride synthesis in estrogen-induced 
hypertriglyceridemia which suggests that estrogens may in-
teract with the growth hormone-dependent receptor protein 
for glucocorticoids. The presence of lysolecithinase ac-
tivity in plasma (848) may explain the instability of the 
B-lipoprotein insulin inhibitor which was reported by 
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Bornstein (98). 
The anoxia suggested by the low recoveries of glycogen 
is probably due to respiratory depression produced by the 
anesthetic methoxyflurane. This respiratory depression is 
accentuated by the absence of carbon dioxide, a respiratory 
stimulant, in the inspired air. Methoxyflurane, unlike 
nitrous oxide, does not contribute to anoxia by displacing 
oxygen because its partial pressure is only 10 mm Hg at 
6.27°C and approximately 5 mm Hg at the temperature of 
-21.1°C used in these experiments. Respiratory depression 
leading to anoxia might be counteracted by a slight reduc-
tion in the_pH of the glucose infusion solution. Alter-
nately, diethyl ether, _which is a respiratory stimulant, 
may be used as a substitute anesthetic with exactly the 
·same apparatu·s. 
Restatement of the Problem 
The general problem treated was the role of cortisol 
in Diabetes Mellitus. The particular aspect studied was 
the evaluation in vivo of insulin antagonists transported 
' 
by rat 8-lipoproteins in response to the glucocorticoid 
6a-fluoro-11$,17a,21-trihydroxy-l,4-pregnadiene-3,20-dione. 
The specificity of the steroid effect was also evaluated 
by comparison with its derivative 6a-fluoro-11$,17a,208,21-
tetrahydroxy-1,4-pregnadiene-3-one• 
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Restatement of the Approach 
8-lipoproteins were isolated from the sera of steroid-
treated donors and administered to recipient rats and the ef-
fect of the lipoprotein on the oxidation of glucose-6-14c to 
carbon dioxide was measured. The assumptions made were: 
1) that the rate of glycolysis was the main determinant in 
14 . 14 the rate of co2 formation from glucose-6- C; 2) that the 
14co2 was mainly formed in extra hepatic tissues; 3) that 
the proportion of glucose metabolized directly to 14co2 is 
the same in all experiments, and 4) that gluconeogenesis 
is not a factor in these experiments. 
Results 
Provided .that the reduced steroid 6a-fluoro-11B,17a, 
20a,21-tetrahydroxy-l,4-pregnadiene-3-one does not stimulate 
glucose oxidation, the rate of glucose oxidation was lower 
with lipoproteins from rats treated with 6a-fluoro~llB,17a, 
21-trihydroxy-l,4-pregnadiene-3,20-dione. However, this 
difference was not statistically significant. 
Discussion 
An approach to the evaluation of insulin antagonism 
in vivo has been developed and its limitations have been 
determined. The frequency with which specific activity 
measurements could be made was the limiting factor in these 
experiments. The absolute specificity of the steroid effect 
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cannot be determined until the absolute effect of the ster-
oid on glucose oxidation is determined with respect to a 
non-treatment control. The insulin inhibitor appears to be 
a species of lysolecithin which inhibits but does not un-
couple oxidative phosphorylation leading to lower levels of 
ATP as a function of NADH concentration, or, conversely, to 
higher levels of NADH as a function of ATP concentration. 
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